data_2lqa_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lqa _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.0 p . . . . . 0 C--O 1.235 0.325 0 CA-C-O 120.458 0.17 . . . . 0.0 110.993 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.537 ' HB1' ' OE1' ' A' ' 8' ' ' GLU . . . -92.01 151.14 20.62 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.781 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.6 p90 -98.93 171.82 7.82 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.856 179.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.578 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.2 tt0 -59.94 129.04 39.87 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 123.362 0.665 . . . . 0.0 112.428 -179.267 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.29 -20.86 29.84 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 115.572 -0.74 . . . . 0.0 114.388 178.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.537 ' OE1' ' HB1' ' A' ' 4' ' ' ALA . 6.0 pt-20 -107.02 177.47 4.85 Favored 'General case' 0 CA--C 1.539 0.558 0 CA-C-N 117.42 0.61 . . . . 0.0 111.828 -179.332 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 40.8 p -91.5 146.95 23.38 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.09 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.6 p -134.84 128.26 32.37 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.975 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -98.01 119.66 37.03 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.702 179.419 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.586 HG23 ' O ' ' A' ' 30' ' ' PRO . 24.2 m -72.41 10.35 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -178.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.402 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.7 tp60 -104.76 -29.22 10.69 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.637 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.402 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.94 -26.61 0.26 Allowed 'General case' 0 N--CA 1.477 0.899 0 N-CA-C 112.907 0.706 . . . . 0.0 112.907 -178.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.2 t80 -125.22 87.22 55.87 Favored Pre-proline 0 CA--C 1.545 0.779 0 N-CA-C 111.687 0.254 . . . . 0.0 111.687 -178.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -77.88 176.84 9.52 Favored 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.311 2.007 . . . . 0.0 112.734 179.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.687 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -88.54 160.88 17.25 Favored 'General case' 0 N--CA 1.468 0.441 0 O-C-N 123.201 0.313 . . . . 0.0 110.809 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.9 m -79.94 108.45 9.23 Favored Pre-proline 0 CA--C 1.544 0.728 0 N-CA-C 112.078 0.399 . . . . 0.0 112.078 -179.284 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.44 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.1 Cg_endo -83.51 177.66 6.2 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.469 2.113 . . . . 0.0 112.896 179.341 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.82 -40.22 2.5 Favored Glycine 0 C--N 1.339 0.741 0 C-N-CA 121.349 -0.453 . . . . 0.0 112.985 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.8 mt -88.76 -38.52 14.62 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 122.456 0.302 . . . . 0.0 111.458 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.55 51.65 0.2 Allowed Glycine 0 C--N 1.338 0.69 0 O-C-N 123.475 0.485 . . . . 0.0 112.53 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.465 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 22.0 mt -115.72 149.17 38.85 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-O 120.618 0.247 . . . . 0.0 110.858 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t -138.93 154.84 48.37 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.201 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.687 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 65.7 m -97.19 123.28 40.92 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.709 179.548 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 12.2 mt -127.38 122.85 23.01 Favored Pre-proline 0 CA--C 1.545 0.775 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.231 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.423 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.3 Cg_exo -75.42 -40.82 1.09 Allowed 'Cis proline' 0 C--N 1.375 1.922 0 C-N-CA 124.697 -0.96 . . . . 0.0 112.648 0.133 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.03 33.85 8.65 Favored Glycine 0 C--N 1.343 0.918 0 CA-C-N 115.993 -0.549 . . . . 0.0 113.085 179.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.423 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.8 p30 -147.06 79.63 9.84 Favored Pre-proline 0 CA--C 1.546 0.824 0 CA-C-N 116.641 0.221 . . . . 0.0 111.427 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.586 ' O ' HG23 ' A' ' 12' ' ' VAL . 56.1 Cg_endo -89.8 -27.4 3.9 Favored 'Cis proline' 0 C--N 1.37 1.671 0 C-N-CA 124.723 -0.949 . . . . 0.0 113.477 -0.368 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -86.11 149.59 25.02 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.633 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -151.13 -179.15 26.61 Favored Glycine 0 C--N 1.335 0.521 0 CA-C-N 115.654 -0.703 . . . . 0.0 112.627 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.43 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.9 OUTLIER -123.33 140.9 52.54 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 179.349 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.9 m -86.46 110.6 19.86 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 121.015 0.436 . . . . 0.0 111.698 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' TYR . . . . . 0.465 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 32.8 m-85 -125.47 158.37 34.61 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.624 179.546 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.578 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.1 t80 -92.89 135.65 33.95 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.943 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.6 mt . . . . . 0 C--O 1.249 1.059 0 CA-C-O 118.095 -0.955 . . . . 0.0 110.871 179.806 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.409 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.5 p . . . . . 0 C--O 1.235 0.305 0 CA-C-O 120.479 0.181 . . . . 0.0 110.961 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.508 ' HB2' ' OE1' ' A' ' 8' ' ' GLU . . . -92.07 152.88 19.74 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.757 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 18.6 p90 -98.23 174.08 6.68 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.725 179.161 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.561 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.3 tt0 -63.89 131.3 47.31 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 123.227 0.611 . . . . 0.0 112.348 -179.282 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.72 3.97 52.29 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-N 115.564 -0.744 . . . . 0.0 114.759 178.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.508 ' OE1' ' HB2' ' A' ' 4' ' ' ALA . 5.1 pt-20 -130.55 177.91 7.02 Favored 'General case' 0 CA--C 1.54 0.558 0 CA-C-N 117.636 0.718 . . . . 0.0 111.605 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' SER . . . . . 0.413 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 42.5 p -90.4 146.11 24.41 Favored 'General case' 0 C--N 1.343 0.315 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.293 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.9 p -136.47 128.01 28.69 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.782 -179.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -98.22 119.57 37.11 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.87 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.584 HG22 ' O ' ' A' ' 30' ' ' PRO . 23.1 m -72.38 10.02 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 N-CA-C 112.963 0.727 . . . . 0.0 112.963 -178.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.433 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 15.0 tt0 -99.81 -30.23 12.17 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.206 -179.572 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.433 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.1 p90 -154.01 -26.77 0.13 Allowed 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 112.729 0.64 . . . . 0.0 112.729 -178.55 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -120.43 85.23 37.01 Favored Pre-proline 0 CA--C 1.544 0.749 0 N-CA-C 111.613 0.227 . . . . 0.0 111.613 -178.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.409 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.8 Cg_endo -78.2 179.12 6.79 Favored 'Trans proline' 0 C--N 1.369 1.65 0 C-N-CA 122.306 2.004 . . . . 0.0 112.664 179.478 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.697 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -89.62 159.82 16.96 Favored 'General case' 0 N--CA 1.467 0.402 0 O-C-N 123.163 0.29 . . . . 0.0 110.917 179.788 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.2 m -79.97 108.56 9.51 Favored Pre-proline 0 CA--C 1.545 0.76 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.881 -179.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.2 Cg_endo -83.27 177.42 6.54 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 122.521 2.147 . . . . 0.0 112.959 179.376 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.27 -40.12 2.53 Favored Glycine 0 C--N 1.34 0.751 0 C-N-CA 121.336 -0.459 . . . . 0.0 113.015 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.4 -38.91 13.76 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 122.462 0.305 . . . . 0.0 111.494 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.06 50.51 0.21 Allowed Glycine 0 C--N 1.339 0.723 0 O-C-N 123.479 0.487 . . . . 0.0 112.485 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.451 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.7 mt -113.87 150.33 33.77 Favored 'General case' 0 C--O 1.235 0.324 0 O-C-N 123.661 0.271 . . . . 0.0 110.854 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 t -139.28 154.59 47.98 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.347 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.697 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 56.9 m -97.49 123.17 41.25 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.822 -0.627 . . . . 0.0 110.595 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.9 mt -127.53 123.35 23.07 Favored Pre-proline 0 CA--C 1.544 0.741 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.238 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.416 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.2 Cg_exo -75.69 -40.85 1.08 Allowed 'Cis proline' 0 C--N 1.375 1.927 0 C-N-CA 124.69 -0.962 . . . . 0.0 112.527 0.085 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.19 33.49 8.77 Favored Glycine 0 C--N 1.342 0.915 0 CA-C-N 115.964 -0.562 . . . . 0.0 113.147 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.416 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.8 p30 -147.06 79.86 9.73 Favored Pre-proline 0 CA--C 1.546 0.821 0 CA-C-N 116.649 0.224 . . . . 0.0 111.509 179.64 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.584 ' O ' HG22 ' A' ' 12' ' ' VAL . 57.5 Cg_endo -89.62 -27.23 4.11 Favored 'Cis proline' 0 C--N 1.37 1.681 0 C-N-CA 124.666 -0.973 . . . . 0.0 113.496 -0.367 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -86.83 150.03 24.41 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.559 -179.49 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.413 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -151.6 -178.09 26.01 Favored Glycine 0 C--N 1.336 0.535 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.45 179.453 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.461 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -125.75 142.25 51.6 Favored 'General case' 0 C--O 1.234 0.278 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 179.328 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 54.3 m -87.64 112.23 22.1 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-O 121.093 0.473 . . . . 0.0 111.783 -179.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' TYR . . . . . 0.451 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 34.8 m-85 -125.89 159.43 32.56 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.538 179.361 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.561 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.6 t80 -93.38 135.21 34.84 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.951 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.129 -0.939 . . . . 0.0 110.857 179.738 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.402 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.2 p . . . . . 0 C--O 1.235 0.329 0 CA-C-O 120.453 0.168 . . . . 0.0 110.999 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.525 ' HB2' ' OE1' ' A' ' 8' ' ' GLU . . . -91.9 151.62 20.45 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.701 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.9 p90 -98.75 172.82 7.21 Favored 'General case' 0 CA--C 1.536 0.427 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.873 179.3 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.579 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 14.4 tt0 -61.04 130.31 45.74 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 123.326 0.651 . . . . 0.0 112.334 -179.386 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.08 -25.62 19.77 Favored Glycine 0 C--N 1.338 0.669 0 CA-C-N 115.656 -0.702 . . . . 0.0 114.179 178.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.525 ' OE1' ' HB2' ' A' ' 4' ' ' ALA . 5.1 pt-20 -103.06 178.67 4.49 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 117.273 0.536 . . . . 0.0 111.851 -179.159 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 43.8 p -92.8 151.56 19.94 Favored 'General case' 0 C--N 1.344 0.348 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.221 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 p -139.48 130.49 26.38 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.863 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -100.14 119.88 39.01 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.597 179.322 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.585 HG22 ' O ' ' A' ' 30' ' ' PRO . 25.5 m -71.32 9.43 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -178.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.497 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -100.44 -32.81 10.63 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.3 -179.496 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.497 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.1 p90 -149.93 -26.8 0.26 Allowed 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 112.897 0.703 . . . . 0.0 112.897 -178.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 6.8 t80 -121.09 85.53 41.26 Favored Pre-proline 0 CA--C 1.545 0.757 0 N-CA-C 111.747 0.277 . . . . 0.0 111.747 -178.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.402 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.1 Cg_endo -78.06 177.16 9.12 Favored 'Trans proline' 0 C--N 1.369 1.607 0 C-N-CA 122.202 1.935 . . . . 0.0 112.67 179.385 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.701 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 4.6 t -88.27 160.73 17.54 Favored 'General case' 0 N--CA 1.467 0.418 0 O-C-N 123.186 0.304 . . . . 0.0 110.796 179.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.0 m -79.97 108.67 9.77 Favored Pre-proline 0 CA--C 1.545 0.768 0 N-CA-C 111.99 0.367 . . . . 0.0 111.99 -179.18 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.438 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 76.0 Cg_endo -83.22 177.65 6.4 Favored 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.5 2.133 . . . . 0.0 112.918 179.286 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.94 -41.09 2.25 Favored Glycine 0 C--N 1.34 0.77 0 C-N-CA 121.384 -0.436 . . . . 0.0 112.928 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.1 -38.86 14.03 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 122.486 0.314 . . . . 0.0 111.431 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.425 ' O ' ' HA ' ' A' ' 36' ' ' TYR . . . 124.27 53.41 0.19 Allowed Glycine 0 C--N 1.339 0.715 0 O-C-N 123.521 0.513 . . . . 0.0 112.512 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 23.7 mt -117.64 147.48 42.84 Favored 'General case' 0 C--O 1.234 0.267 0 O-C-N 123.623 0.249 . . . . 0.0 110.785 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -139.3 154.51 47.94 Favored 'General case' 0 CA--C 1.535 0.404 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.391 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.701 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 89.7 m -97.35 118.3 33.5 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.52 179.496 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 11.6 mt -122.75 122.23 27.22 Favored Pre-proline 0 CA--C 1.545 0.756 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.235 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.407 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.42 -40.72 1.12 Allowed 'Cis proline' 0 C--N 1.373 1.843 0 C-N-CA 124.695 -0.961 . . . . 0.0 112.701 0.232 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.13 34.43 8.8 Favored Glycine 0 C--N 1.342 0.868 0 O-C-N 123.588 0.555 . . . . 0.0 112.928 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.407 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -145.74 79.58 11.11 Favored Pre-proline 0 CA--C 1.548 0.876 0 C-N-CA 122.204 0.202 . . . . 0.0 111.423 179.724 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.585 ' O ' HG22 ' A' ' 12' ' ' VAL . 56.8 Cg_endo -88.79 -27.76 4.18 Favored 'Cis proline' 0 C--N 1.37 1.666 0 C-N-CA 124.739 -0.942 . . . . 0.0 113.486 -0.254 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -86.9 149.34 24.87 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.66 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.81 160.29 30.22 Favored Glycine 0 C--N 1.335 0.52 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.137 179.335 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.415 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.5 OUTLIER -99.1 143.96 28.78 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.823 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 18.8 m -88.31 110.04 20.45 Favored 'General case' 0 C--O 1.238 0.476 0 O-C-N 123.464 0.477 . . . . 0.0 111.528 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' TYR . . . . . 0.467 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 38.1 m-85 -124.73 160.13 29.31 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.289 -0.868 . . . . 0.0 110.744 179.628 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.579 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 15.8 t80 -93.07 137.23 32.61 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.872 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 14.6 mt . . . . . 0 C--O 1.251 1.172 0 CA-C-O 118.531 -0.747 . . . . 0.0 110.876 179.742 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.404 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.4 p . . . . . 0 C--O 1.235 0.331 0 CA-C-O 120.438 0.161 . . . . 0.0 110.989 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.554 ' HB2' ' OE1' ' A' ' 8' ' ' GLU . . . -92.52 150.19 20.91 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.654 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.5 p90 -98.65 171.91 7.82 Favored 'General case' 0 CA--C 1.537 0.458 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.848 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.571 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 14.8 tt0 -59.53 128.63 37.96 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 123.305 0.642 . . . . 0.0 112.389 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.3 -21.02 27.34 Favored Glycine 0 C--N 1.339 0.718 0 CA-C-N 115.66 -0.7 . . . . 0.0 114.421 178.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.554 ' OE1' ' HB2' ' A' ' 4' ' ' ALA . 6.8 pt-20 -107.48 177.39 4.85 Favored 'General case' 0 CA--C 1.541 0.604 0 CA-C-N 117.43 0.615 . . . . 0.0 111.835 -179.222 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 53.0 m -91.47 145.4 24.65 Favored 'General case' 0 C--N 1.343 0.312 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.079 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.7 p -134.0 129.09 35.65 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.93 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.27 119.93 39.15 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.818 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.593 HG23 ' O ' ' A' ' 30' ' ' PRO . 28.5 m -72.4 10.48 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 112.994 0.738 . . . . 0.0 112.994 -178.797 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 5.6 tp60 -104.03 -29.31 10.98 Favored 'General case' 0 CA--C 1.535 0.377 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.615 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.0 p90 -149.84 -26.74 0.26 Allowed 'General case' 0 N--CA 1.476 0.874 0 N-CA-C 112.851 0.686 . . . . 0.0 112.851 -178.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 12.6 t80 -125.75 88.33 54.4 Favored Pre-proline 0 CA--C 1.545 0.775 0 N-CA-C 111.702 0.26 . . . . 0.0 111.702 -178.614 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.404 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.8 Cg_endo -77.74 176.17 10.34 Favored 'Trans proline' 0 C--N 1.37 1.686 0 C-N-CA 122.27 1.98 . . . . 0.0 112.708 179.333 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.671 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.1 t -88.26 161.36 17.23 Favored 'General case' 0 N--CA 1.467 0.399 0 O-C-N 123.208 0.318 . . . . 0.0 110.841 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.3 m -79.97 108.47 9.3 Favored Pre-proline 0 CA--C 1.544 0.745 0 N-CA-C 112.03 0.381 . . . . 0.0 112.03 -179.276 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.9 Cg_endo -83.51 177.53 6.29 Favored 'Trans proline' 0 C--N 1.371 1.756 0 C-N-CA 122.512 2.142 . . . . 0.0 112.906 179.369 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.0 -40.56 2.38 Favored Glycine 0 C--N 1.34 0.775 0 C-N-CA 121.313 -0.47 . . . . 0.0 113.003 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.08 -38.91 14.01 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 122.424 0.29 . . . . 0.0 111.453 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.92 51.96 0.2 Allowed Glycine 0 C--N 1.339 0.719 0 O-C-N 123.466 0.479 . . . . 0.0 112.568 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.451 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 22.0 mt -115.26 149.32 37.96 Favored 'General case' 0 C--O 1.234 0.286 0 O-C-N 123.654 0.267 . . . . 0.0 110.847 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -138.95 154.69 48.34 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.266 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.671 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 67.9 m -97.24 123.31 40.99 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.64 179.538 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 12.0 mt -126.63 122.94 23.77 Favored Pre-proline 0 CA--C 1.545 0.775 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.279 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.404 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.85 -40.89 1.06 Allowed 'Cis proline' 0 C--N 1.375 1.929 0 C-N-CA 124.595 -1.002 . . . . 0.0 112.644 0.111 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.08 33.07 9.14 Favored Glycine 0 C--N 1.342 0.883 0 O-C-N 123.548 0.53 . . . . 0.0 112.848 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.404 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.8 79.08 12.4 Favored Pre-proline 0 CA--C 1.547 0.843 0 C-N-CA 122.193 0.197 . . . . 0.0 111.291 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.593 ' O ' HG23 ' A' ' 12' ' ' VAL . 58.6 Cg_endo -89.89 -26.71 4.36 Favored 'Cis proline' 0 C--N 1.37 1.682 0 C-N-CA 124.708 -0.955 . . . . 0.0 113.682 -0.35 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.06 152.56 21.1 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.933 -179.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.41 -174.2 24.2 Favored Glycine 0 C--N 1.337 0.637 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.659 179.591 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.486 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -124.21 143.85 50.28 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.589 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.6 m -88.11 110.24 20.5 Favored 'General case' 0 C--O 1.238 0.448 0 O-C-N 123.44 0.462 . . . . 0.0 111.571 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' TYR . . . . . 0.451 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 33.0 m-85 -124.76 159.1 31.71 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.657 179.603 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.571 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.3 t80 -93.18 136.11 33.75 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.96 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.7 mt . . . . . 0 C--O 1.251 1.146 0 CA-C-O 118.486 -0.769 . . . . 0.0 110.892 179.775 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.409 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.7 p . . . . . 0 C--O 1.235 0.324 0 CA-C-O 120.467 0.175 . . . . 0.0 110.924 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.519 ' HB3' ' OE1' ' A' ' 8' ' ' GLU . . . -91.76 152.03 20.35 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.827 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 19.1 p90 -98.42 173.92 6.72 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.626 179.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.576 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 17.5 tt0 -63.82 130.0 42.38 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 123.213 0.605 . . . . 0.0 112.359 -179.326 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 102.06 9.61 41.89 Favored Glycine 0 C--N 1.339 0.717 0 CA-C-N 115.662 -0.699 . . . . 0.0 114.764 178.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.519 ' OE1' ' HB3' ' A' ' 4' ' ' ALA . 5.9 pt-20 -135.23 177.39 7.85 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 117.676 0.738 . . . . 0.0 111.535 179.756 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.4 m -90.82 141.65 28.59 Favored 'General case' 0 C--N 1.343 0.314 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.137 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.5 p -133.17 128.8 36.8 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.844 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.33 119.88 39.09 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.868 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.594 HG23 ' O ' ' A' ' 30' ' ' PRO . 28.3 m -72.78 12.2 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.031 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -178.823 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.7 tp-100 -105.51 -29.91 9.88 Favored 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 116.593 -0.276 . . . . 0.0 111.559 -179.391 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -148.78 -26.68 0.31 Allowed 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 8.8 t80 -126.21 88.19 54.77 Favored Pre-proline 0 CA--C 1.546 0.805 0 N-CA-C 111.696 0.258 . . . . 0.0 111.696 -178.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.409 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.4 Cg_endo -77.91 177.89 8.25 Favored 'Trans proline' 0 C--N 1.369 1.635 0 C-N-CA 122.31 2.007 . . . . 0.0 112.724 179.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.687 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.9 t -90.09 160.13 16.46 Favored 'General case' 0 N--CA 1.468 0.447 0 O-C-N 123.218 0.324 . . . . 0.0 110.799 179.802 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 76.3 m -80.06 108.45 9.34 Favored Pre-proline 0 CA--C 1.545 0.774 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.93 -179.322 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.444 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 80.5 Cg_endo -83.41 177.44 6.43 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.465 2.11 . . . . 0.0 112.961 179.296 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.04 -40.44 2.42 Favored Glycine 0 C--N 1.339 0.741 0 O-C-N 123.434 0.459 . . . . 0.0 113.016 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.07 -39.13 13.85 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 122.437 0.295 . . . . 0.0 111.52 -179.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.47 50.66 0.2 Allowed Glycine 0 C--N 1.339 0.736 0 O-C-N 123.505 0.503 . . . . 0.0 112.51 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.435 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.8 mt -113.86 150.21 33.94 Favored 'General case' 0 C--O 1.235 0.329 0 O-C-N 123.617 0.245 . . . . 0.0 110.846 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 t -139.58 154.27 47.58 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.326 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.687 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.9 m -97.33 123.3 41.1 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.582 179.366 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.8 mt -126.9 123.32 23.62 Favored Pre-proline 0 CA--C 1.545 0.772 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.333 -179.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.403 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.9 -40.84 1.07 Allowed 'Cis proline' 0 C--N 1.375 1.949 0 C-N-CA 124.66 -0.975 . . . . 0.0 112.554 0.055 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.98 32.45 9.88 Favored Glycine 0 C--N 1.341 0.859 0 O-C-N 123.621 0.576 . . . . 0.0 112.899 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.403 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -144.34 78.9 13.14 Favored Pre-proline 0 CA--C 1.546 0.817 0 C-N-CA 122.245 0.218 . . . . 0.0 111.313 179.776 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.594 ' O ' HG23 ' A' ' 12' ' ' VAL . 59.2 Cg_endo -90.02 -26.5 4.46 Favored 'Cis proline' 0 C--N 1.369 1.634 0 C-N-CA 124.74 -0.942 . . . . 0.0 113.668 -0.306 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.85 152.78 20.62 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.972 -179.362 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -155.47 -171.84 22.44 Favored Glycine 0 C--N 1.338 0.647 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.589 179.502 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.505 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -127.22 145.33 50.81 Favored 'General case' 0 C--O 1.235 0.316 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 179.553 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 51.6 m -89.22 111.93 22.84 Favored 'General case' 0 C--O 1.24 0.565 0 O-C-N 123.481 0.488 . . . . 0.0 111.627 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' TYR . . . . . 0.435 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.5 m-85 -125.72 159.76 31.48 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.523 179.423 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.576 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.6 t80 -93.35 136.03 34.01 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.005 -179.83 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.0 mt . . . . . 0 C--O 1.251 1.148 0 CA-C-O 118.502 -0.761 . . . . 0.0 110.891 179.745 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.4 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.1 p . . . . . 0 C--O 1.235 0.314 0 CA-C-O 120.497 0.189 . . . . 0.0 111.003 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.537 ' HB2' ' OE1' ' A' ' 8' ' ' GLU . . . -91.83 150.48 21.05 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.676 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.9 p90 -98.7 171.88 7.83 Favored 'General case' 0 CA--C 1.536 0.44 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.93 179.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.578 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.0 tt0 -59.98 128.63 37.82 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.352 0.661 . . . . 0.0 112.381 -179.312 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.25 -20.89 27.62 Favored Glycine 0 C--N 1.338 0.68 0 CA-C-N 115.688 -0.687 . . . . 0.0 114.421 178.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.537 ' OE1' ' HB2' ' A' ' 4' ' ' ALA . 6.5 pt-20 -107.29 177.47 4.83 Favored 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 117.444 0.622 . . . . 0.0 111.813 -179.289 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.7 m -91.42 144.9 25.1 Favored 'General case' 0 C--N 1.344 0.337 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.063 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.9 p -133.61 128.45 35.17 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.974 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.07 120.08 39.3 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.754 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.598 HG23 ' O ' ' A' ' 30' ' ' PRO . 28.0 m -72.28 10.38 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 113.023 0.749 . . . . 0.0 113.023 -178.776 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.402 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 1.6 tp-100 -104.12 -29.69 10.7 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.661 -179.358 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.402 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.48 -26.63 0.28 Allowed 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -178.791 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -125.32 87.79 55.1 Favored Pre-proline 0 CA--C 1.546 0.803 0 N-CA-C 111.652 0.242 . . . . 0.0 111.652 -178.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.4 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.7 Cg_endo -77.66 175.4 11.29 Favored 'Trans proline' 0 C--N 1.369 1.632 0 C-N-CA 122.304 2.003 . . . . 0.0 112.706 179.444 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.669 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -88.46 161.06 17.24 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.848 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 72.0 m -79.91 108.6 9.56 Favored Pre-proline 0 CA--C 1.544 0.738 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.206 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.437 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.5 Cg_endo -83.43 177.63 6.28 Favored 'Trans proline' 0 C--N 1.371 1.753 0 C-N-CA 122.491 2.128 . . . . 0.0 112.933 179.262 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.07 -40.01 2.57 Favored Glycine 0 C--N 1.339 0.727 0 C-N-CA 121.386 -0.435 . . . . 0.0 112.969 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.9 mt -88.83 -38.64 14.44 Favored 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 122.488 0.315 . . . . 0.0 111.466 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.19 51.26 0.21 Allowed Glycine 0 C--N 1.339 0.721 0 O-C-N 123.481 0.488 . . . . 0.0 112.539 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.459 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.6 mt -114.58 149.19 36.92 Favored 'General case' 0 C--O 1.235 0.308 0 O-C-N 123.65 0.265 . . . . 0.0 110.881 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t -138.85 154.34 48.41 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.201 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.669 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 68.3 m -97.0 123.23 40.66 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.659 179.514 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 12.7 mt -125.92 122.63 24.46 Favored Pre-proline 0 CA--C 1.545 0.768 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.26 -179.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.417 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.51 -41.08 1.03 Allowed 'Cis proline' 0 C--N 1.375 1.923 0 C-N-CA 124.664 -0.973 . . . . 0.0 112.641 0.072 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.78 31.84 9.73 Favored Glycine 0 C--N 1.341 0.847 0 O-C-N 123.548 0.53 . . . . 0.0 113.043 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.417 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.8 p30 -145.42 80.12 11.08 Favored Pre-proline 0 CA--C 1.547 0.841 0 C-N-CA 122.131 0.173 . . . . 0.0 111.229 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.598 ' O ' HG23 ' A' ' 12' ' ' VAL . 59.1 Cg_endo -89.65 -26.92 4.33 Favored 'Cis proline' 0 C--N 1.369 1.636 0 C-N-CA 124.676 -0.968 . . . . 0.0 113.681 -0.321 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -90.97 152.45 20.69 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.912 -179.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.44 -174.48 24.54 Favored Glycine 0 C--N 1.338 0.652 0 CA-C-N 115.442 -0.799 . . . . 0.0 112.634 179.593 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.484 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -123.79 143.93 50.01 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.561 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.6 m -88.08 110.23 20.48 Favored 'General case' 0 C--O 1.238 0.468 0 O-C-N 123.477 0.485 . . . . 0.0 111.588 -179.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' TYR . . . . . 0.459 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 33.0 m-85 -125.2 158.78 33.15 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 115.178 -0.919 . . . . 0.0 110.65 179.586 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.578 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.8 t80 -93.02 136.47 33.25 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.912 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.2 mt . . . . . 0 C--O 1.251 1.181 0 CA-C-O 118.478 -0.772 . . . . 0.0 110.878 179.754 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.409 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.1 p . . . . . 0 C--O 1.234 0.289 0 CA-C-O 120.468 0.175 . . . . 0.0 110.864 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.28 152.8 18.95 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.828 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . 0.433 ' O ' ' HG2' ' A' ' 8' ' ' GLU . 14.2 p90 -97.64 174.99 6.36 Favored 'General case' 0 CA--C 1.537 0.464 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.615 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.572 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.4 tt0 -65.23 130.99 45.35 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 123.095 0.558 . . . . 0.0 112.362 -179.287 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 100.08 12.85 38.34 Favored Glycine 0 C--N 1.339 0.723 0 CA-C-N 115.628 -0.714 . . . . 0.0 114.661 178.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.433 ' HG2' ' O ' ' A' ' 5' ' ' PHE . 8.8 pt-20 -136.87 175.96 9.14 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 117.592 0.696 . . . . 0.0 111.455 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 53.0 m -90.85 138.39 31.63 Favored 'General case' 0 C--N 1.343 0.299 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.132 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 p -131.52 128.18 38.78 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.837 -179.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -97.07 118.86 34.42 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.02 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.6 HG21 ' O ' ' A' ' 30' ' ' PRO . 26.8 m -72.45 12.74 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.86 -178.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 5.9 tp60 -106.46 -31.02 8.73 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.518 -179.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.7 p90 -146.87 -27.22 0.4 Allowed 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 112.81 0.67 . . . . 0.0 112.81 -178.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -126.45 88.37 54.48 Favored Pre-proline 0 CA--C 1.545 0.766 0 N-CA-C 111.607 0.225 . . . . 0.0 111.607 -178.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.409 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 62.3 Cg_endo -78.16 177.86 8.27 Favored 'Trans proline' 0 C--N 1.37 1.681 0 C-N-CA 122.348 2.032 . . . . 0.0 112.732 179.366 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.697 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.7 t -88.91 161.15 16.82 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.904 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 75.5 m -79.96 108.49 9.33 Favored Pre-proline 0 CA--C 1.545 0.758 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.87 -179.383 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.438 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 75.7 Cg_endo -83.07 177.52 6.6 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.485 2.123 . . . . 0.0 112.929 179.423 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.81 -40.11 2.53 Favored Glycine 0 C--N 1.34 0.759 0 C-N-CA 121.392 -0.432 . . . . 0.0 112.969 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.86 -39.18 13.22 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 122.408 0.283 . . . . 0.0 111.427 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.01 52.33 0.19 Allowed Glycine 0 C--N 1.339 0.709 0 O-C-N 123.467 0.479 . . . . 0.0 112.497 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.457 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.9 mt -115.74 149.79 37.9 Favored 'General case' 0 C--O 1.235 0.319 0 O-C-N 123.584 0.226 . . . . 0.0 110.86 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.422 ' O ' ' HA ' ' A' ' 34' ' ' CYS . 8.8 t -139.36 155.34 47.73 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.353 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.697 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 68.1 m -98.66 118.8 36.2 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.548 179.53 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.5 mt -129.1 126.55 23.13 Favored Pre-proline 0 CA--C 1.544 0.736 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.433 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.477 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 38.3 Cg_endo -68.69 -42.5 0.7 Allowed 'Cis proline' 0 C--N 1.376 2.005 0 C-N-CA 124.597 -1.001 . . . . 0.0 113.453 -0.208 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 82.29 35.56 20.2 Favored Glycine 0 C--N 1.344 1.013 0 O-C-N 123.349 0.406 . . . . 0.0 113.524 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.477 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.8 p30 -148.09 80.81 8.5 Favored Pre-proline 0 CA--C 1.547 0.852 0 CA-C-N 116.653 0.226 . . . . 0.0 111.352 179.744 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.6 ' O ' HG21 ' A' ' 12' ' ' VAL . 58.3 Cg_endo -87.25 -27.73 5.04 Favored 'Cis proline' 0 C--N 1.37 1.684 0 C-N-CA 124.516 -1.035 . . . . 0.0 113.353 -0.246 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -88.73 147.98 24.21 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.675 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -150.2 -174.27 21.24 Favored Glycine 0 C--N 1.335 0.526 0 CA-C-N 115.624 -0.716 . . . . 0.0 112.674 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.493 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.3 OUTLIER -127.22 143.38 51.26 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.321 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.422 ' HA ' ' O ' ' A' ' 24' ' ' THR . 55.6 m -87.58 114.17 23.94 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-O 121.095 0.474 . . . . 0.0 111.962 -179.433 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' TYR . . . . . 0.457 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 43.8 m-85 -126.7 160.22 31.43 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 114.988 -1.006 . . . . 0.0 110.429 179.274 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.572 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.5 t80 -94.07 134.33 36.61 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.979 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.112 -0.947 . . . . 0.0 110.833 179.779 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.1 p . . . . . 0 C--O 1.235 0.315 0 CA-C-O 120.513 0.196 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.537 ' HB3' ' OE1' ' A' ' 8' ' ' GLU . . . -92.8 151.94 19.73 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.664 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 17.1 p90 -99.05 173.12 6.98 Favored 'General case' 0 CA--C 1.537 0.468 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.839 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.57 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 14.0 tt0 -60.87 130.91 48.83 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.308 0.643 . . . . 0.0 112.284 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 107.62 -25.33 21.54 Favored Glycine 0 C--N 1.337 0.618 0 CA-C-N 115.657 -0.702 . . . . 0.0 114.217 178.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.537 ' OE1' ' HB3' ' A' ' 4' ' ' ALA . 5.4 pt-20 -103.72 178.75 4.47 Favored 'General case' 0 CA--C 1.541 0.608 0 CA-C-N 117.251 0.525 . . . . 0.0 111.833 -179.145 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 51.3 m -93.34 151.1 19.99 Favored 'General case' 0 C--N 1.344 0.362 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.163 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.1 p -139.77 132.2 28.54 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.843 -179.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -99.78 118.42 36.23 Favored 'General case' 0 C--O 1.236 0.387 0 O-C-N 123.635 0.584 . . . . 0.0 110.657 179.366 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.586 HG22 ' O ' ' A' ' 30' ' ' PRO . 30.6 m -71.05 10.45 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -178.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.499 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.1 OUTLIER -101.58 -34.86 9.34 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.204 -179.479 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.499 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.8 p90 -146.72 -27.35 0.4 Allowed 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -178.497 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.8 t80 -121.79 86.12 45.31 Favored Pre-proline 0 CA--C 1.545 0.77 0 N-CA-C 111.75 0.278 . . . . 0.0 111.75 -178.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -78.0 176.53 9.87 Favored 'Trans proline' 0 C--N 1.369 1.607 0 C-N-CA 122.251 1.967 . . . . 0.0 112.671 179.356 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.7 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 4.6 t -86.45 162.14 18.27 Favored 'General case' 0 N--CA 1.468 0.452 0 O-C-N 123.203 0.314 . . . . 0.0 110.824 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.7 m -79.94 108.64 9.68 Favored Pre-proline 0 CA--C 1.545 0.756 0 N-CA-C 112.06 0.393 . . . . 0.0 112.06 -179.224 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.432 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 74.7 Cg_endo -83.02 177.67 6.52 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.467 2.111 . . . . 0.0 112.927 179.363 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.49 -41.17 2.24 Favored Glycine 0 C--N 1.339 0.731 0 C-N-CA 121.352 -0.451 . . . . 0.0 112.909 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.27 -39.02 13.78 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 122.464 0.306 . . . . 0.0 111.402 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.408 ' O ' ' HA ' ' A' ' 36' ' ' TYR . . . 124.02 55.05 0.19 Allowed Glycine 0 C--N 1.338 0.69 0 O-C-N 123.509 0.506 . . . . 0.0 112.535 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.469 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 25.4 mt -119.73 147.96 43.97 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-O 120.571 0.224 . . . . 0.0 110.897 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -140.1 155.36 47.04 Favored 'General case' 0 CA--C 1.536 0.434 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.358 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.7 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 91.0 m -98.3 117.42 32.66 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.512 179.446 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.8 mt -127.2 125.82 24.13 Favored Pre-proline 0 CA--C 1.544 0.743 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.348 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.458 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 41.8 Cg_endo -69.18 -41.9 0.82 Allowed 'Cis proline' 0 C--N 1.376 1.985 0 C-N-CA 124.569 -1.013 . . . . 0.0 113.509 -0.038 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 84.42 38.2 10.1 Favored Glycine 0 C--N 1.344 0.991 0 O-C-N 123.376 0.422 . . . . 0.0 113.471 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.458 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.9 p30 -150.92 81.05 6.44 Favored Pre-proline 0 CA--C 1.547 0.859 0 C-N-CA 122.279 0.231 . . . . 0.0 111.232 179.54 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.586 ' O ' HG22 ' A' ' 12' ' ' VAL . 57.0 Cg_endo -87.25 -28.25 4.59 Favored 'Cis proline' 0 C--N 1.37 1.663 0 C-N-CA 124.584 -1.007 . . . . 0.0 113.35 -0.312 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -87.15 148.7 25.08 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.637 -179.608 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.91 158.58 28.93 Favored Glycine 0 C--N 1.335 0.513 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.13 179.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.404 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.2 OUTLIER -97.2 144.15 27.29 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 110.285 -0.265 . . . . 0.0 110.285 179.868 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 19.5 m -88.07 110.94 21.02 Favored 'General case' 0 C--O 1.239 0.528 0 O-C-N 123.428 0.455 . . . . 0.0 111.584 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' TYR . . . . . 0.469 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 45.7 m-85 -123.55 161.04 25.73 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.703 179.569 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.57 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.1 t80 -94.15 136.21 34.68 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.872 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.2 mt . . . . . 0 C--O 1.249 1.029 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.847 179.75 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.411 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.6 p . . . . . 0 C--O 1.236 0.344 0 CA-C-O 120.459 0.171 . . . . 0.0 110.923 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.517 ' HB1' ' OE1' ' A' ' 8' ' ' GLU . . . -91.8 152.11 20.28 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.811 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 18.7 p90 -98.0 174.03 6.76 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.705 179.083 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.574 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.1 tt0 -64.16 130.1 42.6 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 123.186 0.594 . . . . 0.0 112.326 -179.291 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 102.19 9.61 41.51 Favored Glycine 0 C--N 1.339 0.71 0 CA-C-N 115.68 -0.691 . . . . 0.0 114.702 178.659 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.517 ' OE1' ' HB1' ' A' ' 4' ' ' ALA . 6.0 pt-20 -135.16 177.53 7.74 Favored 'General case' 0 CA--C 1.541 0.596 0 CA-C-N 117.707 0.754 . . . . 0.0 111.545 179.729 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 15.9 t -90.71 141.75 28.47 Favored 'General case' 0 C--N 1.343 0.317 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.941 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.5 p -133.66 128.91 36.03 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.894 -179.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.16 119.92 39.08 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.912 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.593 HG23 ' O ' ' A' ' 30' ' ' PRO . 28.8 m -72.68 11.85 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 N-CA-C 112.926 0.713 . . . . 0.0 112.926 -178.839 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 5.7 tp60 -105.41 -29.91 9.93 Favored 'General case' 0 CA--C 1.535 0.372 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.6 -179.369 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -148.99 -26.57 0.3 Allowed 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 112.789 0.663 . . . . 0.0 112.789 -178.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.2 t80 -125.65 87.62 55.54 Favored Pre-proline 0 CA--C 1.545 0.76 0 N-CA-C 111.67 0.248 . . . . 0.0 111.67 -178.754 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.411 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.5 Cg_endo -77.86 177.47 8.76 Favored 'Trans proline' 0 C--N 1.369 1.648 0 C-N-CA 122.267 1.978 . . . . 0.0 112.796 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.677 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.9 t -89.92 160.01 16.65 Favored 'General case' 0 N--CA 1.467 0.387 0 O-C-N 123.233 0.333 . . . . 0.0 110.837 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 74.8 m -79.94 108.55 9.47 Favored Pre-proline 0 CA--C 1.545 0.763 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.953 -179.342 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.2 Cg_endo -83.28 177.43 6.52 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.49 2.127 . . . . 0.0 112.911 179.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.33 -40.24 2.49 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 121.373 -0.441 . . . . 0.0 113.003 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.34 -38.64 14.0 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 122.439 0.296 . . . . 0.0 111.508 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.58 50.46 0.21 Allowed Glycine 0 C--N 1.339 0.728 0 O-C-N 123.491 0.494 . . . . 0.0 112.495 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.434 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.2 mt -113.24 150.12 32.83 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 122.294 0.238 . . . . 0.0 110.92 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -139.54 154.45 47.66 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.392 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.677 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 60.0 m -97.45 123.2 41.22 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.536 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.8 mt -126.58 123.45 23.97 Favored Pre-proline 0 CA--C 1.545 0.758 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.322 -179.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.403 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.85 -40.76 1.1 Allowed 'Cis proline' 0 C--N 1.375 1.965 0 C-N-CA 124.646 -0.981 . . . . 0.0 112.561 0.062 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.81 32.6 9.86 Favored Glycine 0 C--N 1.342 0.885 0 CA-C-N 116.017 -0.538 . . . . 0.0 112.887 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.403 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.11 78.7 13.58 Favored Pre-proline 0 CA--C 1.546 0.821 0 C-N-CA 122.156 0.182 . . . . 0.0 111.321 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.593 ' O ' HG23 ' A' ' 12' ' ' VAL . 59.3 Cg_endo -90.18 -26.4 4.45 Favored 'Cis proline' 0 C--N 1.369 1.636 0 C-N-CA 124.686 -0.964 . . . . 0.0 113.676 -0.276 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.6 152.63 20.81 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 115.96 -0.564 . . . . 0.0 112.011 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -155.33 -171.72 22.22 Favored Glycine 0 C--N 1.337 0.619 0 CA-C-N 115.449 -0.796 . . . . 0.0 112.57 179.561 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.507 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -127.25 145.26 50.84 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.55 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 51.3 m -89.06 111.89 22.72 Favored 'General case' 0 C--O 1.24 0.554 0 CA-C-O 121.076 0.465 . . . . 0.0 111.675 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' TYR . . . . . 0.434 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.8 m-85 -125.94 159.86 31.5 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.527 179.43 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.574 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 14.5 t80 -93.32 136.06 33.94 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.988 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.4 mt . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.151 -0.928 . . . . 0.0 110.943 179.693 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.0 p . . . . . 0 C--O 1.236 0.369 0 CA-C-O 120.43 0.157 . . . . 0.0 111.01 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.534 ' HB1' ' OE1' ' A' ' 8' ' ' GLU . . . -91.72 151.14 20.78 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.752 -179.81 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 17.0 p90 -98.96 171.95 7.72 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.842 179.351 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.579 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.2 tt0 -60.45 129.55 42.19 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 123.38 0.672 . . . . 0.0 112.395 -179.337 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.18 -19.93 31.47 Favored Glycine 0 C--N 1.338 0.687 0 CA-C-N 115.659 -0.701 . . . . 0.0 114.468 178.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.534 ' OE1' ' HB1' ' A' ' 4' ' ' ALA . 6.2 pt-20 -108.04 177.54 4.78 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 117.464 0.632 . . . . 0.0 111.817 -179.303 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 41.0 p -91.56 144.45 25.53 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.078 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.1 p -133.1 128.7 36.72 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.946 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -99.91 120.19 39.4 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.764 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.599 HG22 ' O ' ' A' ' 30' ' ' PRO . 29.5 m -72.25 10.45 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 N-CA-C 113.051 0.76 . . . . 0.0 113.051 -178.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.404 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 1.6 tp-100 -104.43 -29.51 10.67 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.693 -179.4 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.404 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.7 -26.55 0.27 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -178.793 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -125.12 87.51 55.4 Favored Pre-proline 0 CA--C 1.546 0.793 0 N-CA-C 111.694 0.257 . . . . 0.0 111.694 -178.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -77.82 175.68 10.92 Favored 'Trans proline' 0 C--N 1.369 1.654 0 C-N-CA 122.28 1.987 . . . . 0.0 112.704 179.466 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.685 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.8 t -88.68 160.78 17.19 Favored 'General case' 0 N--CA 1.468 0.467 0 O-C-N 123.221 0.325 . . . . 0.0 110.793 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.9 m -79.99 108.44 9.25 Favored Pre-proline 0 CA--C 1.545 0.777 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.6 Cg_endo -83.54 177.59 6.23 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.453 2.102 . . . . 0.0 112.93 179.286 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.89 -40.44 2.44 Favored Glycine 0 C--N 1.34 0.767 0 C-N-CA 121.324 -0.465 . . . . 0.0 112.951 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.9 mt -88.57 -38.63 14.74 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 122.418 0.287 . . . . 0.0 111.551 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.75 51.76 0.2 Allowed Glycine 0 C--N 1.339 0.723 0 O-C-N 123.461 0.475 . . . . 0.0 112.565 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.465 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 22.7 mt -115.76 149.26 38.77 Favored 'General case' 0 C--O 1.235 0.3 0 O-C-N 123.607 0.239 . . . . 0.0 110.874 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t -139.1 154.4 48.14 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.246 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.685 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 66.4 m -97.22 123.26 40.95 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.645 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 11.3 mt -127.16 122.94 23.24 Favored Pre-proline 0 CA--C 1.546 0.789 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.315 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -75.87 -41.01 1.03 Allowed 'Cis proline' 0 C--N 1.374 1.893 0 C-N-CA 124.696 -0.96 . . . . 0.0 112.64 0.112 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.18 32.8 9.32 Favored Glycine 0 C--N 1.343 0.931 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.93 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -144.49 79.08 12.81 Favored Pre-proline 0 CA--C 1.547 0.842 0 C-N-CA 122.215 0.206 . . . . 0.0 111.322 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.599 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.2 Cg_endo -89.88 -26.59 4.48 Favored 'Cis proline' 0 C--N 1.37 1.682 0 C-N-CA 124.667 -0.972 . . . . 0.0 113.68 -0.284 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.43 152.65 20.87 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.941 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.27 -173.95 23.82 Favored Glycine 0 C--N 1.337 0.632 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.649 179.577 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.463 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.6 OUTLIER -124.54 143.66 50.55 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.563 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.3 m -88.11 110.41 20.63 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-O 121.085 0.469 . . . . 0.0 111.607 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' TYR . . . . . 0.465 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 34.2 m-85 -124.57 158.95 31.77 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.681 179.549 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.579 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 11.9 t80 -93.33 135.93 34.08 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.964 -179.878 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.7 mt . . . . . 0 C--O 1.249 1.05 0 CA-C-O 118.115 -0.945 . . . . 0.0 110.901 179.765 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.409 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.4 p . . . . . 0 C--O 1.235 0.336 0 CA-C-O 120.474 0.178 . . . . 0.0 110.805 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.521 ' HB3' ' OE1' ' A' ' 8' ' ' GLU . . . -91.43 151.58 20.75 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.763 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 18.2 p90 -98.27 173.6 6.91 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.688 179.263 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.573 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.0 tt0 -63.23 129.93 42.41 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.185 0.594 . . . . 0.0 112.364 -179.299 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 102.37 5.37 49.15 Favored Glycine 0 C--N 1.339 0.717 0 CA-C-N 115.673 -0.694 . . . . 0.0 114.725 178.606 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.521 ' OE1' ' HB3' ' A' ' 4' ' ' ALA . 5.0 pt-20 -131.72 177.86 7.19 Favored 'General case' 0 CA--C 1.539 0.538 0 CA-C-N 117.678 0.739 . . . . 0.0 111.599 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' SER . . . . . 0.429 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 43.1 p -90.24 146.49 24.2 Favored 'General case' 0 C--N 1.344 0.331 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.301 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.4 p -137.42 128.08 26.95 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.835 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -97.68 118.99 35.44 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.839 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.575 HG21 ' O ' ' A' ' 30' ' ' PRO . 22.6 m -71.25 9.61 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 N-CA-C 113.239 0.829 . . . . 0.0 113.239 -178.826 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.503 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.1 OUTLIER -101.28 -34.67 9.55 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.222 -179.548 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.503 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.9 p90 -147.33 -27.01 0.38 Allowed 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 -178.484 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 6.5 t80 -120.83 85.07 39.12 Favored Pre-proline 0 CA--C 1.544 0.732 0 N-CA-C 111.705 0.261 . . . . 0.0 111.705 -178.712 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.409 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.2 Cg_endo -77.95 177.96 8.17 Favored 'Trans proline' 0 C--N 1.369 1.619 0 C-N-CA 122.241 1.961 . . . . 0.0 112.704 179.461 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.687 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -89.17 160.47 16.97 Favored 'General case' 0 N--CA 1.468 0.437 0 O-C-N 123.157 0.285 . . . . 0.0 110.921 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 75.8 m -79.93 108.41 9.11 Favored Pre-proline 0 CA--C 1.545 0.772 0 N-CA-C 111.976 0.361 . . . . 0.0 111.976 -179.394 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.44 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 79.1 Cg_endo -83.07 177.47 6.63 Favored 'Trans proline' 0 C--N 1.371 1.732 0 C-N-CA 122.445 2.097 . . . . 0.0 113.002 179.411 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.01 -39.64 2.68 Favored Glycine 0 C--N 1.34 0.791 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.986 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.8 mt -89.14 -38.73 14.09 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 122.493 0.317 . . . . 0.0 111.503 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.15 50.07 0.22 Allowed Glycine 0 C--N 1.339 0.748 0 O-C-N 123.448 0.468 . . . . 0.0 112.474 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.441 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 20.6 mt -113.51 150.02 33.5 Favored 'General case' 0 C--O 1.235 0.315 0 O-C-N 123.628 0.252 . . . . 0.0 110.872 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -138.99 154.18 48.24 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.232 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.687 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 59.5 m -97.12 123.06 40.78 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.659 179.429 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 11.3 mt -127.34 123.24 23.19 Favored Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.268 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.421 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.3 Cg_exo -75.64 -40.87 1.07 Allowed 'Cis proline' 0 C--N 1.375 1.947 0 C-N-CA 124.636 -0.985 . . . . 0.0 112.507 0.094 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.04 33.62 8.79 Favored Glycine 0 C--N 1.342 0.877 0 O-C-N 123.596 0.56 . . . . 0.0 113.227 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.421 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.9 p30 -146.36 80.28 10.13 Favored Pre-proline 0 CA--C 1.547 0.855 0 CA-C-N 116.727 0.263 . . . . 0.0 111.556 179.575 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.575 ' O ' HG21 ' A' ' 12' ' ' VAL . 58.7 Cg_endo -89.27 -26.9 4.59 Favored 'Cis proline' 0 C--N 1.37 1.675 0 C-N-CA 124.729 -0.946 . . . . 0.0 113.463 -0.345 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -86.94 149.92 24.44 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.578 -179.634 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.429 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -151.09 -178.82 26.28 Favored Glycine 0 C--N 1.335 0.509 0 CA-C-N 115.581 -0.736 . . . . 0.0 112.394 179.425 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.469 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -124.62 141.6 51.98 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 179.282 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 54.1 m -87.3 112.2 21.82 Favored 'General case' 0 C--O 1.24 0.575 0 O-C-N 123.48 0.488 . . . . 0.0 111.792 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' TYR . . . . . 0.441 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 35.0 m-85 -126.05 159.14 33.55 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.081 -0.963 . . . . 0.0 110.552 179.304 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.573 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.8 t80 -93.23 135.01 34.85 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.937 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.0 mt . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.11 -0.948 . . . . 0.0 110.898 179.776 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.414 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.2 p . . . . . 0 C--O 1.236 0.35 0 CA-C-O 120.404 0.145 . . . . 0.0 110.981 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.6 147.97 22.45 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 112.138 0.422 . . . . 0.0 112.138 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . 0.476 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.25 177.4 7.51 Favored 'General case' 0 CA--C 1.538 0.491 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.463 178.813 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.55 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.4 tt0 -74.46 136.14 42.29 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 122.844 0.458 . . . . 0.0 111.695 -179.743 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.87 9.49 58.44 Favored Glycine 0 C--N 1.338 0.671 0 CA-C-N 115.633 -0.712 . . . . 0.0 114.258 179.017 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.476 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.2 pt-20 -132.83 177.66 7.47 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 117.321 0.561 . . . . 0.0 111.376 179.8 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 42.8 p -88.16 147.28 24.97 Favored 'General case' 0 C--N 1.345 0.372 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.603 -179.409 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.5 p -138.7 128.02 24.35 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.684 -179.743 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.35 119.07 37.87 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.896 179.678 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.597 HG23 ' O ' ' A' ' 30' ' ' PRO . 27.7 m -72.11 9.39 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 -178.741 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.5 tp-100 -102.65 -29.91 11.25 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 116.625 -0.261 . . . . 0.0 111.685 -179.361 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -149.28 -26.82 0.28 Allowed 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 -178.715 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 12.4 t80 -125.32 87.84 55.03 Favored Pre-proline 0 CA--C 1.546 0.803 0 N-CA-C 111.596 0.221 . . . . 0.0 111.596 -178.649 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.414 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.2 Cg_endo -77.05 177.93 8.28 Favored 'Trans proline' 0 C--N 1.371 1.715 0 C-N-CA 122.29 1.993 . . . . 0.0 112.704 179.484 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.695 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.5 t -90.06 159.94 16.58 Favored 'General case' 0 N--CA 1.468 0.468 0 O-C-N 123.265 0.353 . . . . 0.0 110.923 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.414 ' O ' HD13 ' A' ' 23' ' ' LEU . 74.7 m -79.87 108.06 8.22 Favored Pre-proline 0 CA--C 1.546 0.799 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -179.473 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.465 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 80.2 Cg_endo -84.02 177.91 5.7 Favored 'Trans proline' 0 C--N 1.372 1.778 0 C-N-CA 122.493 2.128 . . . . 0.0 112.955 179.453 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.64 -39.56 2.72 Favored Glycine 0 C--N 1.34 0.752 0 C-N-CA 121.371 -0.442 . . . . 0.0 112.953 179.76 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.6 mp -89.79 -37.07 14.76 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 122.45 0.3 . . . . 0.0 111.464 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.43 52.04 0.22 Allowed Glycine 0 C--N 1.338 0.687 0 O-C-N 123.455 0.472 . . . . 0.0 112.357 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.415 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 19.0 mt -113.62 149.56 34.39 Favored 'General case' 0 C--O 1.234 0.265 0 O-C-N 123.624 0.25 . . . . 0.0 110.972 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.2 t -138.94 152.08 47.42 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.315 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.695 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 55.7 m -96.76 122.69 39.99 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.608 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.9 mt -127.13 122.88 23.25 Favored Pre-proline 0 CA--C 1.545 0.772 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.328 -179.753 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.402 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.69 -41.28 0.99 Allowed 'Cis proline' 0 C--N 1.375 1.933 0 C-N-CA 124.651 -0.979 . . . . 0.0 112.593 0.04 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.7 31.68 9.97 Favored Glycine 0 C--N 1.342 0.905 0 O-C-N 123.582 0.551 . . . . 0.0 113.044 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.402 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.8 p30 -145.12 80.8 10.92 Favored Pre-proline 0 CA--C 1.547 0.832 0 CA-C-N 116.569 0.184 . . . . 0.0 111.258 179.705 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.597 ' O ' HG23 ' A' ' 12' ' ' VAL . 59.8 Cg_endo -89.31 -26.57 4.86 Favored 'Cis proline' 0 C--N 1.369 1.648 0 C-N-CA 124.654 -0.978 . . . . 0.0 113.609 -0.336 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -92.29 153.96 18.91 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.891 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -155.97 -172.87 23.91 Favored Glycine 0 C--N 1.337 0.625 0 CA-C-N 115.482 -0.781 . . . . 0.0 112.608 179.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.486 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -126.51 144.95 50.7 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.576 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 60.8 m -89.61 113.92 25.44 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-O 121.072 0.463 . . . . 0.0 111.765 -179.634 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' TYR . . . . . 0.415 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 35.3 m-85 -125.58 157.45 37.1 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.471 179.327 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.55 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 19.4 t80 -92.5 133.65 35.73 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.985 -179.835 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt . . . . . 0 C--O 1.252 1.192 0 CA-C-O 118.507 -0.758 . . . . 0.0 110.898 179.787 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.414 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.1 p . . . . . 0 C--O 1.235 0.311 0 CA-C-O 120.409 0.147 . . . . 0.0 110.971 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.54 147.84 22.57 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 116.235 -0.439 . . . . 0.0 112.184 -179.696 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . 0.479 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.15 177.62 7.47 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.478 178.779 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.543 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.1 tt0 -74.64 135.92 41.95 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 122.905 0.482 . . . . 0.0 111.712 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.71 10.17 58.04 Favored Glycine 0 C--N 1.339 0.716 0 CA-C-N 115.596 -0.729 . . . . 0.0 114.292 179.027 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.479 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.3 pt-20 -132.99 177.55 7.57 Favored 'General case' 0 CA--C 1.54 0.578 0 CA-C-N 117.342 0.571 . . . . 0.0 111.403 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.8 m -88.33 146.42 25.3 Favored 'General case' 0 C--N 1.344 0.346 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.567 -179.478 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.5 p -138.26 128.57 26.03 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.689 -179.759 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -100.76 119.27 38.38 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.87 179.749 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.0 m -72.12 9.39 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 N-CA-C 113.063 0.764 . . . . 0.0 113.063 -178.785 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.6 tp-100 -102.72 -30.04 11.14 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.583 -0.28 . . . . 0.0 111.661 -179.331 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -149.0 -26.83 0.29 Allowed 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 112.864 0.69 . . . . 0.0 112.864 -178.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 12.5 t80 -125.28 87.77 55.12 Favored Pre-proline 0 CA--C 1.546 0.818 0 N-CA-C 111.63 0.233 . . . . 0.0 111.63 -178.639 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.414 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.2 Cg_endo -77.11 177.67 8.58 Favored 'Trans proline' 0 C--N 1.37 1.671 0 C-N-CA 122.269 1.979 . . . . 0.0 112.682 179.527 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.693 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.3 t -89.85 160.05 16.67 Favored 'General case' 0 N--CA 1.467 0.397 0 O-C-N 123.234 0.334 . . . . 0.0 110.947 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.421 ' O ' HD11 ' A' ' 23' ' ' LEU . 74.2 m -79.85 108.08 8.26 Favored Pre-proline 0 CA--C 1.545 0.782 0 O-C-N 123.247 0.342 . . . . 0.0 111.916 -179.47 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 79.6 Cg_endo -83.91 177.92 5.76 Favored 'Trans proline' 0 C--N 1.371 1.728 0 C-N-CA 122.554 2.169 . . . . 0.0 112.972 179.42 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.54 -38.97 2.9 Favored Glycine 0 C--N 1.34 0.773 0 C-N-CA 121.374 -0.441 . . . . 0.0 113.007 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.1 mt -89.83 -36.97 14.79 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 122.461 0.304 . . . . 0.0 111.469 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.06 52.08 0.23 Allowed Glycine 0 C--N 1.339 0.713 0 O-C-N 123.514 0.509 . . . . 0.0 112.335 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.421 HD11 ' O ' ' A' ' 18' ' ' CYS . 18.9 mt -114.22 149.21 36.14 Favored 'General case' 0 C--O 1.235 0.321 0 O-C-N 123.671 0.277 . . . . 0.0 110.965 -179.687 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.1 t -138.83 151.93 47.42 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.29 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.693 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 56.1 m -96.76 122.48 39.76 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.595 179.411 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.6 mt -127.21 123.09 23.25 Favored Pre-proline 0 CA--C 1.545 0.759 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.372 -179.76 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.401 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -76.0 -41.0 1.03 Allowed 'Cis proline' 0 C--N 1.374 1.914 0 C-N-CA 124.625 -0.99 . . . . 0.0 112.612 0.055 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.77 32.78 9.69 Favored Glycine 0 C--N 1.343 0.929 0 O-C-N 123.548 0.53 . . . . 0.0 112.945 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.401 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.37 79.42 12.73 Favored Pre-proline 0 CA--C 1.546 0.823 0 C-N-CA 122.213 0.205 . . . . 0.0 111.343 179.762 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.595 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.2 Cg_endo -89.73 -26.53 4.63 Favored 'Cis proline' 0 C--N 1.37 1.66 0 C-N-CA 124.722 -0.949 . . . . 0.0 113.58 -0.213 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -91.18 153.79 19.77 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.892 -179.363 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.34 -172.54 23.83 Favored Glycine 0 C--N 1.337 0.622 0 CA-C-N 115.518 -0.765 . . . . 0.0 112.646 179.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.495 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -126.7 145.44 50.59 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.601 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 59.3 m -90.01 114.09 25.89 Favored 'General case' 0 C--O 1.239 0.545 0 O-C-N 123.42 0.45 . . . . 0.0 111.779 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' TYR . . . . . 0.417 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 35.9 m-85 -125.39 157.33 37.06 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.103 -0.953 . . . . 0.0 110.419 179.326 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.543 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 17.5 t80 -92.58 133.41 35.99 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.003 -179.808 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.251 1.169 0 CA-C-O 118.507 -0.758 . . . . 0.0 110.907 179.835 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.5 p . . . . . 0 C--O 1.235 0.314 0 CA-C-O 120.477 0.179 . . . . 0.0 111.063 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.546 ' HB3' ' OE1' ' A' ' 8' ' ' GLU . . . -93.72 152.28 19.06 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.693 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -99.1 172.16 7.56 Favored 'General case' 0 CA--C 1.537 0.45 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.865 179.351 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.572 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.9 tt0 -60.63 129.81 43.39 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 123.36 0.664 . . . . 0.0 112.396 -179.29 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.3 -21.93 27.88 Favored Glycine 0 C--N 1.338 0.687 0 CA-C-N 115.639 -0.709 . . . . 0.0 114.383 178.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.546 ' OE1' ' HB3' ' A' ' 4' ' ' ALA . 6.6 pt-20 -105.61 177.42 4.86 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-N 117.458 0.629 . . . . 0.0 111.821 -179.303 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 15.7 t -92.55 142.63 27.19 Favored 'General case' 0 C--N 1.343 0.321 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.966 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.8 p -132.46 129.27 39.01 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.853 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -97.59 119.11 35.55 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.049 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.596 HG23 ' O ' ' A' ' 30' ' ' PRO . 27.2 m -71.71 9.12 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.856 -179.021 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.451 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 23.1 tt0 -100.14 -30.17 12.08 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.251 -179.387 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.451 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.9 p90 -153.4 -27.68 0.14 Allowed 'General case' 0 N--CA 1.476 0.826 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -178.544 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.5 t80 -119.63 85.25 32.35 Favored Pre-proline 0 CA--C 1.545 0.757 0 N-CA-C 111.503 0.186 . . . . 0.0 111.503 -178.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.405 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.3 Cg_endo -77.69 175.28 11.42 Favored 'Trans proline' 0 C--N 1.368 1.597 0 C-N-CA 122.212 1.941 . . . . 0.0 112.757 179.619 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.638 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.2 t -87.28 162.28 17.51 Favored 'General case' 0 N--CA 1.467 0.396 0 O-C-N 123.246 0.341 . . . . 0.0 110.944 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.9 m -79.92 108.58 9.52 Favored Pre-proline 0 CA--C 1.545 0.762 0 N-CA-C 111.907 0.336 . . . . 0.0 111.907 -179.328 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.436 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 74.7 Cg_endo -82.85 177.58 6.69 Favored 'Trans proline' 0 C--N 1.372 1.792 0 C-N-CA 122.453 2.102 . . . . 0.0 112.993 179.385 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.08 -40.04 2.55 Favored Glycine 0 C--N 1.339 0.735 0 C-N-CA 121.356 -0.449 . . . . 0.0 112.904 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -90.16 -39.49 12.81 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 122.446 0.298 . . . . 0.0 111.386 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.28 53.76 0.19 Allowed Glycine 0 C--N 1.339 0.75 0 O-C-N 123.516 0.51 . . . . 0.0 112.514 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.462 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 23.0 mt -117.3 149.24 40.79 Favored 'General case' 0 C--O 1.235 0.297 0 O-C-N 123.632 0.254 . . . . 0.0 110.962 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 t -139.58 156.97 46.56 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.276 -179.816 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.638 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 98.9 m -99.25 119.54 38.08 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.699 179.619 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.8 mt -129.79 126.12 22.45 Favored Pre-proline 0 CA--C 1.545 0.783 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.348 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.544 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 43.1 Cg_endo -69.81 -42.58 0.73 Allowed 'Cis proline' 0 C--N 1.375 1.956 0 C-N-CA 124.578 -1.009 . . . . 0.0 113.449 -0.22 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 82.1 39.34 11.58 Favored Glycine 0 C--N 1.345 1.03 0 O-C-N 123.358 0.411 . . . . 0.0 113.275 179.785 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.544 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -147.81 78.52 9.77 Favored Pre-proline 0 CA--C 1.548 0.87 0 C-N-CA 122.3 0.24 . . . . 0.0 111.402 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.596 ' O ' HG23 ' A' ' 12' ' ' VAL . 59.6 Cg_endo -87.83 -26.86 5.5 Favored 'Cis proline' 0 C--N 1.369 1.612 0 C-N-CA 124.571 -1.012 . . . . 0.0 113.355 -0.273 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -87.06 147.54 25.64 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.705 -179.591 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -149.54 -175.78 22.14 Favored Glycine 0 C--N 1.336 0.556 0 CA-C-N 115.612 -0.722 . . . . 0.0 112.712 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.495 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.8 OUTLIER -124.24 143.15 50.69 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.505 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.5 m -87.47 112.01 21.75 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-O 121.086 0.469 . . . . 0.0 111.778 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' TYR . . . . . 0.462 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 40.5 m-85 -125.81 159.87 31.31 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.605 179.458 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.572 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.4 t80 -93.74 135.15 35.33 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.94 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.5 mt . . . . . 0 C--O 1.251 1.136 0 CA-C-O 118.472 -0.775 . . . . 0.0 110.875 179.759 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.409 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 28.2 p . . . . . 0 C--O 1.235 0.339 0 CA-C-O 120.449 0.166 . . . . 0.0 111.03 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.3 147.72 22.85 Favored 'General case' 0 C--O 1.237 0.417 0 N-CA-C 112.176 0.435 . . . . 0.0 112.176 -179.621 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . 0.473 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.08 177.5 7.54 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 115.098 -0.955 . . . . 0.0 110.426 178.847 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.541 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.4 tt0 -74.85 135.89 41.56 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 122.875 0.47 . . . . 0.0 111.693 -179.698 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.44 10.91 57.72 Favored Glycine 0 C--N 1.339 0.725 0 CA-C-N 115.587 -0.733 . . . . 0.0 114.34 178.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.473 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.4 pt-20 -133.32 177.47 7.66 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 117.271 0.536 . . . . 0.0 111.392 179.821 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 43.1 p -88.04 145.65 25.87 Favored 'General case' 0 C--N 1.344 0.364 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.601 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.2 p -137.65 128.03 26.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.639 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.58 119.52 38.66 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.903 179.684 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.602 HG23 ' O ' ' A' ' 30' ' ' PRO . 28.6 m -72.03 8.9 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 N-CA-C 113.024 0.749 . . . . 0.0 113.024 -178.752 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.404 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 1.5 tp-100 -102.55 -29.86 11.31 Favored 'General case' 0 CA--C 1.535 0.388 0 N-CA-C 111.706 0.262 . . . . 0.0 111.706 -179.333 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.404 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.9 p90 -149.43 -26.74 0.28 Allowed 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -178.761 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.6 t80 -124.64 87.17 54.91 Favored Pre-proline 0 CA--C 1.547 0.829 0 N-CA-C 111.577 0.214 . . . . 0.0 111.577 -178.657 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -77.18 175.86 10.83 Favored 'Trans proline' 0 C--N 1.369 1.624 0 C-N-CA 122.293 1.995 . . . . 0.0 112.69 179.495 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.7 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.3 t -89.31 160.35 16.92 Favored 'General case' 0 N--CA 1.468 0.444 0 O-C-N 123.257 0.348 . . . . 0.0 110.886 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.443 ' O ' HD11 ' A' ' 23' ' ' LEU . 73.9 m -79.84 107.68 7.3 Favored Pre-proline 0 CA--C 1.545 0.777 0 O-C-N 123.286 0.367 . . . . 0.0 111.985 -179.561 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.472 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 81.5 Cg_endo -84.39 177.99 5.41 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.529 2.153 . . . . 0.0 112.984 179.41 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.66 -39.36 2.77 Favored Glycine 0 C--N 1.34 0.777 0 C-N-CA 121.41 -0.424 . . . . 0.0 113.033 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.6 mp -89.71 -38.05 14.14 Favored 'General case' 0 N--CA 1.467 0.423 0 C-N-CA 122.435 0.294 . . . . 0.0 111.489 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.65 52.55 0.19 Allowed Glycine 0 C--N 1.339 0.7 0 O-C-N 123.452 0.47 . . . . 0.0 112.422 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.443 HD11 ' O ' ' A' ' 18' ' ' CYS . 19.6 mt -115.3 148.56 39.08 Favored 'General case' 0 C--O 1.235 0.323 0 O-C-N 123.668 0.276 . . . . 0.0 110.846 -179.7 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.411 ' HG1' ' N ' ' A' ' 25' ' ' CYS . 10.2 t -138.53 151.69 47.57 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.374 -179.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.7 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 54.3 m -97.03 121.98 39.52 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.597 179.412 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.5 mt -127.4 123.36 23.18 Favored Pre-proline 0 CA--C 1.545 0.786 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.364 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -75.95 -41.06 1.02 Allowed 'Cis proline' 0 C--N 1.375 1.923 0 C-N-CA 124.652 -0.978 . . . . 0.0 112.598 0.067 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.55 32.71 9.95 Favored Glycine 0 C--N 1.343 0.947 0 O-C-N 123.55 0.531 . . . . 0.0 112.95 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -144.09 79.33 13.15 Favored Pre-proline 0 CA--C 1.546 0.822 0 C-N-CA 122.178 0.191 . . . . 0.0 111.291 179.722 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.602 ' O ' HG23 ' A' ' 12' ' ' VAL . 59.7 Cg_endo -89.86 -26.32 4.73 Favored 'Cis proline' 0 C--N 1.37 1.708 0 C-N-CA 124.671 -0.97 . . . . 0.0 113.685 -0.338 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -91.1 153.65 19.93 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.93 -179.406 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.17 -172.37 23.52 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-N 115.533 -0.758 . . . . 0.0 112.662 179.467 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.479 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.6 OUTLIER -126.99 145.78 50.58 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.567 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 61.3 m -89.98 113.47 25.14 Favored 'General case' 0 C--O 1.239 0.549 0 O-C-N 123.455 0.472 . . . . 0.0 111.739 -179.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' TYR . . . . . 0.424 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 34.7 m-85 -123.77 157.19 34.58 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.47 179.316 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.541 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.7 t80 -93.41 132.72 37.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.989 -179.765 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt . . . . . 0 C--O 1.251 1.181 0 CA-C-O 118.455 -0.783 . . . . 0.0 110.872 179.797 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.406 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 28.5 p . . . . . 0 C--O 1.236 0.353 0 CA-C-O 120.435 0.16 . . . . 0.0 111.043 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.84 147.22 23.14 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 116.259 -0.428 . . . . 0.0 112.093 -179.609 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . 0.467 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.61 177.19 7.45 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.412 178.756 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.549 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 23.7 tt0 -74.1 134.69 42.91 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 122.9 0.48 . . . . 0.0 111.677 -179.649 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.45 9.73 57.55 Favored Glycine 0 C--N 1.339 0.712 0 CA-C-N 115.597 -0.729 . . . . 0.0 114.319 179.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.467 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.0 pt-20 -132.72 177.84 7.32 Favored 'General case' 0 CA--C 1.54 0.595 0 CA-C-N 117.371 0.586 . . . . 0.0 111.373 179.849 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' SER . . . . . 0.414 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 52.8 m -88.58 149.03 23.79 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.645 -179.379 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.2 p -141.38 129.12 21.64 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.615 -179.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -101.29 120.94 41.01 Favored 'General case' 0 N--CA 1.466 0.328 0 O-C-N 123.447 0.467 . . . . 0.0 110.516 179.632 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.573 HG21 ' O ' ' A' ' 30' ' ' PRO . 27.6 m -70.86 6.66 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 N-CA-C 113.689 0.996 . . . . 0.0 113.689 -178.228 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 5.9 tp60 -101.41 -30.3 11.53 Favored 'General case' 0 CA--C 1.534 0.354 0 N-CA-C 111.736 0.273 . . . . 0.0 111.736 -179.473 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.8 p90 -148.24 -27.55 0.33 Allowed 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 112.882 0.697 . . . . 0.0 112.882 -178.803 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -121.8 85.88 45.12 Favored Pre-proline 0 CA--C 1.545 0.786 0 N-CA-C 111.584 0.216 . . . . 0.0 111.584 -178.719 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -77.4 176.83 9.59 Favored 'Trans proline' 0 C--N 1.369 1.614 0 C-N-CA 122.265 1.976 . . . . 0.0 112.606 179.51 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.696 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.0 t -89.07 160.1 17.23 Favored 'General case' 0 N--CA 1.468 0.442 0 O-C-N 123.226 0.329 . . . . 0.0 110.944 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 72.3 m -79.84 108.09 8.27 Favored Pre-proline 0 CA--C 1.546 0.805 0 N-CA-C 111.948 0.351 . . . . 0.0 111.948 -179.542 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.463 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 76.4 Cg_endo -83.69 178.0 5.84 Favored 'Trans proline' 0 C--N 1.372 1.797 0 C-N-CA 122.534 2.156 . . . . 0.0 112.979 179.473 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.69 -39.35 2.77 Favored Glycine 0 C--N 1.34 0.789 0 C-N-CA 121.401 -0.428 . . . . 0.0 112.935 179.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.6 mt -89.9 -36.68 14.9 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 122.447 0.299 . . . . 0.0 111.442 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.35 52.92 0.23 Allowed Glycine 0 C--N 1.339 0.716 0 O-C-N 123.496 0.498 . . . . 0.0 112.376 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.45 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 18.8 mt -115.4 148.53 39.24 Favored 'General case' 0 C--O 1.235 0.334 0 O-C-N 123.67 0.277 . . . . 0.0 110.953 -179.683 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.414 ' HG1' ' N ' ' A' ' 25' ' ' CYS . 9.8 t -138.83 152.22 47.67 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.296 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.696 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 61.7 m -96.47 122.34 39.26 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.551 179.43 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.6 mt -127.41 122.73 22.93 Favored Pre-proline 0 CA--C 1.546 0.809 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.385 -179.787 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.416 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.66 -41.54 0.95 Allowed 'Cis proline' 0 C--N 1.374 1.909 0 C-N-CA 124.677 -0.968 . . . . 0.0 112.569 0.083 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 91.17 31.47 9.72 Favored Glycine 0 C--N 1.342 0.914 0 O-C-N 123.562 0.538 . . . . 0.0 113.128 179.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.416 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.9 p30 -143.95 82.79 10.79 Favored Pre-proline 0 CA--C 1.547 0.845 0 CA-C-N 116.707 0.253 . . . . 0.0 111.391 179.633 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.573 ' O ' HG21 ' A' ' 12' ' ' VAL . 75.7 Cg_endo -87.26 -27.01 5.67 Favored 'Cis proline' 0 C--N 1.37 1.707 0 C-N-CA 124.59 -1.004 . . . . 0.0 113.439 -0.43 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -94.12 156.65 16.46 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.67 -179.032 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.414 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.65 -173.6 25.35 Favored Glycine 0 C--N 1.336 0.56 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.452 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.466 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.5 OUTLIER -124.77 143.81 50.59 Favored 'General case' 0 C--O 1.234 0.271 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.607 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.41 ' HA ' ' O ' ' A' ' 24' ' ' THR . 56.7 m -89.08 114.37 25.6 Favored 'General case' 0 C--O 1.239 0.536 0 O-C-N 123.452 0.47 . . . . 0.0 111.818 -179.569 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' TYR . . . . . 0.45 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.0 m-85 -125.51 157.97 35.67 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.051 -0.977 . . . . 0.0 110.466 179.287 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.549 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 17.7 t80 -92.53 133.12 36.25 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.984 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.104 -0.951 . . . . 0.0 110.977 179.827 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.427 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.6 p . . . . . 0 N--CA 1.466 0.332 0 CA-C-O 120.42 0.152 . . . . 0.0 110.868 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.84 151.72 20.44 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.784 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . 0.405 ' O ' ' HG2' ' A' ' 8' ' ' GLU . 15.3 p90 -97.32 174.78 6.53 Favored 'General case' 0 CA--C 1.537 0.477 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.687 179.117 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.569 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.1 tt0 -64.97 130.47 43.51 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 123.164 0.586 . . . . 0.0 112.253 -179.269 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 100.04 12.13 40.72 Favored Glycine 0 C--N 1.339 0.723 0 CA-C-N 115.62 -0.718 . . . . 0.0 114.674 178.656 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.405 ' HG2' ' O ' ' A' ' 5' ' ' PHE . 7.0 pt-20 -136.67 176.85 8.33 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 117.601 0.701 . . . . 0.0 111.47 179.632 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' SER . . . . . 0.424 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 40.6 p -90.23 144.8 25.53 Favored 'General case' 0 C--N 1.343 0.319 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.126 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 p -135.85 130.49 33.99 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.906 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -99.76 119.02 37.48 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.854 179.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.606 HG23 ' O ' ' A' ' 30' ' ' PRO . 30.5 m -72.71 10.58 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 N-CA-C 112.897 0.702 . . . . 0.0 112.897 -179.034 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.404 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.5 tp60 -104.26 -29.74 10.6 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.577 -179.425 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.404 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.48 -26.79 0.27 Allowed 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 112.819 0.674 . . . . 0.0 112.819 -178.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 9.7 t80 -124.98 86.96 55.99 Favored Pre-proline 0 CA--C 1.546 0.798 0 N-CA-C 111.622 0.23 . . . . 0.0 111.622 -178.697 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.427 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.1 Cg_endo -77.75 179.08 6.85 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 122.235 1.957 . . . . 0.0 112.739 179.512 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.688 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -89.91 160.22 16.54 Favored 'General case' 0 N--CA 1.467 0.376 0 O-C-N 123.183 0.302 . . . . 0.0 110.809 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 78.2 m -79.99 108.29 8.88 Favored Pre-proline 0 CA--C 1.545 0.773 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.907 -179.401 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.446 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.9 Cg_endo -83.44 177.53 6.34 Favored 'Trans proline' 0 C--N 1.371 1.753 0 C-N-CA 122.449 2.099 . . . . 0.0 112.95 179.441 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.79 -39.86 2.61 Favored Glycine 0 C--N 1.34 0.751 0 C-N-CA 121.374 -0.441 . . . . 0.0 112.946 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.8 mt -89.05 -38.1 14.64 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 122.444 0.298 . . . . 0.0 111.501 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.97 50.12 0.23 Allowed Glycine 0 C--N 1.339 0.706 0 O-C-N 123.481 0.488 . . . . 0.0 112.497 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.439 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.1 mt -113.85 149.73 34.62 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 122.294 0.238 . . . . 0.0 110.846 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -139.44 154.16 47.71 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.321 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.688 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.0 m -97.13 123.09 40.8 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.575 179.4 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.6 mt -127.2 123.09 23.25 Favored Pre-proline 0 CA--C 1.544 0.746 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.327 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.426 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.2 Cg_exo -75.7 -40.92 1.06 Allowed 'Cis proline' 0 C--N 1.375 1.922 0 C-N-CA 124.698 -0.959 . . . . 0.0 112.527 0.077 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.64 32.97 8.78 Favored Glycine 0 C--N 1.342 0.884 0 O-C-N 123.62 0.575 . . . . 0.0 113.123 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.426 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.7 p30 -145.68 81.39 10.08 Favored Pre-proline 0 CA--C 1.547 0.844 0 CA-C-N 116.756 0.278 . . . . 0.0 111.458 179.611 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.606 ' O ' HG23 ' A' ' 12' ' ' VAL . 60.7 Cg_endo -88.77 -26.53 5.24 Favored 'Cis proline' 0 C--N 1.371 1.715 0 C-N-CA 124.651 -0.979 . . . . 0.0 113.508 -0.407 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -90.46 155.24 19.06 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.347 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.424 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.19 -174.93 26.58 Favored Glycine 0 C--N 1.334 0.465 0 CA-C-N 115.379 -0.828 . . . . 0.0 112.464 179.549 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.485 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.6 OUTLIER -125.72 143.24 51.13 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.493 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 52.8 m -88.69 112.74 23.49 Favored 'General case' 0 C--O 1.239 0.523 0 O-C-N 123.439 0.462 . . . . 0.0 111.75 -179.644 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' TYR . . . . . 0.439 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 37.1 m-85 -126.48 159.26 33.89 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.051 -0.977 . . . . 0.0 110.519 179.36 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.569 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.5 t80 -92.77 135.34 34.2 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.006 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.9 mt . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.115 -0.945 . . . . 0.0 110.87 179.819 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.409 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 29.0 p . . . . . 0 C--O 1.235 0.314 0 CA-C-O 120.407 0.146 . . . . 0.0 111.004 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.0 147.81 22.52 Favored 'General case' 0 C--O 1.237 0.406 0 CA-C-N 116.243 -0.435 . . . . 0.0 112.121 -179.705 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . 0.467 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.4 m-85 -86.53 176.98 7.54 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.432 178.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.57 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.2 tt0 -73.79 136.09 43.55 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 122.905 0.482 . . . . 0.0 111.693 -179.792 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.49 8.81 58.26 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 115.624 -0.716 . . . . 0.0 114.289 179.008 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.467 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.3 pt-20 -132.53 177.39 7.65 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 117.333 0.567 . . . . 0.0 111.41 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.0 m -88.36 146.4 25.29 Favored 'General case' 0 C--N 1.344 0.351 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.619 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.0 p -138.42 128.6 25.74 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.729 -179.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.4 119.57 38.65 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.918 179.678 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.602 HG21 ' O ' ' A' ' 30' ' ' PRO . 29.0 m -71.95 8.93 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 N-CA-C 113.035 0.754 . . . . 0.0 113.035 -178.757 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.403 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.4 tp60 -102.7 -30.1 11.11 Favored 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 111.687 0.254 . . . . 0.0 111.687 -179.34 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.403 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.9 p90 -149.02 -26.92 0.29 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.824 0.676 . . . . 0.0 112.824 -178.763 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -124.32 87.15 54.16 Favored Pre-proline 0 CA--C 1.546 0.804 0 N-CA-C 111.561 0.208 . . . . 0.0 111.561 -178.704 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.406 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.2 Cg_endo -76.97 177.09 9.31 Favored 'Trans proline' 0 C--N 1.37 1.659 0 C-N-CA 122.234 1.956 . . . . 0.0 112.771 179.604 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.689 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.3 t -89.69 159.86 16.89 Favored 'General case' 0 N--CA 1.468 0.442 0 O-C-N 123.272 0.358 . . . . 0.0 110.957 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.1 m -79.85 108.24 8.64 Favored Pre-proline 0 CA--C 1.545 0.779 0 N-CA-C 112.024 0.379 . . . . 0.0 112.024 -179.524 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.455 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 79.1 Cg_endo -83.6 177.88 5.99 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 122.512 2.142 . . . . 0.0 113.025 179.39 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.72 -39.76 2.65 Favored Glycine 0 C--N 1.34 0.759 0 O-C-N 123.395 0.434 . . . . 0.0 112.95 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.6 mp -89.8 -36.64 15.01 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 122.47 0.308 . . . . 0.0 111.444 -179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.43 51.63 0.24 Allowed Glycine 0 C--N 1.338 0.691 0 O-C-N 123.525 0.515 . . . . 0.0 112.323 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.429 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 19.3 mt -113.2 149.46 33.68 Favored 'General case' 0 C--O 1.234 0.288 0 O-C-N 123.632 0.254 . . . . 0.0 110.969 -179.663 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.0 t -139.08 153.0 47.98 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.239 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.689 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.1 m -96.81 123.09 40.41 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.546 179.448 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.9 mt -126.8 122.79 23.54 Favored Pre-proline 0 CA--C 1.545 0.771 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.401 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -75.93 -41.04 1.02 Allowed 'Cis proline' 0 C--N 1.375 1.925 0 C-N-CA 124.695 -0.961 . . . . 0.0 112.643 0.042 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.08 32.64 9.58 Favored Glycine 0 C--N 1.343 0.948 0 CA-C-N 116.024 -0.535 . . . . 0.0 112.914 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.3 p-10 -144.32 79.47 12.75 Favored Pre-proline 0 CA--C 1.546 0.803 0 C-N-CA 122.194 0.198 . . . . 0.0 111.349 179.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.602 ' O ' HG21 ' A' ' 12' ' ' VAL . 59.3 Cg_endo -89.69 -26.47 4.7 Favored 'Cis proline' 0 C--N 1.37 1.666 0 C-N-CA 124.695 -0.96 . . . . 0.0 113.593 -0.252 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -91.14 153.44 20.06 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.937 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -155.91 -172.57 23.54 Favored Glycine 0 C--N 1.338 0.658 0 CA-C-N 115.55 -0.75 . . . . 0.0 112.649 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.493 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.5 OUTLIER -126.55 144.86 50.74 Favored 'General case' 0 C--O 1.235 0.318 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.556 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 57.5 m -89.47 114.82 26.37 Favored 'General case' 0 C--O 1.239 0.538 0 O-C-N 123.429 0.456 . . . . 0.0 111.832 -179.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' TYR . . . . . 0.429 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 38.0 m-85 -128.14 157.87 39.6 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.512 179.291 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.57 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 20.4 t80 -91.75 134.86 34.36 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.995 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.3 mt . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.085 -0.96 . . . . 0.0 110.963 179.797 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.408 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.0 p . . . . . 0 C--O 1.236 0.368 0 CA-C-O 120.453 0.168 . . . . 0.0 110.942 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.07 147.18 23.14 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-N 116.226 -0.443 . . . . 0.0 112.158 -179.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . 0.475 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.28 177.2 7.56 Favored 'General case' 0 CA--C 1.538 0.505 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.442 178.764 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.549 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 23.8 tt0 -73.95 134.87 43.18 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 122.932 0.493 . . . . 0.0 111.711 -179.755 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.27 9.39 58.05 Favored Glycine 0 C--N 1.339 0.713 0 CA-C-N 115.659 -0.7 . . . . 0.0 114.33 178.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.475 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.0 pt-20 -132.39 177.85 7.27 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 117.345 0.573 . . . . 0.0 111.419 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' SER . . . . . 0.426 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 51.8 m -88.47 149.15 23.81 Favored 'General case' 0 C--N 1.345 0.375 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.722 -179.393 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.4 p -141.56 129.48 21.87 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.656 -179.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -101.36 120.9 40.97 Favored 'General case' 0 C--O 1.235 0.326 0 O-C-N 123.384 0.428 . . . . 0.0 110.523 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.567 HG23 ' O ' ' A' ' 30' ' ' PRO . 27.4 m -71.04 7.12 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 N-CA-C 113.626 0.972 . . . . 0.0 113.626 -178.178 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.7 tp-100 -101.77 -30.6 11.2 Favored 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 -179.429 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.8 p90 -147.95 -27.44 0.34 Allowed 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 112.896 0.702 . . . . 0.0 112.896 -178.82 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -122.24 86.1 47.37 Favored Pre-proline 0 CA--C 1.546 0.798 0 N-CA-C 111.62 0.229 . . . . 0.0 111.62 -178.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.408 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.3 Cg_endo -77.51 177.59 8.66 Favored 'Trans proline' 0 C--N 1.369 1.653 0 C-N-CA 122.22 1.947 . . . . 0.0 112.573 179.458 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.696 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.0 t -89.19 160.11 17.13 Favored 'General case' 0 N--CA 1.468 0.44 0 O-C-N 123.202 0.314 . . . . 0.0 110.939 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.416 ' O ' HD13 ' A' ' 23' ' ' LEU . 73.5 m -79.82 108.27 8.67 Favored Pre-proline 0 CA--C 1.544 0.744 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.913 -179.589 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.456 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 75.8 Cg_endo -83.45 177.92 6.05 Favored 'Trans proline' 0 C--N 1.372 1.815 0 C-N-CA 122.525 2.15 . . . . 0.0 113.011 179.479 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.27 -39.05 2.86 Favored Glycine 0 C--N 1.34 0.771 0 C-N-CA 121.389 -0.434 . . . . 0.0 112.924 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.2 mt -90.25 -36.81 14.51 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 122.481 0.312 . . . . 0.0 111.468 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.1 53.05 0.23 Allowed Glycine 0 C--N 1.339 0.719 0 O-C-N 123.54 0.525 . . . . 0.0 112.338 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.441 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 18.3 mt -114.75 148.98 37.61 Favored 'General case' 0 C--O 1.235 0.317 0 O-C-N 123.686 0.286 . . . . 0.0 110.945 -179.648 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.407 ' O ' ' HA ' ' A' ' 34' ' ' CYS . 10.0 t -138.79 151.99 47.52 Favored 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.312 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.696 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 59.6 m -96.94 121.64 39.04 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.52 179.486 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.7 mt -127.69 123.69 23.08 Favored Pre-proline 0 CA--C 1.546 0.799 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.332 -179.758 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.407 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -76.01 -41.42 0.96 Allowed 'Cis proline' 0 C--N 1.374 1.903 0 C-N-CA 124.691 -0.962 . . . . 0.0 112.602 0.037 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.53 32.02 9.81 Favored Glycine 0 C--N 1.342 0.886 0 O-C-N 123.545 0.528 . . . . 0.0 113.062 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.407 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -141.86 81.17 14.94 Favored Pre-proline 0 CA--C 1.547 0.854 0 CA-C-N 116.65 0.225 . . . . 0.0 111.489 179.713 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.567 ' O ' HG23 ' A' ' 12' ' ' VAL . 76.3 Cg_endo -88.09 -26.0 6.19 Favored 'Cis proline' 0 C--N 1.371 1.719 0 C-N-CA 124.617 -0.993 . . . . 0.0 113.486 -0.326 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -93.68 156.71 16.54 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.637 -179.061 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.426 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.91 -172.5 24.22 Favored Glycine 0 C--N 1.337 0.59 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.436 179.558 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.475 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.3 OUTLIER -125.59 144.81 50.41 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.612 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . 0.407 ' HA ' ' O ' ' A' ' 24' ' ' THR . 57.0 m -89.44 114.3 25.76 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-O 121.094 0.473 . . . . 0.0 111.836 -179.676 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' TYR . . . . . 0.441 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 37.8 m-85 -124.92 157.74 35.28 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.418 179.302 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.549 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 19.8 t80 -92.85 133.03 36.48 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.959 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.251 1.146 0 CA-C-O 118.463 -0.78 . . . . 0.0 110.873 179.844 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.416 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.7 p . . . . . 0 C--O 1.235 0.328 0 CA-C-O 120.494 0.187 . . . . 0.0 110.874 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.473 ' HB1' ' OE1' ' A' ' 8' ' ' GLU . . . -92.15 151.15 20.53 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.755 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 17.4 p90 -97.8 174.42 6.61 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.733 179.206 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.576 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 16.4 tt0 -63.06 130.52 45.05 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.253 0.621 . . . . 0.0 112.382 -179.308 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.1 9.09 46.08 Favored Glycine 0 C--N 1.339 0.696 0 CA-C-N 115.663 -0.699 . . . . 0.0 114.78 178.483 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . 0.473 ' OE1' ' HB1' ' A' ' 4' ' ' ALA . 6.4 pt-20 -134.93 176.94 8.2 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 117.708 0.754 . . . . 0.0 111.565 179.703 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' SER . . . . . 0.435 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 40.0 p -90.79 143.69 26.47 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.199 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.5 p -134.55 131.37 37.85 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.957 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -100.61 118.88 37.67 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.842 179.576 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.593 HG23 ' O ' ' A' ' 30' ' ' PRO . 30.4 m -71.7 10.31 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -178.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.505 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.1 OUTLIER -100.99 -35.12 9.49 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.254 -179.428 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.505 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.9 p90 -146.84 -26.7 0.4 Allowed 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 -178.494 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.0 t80 -122.3 86.3 47.76 Favored Pre-proline 0 CA--C 1.545 0.767 0 N-CA-C 111.725 0.269 . . . . 0.0 111.725 -178.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.416 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.4 Cg_endo -77.98 179.08 6.84 Favored 'Trans proline' 0 C--N 1.369 1.633 0 C-N-CA 122.279 1.986 . . . . 0.0 112.729 179.435 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.7 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.8 t -89.21 160.09 17.13 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 123.157 0.285 . . . . 0.0 110.87 179.756 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 72.6 m -79.99 108.64 9.74 Favored Pre-proline 0 CA--C 1.544 0.74 0 N-CA-C 111.96 0.356 . . . . 0.0 111.96 -179.356 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.432 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.6 Cg_endo -83.03 177.2 6.87 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 122.485 2.123 . . . . 0.0 112.905 179.316 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.21 -39.83 2.62 Favored Glycine 0 C--N 1.34 0.762 0 C-N-CA 121.312 -0.47 . . . . 0.0 112.992 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.1 mt -89.58 -38.16 14.16 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 122.435 0.294 . . . . 0.0 111.477 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.28 51.6 0.23 Allowed Glycine 0 C--N 1.34 0.751 0 CA-C-N 116.17 -0.468 . . . . 0.0 112.461 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.452 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.3 mt -114.88 150.74 35.13 Favored 'General case' 0 C--O 1.235 0.309 0 O-C-N 123.611 0.242 . . . . 0.0 110.958 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 t -139.73 154.26 47.4 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.305 -179.752 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.7 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.0 m -97.61 122.41 40.65 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.492 179.409 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.6 mt -127.35 123.78 23.4 Favored Pre-proline 0 CA--C 1.545 0.765 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.4 -179.786 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.421 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.3 Cg_exo -76.0 -40.56 1.14 Allowed 'Cis proline' 0 C--N 1.375 1.934 0 C-N-CA 124.636 -0.985 . . . . 0.0 112.552 0.026 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.72 34.27 8.55 Favored Glycine 0 C--N 1.342 0.895 0 CA-C-N 115.915 -0.584 . . . . 0.0 113.045 179.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.421 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -144.71 79.96 11.92 Favored Pre-proline 0 CA--C 1.547 0.86 0 CA-C-N 116.68 0.24 . . . . 0.0 111.508 179.705 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.593 ' O ' HG23 ' A' ' 12' ' ' VAL . 65.6 Cg_endo -89.15 -26.0 5.47 Favored 'Cis proline' 0 C--N 1.37 1.692 0 C-N-CA 124.714 -0.952 . . . . 0.0 113.457 -0.348 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -89.75 155.25 19.32 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.349 -179.474 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.435 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.31 -174.49 26.15 Favored Glycine 0 C--N 1.335 0.493 0 CA-C-N 115.371 -0.831 . . . . 0.0 112.396 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' THR . . . . . 0.48 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -126.15 143.41 51.14 Favored 'General case' 0 C--O 1.234 0.258 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.511 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 45.9 m -88.56 112.52 23.13 Favored 'General case' 0 C--O 1.24 0.582 0 O-C-N 123.409 0.443 . . . . 0.0 111.681 -179.697 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' TYR . . . . . 0.452 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.9 m-85 -125.56 159.85 31.04 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.592 179.416 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.576 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.3 t80 -93.49 134.96 35.2 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.964 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.2 mt . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.145 -0.931 . . . . 0.0 110.903 179.751 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.272 . . . . . . . 0 C--O 1.235 0.327 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -106.75 -53.69 0.7 Allowed Glycine 0 C--N 1.336 0.541 0 O-C-N 123.685 0.616 . . . . 0.0 112.56 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.0 p -99.18 155.32 17.54 Favored 'General case' 0 C--O 1.235 0.325 0 C-N-CA 122.306 0.242 . . . . 0.0 110.993 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.537 ' HB1' ' OE1' ' A' ' 8' ' ' GLU . . . -92.01 151.14 20.62 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.781 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.6 p90 -98.93 171.82 7.82 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.856 179.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.578 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.2 tt0 -59.94 129.04 39.87 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 123.362 0.665 . . . . 0.0 112.428 -179.267 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.29 -20.86 29.84 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 115.572 -0.74 . . . . 0.0 114.388 178.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.537 ' OE1' ' HB1' ' A' ' 4' ' ' ALA . 6.0 pt-20 -107.02 177.47 4.85 Favored 'General case' 0 CA--C 1.539 0.558 0 CA-C-N 117.42 0.61 . . . . 0.0 111.828 -179.332 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 40.8 p -91.5 146.95 23.38 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.09 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.6 p -134.84 128.26 32.37 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.975 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -98.01 119.66 37.03 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.702 179.419 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.586 HG23 ' O ' ' A' ' 30' ' ' PRO . 24.2 m -72.41 10.35 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -178.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.402 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.7 tp60 -104.76 -29.22 10.69 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.637 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.402 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.94 -26.61 0.26 Allowed 'General case' 0 N--CA 1.477 0.899 0 N-CA-C 112.907 0.706 . . . . 0.0 112.907 -178.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.2 t80 -125.22 87.22 55.87 Favored Pre-proline 0 CA--C 1.545 0.779 0 N-CA-C 111.687 0.254 . . . . 0.0 111.687 -178.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -77.88 176.84 9.52 Favored 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.311 2.007 . . . . 0.0 112.734 179.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.687 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -88.54 160.88 17.25 Favored 'General case' 0 N--CA 1.468 0.441 0 O-C-N 123.201 0.313 . . . . 0.0 110.809 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.9 m -79.94 108.45 9.23 Favored Pre-proline 0 CA--C 1.544 0.728 0 N-CA-C 112.078 0.399 . . . . 0.0 112.078 -179.284 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.44 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.1 Cg_endo -83.51 177.66 6.2 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.469 2.113 . . . . 0.0 112.896 179.341 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.82 -40.22 2.5 Favored Glycine 0 C--N 1.339 0.741 0 C-N-CA 121.349 -0.453 . . . . 0.0 112.985 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.8 mt -88.76 -38.52 14.62 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 122.456 0.302 . . . . 0.0 111.458 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.55 51.65 0.2 Allowed Glycine 0 C--N 1.338 0.69 0 O-C-N 123.475 0.485 . . . . 0.0 112.53 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.465 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 22.0 mt -115.72 149.17 38.85 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-O 120.618 0.247 . . . . 0.0 110.858 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t -138.93 154.84 48.37 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.201 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.687 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 65.7 m -97.19 123.28 40.92 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.709 179.548 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 12.2 mt -127.38 122.85 23.01 Favored Pre-proline 0 CA--C 1.545 0.775 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.231 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.423 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.3 Cg_exo -75.42 -40.82 1.09 Allowed 'Cis proline' 0 C--N 1.375 1.922 0 C-N-CA 124.697 -0.96 . . . . 0.0 112.648 0.133 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.03 33.85 8.65 Favored Glycine 0 C--N 1.343 0.918 0 CA-C-N 115.993 -0.549 . . . . 0.0 113.085 179.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.423 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.8 p30 -147.06 79.63 9.84 Favored Pre-proline 0 CA--C 1.546 0.824 0 CA-C-N 116.641 0.221 . . . . 0.0 111.427 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.586 ' O ' HG23 ' A' ' 12' ' ' VAL . 56.1 Cg_endo -89.8 -27.4 3.9 Favored 'Cis proline' 0 C--N 1.37 1.671 0 C-N-CA 124.723 -0.949 . . . . 0.0 113.477 -0.368 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -86.11 149.59 25.02 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.633 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -151.13 -179.15 26.61 Favored Glycine 0 C--N 1.335 0.521 0 CA-C-N 115.654 -0.703 . . . . 0.0 112.627 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.43 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.9 OUTLIER -123.33 140.9 52.54 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 179.349 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.9 m -86.46 110.6 19.86 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 121.015 0.436 . . . . 0.0 111.698 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . 0.465 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 32.8 m-85 -125.47 158.37 34.61 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.624 179.546 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.578 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.1 t80 -92.89 135.65 33.95 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.943 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.6 mt . . . . . 0 C--O 1.249 1.059 0 CA-C-O 118.095 -0.955 . . . . 0.0 110.871 179.806 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.27 . . . . . . . 0 C--O 1.235 0.334 0 N-CA-C 112.46 0.541 . . . . 0.0 112.46 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.62 -62.15 0.62 Allowed Glycine 0 C--N 1.34 0.767 0 O-C-N 123.433 0.458 . . . . 0.0 112.452 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.409 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.5 p -100.29 154.49 18.44 Favored 'General case' 0 C--O 1.235 0.305 0 O-C-N 123.613 0.243 . . . . 0.0 110.961 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.508 ' HB2' ' OE1' ' A' ' 8' ' ' GLU . . . -92.07 152.88 19.74 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.757 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 18.6 p90 -98.23 174.08 6.68 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.725 179.161 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.561 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.3 tt0 -63.89 131.3 47.31 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 123.227 0.611 . . . . 0.0 112.348 -179.282 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.72 3.97 52.29 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-N 115.564 -0.744 . . . . 0.0 114.759 178.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.508 ' OE1' ' HB2' ' A' ' 4' ' ' ALA . 5.1 pt-20 -130.55 177.91 7.02 Favored 'General case' 0 CA--C 1.54 0.558 0 CA-C-N 117.636 0.718 . . . . 0.0 111.605 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.413 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 42.5 p -90.4 146.11 24.41 Favored 'General case' 0 C--N 1.343 0.315 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.293 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.9 p -136.47 128.01 28.69 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.782 -179.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -98.22 119.57 37.11 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.87 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.584 HG22 ' O ' ' A' ' 30' ' ' PRO . 23.1 m -72.38 10.02 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 N-CA-C 112.963 0.727 . . . . 0.0 112.963 -178.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.433 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 15.0 tt0 -99.81 -30.23 12.17 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.206 -179.572 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.433 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.1 p90 -154.01 -26.77 0.13 Allowed 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 112.729 0.64 . . . . 0.0 112.729 -178.55 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -120.43 85.23 37.01 Favored Pre-proline 0 CA--C 1.544 0.749 0 N-CA-C 111.613 0.227 . . . . 0.0 111.613 -178.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.409 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.8 Cg_endo -78.2 179.12 6.79 Favored 'Trans proline' 0 C--N 1.369 1.65 0 C-N-CA 122.306 2.004 . . . . 0.0 112.664 179.478 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.697 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -89.62 159.82 16.96 Favored 'General case' 0 N--CA 1.467 0.402 0 O-C-N 123.163 0.29 . . . . 0.0 110.917 179.788 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.2 m -79.97 108.56 9.51 Favored Pre-proline 0 CA--C 1.545 0.76 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.881 -179.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.2 Cg_endo -83.27 177.42 6.54 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 122.521 2.147 . . . . 0.0 112.959 179.376 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.27 -40.12 2.53 Favored Glycine 0 C--N 1.34 0.751 0 C-N-CA 121.336 -0.459 . . . . 0.0 113.015 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.4 -38.91 13.76 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 122.462 0.305 . . . . 0.0 111.494 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.06 50.51 0.21 Allowed Glycine 0 C--N 1.339 0.723 0 O-C-N 123.479 0.487 . . . . 0.0 112.485 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.451 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.7 mt -113.87 150.33 33.77 Favored 'General case' 0 C--O 1.235 0.324 0 O-C-N 123.661 0.271 . . . . 0.0 110.854 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 t -139.28 154.59 47.98 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.347 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.697 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 56.9 m -97.49 123.17 41.25 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.822 -0.627 . . . . 0.0 110.595 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.9 mt -127.53 123.35 23.07 Favored Pre-proline 0 CA--C 1.544 0.741 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.238 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.416 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.2 Cg_exo -75.69 -40.85 1.08 Allowed 'Cis proline' 0 C--N 1.375 1.927 0 C-N-CA 124.69 -0.962 . . . . 0.0 112.527 0.085 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.19 33.49 8.77 Favored Glycine 0 C--N 1.342 0.915 0 CA-C-N 115.964 -0.562 . . . . 0.0 113.147 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.416 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.8 p30 -147.06 79.86 9.73 Favored Pre-proline 0 CA--C 1.546 0.821 0 CA-C-N 116.649 0.224 . . . . 0.0 111.509 179.64 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.584 ' O ' HG22 ' A' ' 12' ' ' VAL . 57.5 Cg_endo -89.62 -27.23 4.11 Favored 'Cis proline' 0 C--N 1.37 1.681 0 C-N-CA 124.666 -0.973 . . . . 0.0 113.496 -0.367 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -86.83 150.03 24.41 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.559 -179.49 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.413 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -151.6 -178.09 26.01 Favored Glycine 0 C--N 1.336 0.535 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.45 179.453 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.461 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -125.75 142.25 51.6 Favored 'General case' 0 C--O 1.234 0.278 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 179.328 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 54.3 m -87.64 112.23 22.1 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-O 121.093 0.473 . . . . 0.0 111.783 -179.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . 0.451 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 34.8 m-85 -125.89 159.43 32.56 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.538 179.361 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.561 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.6 t80 -93.38 135.21 34.84 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.951 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.129 -0.939 . . . . 0.0 110.857 179.738 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . 0.539 ' HB3' ' OH ' ' A' ' 15' ' ' TYR 0.273 . . . . . . . 0 C--O 1.234 0.287 0 N-CA-C 112.177 0.436 . . . . 0.0 112.177 . . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -106.99 -56.19 0.63 Allowed Glycine 0 C--N 1.336 0.566 0 CA-C-N 115.841 -0.618 . . . . 0.0 112.498 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.402 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.2 p -100.39 154.84 18.19 Favored 'General case' 0 C--O 1.235 0.329 0 O-C-N 123.617 0.245 . . . . 0.0 110.999 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.525 ' HB2' ' OE1' ' A' ' 8' ' ' GLU . . . -91.9 151.62 20.45 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.701 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.9 p90 -98.75 172.82 7.21 Favored 'General case' 0 CA--C 1.536 0.427 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.873 179.3 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.579 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 14.4 tt0 -61.04 130.31 45.74 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 123.326 0.651 . . . . 0.0 112.334 -179.386 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.08 -25.62 19.77 Favored Glycine 0 C--N 1.338 0.669 0 CA-C-N 115.656 -0.702 . . . . 0.0 114.179 178.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.525 ' OE1' ' HB2' ' A' ' 4' ' ' ALA . 5.1 pt-20 -103.06 178.67 4.49 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 117.273 0.536 . . . . 0.0 111.851 -179.159 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 43.8 p -92.8 151.56 19.94 Favored 'General case' 0 C--N 1.344 0.348 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.221 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 p -139.48 130.49 26.38 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.863 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -100.14 119.88 39.01 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.597 179.322 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.585 HG22 ' O ' ' A' ' 30' ' ' PRO . 25.5 m -71.32 9.43 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -178.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.497 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -100.44 -32.81 10.63 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.3 -179.496 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.497 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.1 p90 -149.93 -26.8 0.26 Allowed 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 112.897 0.703 . . . . 0.0 112.897 -178.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.539 ' OH ' ' HB3' ' A' ' 1' ' ' PCA . 6.8 t80 -121.09 85.53 41.26 Favored Pre-proline 0 CA--C 1.545 0.757 0 N-CA-C 111.747 0.277 . . . . 0.0 111.747 -178.663 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.402 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.1 Cg_endo -78.06 177.16 9.12 Favored 'Trans proline' 0 C--N 1.369 1.607 0 C-N-CA 122.202 1.935 . . . . 0.0 112.67 179.385 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.701 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 4.6 t -88.27 160.73 17.54 Favored 'General case' 0 N--CA 1.467 0.418 0 O-C-N 123.186 0.304 . . . . 0.0 110.796 179.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.0 m -79.97 108.67 9.77 Favored Pre-proline 0 CA--C 1.545 0.768 0 N-CA-C 111.99 0.367 . . . . 0.0 111.99 -179.18 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.438 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 76.0 Cg_endo -83.22 177.65 6.4 Favored 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.5 2.133 . . . . 0.0 112.918 179.286 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.94 -41.09 2.25 Favored Glycine 0 C--N 1.34 0.77 0 C-N-CA 121.384 -0.436 . . . . 0.0 112.928 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.1 -38.86 14.03 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 122.486 0.314 . . . . 0.0 111.431 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.425 ' O ' ' HA ' ' A' ' 36' ' ' TYR . . . 124.27 53.41 0.19 Allowed Glycine 0 C--N 1.339 0.715 0 O-C-N 123.521 0.513 . . . . 0.0 112.512 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 23.7 mt -117.64 147.48 42.84 Favored 'General case' 0 C--O 1.234 0.267 0 O-C-N 123.623 0.249 . . . . 0.0 110.785 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -139.3 154.51 47.94 Favored 'General case' 0 CA--C 1.535 0.404 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.391 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.701 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 89.7 m -97.35 118.3 33.5 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.52 179.496 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 11.6 mt -122.75 122.23 27.22 Favored Pre-proline 0 CA--C 1.545 0.756 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.235 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.407 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.42 -40.72 1.12 Allowed 'Cis proline' 0 C--N 1.373 1.843 0 C-N-CA 124.695 -0.961 . . . . 0.0 112.701 0.232 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.13 34.43 8.8 Favored Glycine 0 C--N 1.342 0.868 0 O-C-N 123.588 0.555 . . . . 0.0 112.928 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.407 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -145.74 79.58 11.11 Favored Pre-proline 0 CA--C 1.548 0.876 0 C-N-CA 122.204 0.202 . . . . 0.0 111.423 179.724 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.585 ' O ' HG22 ' A' ' 12' ' ' VAL . 56.8 Cg_endo -88.79 -27.76 4.18 Favored 'Cis proline' 0 C--N 1.37 1.666 0 C-N-CA 124.739 -0.942 . . . . 0.0 113.486 -0.254 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -86.9 149.34 24.87 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.66 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.81 160.29 30.22 Favored Glycine 0 C--N 1.335 0.52 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.137 179.335 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.415 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.5 OUTLIER -99.1 143.96 28.78 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.823 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 18.8 m -88.31 110.04 20.45 Favored 'General case' 0 C--O 1.238 0.476 0 O-C-N 123.464 0.477 . . . . 0.0 111.528 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . 0.467 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 38.1 m-85 -124.73 160.13 29.31 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.289 -0.868 . . . . 0.0 110.744 179.628 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.579 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 15.8 t80 -93.07 137.23 32.61 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.872 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 14.6 mt . . . . . 0 C--O 1.251 1.172 0 CA-C-O 118.531 -0.747 . . . . 0.0 110.876 179.742 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.273 . . . . . . . 0 C--O 1.234 0.285 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -154.78 54.35 0.43 Allowed Glycine 0 C--N 1.337 0.613 0 O-C-N 123.713 0.633 . . . . 0.0 112.507 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.404 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.4 p -104.1 154.91 19.16 Favored 'General case' 0 C--O 1.235 0.331 0 O-C-N 123.609 0.241 . . . . 0.0 110.989 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.554 ' HB2' ' OE1' ' A' ' 8' ' ' GLU . . . -92.52 150.19 20.91 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.654 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.5 p90 -98.65 171.91 7.82 Favored 'General case' 0 CA--C 1.537 0.458 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.848 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.571 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 14.8 tt0 -59.53 128.63 37.96 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 123.305 0.642 . . . . 0.0 112.389 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.3 -21.02 27.34 Favored Glycine 0 C--N 1.339 0.718 0 CA-C-N 115.66 -0.7 . . . . 0.0 114.421 178.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.554 ' OE1' ' HB2' ' A' ' 4' ' ' ALA . 6.8 pt-20 -107.48 177.39 4.85 Favored 'General case' 0 CA--C 1.541 0.604 0 CA-C-N 117.43 0.615 . . . . 0.0 111.835 -179.222 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 53.0 m -91.47 145.4 24.65 Favored 'General case' 0 C--N 1.343 0.312 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.079 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.7 p -134.0 129.09 35.65 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.93 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.27 119.93 39.15 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.818 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.593 HG23 ' O ' ' A' ' 30' ' ' PRO . 28.5 m -72.4 10.48 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 112.994 0.738 . . . . 0.0 112.994 -178.797 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 5.6 tp60 -104.03 -29.31 10.98 Favored 'General case' 0 CA--C 1.535 0.377 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.615 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.0 p90 -149.84 -26.74 0.26 Allowed 'General case' 0 N--CA 1.476 0.874 0 N-CA-C 112.851 0.686 . . . . 0.0 112.851 -178.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 12.6 t80 -125.75 88.33 54.4 Favored Pre-proline 0 CA--C 1.545 0.775 0 N-CA-C 111.702 0.26 . . . . 0.0 111.702 -178.614 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.404 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.8 Cg_endo -77.74 176.17 10.34 Favored 'Trans proline' 0 C--N 1.37 1.686 0 C-N-CA 122.27 1.98 . . . . 0.0 112.708 179.333 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.671 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.1 t -88.26 161.36 17.23 Favored 'General case' 0 N--CA 1.467 0.399 0 O-C-N 123.208 0.318 . . . . 0.0 110.841 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.3 m -79.97 108.47 9.3 Favored Pre-proline 0 CA--C 1.544 0.745 0 N-CA-C 112.03 0.381 . . . . 0.0 112.03 -179.276 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.9 Cg_endo -83.51 177.53 6.29 Favored 'Trans proline' 0 C--N 1.371 1.756 0 C-N-CA 122.512 2.142 . . . . 0.0 112.906 179.369 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.0 -40.56 2.38 Favored Glycine 0 C--N 1.34 0.775 0 C-N-CA 121.313 -0.47 . . . . 0.0 113.003 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.08 -38.91 14.01 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 122.424 0.29 . . . . 0.0 111.453 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.92 51.96 0.2 Allowed Glycine 0 C--N 1.339 0.719 0 O-C-N 123.466 0.479 . . . . 0.0 112.568 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.451 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 22.0 mt -115.26 149.32 37.96 Favored 'General case' 0 C--O 1.234 0.286 0 O-C-N 123.654 0.267 . . . . 0.0 110.847 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -138.95 154.69 48.34 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.266 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.671 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 67.9 m -97.24 123.31 40.99 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.64 179.538 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 12.0 mt -126.63 122.94 23.77 Favored Pre-proline 0 CA--C 1.545 0.775 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.279 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.404 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.85 -40.89 1.06 Allowed 'Cis proline' 0 C--N 1.375 1.929 0 C-N-CA 124.595 -1.002 . . . . 0.0 112.644 0.111 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.08 33.07 9.14 Favored Glycine 0 C--N 1.342 0.883 0 O-C-N 123.548 0.53 . . . . 0.0 112.848 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.404 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.8 79.08 12.4 Favored Pre-proline 0 CA--C 1.547 0.843 0 C-N-CA 122.193 0.197 . . . . 0.0 111.291 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.593 ' O ' HG23 ' A' ' 12' ' ' VAL . 58.6 Cg_endo -89.89 -26.71 4.36 Favored 'Cis proline' 0 C--N 1.37 1.682 0 C-N-CA 124.708 -0.955 . . . . 0.0 113.682 -0.35 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.06 152.56 21.1 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.933 -179.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.41 -174.2 24.2 Favored Glycine 0 C--N 1.337 0.637 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.659 179.591 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.486 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -124.21 143.85 50.28 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.589 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.6 m -88.11 110.24 20.5 Favored 'General case' 0 C--O 1.238 0.448 0 O-C-N 123.44 0.462 . . . . 0.0 111.571 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . 0.451 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 33.0 m-85 -124.76 159.1 31.71 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.657 179.603 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.571 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.3 t80 -93.18 136.11 33.75 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.96 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.7 mt . . . . . 0 C--O 1.251 1.146 0 CA-C-O 118.486 -0.769 . . . . 0.0 110.892 179.775 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.271 . . . . . . . 0 C--O 1.235 0.32 0 N-CA-C 112.144 0.424 . . . . 0.0 112.144 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 171.44 54.7 0.04 OUTLIER Glycine 0 C--N 1.336 0.582 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.55 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.409 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.7 p -100.54 154.63 18.4 Favored 'General case' 0 C--O 1.235 0.324 0 O-C-N 123.67 0.277 . . . . 0.0 110.924 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.519 ' HB3' ' OE1' ' A' ' 8' ' ' GLU . . . -91.76 152.03 20.35 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.827 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 19.1 p90 -98.42 173.92 6.72 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.626 179.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.576 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 17.5 tt0 -63.82 130.0 42.38 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 123.213 0.605 . . . . 0.0 112.359 -179.326 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 102.06 9.61 41.89 Favored Glycine 0 C--N 1.339 0.717 0 CA-C-N 115.662 -0.699 . . . . 0.0 114.764 178.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.519 ' OE1' ' HB3' ' A' ' 4' ' ' ALA . 5.9 pt-20 -135.23 177.39 7.85 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 117.676 0.738 . . . . 0.0 111.535 179.756 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.4 m -90.82 141.65 28.59 Favored 'General case' 0 C--N 1.343 0.314 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.137 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.5 p -133.17 128.8 36.8 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.844 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.33 119.88 39.09 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.868 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.594 HG23 ' O ' ' A' ' 30' ' ' PRO . 28.3 m -72.78 12.2 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.031 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -178.823 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.7 tp-100 -105.51 -29.91 9.88 Favored 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 116.593 -0.276 . . . . 0.0 111.559 -179.391 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -148.78 -26.68 0.31 Allowed 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 8.8 t80 -126.21 88.19 54.77 Favored Pre-proline 0 CA--C 1.546 0.805 0 N-CA-C 111.696 0.258 . . . . 0.0 111.696 -178.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.409 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.4 Cg_endo -77.91 177.89 8.25 Favored 'Trans proline' 0 C--N 1.369 1.635 0 C-N-CA 122.31 2.007 . . . . 0.0 112.724 179.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.687 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.9 t -90.09 160.13 16.46 Favored 'General case' 0 N--CA 1.468 0.447 0 O-C-N 123.218 0.324 . . . . 0.0 110.799 179.802 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 76.3 m -80.06 108.45 9.34 Favored Pre-proline 0 CA--C 1.545 0.774 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.93 -179.322 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.444 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 80.5 Cg_endo -83.41 177.44 6.43 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.465 2.11 . . . . 0.0 112.961 179.296 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.04 -40.44 2.42 Favored Glycine 0 C--N 1.339 0.741 0 O-C-N 123.434 0.459 . . . . 0.0 113.016 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.07 -39.13 13.85 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 122.437 0.295 . . . . 0.0 111.52 -179.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.47 50.66 0.2 Allowed Glycine 0 C--N 1.339 0.736 0 O-C-N 123.505 0.503 . . . . 0.0 112.51 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.435 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.8 mt -113.86 150.21 33.94 Favored 'General case' 0 C--O 1.235 0.329 0 O-C-N 123.617 0.245 . . . . 0.0 110.846 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 t -139.58 154.27 47.58 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.326 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.687 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.9 m -97.33 123.3 41.1 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.582 179.366 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.8 mt -126.9 123.32 23.62 Favored Pre-proline 0 CA--C 1.545 0.772 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.333 -179.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.403 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.9 -40.84 1.07 Allowed 'Cis proline' 0 C--N 1.375 1.949 0 C-N-CA 124.66 -0.975 . . . . 0.0 112.554 0.055 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.98 32.45 9.88 Favored Glycine 0 C--N 1.341 0.859 0 O-C-N 123.621 0.576 . . . . 0.0 112.899 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.403 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -144.34 78.9 13.14 Favored Pre-proline 0 CA--C 1.546 0.817 0 C-N-CA 122.245 0.218 . . . . 0.0 111.313 179.776 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.594 ' O ' HG23 ' A' ' 12' ' ' VAL . 59.2 Cg_endo -90.02 -26.5 4.46 Favored 'Cis proline' 0 C--N 1.369 1.634 0 C-N-CA 124.74 -0.942 . . . . 0.0 113.668 -0.306 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.85 152.78 20.62 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.972 -179.362 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -155.47 -171.84 22.44 Favored Glycine 0 C--N 1.338 0.647 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.589 179.502 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.505 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -127.22 145.33 50.81 Favored 'General case' 0 C--O 1.235 0.316 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 179.553 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 51.6 m -89.22 111.93 22.84 Favored 'General case' 0 C--O 1.24 0.565 0 O-C-N 123.481 0.488 . . . . 0.0 111.627 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . 0.435 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.5 m-85 -125.72 159.76 31.48 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.523 179.423 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.576 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.6 t80 -93.35 136.03 34.01 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.005 -179.83 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.0 mt . . . . . 0 C--O 1.251 1.148 0 CA-C-O 118.502 -0.761 . . . . 0.0 110.891 179.745 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.273 . . . . . . . 0 C--O 1.235 0.314 0 N-CA-C 112.149 0.425 . . . . 0.0 112.149 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -105.17 -54.74 0.74 Allowed Glycine 0 C--N 1.336 0.571 0 O-C-N 123.737 0.648 . . . . 0.0 112.53 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.4 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.1 p -99.25 155.06 17.69 Favored 'General case' 0 C--O 1.235 0.314 0 O-C-N 123.593 0.231 . . . . 0.0 111.003 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.537 ' HB2' ' OE1' ' A' ' 8' ' ' GLU . . . -91.83 150.48 21.05 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.676 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.9 p90 -98.7 171.88 7.83 Favored 'General case' 0 CA--C 1.536 0.44 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.93 179.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.578 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.0 tt0 -59.98 128.63 37.82 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.352 0.661 . . . . 0.0 112.381 -179.312 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.25 -20.89 27.62 Favored Glycine 0 C--N 1.338 0.68 0 CA-C-N 115.688 -0.687 . . . . 0.0 114.421 178.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.537 ' OE1' ' HB2' ' A' ' 4' ' ' ALA . 6.5 pt-20 -107.29 177.47 4.83 Favored 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 117.444 0.622 . . . . 0.0 111.813 -179.289 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.7 m -91.42 144.9 25.1 Favored 'General case' 0 C--N 1.344 0.337 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.063 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.9 p -133.61 128.45 35.17 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.974 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.07 120.08 39.3 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.754 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.598 HG23 ' O ' ' A' ' 30' ' ' PRO . 28.0 m -72.28 10.38 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 113.023 0.749 . . . . 0.0 113.023 -178.776 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.402 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 1.6 tp-100 -104.12 -29.69 10.7 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.661 -179.358 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.402 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.48 -26.63 0.28 Allowed 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -178.791 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -125.32 87.79 55.1 Favored Pre-proline 0 CA--C 1.546 0.803 0 N-CA-C 111.652 0.242 . . . . 0.0 111.652 -178.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.4 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.7 Cg_endo -77.66 175.4 11.29 Favored 'Trans proline' 0 C--N 1.369 1.632 0 C-N-CA 122.304 2.003 . . . . 0.0 112.706 179.444 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.669 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -88.46 161.06 17.24 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.848 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 72.0 m -79.91 108.6 9.56 Favored Pre-proline 0 CA--C 1.544 0.738 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.206 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.437 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.5 Cg_endo -83.43 177.63 6.28 Favored 'Trans proline' 0 C--N 1.371 1.753 0 C-N-CA 122.491 2.128 . . . . 0.0 112.933 179.262 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.07 -40.01 2.57 Favored Glycine 0 C--N 1.339 0.727 0 C-N-CA 121.386 -0.435 . . . . 0.0 112.969 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.9 mt -88.83 -38.64 14.44 Favored 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 122.488 0.315 . . . . 0.0 111.466 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.19 51.26 0.21 Allowed Glycine 0 C--N 1.339 0.721 0 O-C-N 123.481 0.488 . . . . 0.0 112.539 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.459 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.6 mt -114.58 149.19 36.92 Favored 'General case' 0 C--O 1.235 0.308 0 O-C-N 123.65 0.265 . . . . 0.0 110.881 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t -138.85 154.34 48.41 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.201 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.669 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 68.3 m -97.0 123.23 40.66 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.659 179.514 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 12.7 mt -125.92 122.63 24.46 Favored Pre-proline 0 CA--C 1.545 0.768 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.26 -179.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.417 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.51 -41.08 1.03 Allowed 'Cis proline' 0 C--N 1.375 1.923 0 C-N-CA 124.664 -0.973 . . . . 0.0 112.641 0.072 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.78 31.84 9.73 Favored Glycine 0 C--N 1.341 0.847 0 O-C-N 123.548 0.53 . . . . 0.0 113.043 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.417 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.8 p30 -145.42 80.12 11.08 Favored Pre-proline 0 CA--C 1.547 0.841 0 C-N-CA 122.131 0.173 . . . . 0.0 111.229 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.598 ' O ' HG23 ' A' ' 12' ' ' VAL . 59.1 Cg_endo -89.65 -26.92 4.33 Favored 'Cis proline' 0 C--N 1.369 1.636 0 C-N-CA 124.676 -0.968 . . . . 0.0 113.681 -0.321 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -90.97 152.45 20.69 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.912 -179.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.44 -174.48 24.54 Favored Glycine 0 C--N 1.338 0.652 0 CA-C-N 115.442 -0.799 . . . . 0.0 112.634 179.593 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.484 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -123.79 143.93 50.01 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.561 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.6 m -88.08 110.23 20.48 Favored 'General case' 0 C--O 1.238 0.468 0 O-C-N 123.477 0.485 . . . . 0.0 111.588 -179.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . 0.459 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 33.0 m-85 -125.2 158.78 33.15 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 115.178 -0.919 . . . . 0.0 110.65 179.586 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.578 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.8 t80 -93.02 136.47 33.25 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.912 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.2 mt . . . . . 0 C--O 1.251 1.181 0 CA-C-O 118.478 -0.772 . . . . 0.0 110.878 179.754 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.272 . . . . . . . 0 C--O 1.235 0.307 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 170.42 51.35 0.04 OUTLIER Glycine 0 C--N 1.337 0.592 0 CA-C-N 115.791 -0.641 . . . . 0.0 112.576 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.409 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.1 p -129.03 155.27 45.67 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 122.298 0.239 . . . . 0.0 110.864 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.28 152.8 18.95 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.828 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.433 ' O ' ' HG2' ' A' ' 8' ' ' GLU . 14.2 p90 -97.64 174.99 6.36 Favored 'General case' 0 CA--C 1.537 0.464 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.615 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.572 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.4 tt0 -65.23 130.99 45.35 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 123.095 0.558 . . . . 0.0 112.362 -179.287 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 100.08 12.85 38.34 Favored Glycine 0 C--N 1.339 0.723 0 CA-C-N 115.628 -0.714 . . . . 0.0 114.661 178.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.433 ' HG2' ' O ' ' A' ' 5' ' ' PHE . 8.8 pt-20 -136.87 175.96 9.14 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 117.592 0.696 . . . . 0.0 111.455 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 53.0 m -90.85 138.39 31.63 Favored 'General case' 0 C--N 1.343 0.299 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.132 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 p -131.52 128.18 38.78 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.837 -179.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -97.07 118.86 34.42 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.02 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.6 HG21 ' O ' ' A' ' 30' ' ' PRO . 26.8 m -72.45 12.74 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.86 -178.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 5.9 tp60 -106.46 -31.02 8.73 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.518 -179.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.7 p90 -146.87 -27.22 0.4 Allowed 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 112.81 0.67 . . . . 0.0 112.81 -178.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -126.45 88.37 54.48 Favored Pre-proline 0 CA--C 1.545 0.766 0 N-CA-C 111.607 0.225 . . . . 0.0 111.607 -178.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.409 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 62.3 Cg_endo -78.16 177.86 8.27 Favored 'Trans proline' 0 C--N 1.37 1.681 0 C-N-CA 122.348 2.032 . . . . 0.0 112.732 179.366 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.697 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.7 t -88.91 161.15 16.82 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.904 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 75.5 m -79.96 108.49 9.33 Favored Pre-proline 0 CA--C 1.545 0.758 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.87 -179.383 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.438 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 75.7 Cg_endo -83.07 177.52 6.6 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.485 2.123 . . . . 0.0 112.929 179.423 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.81 -40.11 2.53 Favored Glycine 0 C--N 1.34 0.759 0 C-N-CA 121.392 -0.432 . . . . 0.0 112.969 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.86 -39.18 13.22 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 122.408 0.283 . . . . 0.0 111.427 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.01 52.33 0.19 Allowed Glycine 0 C--N 1.339 0.709 0 O-C-N 123.467 0.479 . . . . 0.0 112.497 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.457 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.9 mt -115.74 149.79 37.9 Favored 'General case' 0 C--O 1.235 0.319 0 O-C-N 123.584 0.226 . . . . 0.0 110.86 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.422 ' O ' ' HA ' ' A' ' 34' ' ' CYS . 8.8 t -139.36 155.34 47.73 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.353 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.697 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 68.1 m -98.66 118.8 36.2 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.548 179.53 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.5 mt -129.1 126.55 23.13 Favored Pre-proline 0 CA--C 1.544 0.736 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.433 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.477 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 38.3 Cg_endo -68.69 -42.5 0.7 Allowed 'Cis proline' 0 C--N 1.376 2.005 0 C-N-CA 124.597 -1.001 . . . . 0.0 113.453 -0.208 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 82.29 35.56 20.2 Favored Glycine 0 C--N 1.344 1.013 0 O-C-N 123.349 0.406 . . . . 0.0 113.524 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.477 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.8 p30 -148.09 80.81 8.5 Favored Pre-proline 0 CA--C 1.547 0.852 0 CA-C-N 116.653 0.226 . . . . 0.0 111.352 179.744 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.6 ' O ' HG21 ' A' ' 12' ' ' VAL . 58.3 Cg_endo -87.25 -27.73 5.04 Favored 'Cis proline' 0 C--N 1.37 1.684 0 C-N-CA 124.516 -1.035 . . . . 0.0 113.353 -0.246 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -88.73 147.98 24.21 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.675 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -150.2 -174.27 21.24 Favored Glycine 0 C--N 1.335 0.526 0 CA-C-N 115.624 -0.716 . . . . 0.0 112.674 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.493 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.3 OUTLIER -127.22 143.38 51.26 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.321 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.422 ' HA ' ' O ' ' A' ' 24' ' ' THR . 55.6 m -87.58 114.17 23.94 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-O 121.095 0.474 . . . . 0.0 111.962 -179.433 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . 0.457 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 43.8 m-85 -126.7 160.22 31.43 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 114.988 -1.006 . . . . 0.0 110.429 179.274 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.572 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.5 t80 -94.07 134.33 36.61 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.979 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.112 -0.947 . . . . 0.0 110.833 179.779 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.268 . . . . . . . 0 CA--C 1.534 0.332 0 N-CA-C 112.493 0.553 . . . . 0.0 112.493 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.15 53.4 1.09 Allowed Glycine 0 C--N 1.341 0.82 0 O-C-N 123.436 0.46 . . . . 0.0 112.541 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.1 p -128.94 155.09 45.87 Favored 'General case' 0 C--O 1.235 0.315 0 C-N-CA 122.296 0.238 . . . . 0.0 110.928 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.537 ' HB3' ' OE1' ' A' ' 8' ' ' GLU . . . -92.8 151.94 19.73 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.664 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 17.1 p90 -99.05 173.12 6.98 Favored 'General case' 0 CA--C 1.537 0.468 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.839 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.57 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 14.0 tt0 -60.87 130.91 48.83 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.308 0.643 . . . . 0.0 112.284 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 107.62 -25.33 21.54 Favored Glycine 0 C--N 1.337 0.618 0 CA-C-N 115.657 -0.702 . . . . 0.0 114.217 178.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.537 ' OE1' ' HB3' ' A' ' 4' ' ' ALA . 5.4 pt-20 -103.72 178.75 4.47 Favored 'General case' 0 CA--C 1.541 0.608 0 CA-C-N 117.251 0.525 . . . . 0.0 111.833 -179.145 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 51.3 m -93.34 151.1 19.99 Favored 'General case' 0 C--N 1.344 0.362 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.163 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.1 p -139.77 132.2 28.54 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.843 -179.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -99.78 118.42 36.23 Favored 'General case' 0 C--O 1.236 0.387 0 O-C-N 123.635 0.584 . . . . 0.0 110.657 179.366 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.586 HG22 ' O ' ' A' ' 30' ' ' PRO . 30.6 m -71.05 10.45 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -178.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.499 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.1 OUTLIER -101.58 -34.86 9.34 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.204 -179.479 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.499 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.8 p90 -146.72 -27.35 0.4 Allowed 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -178.497 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.8 t80 -121.79 86.12 45.31 Favored Pre-proline 0 CA--C 1.545 0.77 0 N-CA-C 111.75 0.278 . . . . 0.0 111.75 -178.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -78.0 176.53 9.87 Favored 'Trans proline' 0 C--N 1.369 1.607 0 C-N-CA 122.251 1.967 . . . . 0.0 112.671 179.356 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.7 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 4.6 t -86.45 162.14 18.27 Favored 'General case' 0 N--CA 1.468 0.452 0 O-C-N 123.203 0.314 . . . . 0.0 110.824 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.7 m -79.94 108.64 9.68 Favored Pre-proline 0 CA--C 1.545 0.756 0 N-CA-C 112.06 0.393 . . . . 0.0 112.06 -179.224 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.432 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 74.7 Cg_endo -83.02 177.67 6.52 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.467 2.111 . . . . 0.0 112.927 179.363 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.49 -41.17 2.24 Favored Glycine 0 C--N 1.339 0.731 0 C-N-CA 121.352 -0.451 . . . . 0.0 112.909 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.27 -39.02 13.78 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 122.464 0.306 . . . . 0.0 111.402 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.408 ' O ' ' HA ' ' A' ' 36' ' ' TYR . . . 124.02 55.05 0.19 Allowed Glycine 0 C--N 1.338 0.69 0 O-C-N 123.509 0.506 . . . . 0.0 112.535 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.469 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 25.4 mt -119.73 147.96 43.97 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-O 120.571 0.224 . . . . 0.0 110.897 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -140.1 155.36 47.04 Favored 'General case' 0 CA--C 1.536 0.434 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.358 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.7 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 91.0 m -98.3 117.42 32.66 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.512 179.446 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.8 mt -127.2 125.82 24.13 Favored Pre-proline 0 CA--C 1.544 0.743 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.348 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.458 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 41.8 Cg_endo -69.18 -41.9 0.82 Allowed 'Cis proline' 0 C--N 1.376 1.985 0 C-N-CA 124.569 -1.013 . . . . 0.0 113.509 -0.038 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 84.42 38.2 10.1 Favored Glycine 0 C--N 1.344 0.991 0 O-C-N 123.376 0.422 . . . . 0.0 113.471 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.458 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.9 p30 -150.92 81.05 6.44 Favored Pre-proline 0 CA--C 1.547 0.859 0 C-N-CA 122.279 0.231 . . . . 0.0 111.232 179.54 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.586 ' O ' HG22 ' A' ' 12' ' ' VAL . 57.0 Cg_endo -87.25 -28.25 4.59 Favored 'Cis proline' 0 C--N 1.37 1.663 0 C-N-CA 124.584 -1.007 . . . . 0.0 113.35 -0.312 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -87.15 148.7 25.08 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.637 -179.608 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.91 158.58 28.93 Favored Glycine 0 C--N 1.335 0.513 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.13 179.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.404 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.2 OUTLIER -97.2 144.15 27.29 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 110.285 -0.265 . . . . 0.0 110.285 179.868 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 19.5 m -88.07 110.94 21.02 Favored 'General case' 0 C--O 1.239 0.528 0 O-C-N 123.428 0.455 . . . . 0.0 111.584 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . 0.469 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 45.7 m-85 -123.55 161.04 25.73 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.703 179.569 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.57 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.1 t80 -94.15 136.21 34.68 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.872 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.2 mt . . . . . 0 C--O 1.249 1.029 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.847 179.75 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.273 . . . . . . . 0 C--O 1.235 0.337 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -112.31 65.93 0.25 Allowed Glycine 0 C--N 1.337 0.602 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.536 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.411 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.6 p -100.19 154.64 18.28 Favored 'General case' 0 C--O 1.236 0.344 0 O-C-N 123.593 0.231 . . . . 0.0 110.923 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.517 ' HB1' ' OE1' ' A' ' 8' ' ' GLU . . . -91.8 152.11 20.28 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.811 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 18.7 p90 -98.0 174.03 6.76 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.705 179.083 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.574 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.1 tt0 -64.16 130.1 42.6 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 123.186 0.594 . . . . 0.0 112.326 -179.291 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 102.19 9.61 41.51 Favored Glycine 0 C--N 1.339 0.71 0 CA-C-N 115.68 -0.691 . . . . 0.0 114.702 178.659 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.517 ' OE1' ' HB1' ' A' ' 4' ' ' ALA . 6.0 pt-20 -135.16 177.53 7.74 Favored 'General case' 0 CA--C 1.541 0.596 0 CA-C-N 117.707 0.754 . . . . 0.0 111.545 179.729 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 15.9 t -90.71 141.75 28.47 Favored 'General case' 0 C--N 1.343 0.317 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.941 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.5 p -133.66 128.91 36.03 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.894 -179.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.16 119.92 39.08 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.912 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.593 HG23 ' O ' ' A' ' 30' ' ' PRO . 28.8 m -72.68 11.85 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 N-CA-C 112.926 0.713 . . . . 0.0 112.926 -178.839 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 5.7 tp60 -105.41 -29.91 9.93 Favored 'General case' 0 CA--C 1.535 0.372 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.6 -179.369 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -148.99 -26.57 0.3 Allowed 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 112.789 0.663 . . . . 0.0 112.789 -178.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.2 t80 -125.65 87.62 55.54 Favored Pre-proline 0 CA--C 1.545 0.76 0 N-CA-C 111.67 0.248 . . . . 0.0 111.67 -178.754 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.411 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.5 Cg_endo -77.86 177.47 8.76 Favored 'Trans proline' 0 C--N 1.369 1.648 0 C-N-CA 122.267 1.978 . . . . 0.0 112.796 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.677 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.9 t -89.92 160.01 16.65 Favored 'General case' 0 N--CA 1.467 0.387 0 O-C-N 123.233 0.333 . . . . 0.0 110.837 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 74.8 m -79.94 108.55 9.47 Favored Pre-proline 0 CA--C 1.545 0.763 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.953 -179.342 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.2 Cg_endo -83.28 177.43 6.52 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.49 2.127 . . . . 0.0 112.911 179.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.33 -40.24 2.49 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 121.373 -0.441 . . . . 0.0 113.003 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.34 -38.64 14.0 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 122.439 0.296 . . . . 0.0 111.508 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.58 50.46 0.21 Allowed Glycine 0 C--N 1.339 0.728 0 O-C-N 123.491 0.494 . . . . 0.0 112.495 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.434 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.2 mt -113.24 150.12 32.83 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 122.294 0.238 . . . . 0.0 110.92 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -139.54 154.45 47.66 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.392 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.677 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 60.0 m -97.45 123.2 41.22 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.536 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.8 mt -126.58 123.45 23.97 Favored Pre-proline 0 CA--C 1.545 0.758 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.322 -179.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.403 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.85 -40.76 1.1 Allowed 'Cis proline' 0 C--N 1.375 1.965 0 C-N-CA 124.646 -0.981 . . . . 0.0 112.561 0.062 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.81 32.6 9.86 Favored Glycine 0 C--N 1.342 0.885 0 CA-C-N 116.017 -0.538 . . . . 0.0 112.887 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.403 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.11 78.7 13.58 Favored Pre-proline 0 CA--C 1.546 0.821 0 C-N-CA 122.156 0.182 . . . . 0.0 111.321 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.593 ' O ' HG23 ' A' ' 12' ' ' VAL . 59.3 Cg_endo -90.18 -26.4 4.45 Favored 'Cis proline' 0 C--N 1.369 1.636 0 C-N-CA 124.686 -0.964 . . . . 0.0 113.676 -0.276 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.6 152.63 20.81 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 115.96 -0.564 . . . . 0.0 112.011 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -155.33 -171.72 22.22 Favored Glycine 0 C--N 1.337 0.619 0 CA-C-N 115.449 -0.796 . . . . 0.0 112.57 179.561 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.507 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -127.25 145.26 50.84 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.55 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 51.3 m -89.06 111.89 22.72 Favored 'General case' 0 C--O 1.24 0.554 0 CA-C-O 121.076 0.465 . . . . 0.0 111.675 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . 0.434 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.8 m-85 -125.94 159.86 31.5 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.527 179.43 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.574 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 14.5 t80 -93.32 136.06 33.94 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.988 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.4 mt . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.151 -0.928 . . . . 0.0 110.943 179.693 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.272 . . . . . . . 0 C--O 1.235 0.317 0 N-CA-C 112.152 0.427 . . . . 0.0 112.152 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -100.2 -52.82 1.13 Allowed Glycine 0 C--N 1.337 0.612 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.61 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.0 p -98.57 155.29 17.36 Favored 'General case' 0 C--O 1.236 0.369 0 C-N-CA 122.316 0.247 . . . . 0.0 111.01 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.534 ' HB1' ' OE1' ' A' ' 8' ' ' GLU . . . -91.72 151.14 20.78 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.752 -179.81 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 17.0 p90 -98.96 171.95 7.72 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.842 179.351 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.579 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.2 tt0 -60.45 129.55 42.19 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 123.38 0.672 . . . . 0.0 112.395 -179.337 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.18 -19.93 31.47 Favored Glycine 0 C--N 1.338 0.687 0 CA-C-N 115.659 -0.701 . . . . 0.0 114.468 178.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.534 ' OE1' ' HB1' ' A' ' 4' ' ' ALA . 6.2 pt-20 -108.04 177.54 4.78 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 117.464 0.632 . . . . 0.0 111.817 -179.303 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 41.0 p -91.56 144.45 25.53 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.078 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.1 p -133.1 128.7 36.72 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.946 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -99.91 120.19 39.4 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.764 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.599 HG22 ' O ' ' A' ' 30' ' ' PRO . 29.5 m -72.25 10.45 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 N-CA-C 113.051 0.76 . . . . 0.0 113.051 -178.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.404 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 1.6 tp-100 -104.43 -29.51 10.67 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.693 -179.4 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.404 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.7 -26.55 0.27 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -178.793 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -125.12 87.51 55.4 Favored Pre-proline 0 CA--C 1.546 0.793 0 N-CA-C 111.694 0.257 . . . . 0.0 111.694 -178.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -77.82 175.68 10.92 Favored 'Trans proline' 0 C--N 1.369 1.654 0 C-N-CA 122.28 1.987 . . . . 0.0 112.704 179.466 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.685 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.8 t -88.68 160.78 17.19 Favored 'General case' 0 N--CA 1.468 0.467 0 O-C-N 123.221 0.325 . . . . 0.0 110.793 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.9 m -79.99 108.44 9.25 Favored Pre-proline 0 CA--C 1.545 0.777 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.6 Cg_endo -83.54 177.59 6.23 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.453 2.102 . . . . 0.0 112.93 179.286 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.89 -40.44 2.44 Favored Glycine 0 C--N 1.34 0.767 0 C-N-CA 121.324 -0.465 . . . . 0.0 112.951 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.9 mt -88.57 -38.63 14.74 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 122.418 0.287 . . . . 0.0 111.551 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.75 51.76 0.2 Allowed Glycine 0 C--N 1.339 0.723 0 O-C-N 123.461 0.475 . . . . 0.0 112.565 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.465 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 22.7 mt -115.76 149.26 38.77 Favored 'General case' 0 C--O 1.235 0.3 0 O-C-N 123.607 0.239 . . . . 0.0 110.874 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t -139.1 154.4 48.14 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.246 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.685 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 66.4 m -97.22 123.26 40.95 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.645 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 11.3 mt -127.16 122.94 23.24 Favored Pre-proline 0 CA--C 1.546 0.789 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.315 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -75.87 -41.01 1.03 Allowed 'Cis proline' 0 C--N 1.374 1.893 0 C-N-CA 124.696 -0.96 . . . . 0.0 112.64 0.112 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.18 32.8 9.32 Favored Glycine 0 C--N 1.343 0.931 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.93 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -144.49 79.08 12.81 Favored Pre-proline 0 CA--C 1.547 0.842 0 C-N-CA 122.215 0.206 . . . . 0.0 111.322 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.599 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.2 Cg_endo -89.88 -26.59 4.48 Favored 'Cis proline' 0 C--N 1.37 1.682 0 C-N-CA 124.667 -0.972 . . . . 0.0 113.68 -0.284 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.43 152.65 20.87 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.941 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.27 -173.95 23.82 Favored Glycine 0 C--N 1.337 0.632 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.649 179.577 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.463 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.6 OUTLIER -124.54 143.66 50.55 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.563 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.3 m -88.11 110.41 20.63 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-O 121.085 0.469 . . . . 0.0 111.607 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . 0.465 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 34.2 m-85 -124.57 158.95 31.77 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.681 179.549 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.579 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 11.9 t80 -93.33 135.93 34.08 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.964 -179.878 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.7 mt . . . . . 0 C--O 1.249 1.05 0 CA-C-O 118.115 -0.945 . . . . 0.0 110.901 179.765 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.269 . . . . . . . 0 CA--C 1.534 0.338 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 137.65 38.94 0.13 Allowed Glycine 0 C--N 1.34 0.777 0 O-C-N 123.434 0.459 . . . . 0.0 112.886 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.409 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.4 p -134.96 154.36 51.74 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 122.481 0.312 . . . . 0.0 110.805 179.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.521 ' HB3' ' OE1' ' A' ' 8' ' ' GLU . . . -91.43 151.58 20.75 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.763 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 18.2 p90 -98.27 173.6 6.91 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.688 179.263 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.573 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.0 tt0 -63.23 129.93 42.41 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.185 0.594 . . . . 0.0 112.364 -179.299 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 102.37 5.37 49.15 Favored Glycine 0 C--N 1.339 0.717 0 CA-C-N 115.673 -0.694 . . . . 0.0 114.725 178.606 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.521 ' OE1' ' HB3' ' A' ' 4' ' ' ALA . 5.0 pt-20 -131.72 177.86 7.19 Favored 'General case' 0 CA--C 1.539 0.538 0 CA-C-N 117.678 0.739 . . . . 0.0 111.599 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.429 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 43.1 p -90.24 146.49 24.2 Favored 'General case' 0 C--N 1.344 0.331 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.301 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.4 p -137.42 128.08 26.95 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.835 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -97.68 118.99 35.44 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.839 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.575 HG21 ' O ' ' A' ' 30' ' ' PRO . 22.6 m -71.25 9.61 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 N-CA-C 113.239 0.829 . . . . 0.0 113.239 -178.826 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.503 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.1 OUTLIER -101.28 -34.67 9.55 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.222 -179.548 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.503 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.9 p90 -147.33 -27.01 0.38 Allowed 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 -178.484 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 6.5 t80 -120.83 85.07 39.12 Favored Pre-proline 0 CA--C 1.544 0.732 0 N-CA-C 111.705 0.261 . . . . 0.0 111.705 -178.712 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.409 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.2 Cg_endo -77.95 177.96 8.17 Favored 'Trans proline' 0 C--N 1.369 1.619 0 C-N-CA 122.241 1.961 . . . . 0.0 112.704 179.461 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.687 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -89.17 160.47 16.97 Favored 'General case' 0 N--CA 1.468 0.437 0 O-C-N 123.157 0.285 . . . . 0.0 110.921 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 75.8 m -79.93 108.41 9.11 Favored Pre-proline 0 CA--C 1.545 0.772 0 N-CA-C 111.976 0.361 . . . . 0.0 111.976 -179.394 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.44 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 79.1 Cg_endo -83.07 177.47 6.63 Favored 'Trans proline' 0 C--N 1.371 1.732 0 C-N-CA 122.445 2.097 . . . . 0.0 113.002 179.411 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.01 -39.64 2.68 Favored Glycine 0 C--N 1.34 0.791 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.986 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.8 mt -89.14 -38.73 14.09 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 122.493 0.317 . . . . 0.0 111.503 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.15 50.07 0.22 Allowed Glycine 0 C--N 1.339 0.748 0 O-C-N 123.448 0.468 . . . . 0.0 112.474 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.441 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 20.6 mt -113.51 150.02 33.5 Favored 'General case' 0 C--O 1.235 0.315 0 O-C-N 123.628 0.252 . . . . 0.0 110.872 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -138.99 154.18 48.24 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.232 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.687 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 59.5 m -97.12 123.06 40.78 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.659 179.429 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 11.3 mt -127.34 123.24 23.19 Favored Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.268 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.421 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.3 Cg_exo -75.64 -40.87 1.07 Allowed 'Cis proline' 0 C--N 1.375 1.947 0 C-N-CA 124.636 -0.985 . . . . 0.0 112.507 0.094 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.04 33.62 8.79 Favored Glycine 0 C--N 1.342 0.877 0 O-C-N 123.596 0.56 . . . . 0.0 113.227 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.421 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.9 p30 -146.36 80.28 10.13 Favored Pre-proline 0 CA--C 1.547 0.855 0 CA-C-N 116.727 0.263 . . . . 0.0 111.556 179.575 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.575 ' O ' HG21 ' A' ' 12' ' ' VAL . 58.7 Cg_endo -89.27 -26.9 4.59 Favored 'Cis proline' 0 C--N 1.37 1.675 0 C-N-CA 124.729 -0.946 . . . . 0.0 113.463 -0.345 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -86.94 149.92 24.44 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.578 -179.634 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.429 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -151.09 -178.82 26.28 Favored Glycine 0 C--N 1.335 0.509 0 CA-C-N 115.581 -0.736 . . . . 0.0 112.394 179.425 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.469 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -124.62 141.6 51.98 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 179.282 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 54.1 m -87.3 112.2 21.82 Favored 'General case' 0 C--O 1.24 0.575 0 O-C-N 123.48 0.488 . . . . 0.0 111.792 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . 0.441 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 35.0 m-85 -126.05 159.14 33.55 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.081 -0.963 . . . . 0.0 110.552 179.304 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.573 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.8 t80 -93.23 135.01 34.85 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.937 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.0 mt . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.11 -0.948 . . . . 0.0 110.898 179.776 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.272 . . . . . . . 0 C--O 1.235 0.34 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -125.05 57.46 0.68 Allowed Glycine 0 C--N 1.337 0.628 0 CA-C-N 115.897 -0.592 . . . . 0.0 112.489 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.414 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.2 p -99.93 156.69 17.01 Favored 'General case' 0 C--O 1.236 0.35 0 O-C-N 123.62 0.247 . . . . 0.0 110.981 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.6 147.97 22.45 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 112.138 0.422 . . . . 0.0 112.138 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.476 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.25 177.4 7.51 Favored 'General case' 0 CA--C 1.538 0.491 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.463 178.813 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.55 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.4 tt0 -74.46 136.14 42.29 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 122.844 0.458 . . . . 0.0 111.695 -179.743 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.87 9.49 58.44 Favored Glycine 0 C--N 1.338 0.671 0 CA-C-N 115.633 -0.712 . . . . 0.0 114.258 179.017 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.476 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.2 pt-20 -132.83 177.66 7.47 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 117.321 0.561 . . . . 0.0 111.376 179.8 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 42.8 p -88.16 147.28 24.97 Favored 'General case' 0 C--N 1.345 0.372 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.603 -179.409 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.5 p -138.7 128.02 24.35 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.684 -179.743 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.35 119.07 37.87 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.896 179.678 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.597 HG23 ' O ' ' A' ' 30' ' ' PRO . 27.7 m -72.11 9.39 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 -178.741 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.5 tp-100 -102.65 -29.91 11.25 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 116.625 -0.261 . . . . 0.0 111.685 -179.361 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -149.28 -26.82 0.28 Allowed 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 -178.715 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 12.4 t80 -125.32 87.84 55.03 Favored Pre-proline 0 CA--C 1.546 0.803 0 N-CA-C 111.596 0.221 . . . . 0.0 111.596 -178.649 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.414 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.2 Cg_endo -77.05 177.93 8.28 Favored 'Trans proline' 0 C--N 1.371 1.715 0 C-N-CA 122.29 1.993 . . . . 0.0 112.704 179.484 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.695 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.5 t -90.06 159.94 16.58 Favored 'General case' 0 N--CA 1.468 0.468 0 O-C-N 123.265 0.353 . . . . 0.0 110.923 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.414 ' O ' HD13 ' A' ' 23' ' ' LEU . 74.7 m -79.87 108.06 8.22 Favored Pre-proline 0 CA--C 1.546 0.799 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -179.473 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.465 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 80.2 Cg_endo -84.02 177.91 5.7 Favored 'Trans proline' 0 C--N 1.372 1.778 0 C-N-CA 122.493 2.128 . . . . 0.0 112.955 179.453 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.64 -39.56 2.72 Favored Glycine 0 C--N 1.34 0.752 0 C-N-CA 121.371 -0.442 . . . . 0.0 112.953 179.76 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.6 mp -89.79 -37.07 14.76 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 122.45 0.3 . . . . 0.0 111.464 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.43 52.04 0.22 Allowed Glycine 0 C--N 1.338 0.687 0 O-C-N 123.455 0.472 . . . . 0.0 112.357 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.415 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 19.0 mt -113.62 149.56 34.39 Favored 'General case' 0 C--O 1.234 0.265 0 O-C-N 123.624 0.25 . . . . 0.0 110.972 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.2 t -138.94 152.08 47.42 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.315 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.695 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 55.7 m -96.76 122.69 39.99 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.608 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.9 mt -127.13 122.88 23.25 Favored Pre-proline 0 CA--C 1.545 0.772 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.328 -179.753 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.402 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.69 -41.28 0.99 Allowed 'Cis proline' 0 C--N 1.375 1.933 0 C-N-CA 124.651 -0.979 . . . . 0.0 112.593 0.04 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.7 31.68 9.97 Favored Glycine 0 C--N 1.342 0.905 0 O-C-N 123.582 0.551 . . . . 0.0 113.044 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.402 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.8 p30 -145.12 80.8 10.92 Favored Pre-proline 0 CA--C 1.547 0.832 0 CA-C-N 116.569 0.184 . . . . 0.0 111.258 179.705 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.597 ' O ' HG23 ' A' ' 12' ' ' VAL . 59.8 Cg_endo -89.31 -26.57 4.86 Favored 'Cis proline' 0 C--N 1.369 1.648 0 C-N-CA 124.654 -0.978 . . . . 0.0 113.609 -0.336 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -92.29 153.96 18.91 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.891 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -155.97 -172.87 23.91 Favored Glycine 0 C--N 1.337 0.625 0 CA-C-N 115.482 -0.781 . . . . 0.0 112.608 179.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.486 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -126.51 144.95 50.7 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.576 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 60.8 m -89.61 113.92 25.44 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-O 121.072 0.463 . . . . 0.0 111.765 -179.634 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . 0.415 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 35.3 m-85 -125.58 157.45 37.1 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.471 179.327 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.55 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 19.4 t80 -92.5 133.65 35.73 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.985 -179.835 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt . . . . . 0 C--O 1.252 1.192 0 CA-C-O 118.507 -0.758 . . . . 0.0 110.898 179.787 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.271 . . . . . . . 0 C--O 1.236 0.354 0 N-CA-C 112.202 0.445 . . . . 0.0 112.202 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -145.17 59.77 0.5 Allowed Glycine 0 C--N 1.336 0.568 0 CA-C-N 115.875 -0.602 . . . . 0.0 112.511 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.414 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.1 p -99.82 156.8 16.92 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 122.305 0.242 . . . . 0.0 110.971 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.54 147.84 22.57 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 116.235 -0.439 . . . . 0.0 112.184 -179.696 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.479 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.15 177.62 7.47 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.478 178.779 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.543 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.1 tt0 -74.64 135.92 41.95 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 122.905 0.482 . . . . 0.0 111.712 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.71 10.17 58.04 Favored Glycine 0 C--N 1.339 0.716 0 CA-C-N 115.596 -0.729 . . . . 0.0 114.292 179.027 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.479 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.3 pt-20 -132.99 177.55 7.57 Favored 'General case' 0 CA--C 1.54 0.578 0 CA-C-N 117.342 0.571 . . . . 0.0 111.403 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.8 m -88.33 146.42 25.3 Favored 'General case' 0 C--N 1.344 0.346 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.567 -179.478 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.5 p -138.26 128.57 26.03 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.689 -179.759 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -100.76 119.27 38.38 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.87 179.749 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.0 m -72.12 9.39 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 N-CA-C 113.063 0.764 . . . . 0.0 113.063 -178.785 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.6 tp-100 -102.72 -30.04 11.14 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.583 -0.28 . . . . 0.0 111.661 -179.331 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -149.0 -26.83 0.29 Allowed 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 112.864 0.69 . . . . 0.0 112.864 -178.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 12.5 t80 -125.28 87.77 55.12 Favored Pre-proline 0 CA--C 1.546 0.818 0 N-CA-C 111.63 0.233 . . . . 0.0 111.63 -178.639 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.414 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.2 Cg_endo -77.11 177.67 8.58 Favored 'Trans proline' 0 C--N 1.37 1.671 0 C-N-CA 122.269 1.979 . . . . 0.0 112.682 179.527 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.693 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.3 t -89.85 160.05 16.67 Favored 'General case' 0 N--CA 1.467 0.397 0 O-C-N 123.234 0.334 . . . . 0.0 110.947 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.421 ' O ' HD11 ' A' ' 23' ' ' LEU . 74.2 m -79.85 108.08 8.26 Favored Pre-proline 0 CA--C 1.545 0.782 0 O-C-N 123.247 0.342 . . . . 0.0 111.916 -179.47 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 79.6 Cg_endo -83.91 177.92 5.76 Favored 'Trans proline' 0 C--N 1.371 1.728 0 C-N-CA 122.554 2.169 . . . . 0.0 112.972 179.42 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.54 -38.97 2.9 Favored Glycine 0 C--N 1.34 0.773 0 C-N-CA 121.374 -0.441 . . . . 0.0 113.007 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.1 mt -89.83 -36.97 14.79 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 122.461 0.304 . . . . 0.0 111.469 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.06 52.08 0.23 Allowed Glycine 0 C--N 1.339 0.713 0 O-C-N 123.514 0.509 . . . . 0.0 112.335 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.421 HD11 ' O ' ' A' ' 18' ' ' CYS . 18.9 mt -114.22 149.21 36.14 Favored 'General case' 0 C--O 1.235 0.321 0 O-C-N 123.671 0.277 . . . . 0.0 110.965 -179.687 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.1 t -138.83 151.93 47.42 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.29 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.693 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 56.1 m -96.76 122.48 39.76 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.595 179.411 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.6 mt -127.21 123.09 23.25 Favored Pre-proline 0 CA--C 1.545 0.759 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.372 -179.76 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.401 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -76.0 -41.0 1.03 Allowed 'Cis proline' 0 C--N 1.374 1.914 0 C-N-CA 124.625 -0.99 . . . . 0.0 112.612 0.055 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.77 32.78 9.69 Favored Glycine 0 C--N 1.343 0.929 0 O-C-N 123.548 0.53 . . . . 0.0 112.945 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.401 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.37 79.42 12.73 Favored Pre-proline 0 CA--C 1.546 0.823 0 C-N-CA 122.213 0.205 . . . . 0.0 111.343 179.762 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.595 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.2 Cg_endo -89.73 -26.53 4.63 Favored 'Cis proline' 0 C--N 1.37 1.66 0 C-N-CA 124.722 -0.949 . . . . 0.0 113.58 -0.213 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -91.18 153.79 19.77 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.892 -179.363 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.34 -172.54 23.83 Favored Glycine 0 C--N 1.337 0.622 0 CA-C-N 115.518 -0.765 . . . . 0.0 112.646 179.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.495 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -126.7 145.44 50.59 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.601 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 59.3 m -90.01 114.09 25.89 Favored 'General case' 0 C--O 1.239 0.545 0 O-C-N 123.42 0.45 . . . . 0.0 111.779 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . 0.417 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 35.9 m-85 -125.39 157.33 37.06 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.103 -0.953 . . . . 0.0 110.419 179.326 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.543 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 17.5 t80 -92.58 133.41 35.99 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.003 -179.808 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.251 1.169 0 CA-C-O 118.507 -0.758 . . . . 0.0 110.907 179.835 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.272 . . . . . . . 0 C--O 1.235 0.32 0 N-CA-C 112.122 0.416 . . . . 0.0 112.122 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -140.77 81.62 0.25 Allowed Glycine 0 C--N 1.337 0.616 0 CA-C-N 115.868 -0.606 . . . . 0.0 112.48 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.5 p -99.56 155.57 17.51 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 122.259 0.224 . . . . 0.0 111.063 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.546 ' HB3' ' OE1' ' A' ' 8' ' ' GLU . . . -93.72 152.28 19.06 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.693 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -99.1 172.16 7.56 Favored 'General case' 0 CA--C 1.537 0.45 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.865 179.351 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.572 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.9 tt0 -60.63 129.81 43.39 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 123.36 0.664 . . . . 0.0 112.396 -179.29 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.3 -21.93 27.88 Favored Glycine 0 C--N 1.338 0.687 0 CA-C-N 115.639 -0.709 . . . . 0.0 114.383 178.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.546 ' OE1' ' HB3' ' A' ' 4' ' ' ALA . 6.6 pt-20 -105.61 177.42 4.86 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-N 117.458 0.629 . . . . 0.0 111.821 -179.303 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 15.7 t -92.55 142.63 27.19 Favored 'General case' 0 C--N 1.343 0.321 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.966 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.8 p -132.46 129.27 39.01 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.853 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -97.59 119.11 35.55 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.049 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.596 HG23 ' O ' ' A' ' 30' ' ' PRO . 27.2 m -71.71 9.12 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.856 -179.021 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.451 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 23.1 tt0 -100.14 -30.17 12.08 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.251 -179.387 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.451 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.9 p90 -153.4 -27.68 0.14 Allowed 'General case' 0 N--CA 1.476 0.826 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -178.544 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.5 t80 -119.63 85.25 32.35 Favored Pre-proline 0 CA--C 1.545 0.757 0 N-CA-C 111.503 0.186 . . . . 0.0 111.503 -178.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.405 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.3 Cg_endo -77.69 175.28 11.42 Favored 'Trans proline' 0 C--N 1.368 1.597 0 C-N-CA 122.212 1.941 . . . . 0.0 112.757 179.619 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.638 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.2 t -87.28 162.28 17.51 Favored 'General case' 0 N--CA 1.467 0.396 0 O-C-N 123.246 0.341 . . . . 0.0 110.944 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.9 m -79.92 108.58 9.52 Favored Pre-proline 0 CA--C 1.545 0.762 0 N-CA-C 111.907 0.336 . . . . 0.0 111.907 -179.328 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.436 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 74.7 Cg_endo -82.85 177.58 6.69 Favored 'Trans proline' 0 C--N 1.372 1.792 0 C-N-CA 122.453 2.102 . . . . 0.0 112.993 179.385 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.08 -40.04 2.55 Favored Glycine 0 C--N 1.339 0.735 0 C-N-CA 121.356 -0.449 . . . . 0.0 112.904 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -90.16 -39.49 12.81 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 122.446 0.298 . . . . 0.0 111.386 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.28 53.76 0.19 Allowed Glycine 0 C--N 1.339 0.75 0 O-C-N 123.516 0.51 . . . . 0.0 112.514 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.462 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 23.0 mt -117.3 149.24 40.79 Favored 'General case' 0 C--O 1.235 0.297 0 O-C-N 123.632 0.254 . . . . 0.0 110.962 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 t -139.58 156.97 46.56 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.276 -179.816 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.638 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 98.9 m -99.25 119.54 38.08 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.699 179.619 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.8 mt -129.79 126.12 22.45 Favored Pre-proline 0 CA--C 1.545 0.783 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.348 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.544 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 43.1 Cg_endo -69.81 -42.58 0.73 Allowed 'Cis proline' 0 C--N 1.375 1.956 0 C-N-CA 124.578 -1.009 . . . . 0.0 113.449 -0.22 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 82.1 39.34 11.58 Favored Glycine 0 C--N 1.345 1.03 0 O-C-N 123.358 0.411 . . . . 0.0 113.275 179.785 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.544 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -147.81 78.52 9.77 Favored Pre-proline 0 CA--C 1.548 0.87 0 C-N-CA 122.3 0.24 . . . . 0.0 111.402 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.596 ' O ' HG23 ' A' ' 12' ' ' VAL . 59.6 Cg_endo -87.83 -26.86 5.5 Favored 'Cis proline' 0 C--N 1.369 1.612 0 C-N-CA 124.571 -1.012 . . . . 0.0 113.355 -0.273 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -87.06 147.54 25.64 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.705 -179.591 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -149.54 -175.78 22.14 Favored Glycine 0 C--N 1.336 0.556 0 CA-C-N 115.612 -0.722 . . . . 0.0 112.712 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.495 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.8 OUTLIER -124.24 143.15 50.69 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.505 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.5 m -87.47 112.01 21.75 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-O 121.086 0.469 . . . . 0.0 111.778 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . 0.462 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 40.5 m-85 -125.81 159.87 31.31 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.605 179.458 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.572 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.4 t80 -93.74 135.15 35.33 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.94 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.5 mt . . . . . 0 C--O 1.251 1.136 0 CA-C-O 118.472 -0.775 . . . . 0.0 110.875 179.759 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.271 . . . . . . . 0 C--O 1.235 0.315 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -119.98 -50.19 0.29 Allowed Glycine 0 C--N 1.336 0.56 0 CA-C-N 115.872 -0.604 . . . . 0.0 112.633 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.409 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 28.2 p -97.65 157.22 16.16 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 122.357 0.263 . . . . 0.0 111.03 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.3 147.72 22.85 Favored 'General case' 0 C--O 1.237 0.417 0 N-CA-C 112.176 0.435 . . . . 0.0 112.176 -179.621 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.473 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.08 177.5 7.54 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 115.098 -0.955 . . . . 0.0 110.426 178.847 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.541 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.4 tt0 -74.85 135.89 41.56 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 122.875 0.47 . . . . 0.0 111.693 -179.698 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.44 10.91 57.72 Favored Glycine 0 C--N 1.339 0.725 0 CA-C-N 115.587 -0.733 . . . . 0.0 114.34 178.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.473 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.4 pt-20 -133.32 177.47 7.66 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 117.271 0.536 . . . . 0.0 111.392 179.821 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 43.1 p -88.04 145.65 25.87 Favored 'General case' 0 C--N 1.344 0.364 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.601 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.2 p -137.65 128.03 26.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.639 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.58 119.52 38.66 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.903 179.684 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.602 HG23 ' O ' ' A' ' 30' ' ' PRO . 28.6 m -72.03 8.9 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 N-CA-C 113.024 0.749 . . . . 0.0 113.024 -178.752 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.404 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 1.5 tp-100 -102.55 -29.86 11.31 Favored 'General case' 0 CA--C 1.535 0.388 0 N-CA-C 111.706 0.262 . . . . 0.0 111.706 -179.333 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.404 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.9 p90 -149.43 -26.74 0.28 Allowed 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -178.761 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.6 t80 -124.64 87.17 54.91 Favored Pre-proline 0 CA--C 1.547 0.829 0 N-CA-C 111.577 0.214 . . . . 0.0 111.577 -178.657 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -77.18 175.86 10.83 Favored 'Trans proline' 0 C--N 1.369 1.624 0 C-N-CA 122.293 1.995 . . . . 0.0 112.69 179.495 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.7 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.3 t -89.31 160.35 16.92 Favored 'General case' 0 N--CA 1.468 0.444 0 O-C-N 123.257 0.348 . . . . 0.0 110.886 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.443 ' O ' HD11 ' A' ' 23' ' ' LEU . 73.9 m -79.84 107.68 7.3 Favored Pre-proline 0 CA--C 1.545 0.777 0 O-C-N 123.286 0.367 . . . . 0.0 111.985 -179.561 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.472 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 81.5 Cg_endo -84.39 177.99 5.41 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.529 2.153 . . . . 0.0 112.984 179.41 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.66 -39.36 2.77 Favored Glycine 0 C--N 1.34 0.777 0 C-N-CA 121.41 -0.424 . . . . 0.0 113.033 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.6 mp -89.71 -38.05 14.14 Favored 'General case' 0 N--CA 1.467 0.423 0 C-N-CA 122.435 0.294 . . . . 0.0 111.489 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.65 52.55 0.19 Allowed Glycine 0 C--N 1.339 0.7 0 O-C-N 123.452 0.47 . . . . 0.0 112.422 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.443 HD11 ' O ' ' A' ' 18' ' ' CYS . 19.6 mt -115.3 148.56 39.08 Favored 'General case' 0 C--O 1.235 0.323 0 O-C-N 123.668 0.276 . . . . 0.0 110.846 -179.7 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.411 ' HG1' ' N ' ' A' ' 25' ' ' CYS . 10.2 t -138.53 151.69 47.57 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.374 -179.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.7 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 54.3 m -97.03 121.98 39.52 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.597 179.412 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.5 mt -127.4 123.36 23.18 Favored Pre-proline 0 CA--C 1.545 0.786 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.364 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -75.95 -41.06 1.02 Allowed 'Cis proline' 0 C--N 1.375 1.923 0 C-N-CA 124.652 -0.978 . . . . 0.0 112.598 0.067 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.55 32.71 9.95 Favored Glycine 0 C--N 1.343 0.947 0 O-C-N 123.55 0.531 . . . . 0.0 112.95 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -144.09 79.33 13.15 Favored Pre-proline 0 CA--C 1.546 0.822 0 C-N-CA 122.178 0.191 . . . . 0.0 111.291 179.722 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.602 ' O ' HG23 ' A' ' 12' ' ' VAL . 59.7 Cg_endo -89.86 -26.32 4.73 Favored 'Cis proline' 0 C--N 1.37 1.708 0 C-N-CA 124.671 -0.97 . . . . 0.0 113.685 -0.338 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -91.1 153.65 19.93 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.93 -179.406 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.17 -172.37 23.52 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-N 115.533 -0.758 . . . . 0.0 112.662 179.467 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.479 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.6 OUTLIER -126.99 145.78 50.58 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.567 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 61.3 m -89.98 113.47 25.14 Favored 'General case' 0 C--O 1.239 0.549 0 O-C-N 123.455 0.472 . . . . 0.0 111.739 -179.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . 0.424 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 34.7 m-85 -123.77 157.19 34.58 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.47 179.316 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.541 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.7 t80 -93.41 132.72 37.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.989 -179.765 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt . . . . . 0 C--O 1.251 1.181 0 CA-C-O 118.455 -0.783 . . . . 0.0 110.872 179.797 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.273 . . . . . . . 0 C--O 1.235 0.292 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -122.02 -50.73 0.24 Allowed Glycine 0 C--N 1.337 0.589 0 CA-C-N 115.773 -0.649 . . . . 0.0 112.579 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.406 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 28.5 p -98.65 157.47 16.24 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 122.324 0.25 . . . . 0.0 111.043 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.84 147.22 23.14 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 116.259 -0.428 . . . . 0.0 112.093 -179.609 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.467 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.61 177.19 7.45 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.412 178.756 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.549 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 23.7 tt0 -74.1 134.69 42.91 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 122.9 0.48 . . . . 0.0 111.677 -179.649 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.45 9.73 57.55 Favored Glycine 0 C--N 1.339 0.712 0 CA-C-N 115.597 -0.729 . . . . 0.0 114.319 179.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.467 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.0 pt-20 -132.72 177.84 7.32 Favored 'General case' 0 CA--C 1.54 0.595 0 CA-C-N 117.371 0.586 . . . . 0.0 111.373 179.849 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.414 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 52.8 m -88.58 149.03 23.79 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.645 -179.379 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.2 p -141.38 129.12 21.64 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.615 -179.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -101.29 120.94 41.01 Favored 'General case' 0 N--CA 1.466 0.328 0 O-C-N 123.447 0.467 . . . . 0.0 110.516 179.632 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.573 HG21 ' O ' ' A' ' 30' ' ' PRO . 27.6 m -70.86 6.66 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 N-CA-C 113.689 0.996 . . . . 0.0 113.689 -178.228 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 5.9 tp60 -101.41 -30.3 11.53 Favored 'General case' 0 CA--C 1.534 0.354 0 N-CA-C 111.736 0.273 . . . . 0.0 111.736 -179.473 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.8 p90 -148.24 -27.55 0.33 Allowed 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 112.882 0.697 . . . . 0.0 112.882 -178.803 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -121.8 85.88 45.12 Favored Pre-proline 0 CA--C 1.545 0.786 0 N-CA-C 111.584 0.216 . . . . 0.0 111.584 -178.719 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -77.4 176.83 9.59 Favored 'Trans proline' 0 C--N 1.369 1.614 0 C-N-CA 122.265 1.976 . . . . 0.0 112.606 179.51 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.696 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.0 t -89.07 160.1 17.23 Favored 'General case' 0 N--CA 1.468 0.442 0 O-C-N 123.226 0.329 . . . . 0.0 110.944 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 72.3 m -79.84 108.09 8.27 Favored Pre-proline 0 CA--C 1.546 0.805 0 N-CA-C 111.948 0.351 . . . . 0.0 111.948 -179.542 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.463 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 76.4 Cg_endo -83.69 178.0 5.84 Favored 'Trans proline' 0 C--N 1.372 1.797 0 C-N-CA 122.534 2.156 . . . . 0.0 112.979 179.473 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.69 -39.35 2.77 Favored Glycine 0 C--N 1.34 0.789 0 C-N-CA 121.401 -0.428 . . . . 0.0 112.935 179.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.6 mt -89.9 -36.68 14.9 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 122.447 0.299 . . . . 0.0 111.442 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.35 52.92 0.23 Allowed Glycine 0 C--N 1.339 0.716 0 O-C-N 123.496 0.498 . . . . 0.0 112.376 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.45 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 18.8 mt -115.4 148.53 39.24 Favored 'General case' 0 C--O 1.235 0.334 0 O-C-N 123.67 0.277 . . . . 0.0 110.953 -179.683 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.414 ' HG1' ' N ' ' A' ' 25' ' ' CYS . 9.8 t -138.83 152.22 47.67 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.296 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.696 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 61.7 m -96.47 122.34 39.26 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.551 179.43 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.6 mt -127.41 122.73 22.93 Favored Pre-proline 0 CA--C 1.546 0.809 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.385 -179.787 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.416 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.66 -41.54 0.95 Allowed 'Cis proline' 0 C--N 1.374 1.909 0 C-N-CA 124.677 -0.968 . . . . 0.0 112.569 0.083 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 91.17 31.47 9.72 Favored Glycine 0 C--N 1.342 0.914 0 O-C-N 123.562 0.538 . . . . 0.0 113.128 179.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.416 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.9 p30 -143.95 82.79 10.79 Favored Pre-proline 0 CA--C 1.547 0.845 0 CA-C-N 116.707 0.253 . . . . 0.0 111.391 179.633 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.573 ' O ' HG21 ' A' ' 12' ' ' VAL . 75.7 Cg_endo -87.26 -27.01 5.67 Favored 'Cis proline' 0 C--N 1.37 1.707 0 C-N-CA 124.59 -1.004 . . . . 0.0 113.439 -0.43 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -94.12 156.65 16.46 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.67 -179.032 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.414 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.65 -173.6 25.35 Favored Glycine 0 C--N 1.336 0.56 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.452 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.466 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.5 OUTLIER -124.77 143.81 50.59 Favored 'General case' 0 C--O 1.234 0.271 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.607 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.41 ' HA ' ' O ' ' A' ' 24' ' ' THR . 56.7 m -89.08 114.37 25.6 Favored 'General case' 0 C--O 1.239 0.536 0 O-C-N 123.452 0.47 . . . . 0.0 111.818 -179.569 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . 0.45 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.0 m-85 -125.51 157.97 35.67 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.051 -0.977 . . . . 0.0 110.466 179.287 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.549 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 17.7 t80 -92.53 133.12 36.25 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.984 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.104 -0.951 . . . . 0.0 110.977 179.827 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.273 . . . . . . . 0 C--O 1.236 0.353 0 N-CA-C 112.19 0.441 . . . . 0.0 112.19 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -145.73 24.75 1.8 Allowed Glycine 0 C--N 1.337 0.598 0 CA-C-N 115.95 -0.568 . . . . 0.0 113.195 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.427 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.6 p -134.51 153.89 51.71 Favored 'General case' 0 N--CA 1.466 0.332 0 C-N-CA 122.301 0.24 . . . . 0.0 110.868 179.827 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.84 151.72 20.44 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.784 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.405 ' O ' ' HG2' ' A' ' 8' ' ' GLU . 15.3 p90 -97.32 174.78 6.53 Favored 'General case' 0 CA--C 1.537 0.477 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.687 179.117 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.569 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.1 tt0 -64.97 130.47 43.51 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 123.164 0.586 . . . . 0.0 112.253 -179.269 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 100.04 12.13 40.72 Favored Glycine 0 C--N 1.339 0.723 0 CA-C-N 115.62 -0.718 . . . . 0.0 114.674 178.656 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.405 ' HG2' ' O ' ' A' ' 5' ' ' PHE . 7.0 pt-20 -136.67 176.85 8.33 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 117.601 0.701 . . . . 0.0 111.47 179.632 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.424 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 40.6 p -90.23 144.8 25.53 Favored 'General case' 0 C--N 1.343 0.319 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.126 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 p -135.85 130.49 33.99 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.906 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -99.76 119.02 37.48 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.854 179.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.606 HG23 ' O ' ' A' ' 30' ' ' PRO . 30.5 m -72.71 10.58 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 N-CA-C 112.897 0.702 . . . . 0.0 112.897 -179.034 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.404 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.5 tp60 -104.26 -29.74 10.6 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.577 -179.425 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.404 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.48 -26.79 0.27 Allowed 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 112.819 0.674 . . . . 0.0 112.819 -178.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 9.7 t80 -124.98 86.96 55.99 Favored Pre-proline 0 CA--C 1.546 0.798 0 N-CA-C 111.622 0.23 . . . . 0.0 111.622 -178.697 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.427 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.1 Cg_endo -77.75 179.08 6.85 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 122.235 1.957 . . . . 0.0 112.739 179.512 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.688 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -89.91 160.22 16.54 Favored 'General case' 0 N--CA 1.467 0.376 0 O-C-N 123.183 0.302 . . . . 0.0 110.809 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 78.2 m -79.99 108.29 8.88 Favored Pre-proline 0 CA--C 1.545 0.773 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.907 -179.401 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.446 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.9 Cg_endo -83.44 177.53 6.34 Favored 'Trans proline' 0 C--N 1.371 1.753 0 C-N-CA 122.449 2.099 . . . . 0.0 112.95 179.441 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.79 -39.86 2.61 Favored Glycine 0 C--N 1.34 0.751 0 C-N-CA 121.374 -0.441 . . . . 0.0 112.946 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.8 mt -89.05 -38.1 14.64 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 122.444 0.298 . . . . 0.0 111.501 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.97 50.12 0.23 Allowed Glycine 0 C--N 1.339 0.706 0 O-C-N 123.481 0.488 . . . . 0.0 112.497 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.439 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.1 mt -113.85 149.73 34.62 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 122.294 0.238 . . . . 0.0 110.846 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -139.44 154.16 47.71 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.321 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.688 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.0 m -97.13 123.09 40.8 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.575 179.4 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.6 mt -127.2 123.09 23.25 Favored Pre-proline 0 CA--C 1.544 0.746 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.327 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.426 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.2 Cg_exo -75.7 -40.92 1.06 Allowed 'Cis proline' 0 C--N 1.375 1.922 0 C-N-CA 124.698 -0.959 . . . . 0.0 112.527 0.077 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.64 32.97 8.78 Favored Glycine 0 C--N 1.342 0.884 0 O-C-N 123.62 0.575 . . . . 0.0 113.123 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.426 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.7 p30 -145.68 81.39 10.08 Favored Pre-proline 0 CA--C 1.547 0.844 0 CA-C-N 116.756 0.278 . . . . 0.0 111.458 179.611 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.606 ' O ' HG23 ' A' ' 12' ' ' VAL . 60.7 Cg_endo -88.77 -26.53 5.24 Favored 'Cis proline' 0 C--N 1.371 1.715 0 C-N-CA 124.651 -0.979 . . . . 0.0 113.508 -0.407 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -90.46 155.24 19.06 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.347 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.424 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.19 -174.93 26.58 Favored Glycine 0 C--N 1.334 0.465 0 CA-C-N 115.379 -0.828 . . . . 0.0 112.464 179.549 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.485 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.6 OUTLIER -125.72 143.24 51.13 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.493 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 52.8 m -88.69 112.74 23.49 Favored 'General case' 0 C--O 1.239 0.523 0 O-C-N 123.439 0.462 . . . . 0.0 111.75 -179.644 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . 0.439 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 37.1 m-85 -126.48 159.26 33.89 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.051 -0.977 . . . . 0.0 110.519 179.36 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.569 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.5 t80 -92.77 135.34 34.2 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.006 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.9 mt . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.115 -0.945 . . . . 0.0 110.87 179.819 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.269 . . . . . . . 0 CA--C 1.534 0.347 0 N-CA-C 112.465 0.543 . . . . 0.0 112.465 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 118.32 -74.04 0.29 Allowed Glycine 0 C--N 1.341 0.821 0 O-C-N 123.427 0.454 . . . . 0.0 112.541 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.409 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 29.0 p -100.22 156.9 16.96 Favored 'General case' 0 C--O 1.235 0.314 0 O-C-N 123.625 0.25 . . . . 0.0 111.004 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.0 147.81 22.52 Favored 'General case' 0 C--O 1.237 0.406 0 CA-C-N 116.243 -0.435 . . . . 0.0 112.121 -179.705 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.467 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.4 m-85 -86.53 176.98 7.54 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.432 178.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.57 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.2 tt0 -73.79 136.09 43.55 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 122.905 0.482 . . . . 0.0 111.693 -179.792 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.49 8.81 58.26 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 115.624 -0.716 . . . . 0.0 114.289 179.008 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.467 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.3 pt-20 -132.53 177.39 7.65 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 117.333 0.567 . . . . 0.0 111.41 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.0 m -88.36 146.4 25.29 Favored 'General case' 0 C--N 1.344 0.351 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.619 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.0 p -138.42 128.6 25.74 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.729 -179.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.4 119.57 38.65 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.918 179.678 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.602 HG21 ' O ' ' A' ' 30' ' ' PRO . 29.0 m -71.95 8.93 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 N-CA-C 113.035 0.754 . . . . 0.0 113.035 -178.757 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.403 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.4 tp60 -102.7 -30.1 11.11 Favored 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 111.687 0.254 . . . . 0.0 111.687 -179.34 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.403 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.9 p90 -149.02 -26.92 0.29 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.824 0.676 . . . . 0.0 112.824 -178.763 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -124.32 87.15 54.16 Favored Pre-proline 0 CA--C 1.546 0.804 0 N-CA-C 111.561 0.208 . . . . 0.0 111.561 -178.704 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.406 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.2 Cg_endo -76.97 177.09 9.31 Favored 'Trans proline' 0 C--N 1.37 1.659 0 C-N-CA 122.234 1.956 . . . . 0.0 112.771 179.604 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.689 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.3 t -89.69 159.86 16.89 Favored 'General case' 0 N--CA 1.468 0.442 0 O-C-N 123.272 0.358 . . . . 0.0 110.957 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.1 m -79.85 108.24 8.64 Favored Pre-proline 0 CA--C 1.545 0.779 0 N-CA-C 112.024 0.379 . . . . 0.0 112.024 -179.524 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.455 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 79.1 Cg_endo -83.6 177.88 5.99 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 122.512 2.142 . . . . 0.0 113.025 179.39 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.72 -39.76 2.65 Favored Glycine 0 C--N 1.34 0.759 0 O-C-N 123.395 0.434 . . . . 0.0 112.95 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.6 mp -89.8 -36.64 15.01 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 122.47 0.308 . . . . 0.0 111.444 -179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.43 51.63 0.24 Allowed Glycine 0 C--N 1.338 0.691 0 O-C-N 123.525 0.515 . . . . 0.0 112.323 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.429 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 19.3 mt -113.2 149.46 33.68 Favored 'General case' 0 C--O 1.234 0.288 0 O-C-N 123.632 0.254 . . . . 0.0 110.969 -179.663 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.0 t -139.08 153.0 47.98 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.239 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.689 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.1 m -96.81 123.09 40.41 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.546 179.448 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.9 mt -126.8 122.79 23.54 Favored Pre-proline 0 CA--C 1.545 0.771 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.401 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -75.93 -41.04 1.02 Allowed 'Cis proline' 0 C--N 1.375 1.925 0 C-N-CA 124.695 -0.961 . . . . 0.0 112.643 0.042 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.08 32.64 9.58 Favored Glycine 0 C--N 1.343 0.948 0 CA-C-N 116.024 -0.535 . . . . 0.0 112.914 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.3 p-10 -144.32 79.47 12.75 Favored Pre-proline 0 CA--C 1.546 0.803 0 C-N-CA 122.194 0.198 . . . . 0.0 111.349 179.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.602 ' O ' HG21 ' A' ' 12' ' ' VAL . 59.3 Cg_endo -89.69 -26.47 4.7 Favored 'Cis proline' 0 C--N 1.37 1.666 0 C-N-CA 124.695 -0.96 . . . . 0.0 113.593 -0.252 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -91.14 153.44 20.06 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.937 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -155.91 -172.57 23.54 Favored Glycine 0 C--N 1.338 0.658 0 CA-C-N 115.55 -0.75 . . . . 0.0 112.649 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.493 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.5 OUTLIER -126.55 144.86 50.74 Favored 'General case' 0 C--O 1.235 0.318 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.556 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 57.5 m -89.47 114.82 26.37 Favored 'General case' 0 C--O 1.239 0.538 0 O-C-N 123.429 0.456 . . . . 0.0 111.832 -179.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . 0.429 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 38.0 m-85 -128.14 157.87 39.6 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.512 179.291 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.57 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 20.4 t80 -91.75 134.86 34.36 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.995 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.3 mt . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.085 -0.96 . . . . 0.0 110.963 179.797 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.273 . . . . . . . 0 C--O 1.235 0.323 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -117.19 68.59 0.3 Allowed Glycine 0 C--N 1.337 0.614 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.54 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.408 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.0 p -98.69 156.69 16.7 Favored 'General case' 0 C--O 1.236 0.368 0 O-C-N 123.656 0.268 . . . . 0.0 110.942 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.07 147.18 23.14 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-N 116.226 -0.443 . . . . 0.0 112.158 -179.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.475 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.28 177.2 7.56 Favored 'General case' 0 CA--C 1.538 0.505 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.442 178.764 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.549 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 23.8 tt0 -73.95 134.87 43.18 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 122.932 0.493 . . . . 0.0 111.711 -179.755 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.27 9.39 58.05 Favored Glycine 0 C--N 1.339 0.713 0 CA-C-N 115.659 -0.7 . . . . 0.0 114.33 178.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.475 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.0 pt-20 -132.39 177.85 7.27 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 117.345 0.573 . . . . 0.0 111.419 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.426 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 51.8 m -88.47 149.15 23.81 Favored 'General case' 0 C--N 1.345 0.375 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.722 -179.393 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.4 p -141.56 129.48 21.87 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.656 -179.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -101.36 120.9 40.97 Favored 'General case' 0 C--O 1.235 0.326 0 O-C-N 123.384 0.428 . . . . 0.0 110.523 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.567 HG23 ' O ' ' A' ' 30' ' ' PRO . 27.4 m -71.04 7.12 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 N-CA-C 113.626 0.972 . . . . 0.0 113.626 -178.178 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.7 tp-100 -101.77 -30.6 11.2 Favored 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 -179.429 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.8 p90 -147.95 -27.44 0.34 Allowed 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 112.896 0.702 . . . . 0.0 112.896 -178.82 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -122.24 86.1 47.37 Favored Pre-proline 0 CA--C 1.546 0.798 0 N-CA-C 111.62 0.229 . . . . 0.0 111.62 -178.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.408 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.3 Cg_endo -77.51 177.59 8.66 Favored 'Trans proline' 0 C--N 1.369 1.653 0 C-N-CA 122.22 1.947 . . . . 0.0 112.573 179.458 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.696 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.0 t -89.19 160.11 17.13 Favored 'General case' 0 N--CA 1.468 0.44 0 O-C-N 123.202 0.314 . . . . 0.0 110.939 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.416 ' O ' HD13 ' A' ' 23' ' ' LEU . 73.5 m -79.82 108.27 8.67 Favored Pre-proline 0 CA--C 1.544 0.744 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.913 -179.589 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.456 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 75.8 Cg_endo -83.45 177.92 6.05 Favored 'Trans proline' 0 C--N 1.372 1.815 0 C-N-CA 122.525 2.15 . . . . 0.0 113.011 179.479 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.27 -39.05 2.86 Favored Glycine 0 C--N 1.34 0.771 0 C-N-CA 121.389 -0.434 . . . . 0.0 112.924 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.2 mt -90.25 -36.81 14.51 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 122.481 0.312 . . . . 0.0 111.468 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.1 53.05 0.23 Allowed Glycine 0 C--N 1.339 0.719 0 O-C-N 123.54 0.525 . . . . 0.0 112.338 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.441 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 18.3 mt -114.75 148.98 37.61 Favored 'General case' 0 C--O 1.235 0.317 0 O-C-N 123.686 0.286 . . . . 0.0 110.945 -179.648 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.407 ' O ' ' HA ' ' A' ' 34' ' ' CYS . 10.0 t -138.79 151.99 47.52 Favored 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.312 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.696 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 59.6 m -96.94 121.64 39.04 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.52 179.486 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.7 mt -127.69 123.69 23.08 Favored Pre-proline 0 CA--C 1.546 0.799 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.332 -179.758 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.407 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -76.01 -41.42 0.96 Allowed 'Cis proline' 0 C--N 1.374 1.903 0 C-N-CA 124.691 -0.962 . . . . 0.0 112.602 0.037 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.53 32.02 9.81 Favored Glycine 0 C--N 1.342 0.886 0 O-C-N 123.545 0.528 . . . . 0.0 113.062 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.407 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -141.86 81.17 14.94 Favored Pre-proline 0 CA--C 1.547 0.854 0 CA-C-N 116.65 0.225 . . . . 0.0 111.489 179.713 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.567 ' O ' HG23 ' A' ' 12' ' ' VAL . 76.3 Cg_endo -88.09 -26.0 6.19 Favored 'Cis proline' 0 C--N 1.371 1.719 0 C-N-CA 124.617 -0.993 . . . . 0.0 113.486 -0.326 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -93.68 156.71 16.54 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.637 -179.061 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.426 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.91 -172.5 24.22 Favored Glycine 0 C--N 1.337 0.59 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.436 179.558 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.475 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.3 OUTLIER -125.59 144.81 50.41 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.612 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . 0.407 ' HA ' ' O ' ' A' ' 24' ' ' THR . 57.0 m -89.44 114.3 25.76 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-O 121.094 0.473 . . . . 0.0 111.836 -179.676 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . 0.441 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 37.8 m-85 -124.92 157.74 35.28 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.418 179.302 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.549 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 19.8 t80 -92.85 133.03 36.48 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.959 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.251 1.146 0 CA-C-O 118.463 -0.78 . . . . 0.0 110.873 179.844 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.273 . . . . . . . 0 C--O 1.235 0.337 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -134.76 54.41 0.76 Allowed Glycine 0 C--N 1.336 0.572 0 O-C-N 123.695 0.622 . . . . 0.0 112.515 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.416 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.7 p -99.26 153.88 18.6 Favored 'General case' 0 C--O 1.235 0.328 0 O-C-N 123.608 0.24 . . . . 0.0 110.874 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.473 ' HB1' ' OE1' ' A' ' 8' ' ' GLU . . . -92.15 151.15 20.53 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.755 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 17.4 p90 -97.8 174.42 6.61 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.733 179.206 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.576 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 16.4 tt0 -63.06 130.52 45.05 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.253 0.621 . . . . 0.0 112.382 -179.308 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.1 9.09 46.08 Favored Glycine 0 C--N 1.339 0.696 0 CA-C-N 115.663 -0.699 . . . . 0.0 114.78 178.483 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.473 ' OE1' ' HB1' ' A' ' 4' ' ' ALA . 6.4 pt-20 -134.93 176.94 8.2 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 117.708 0.754 . . . . 0.0 111.565 179.703 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.435 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 40.0 p -90.79 143.69 26.47 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.199 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.5 p -134.55 131.37 37.85 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.957 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -100.61 118.88 37.67 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.842 179.576 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.593 HG23 ' O ' ' A' ' 30' ' ' PRO . 30.4 m -71.7 10.31 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -178.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.505 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.1 OUTLIER -100.99 -35.12 9.49 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.254 -179.428 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.505 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.9 p90 -146.84 -26.7 0.4 Allowed 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 -178.494 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.0 t80 -122.3 86.3 47.76 Favored Pre-proline 0 CA--C 1.545 0.767 0 N-CA-C 111.725 0.269 . . . . 0.0 111.725 -178.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.416 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.4 Cg_endo -77.98 179.08 6.84 Favored 'Trans proline' 0 C--N 1.369 1.633 0 C-N-CA 122.279 1.986 . . . . 0.0 112.729 179.435 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.7 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.8 t -89.21 160.09 17.13 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 123.157 0.285 . . . . 0.0 110.87 179.756 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 72.6 m -79.99 108.64 9.74 Favored Pre-proline 0 CA--C 1.544 0.74 0 N-CA-C 111.96 0.356 . . . . 0.0 111.96 -179.356 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.432 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.6 Cg_endo -83.03 177.2 6.87 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 122.485 2.123 . . . . 0.0 112.905 179.316 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.21 -39.83 2.62 Favored Glycine 0 C--N 1.34 0.762 0 C-N-CA 121.312 -0.47 . . . . 0.0 112.992 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.1 mt -89.58 -38.16 14.16 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 122.435 0.294 . . . . 0.0 111.477 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.28 51.6 0.23 Allowed Glycine 0 C--N 1.34 0.751 0 CA-C-N 116.17 -0.468 . . . . 0.0 112.461 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.452 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.3 mt -114.88 150.74 35.13 Favored 'General case' 0 C--O 1.235 0.309 0 O-C-N 123.611 0.242 . . . . 0.0 110.958 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 t -139.73 154.26 47.4 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.305 -179.752 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.7 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.0 m -97.61 122.41 40.65 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.492 179.409 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.6 mt -127.35 123.78 23.4 Favored Pre-proline 0 CA--C 1.545 0.765 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.4 -179.786 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.421 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.3 Cg_exo -76.0 -40.56 1.14 Allowed 'Cis proline' 0 C--N 1.375 1.934 0 C-N-CA 124.636 -0.985 . . . . 0.0 112.552 0.026 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.72 34.27 8.55 Favored Glycine 0 C--N 1.342 0.895 0 CA-C-N 115.915 -0.584 . . . . 0.0 113.045 179.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.421 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -144.71 79.96 11.92 Favored Pre-proline 0 CA--C 1.547 0.86 0 CA-C-N 116.68 0.24 . . . . 0.0 111.508 179.705 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.593 ' O ' HG23 ' A' ' 12' ' ' VAL . 65.6 Cg_endo -89.15 -26.0 5.47 Favored 'Cis proline' 0 C--N 1.37 1.692 0 C-N-CA 124.714 -0.952 . . . . 0.0 113.457 -0.348 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -89.75 155.25 19.32 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.349 -179.474 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.435 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.31 -174.49 26.15 Favored Glycine 0 C--N 1.335 0.493 0 CA-C-N 115.371 -0.831 . . . . 0.0 112.396 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' THR . . . . . 0.48 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -126.15 143.41 51.14 Favored 'General case' 0 C--O 1.234 0.258 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.511 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 45.9 m -88.56 112.52 23.13 Favored 'General case' 0 C--O 1.24 0.582 0 O-C-N 123.409 0.443 . . . . 0.0 111.681 -179.697 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' TYR . . . . . 0.452 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.9 m-85 -125.56 159.85 31.04 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.592 179.416 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.576 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.3 t80 -93.49 134.96 35.2 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.964 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.2 mt . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.145 -0.931 . . . . 0.0 110.903 179.751 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.413 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.0 p . . . . . 0 C--O 1.235 0.325 0 CA-C-O 120.458 0.17 . . . . 0.0 110.993 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.01 151.14 20.62 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.781 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.6 p90 -98.93 171.82 7.82 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.856 179.415 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.585 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.2 tt0 -59.94 129.04 39.87 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 123.362 0.665 . . . . 0.0 112.428 -179.267 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.29 -20.86 29.84 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 115.572 -0.74 . . . . 0.0 114.388 178.736 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -107.02 177.47 4.85 Favored 'General case' 0 CA--C 1.539 0.558 0 CA-C-N 117.42 0.61 . . . . 0.0 111.828 -179.332 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 40.8 p -91.5 146.95 23.38 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.09 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.6 p -134.84 128.26 32.37 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.975 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -98.01 119.66 37.03 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.702 179.419 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 30' ' ' PRO . 24.2 m -72.41 10.35 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -178.888 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.406 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.7 tp60 -104.76 -29.22 10.69 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.637 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.406 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.94 -26.61 0.26 Allowed 'General case' 0 N--CA 1.477 0.899 0 N-CA-C 112.907 0.706 . . . . 0.0 112.907 -178.759 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.2 t80 -125.22 87.22 55.87 Favored Pre-proline 0 CA--C 1.545 0.779 0 N-CA-C 111.687 0.254 . . . . 0.0 111.687 -178.579 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.413 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.3 Cg_endo -77.88 176.84 9.52 Favored 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.311 2.007 . . . . 0.0 112.734 179.427 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.701 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -88.54 160.88 17.25 Favored 'General case' 0 N--CA 1.468 0.441 0 O-C-N 123.201 0.313 . . . . 0.0 110.809 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.9 m -79.94 108.45 9.23 Favored Pre-proline 0 CA--C 1.544 0.728 0 N-CA-C 112.078 0.399 . . . . 0.0 112.078 -179.284 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.448 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.1 Cg_endo -83.51 177.66 6.2 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.469 2.113 . . . . 0.0 112.896 179.341 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.82 -40.22 2.5 Favored Glycine 0 C--N 1.339 0.741 0 C-N-CA 121.349 -0.453 . . . . 0.0 112.985 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.8 mt -88.76 -38.52 14.62 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 122.456 0.302 . . . . 0.0 111.458 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.55 51.65 0.2 Allowed Glycine 0 C--N 1.338 0.69 0 O-C-N 123.475 0.485 . . . . 0.0 112.53 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.473 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 22.0 mt -115.72 149.17 38.85 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-O 120.618 0.247 . . . . 0.0 110.858 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t -138.93 154.84 48.37 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.201 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.701 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 65.7 m -97.19 123.28 40.92 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.709 179.548 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.47 ' H ' ' H ' ' A' ' 33' ' ' THR . 12.2 mt -127.38 122.85 23.01 Favored Pre-proline 0 CA--C 1.545 0.775 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.231 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -75.42 -40.82 1.09 Allowed 'Cis proline' 0 C--N 1.375 1.922 0 C-N-CA 124.697 -0.96 . . . . 0.0 112.648 0.133 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.03 33.85 8.65 Favored Glycine 0 C--N 1.343 0.918 0 CA-C-N 115.993 -0.549 . . . . 0.0 113.085 179.788 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.403 ' HA ' ' HA ' ' A' ' 30' ' ' PRO . 2.0 p-10 -147.06 79.63 9.84 Favored Pre-proline 0 CA--C 1.546 0.824 0 CA-C-N 116.641 0.221 . . . . 0.0 111.427 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.595 ' O ' HG22 ' A' ' 12' ' ' VAL . 56.1 Cg_endo -89.8 -27.4 3.9 Favored 'Cis proline' 0 C--N 1.37 1.671 0 C-N-CA 124.723 -0.949 . . . . 0.0 113.477 -0.368 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -86.11 149.59 25.02 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.633 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -151.13 -179.15 26.61 Favored Glycine 0 C--N 1.335 0.521 0 CA-C-N 115.654 -0.703 . . . . 0.0 112.627 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.47 ' H ' ' H ' ' A' ' 26' ' ' ILE . 0.9 OUTLIER -123.33 140.9 52.54 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 179.349 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.9 m -86.46 110.6 19.86 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 121.015 0.436 . . . . 0.0 111.698 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' TYR . . . . . 0.473 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 32.8 m-85 -125.47 158.37 34.61 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.624 179.546 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.585 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.1 t80 -92.89 135.65 33.95 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.943 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.6 mt . . . . . 0 C--O 1.249 1.059 0 CA-C-O 118.095 -0.955 . . . . 0.0 110.871 179.806 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.423 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.5 p . . . . . 0 C--O 1.235 0.305 0 CA-C-O 120.479 0.181 . . . . 0.0 110.961 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.07 152.88 19.74 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.757 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 18.6 p90 -98.23 174.08 6.68 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.725 179.161 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.565 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.3 tt0 -63.89 131.3 47.31 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 123.227 0.611 . . . . 0.0 112.348 -179.282 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.72 3.97 52.29 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-N 115.564 -0.744 . . . . 0.0 114.759 178.657 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -130.55 177.91 7.02 Favored 'General case' 0 CA--C 1.54 0.558 0 CA-C-N 117.636 0.718 . . . . 0.0 111.605 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.423 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 42.5 p -90.4 146.11 24.41 Favored 'General case' 0 C--N 1.343 0.315 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.293 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.9 p -136.47 128.01 28.69 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.782 -179.613 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 8.4 m-80 -98.22 119.57 37.11 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.87 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 30' ' ' PRO . 23.1 m -72.38 10.02 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 N-CA-C 112.963 0.727 . . . . 0.0 112.963 -178.988 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.429 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 15.0 tt0 -99.81 -30.23 12.17 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.206 -179.572 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.429 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.1 p90 -154.01 -26.77 0.13 Allowed 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 112.729 0.64 . . . . 0.0 112.729 -178.55 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -120.43 85.23 37.01 Favored Pre-proline 0 CA--C 1.544 0.749 0 N-CA-C 111.613 0.227 . . . . 0.0 111.613 -178.678 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.423 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.8 Cg_endo -78.2 179.12 6.79 Favored 'Trans proline' 0 C--N 1.369 1.65 0 C-N-CA 122.306 2.004 . . . . 0.0 112.664 179.478 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.709 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -89.62 159.82 16.96 Favored 'General case' 0 N--CA 1.467 0.402 0 O-C-N 123.163 0.29 . . . . 0.0 110.917 179.788 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.2 m -79.97 108.56 9.51 Favored Pre-proline 0 CA--C 1.545 0.76 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.881 -179.374 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.445 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.2 Cg_endo -83.27 177.42 6.54 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 122.521 2.147 . . . . 0.0 112.959 179.376 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.27 -40.12 2.53 Favored Glycine 0 C--N 1.34 0.751 0 C-N-CA 121.336 -0.459 . . . . 0.0 113.015 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.4 -38.91 13.76 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 122.462 0.305 . . . . 0.0 111.494 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.06 50.51 0.21 Allowed Glycine 0 C--N 1.339 0.723 0 O-C-N 123.479 0.487 . . . . 0.0 112.485 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.461 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.7 mt -113.87 150.33 33.77 Favored 'General case' 0 C--O 1.235 0.324 0 O-C-N 123.661 0.271 . . . . 0.0 110.854 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 t -139.28 154.59 47.98 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.347 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.709 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 56.9 m -97.49 123.17 41.25 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.822 -0.627 . . . . 0.0 110.595 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.468 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.9 mt -127.53 123.35 23.07 Favored Pre-proline 0 CA--C 1.544 0.741 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.238 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -75.69 -40.85 1.08 Allowed 'Cis proline' 0 C--N 1.375 1.927 0 C-N-CA 124.69 -0.962 . . . . 0.0 112.527 0.085 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.19 33.49 8.77 Favored Glycine 0 C--N 1.342 0.915 0 CA-C-N 115.964 -0.562 . . . . 0.0 113.147 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -147.06 79.86 9.73 Favored Pre-proline 0 CA--C 1.546 0.821 0 CA-C-N 116.649 0.224 . . . . 0.0 111.509 179.64 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.595 ' O ' HG22 ' A' ' 12' ' ' VAL . 57.5 Cg_endo -89.62 -27.23 4.11 Favored 'Cis proline' 0 C--N 1.37 1.681 0 C-N-CA 124.666 -0.973 . . . . 0.0 113.496 -0.367 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -86.83 150.03 24.41 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.559 -179.49 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.423 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -151.6 -178.09 26.01 Favored Glycine 0 C--N 1.336 0.535 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.45 179.453 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.471 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -125.75 142.25 51.6 Favored 'General case' 0 C--O 1.234 0.278 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 179.328 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 54.3 m -87.64 112.23 22.1 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-O 121.093 0.473 . . . . 0.0 111.783 -179.601 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' TYR . . . . . 0.461 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 34.8 m-85 -125.89 159.43 32.56 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.538 179.361 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.565 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.6 t80 -93.38 135.21 34.84 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.951 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.129 -0.939 . . . . 0.0 110.857 179.738 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.416 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.2 p . . . . . 0 C--O 1.235 0.329 0 CA-C-O 120.453 0.168 . . . . 0.0 110.999 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.9 151.62 20.45 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.701 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.9 p90 -98.75 172.82 7.21 Favored 'General case' 0 CA--C 1.536 0.427 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.873 179.3 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.588 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 14.4 tt0 -61.04 130.31 45.74 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 123.326 0.651 . . . . 0.0 112.334 -179.386 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.08 -25.62 19.77 Favored Glycine 0 C--N 1.338 0.669 0 CA-C-N 115.656 -0.702 . . . . 0.0 114.179 178.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -103.06 178.67 4.49 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 117.273 0.536 . . . . 0.0 111.851 -179.159 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 43.8 p -92.8 151.56 19.94 Favored 'General case' 0 C--N 1.344 0.348 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.221 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 p -139.48 130.49 26.38 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.863 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -100.14 119.88 39.01 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.597 179.322 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 30' ' ' PRO . 25.5 m -71.32 9.43 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -178.825 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.501 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -100.44 -32.81 10.63 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.3 -179.496 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.501 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.1 p90 -149.93 -26.8 0.26 Allowed 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 112.897 0.703 . . . . 0.0 112.897 -178.486 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 6.8 t80 -121.09 85.53 41.26 Favored Pre-proline 0 CA--C 1.545 0.757 0 N-CA-C 111.747 0.277 . . . . 0.0 111.747 -178.663 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.416 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.1 Cg_endo -78.06 177.16 9.12 Favored 'Trans proline' 0 C--N 1.369 1.607 0 C-N-CA 122.202 1.935 . . . . 0.0 112.67 179.385 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.712 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 4.6 t -88.27 160.73 17.54 Favored 'General case' 0 N--CA 1.467 0.418 0 O-C-N 123.186 0.304 . . . . 0.0 110.796 179.759 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.0 m -79.97 108.67 9.77 Favored Pre-proline 0 CA--C 1.545 0.768 0 N-CA-C 111.99 0.367 . . . . 0.0 111.99 -179.18 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 76.0 Cg_endo -83.22 177.65 6.4 Favored 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.5 2.133 . . . . 0.0 112.918 179.286 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.94 -41.09 2.25 Favored Glycine 0 C--N 1.34 0.77 0 C-N-CA 121.384 -0.436 . . . . 0.0 112.928 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.1 -38.86 14.03 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 122.486 0.314 . . . . 0.0 111.431 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.442 ' O ' ' HA ' ' A' ' 36' ' ' TYR . . . 124.27 53.41 0.19 Allowed Glycine 0 C--N 1.339 0.715 0 O-C-N 123.521 0.513 . . . . 0.0 112.512 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.475 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 23.7 mt -117.64 147.48 42.84 Favored 'General case' 0 C--O 1.234 0.267 0 O-C-N 123.623 0.249 . . . . 0.0 110.785 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -139.3 154.51 47.94 Favored 'General case' 0 CA--C 1.535 0.404 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.391 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.712 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 89.7 m -97.35 118.3 33.5 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.52 179.496 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 11.6 mt -122.75 122.23 27.22 Favored Pre-proline 0 CA--C 1.545 0.756 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.235 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.424 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.42 -40.72 1.12 Allowed 'Cis proline' 0 C--N 1.373 1.843 0 C-N-CA 124.695 -0.961 . . . . 0.0 112.701 0.232 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.13 34.43 8.8 Favored Glycine 0 C--N 1.342 0.868 0 O-C-N 123.588 0.555 . . . . 0.0 112.928 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.424 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -145.74 79.58 11.11 Favored Pre-proline 0 CA--C 1.548 0.876 0 C-N-CA 122.204 0.202 . . . . 0.0 111.423 179.724 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.595 ' O ' HG22 ' A' ' 12' ' ' VAL . 56.8 Cg_endo -88.79 -27.76 4.18 Favored 'Cis proline' 0 C--N 1.37 1.666 0 C-N-CA 124.739 -0.942 . . . . 0.0 113.486 -0.254 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -86.9 149.34 24.87 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.66 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.81 160.29 30.22 Favored Glycine 0 C--N 1.335 0.52 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.137 179.335 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.426 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.5 OUTLIER -99.1 143.96 28.78 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.823 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 18.8 m -88.31 110.04 20.45 Favored 'General case' 0 C--O 1.238 0.476 0 O-C-N 123.464 0.477 . . . . 0.0 111.528 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' TYR . . . . . 0.475 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 38.1 m-85 -124.73 160.13 29.31 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.289 -0.868 . . . . 0.0 110.744 179.628 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.588 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 15.8 t80 -93.07 137.23 32.61 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.872 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 14.6 mt . . . . . 0 C--O 1.251 1.172 0 CA-C-O 118.531 -0.747 . . . . 0.0 110.876 179.742 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.417 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.4 p . . . . . 0 C--O 1.235 0.331 0 CA-C-O 120.438 0.161 . . . . 0.0 110.989 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.406 ' HB1' ' HG3' ' A' ' 8' ' ' GLU . . . -92.52 150.19 20.91 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.654 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.5 p90 -98.65 171.91 7.82 Favored 'General case' 0 CA--C 1.537 0.458 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.848 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.58 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 14.8 tt0 -59.53 128.63 37.96 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 123.305 0.642 . . . . 0.0 112.389 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.3 -21.02 27.34 Favored Glycine 0 C--N 1.339 0.718 0 CA-C-N 115.66 -0.7 . . . . 0.0 114.421 178.855 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.406 ' HG3' ' HB1' ' A' ' 4' ' ' ALA . 6.8 pt-20 -107.48 177.39 4.85 Favored 'General case' 0 CA--C 1.541 0.604 0 CA-C-N 117.43 0.615 . . . . 0.0 111.835 -179.222 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 53.0 m -91.47 145.4 24.65 Favored 'General case' 0 C--N 1.343 0.312 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.079 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.7 p -134.0 129.09 35.65 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.93 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.27 119.93 39.15 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.818 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.603 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.5 m -72.4 10.48 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 112.994 0.738 . . . . 0.0 112.994 -178.797 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.401 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.6 tp60 -104.03 -29.31 10.98 Favored 'General case' 0 CA--C 1.535 0.377 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.615 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.401 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.84 -26.74 0.26 Allowed 'General case' 0 N--CA 1.476 0.874 0 N-CA-C 112.851 0.686 . . . . 0.0 112.851 -178.759 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.402 ' HE2' ' HB2' ' A' ' 4' ' ' ALA . 12.6 t80 -125.75 88.33 54.4 Favored Pre-proline 0 CA--C 1.545 0.775 0 N-CA-C 111.702 0.26 . . . . 0.0 111.702 -178.614 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.417 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.8 Cg_endo -77.74 176.17 10.34 Favored 'Trans proline' 0 C--N 1.37 1.686 0 C-N-CA 122.27 1.98 . . . . 0.0 112.708 179.333 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.683 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.1 t -88.26 161.36 17.23 Favored 'General case' 0 N--CA 1.467 0.399 0 O-C-N 123.208 0.318 . . . . 0.0 110.841 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.3 m -79.97 108.47 9.3 Favored Pre-proline 0 CA--C 1.544 0.745 0 N-CA-C 112.03 0.381 . . . . 0.0 112.03 -179.276 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.448 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.9 Cg_endo -83.51 177.53 6.29 Favored 'Trans proline' 0 C--N 1.371 1.756 0 C-N-CA 122.512 2.142 . . . . 0.0 112.906 179.369 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.0 -40.56 2.38 Favored Glycine 0 C--N 1.34 0.775 0 C-N-CA 121.313 -0.47 . . . . 0.0 113.003 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.08 -38.91 14.01 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 122.424 0.29 . . . . 0.0 111.453 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.92 51.96 0.2 Allowed Glycine 0 C--N 1.339 0.719 0 O-C-N 123.466 0.479 . . . . 0.0 112.568 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.459 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 22.0 mt -115.26 149.32 37.96 Favored 'General case' 0 C--O 1.234 0.286 0 O-C-N 123.654 0.267 . . . . 0.0 110.847 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -138.95 154.69 48.34 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.266 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.683 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 67.9 m -97.24 123.31 40.99 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.64 179.538 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.445 ' H ' ' H ' ' A' ' 33' ' ' THR . 12.0 mt -126.63 122.94 23.77 Favored Pre-proline 0 CA--C 1.545 0.775 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.279 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.422 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.85 -40.89 1.06 Allowed 'Cis proline' 0 C--N 1.375 1.929 0 C-N-CA 124.595 -1.002 . . . . 0.0 112.644 0.111 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.08 33.07 9.14 Favored Glycine 0 C--N 1.342 0.883 0 O-C-N 123.548 0.53 . . . . 0.0 112.848 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.422 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.8 79.08 12.4 Favored Pre-proline 0 CA--C 1.547 0.843 0 C-N-CA 122.193 0.197 . . . . 0.0 111.291 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.603 ' O ' HG22 ' A' ' 12' ' ' VAL . 58.6 Cg_endo -89.89 -26.71 4.36 Favored 'Cis proline' 0 C--N 1.37 1.682 0 C-N-CA 124.708 -0.955 . . . . 0.0 113.682 -0.35 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.06 152.56 21.1 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.933 -179.406 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.41 -174.2 24.2 Favored Glycine 0 C--N 1.337 0.637 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.659 179.591 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.499 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -124.21 143.85 50.28 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.589 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.6 m -88.11 110.24 20.5 Favored 'General case' 0 C--O 1.238 0.448 0 O-C-N 123.44 0.462 . . . . 0.0 111.571 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' TYR . . . . . 0.459 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 33.0 m-85 -124.76 159.1 31.71 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.657 179.603 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.58 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.3 t80 -93.18 136.11 33.75 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.96 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.7 mt . . . . . 0 C--O 1.251 1.146 0 CA-C-O 118.486 -0.769 . . . . 0.0 110.892 179.775 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.424 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.7 p . . . . . 0 C--O 1.235 0.324 0 CA-C-O 120.467 0.175 . . . . 0.0 110.924 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.76 152.03 20.35 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.827 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 19.1 p90 -98.42 173.92 6.72 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.626 179.165 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.581 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 17.5 tt0 -63.82 130.0 42.38 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 123.213 0.605 . . . . 0.0 112.359 -179.326 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 102.06 9.61 41.89 Favored Glycine 0 C--N 1.339 0.717 0 CA-C-N 115.662 -0.699 . . . . 0.0 114.764 178.627 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -135.23 177.39 7.85 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 117.676 0.738 . . . . 0.0 111.535 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 52.4 m -90.82 141.65 28.59 Favored 'General case' 0 C--N 1.343 0.314 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.137 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.5 p -133.17 128.8 36.8 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.844 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.33 119.88 39.09 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.868 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.604 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.3 m -72.78 12.2 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.031 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -178.823 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.7 tp-100 -105.51 -29.91 9.88 Favored 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 116.593 -0.276 . . . . 0.0 111.559 -179.391 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -148.78 -26.68 0.31 Allowed 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 8.8 t80 -126.21 88.19 54.77 Favored Pre-proline 0 CA--C 1.546 0.805 0 N-CA-C 111.696 0.258 . . . . 0.0 111.696 -178.755 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.424 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.4 Cg_endo -77.91 177.89 8.25 Favored 'Trans proline' 0 C--N 1.369 1.635 0 C-N-CA 122.31 2.007 . . . . 0.0 112.724 179.378 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.698 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.9 t -90.09 160.13 16.46 Favored 'General case' 0 N--CA 1.468 0.447 0 O-C-N 123.218 0.324 . . . . 0.0 110.799 179.802 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 76.3 m -80.06 108.45 9.34 Favored Pre-proline 0 CA--C 1.545 0.774 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.93 -179.322 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.45 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 80.5 Cg_endo -83.41 177.44 6.43 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.465 2.11 . . . . 0.0 112.961 179.296 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.04 -40.44 2.42 Favored Glycine 0 C--N 1.339 0.741 0 O-C-N 123.434 0.459 . . . . 0.0 113.016 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.07 -39.13 13.85 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 122.437 0.295 . . . . 0.0 111.52 -179.823 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.47 50.66 0.2 Allowed Glycine 0 C--N 1.339 0.736 0 O-C-N 123.505 0.503 . . . . 0.0 112.51 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.442 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.8 mt -113.86 150.21 33.94 Favored 'General case' 0 C--O 1.235 0.329 0 O-C-N 123.617 0.245 . . . . 0.0 110.846 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 t -139.58 154.27 47.58 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.326 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.698 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.9 m -97.33 123.3 41.1 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.582 179.366 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.453 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.8 mt -126.9 123.32 23.62 Favored Pre-proline 0 CA--C 1.545 0.772 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.333 -179.77 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.419 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.9 -40.84 1.07 Allowed 'Cis proline' 0 C--N 1.375 1.949 0 C-N-CA 124.66 -0.975 . . . . 0.0 112.554 0.055 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.98 32.45 9.88 Favored Glycine 0 C--N 1.341 0.859 0 O-C-N 123.621 0.576 . . . . 0.0 112.899 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.419 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -144.34 78.9 13.14 Favored Pre-proline 0 CA--C 1.546 0.817 0 C-N-CA 122.245 0.218 . . . . 0.0 111.313 179.776 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.604 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.2 Cg_endo -90.02 -26.5 4.46 Favored 'Cis proline' 0 C--N 1.369 1.634 0 C-N-CA 124.74 -0.942 . . . . 0.0 113.668 -0.306 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.85 152.78 20.62 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.972 -179.362 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.402 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -155.47 -171.84 22.44 Favored Glycine 0 C--N 1.338 0.647 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.589 179.502 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.515 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -127.22 145.33 50.81 Favored 'General case' 0 C--O 1.235 0.316 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 179.553 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 51.6 m -89.22 111.93 22.84 Favored 'General case' 0 C--O 1.24 0.565 0 O-C-N 123.481 0.488 . . . . 0.0 111.627 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' TYR . . . . . 0.442 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.5 m-85 -125.72 159.76 31.48 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.523 179.423 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.581 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.6 t80 -93.35 136.03 34.01 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.005 -179.83 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.0 mt . . . . . 0 C--O 1.251 1.148 0 CA-C-O 118.502 -0.761 . . . . 0.0 110.891 179.745 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.415 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.1 p . . . . . 0 C--O 1.235 0.314 0 CA-C-O 120.497 0.189 . . . . 0.0 111.003 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.83 150.48 21.05 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.676 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.9 p90 -98.7 171.88 7.83 Favored 'General case' 0 CA--C 1.536 0.44 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.93 179.355 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.587 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.0 tt0 -59.98 128.63 37.82 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.352 0.661 . . . . 0.0 112.381 -179.312 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.25 -20.89 27.62 Favored Glycine 0 C--N 1.338 0.68 0 CA-C-N 115.688 -0.687 . . . . 0.0 114.421 178.851 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -107.29 177.47 4.83 Favored 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 117.444 0.622 . . . . 0.0 111.813 -179.289 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.7 m -91.42 144.9 25.1 Favored 'General case' 0 C--N 1.344 0.337 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.063 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.9 p -133.61 128.45 35.17 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.974 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.07 120.08 39.3 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.754 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.608 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.0 m -72.28 10.38 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 113.023 0.749 . . . . 0.0 113.023 -178.776 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.407 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 1.6 tp-100 -104.12 -29.69 10.7 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.661 -179.358 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.407 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.48 -26.63 0.28 Allowed 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -178.791 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -125.32 87.79 55.1 Favored Pre-proline 0 CA--C 1.546 0.803 0 N-CA-C 111.652 0.242 . . . . 0.0 111.652 -178.651 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.415 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.7 Cg_endo -77.66 175.4 11.29 Favored 'Trans proline' 0 C--N 1.369 1.632 0 C-N-CA 122.304 2.003 . . . . 0.0 112.706 179.444 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.681 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -88.46 161.06 17.24 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.848 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 72.0 m -79.91 108.6 9.56 Favored Pre-proline 0 CA--C 1.544 0.738 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.206 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.5 Cg_endo -83.43 177.63 6.28 Favored 'Trans proline' 0 C--N 1.371 1.753 0 C-N-CA 122.491 2.128 . . . . 0.0 112.933 179.262 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.07 -40.01 2.57 Favored Glycine 0 C--N 1.339 0.727 0 C-N-CA 121.386 -0.435 . . . . 0.0 112.969 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.9 mt -88.83 -38.64 14.44 Favored 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 122.488 0.315 . . . . 0.0 111.466 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.19 51.26 0.21 Allowed Glycine 0 C--N 1.339 0.721 0 O-C-N 123.481 0.488 . . . . 0.0 112.539 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.468 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.6 mt -114.58 149.19 36.92 Favored 'General case' 0 C--O 1.235 0.308 0 O-C-N 123.65 0.265 . . . . 0.0 110.881 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t -138.85 154.34 48.41 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.201 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.681 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 68.3 m -97.0 123.23 40.66 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.659 179.514 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.449 ' H ' ' H ' ' A' ' 33' ' ' THR . 12.7 mt -125.92 122.63 24.46 Favored Pre-proline 0 CA--C 1.545 0.768 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.26 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -75.51 -41.08 1.03 Allowed 'Cis proline' 0 C--N 1.375 1.923 0 C-N-CA 124.664 -0.973 . . . . 0.0 112.641 0.072 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.78 31.84 9.73 Favored Glycine 0 C--N 1.341 0.847 0 O-C-N 123.548 0.53 . . . . 0.0 113.043 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -145.42 80.12 11.08 Favored Pre-proline 0 CA--C 1.547 0.841 0 C-N-CA 122.131 0.173 . . . . 0.0 111.229 179.694 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.608 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.1 Cg_endo -89.65 -26.92 4.33 Favored 'Cis proline' 0 C--N 1.369 1.636 0 C-N-CA 124.676 -0.968 . . . . 0.0 113.681 -0.321 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -90.97 152.45 20.69 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.912 -179.273 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.44 -174.48 24.54 Favored Glycine 0 C--N 1.338 0.652 0 CA-C-N 115.442 -0.799 . . . . 0.0 112.634 179.593 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.496 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -123.79 143.93 50.01 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.561 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.6 m -88.08 110.23 20.48 Favored 'General case' 0 C--O 1.238 0.468 0 O-C-N 123.477 0.485 . . . . 0.0 111.588 -179.768 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' TYR . . . . . 0.468 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 33.0 m-85 -125.2 158.78 33.15 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 115.178 -0.919 . . . . 0.0 110.65 179.586 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.587 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.8 t80 -93.02 136.47 33.25 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.912 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.2 mt . . . . . 0 C--O 1.251 1.181 0 CA-C-O 118.478 -0.772 . . . . 0.0 110.878 179.754 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.424 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.1 p . . . . . 0 C--O 1.234 0.289 0 CA-C-O 120.468 0.175 . . . . 0.0 110.864 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.28 152.8 18.95 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.828 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' PHE . . . . . 0.458 ' O ' ' HG2' ' A' ' 8' ' ' GLU . 14.2 p90 -97.64 174.99 6.36 Favored 'General case' 0 CA--C 1.537 0.464 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.615 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.576 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.4 tt0 -65.23 130.99 45.35 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 123.095 0.558 . . . . 0.0 112.362 -179.287 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 100.08 12.85 38.34 Favored Glycine 0 C--N 1.339 0.723 0 CA-C-N 115.628 -0.714 . . . . 0.0 114.661 178.623 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.458 ' HG2' ' O ' ' A' ' 5' ' ' PHE . 8.8 pt-20 -136.87 175.96 9.14 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 117.592 0.696 . . . . 0.0 111.455 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.418 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 53.0 m -90.85 138.39 31.63 Favored 'General case' 0 C--N 1.343 0.299 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.132 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 p -131.52 128.18 38.78 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.837 -179.669 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -97.07 118.86 34.42 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.02 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.611 HG22 ' O ' ' A' ' 30' ' ' PRO . 26.8 m -72.45 12.74 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.86 -178.87 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 5.9 tp60 -106.46 -31.02 8.73 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.518 -179.4 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.7 p90 -146.87 -27.22 0.4 Allowed 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 112.81 0.67 . . . . 0.0 112.81 -178.818 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -126.45 88.37 54.48 Favored Pre-proline 0 CA--C 1.545 0.766 0 N-CA-C 111.607 0.225 . . . . 0.0 111.607 -178.791 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.424 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 62.3 Cg_endo -78.16 177.86 8.27 Favored 'Trans proline' 0 C--N 1.37 1.681 0 C-N-CA 122.348 2.032 . . . . 0.0 112.732 179.366 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.709 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.7 t -88.91 161.15 16.82 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.904 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 75.5 m -79.96 108.49 9.33 Favored Pre-proline 0 CA--C 1.545 0.758 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.87 -179.383 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.442 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 75.7 Cg_endo -83.07 177.52 6.6 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.485 2.123 . . . . 0.0 112.929 179.423 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.81 -40.11 2.53 Favored Glycine 0 C--N 1.34 0.759 0 C-N-CA 121.392 -0.432 . . . . 0.0 112.969 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.86 -39.18 13.22 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 122.408 0.283 . . . . 0.0 111.427 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.01 52.33 0.19 Allowed Glycine 0 C--N 1.339 0.709 0 O-C-N 123.467 0.479 . . . . 0.0 112.497 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.9 mt -115.74 149.79 37.9 Favored 'General case' 0 C--O 1.235 0.319 0 O-C-N 123.584 0.226 . . . . 0.0 110.86 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.438 ' O ' ' HA ' ' A' ' 34' ' ' CYS . 8.8 t -139.36 155.34 47.73 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.353 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.709 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 68.1 m -98.66 118.8 36.2 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.548 179.53 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.5 mt -129.1 126.55 23.13 Favored Pre-proline 0 CA--C 1.544 0.736 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.433 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -68.69 -42.5 0.7 Allowed 'Cis proline' 0 C--N 1.376 2.005 0 C-N-CA 124.597 -1.001 . . . . 0.0 113.453 -0.208 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 82.29 35.56 20.2 Favored Glycine 0 C--N 1.344 1.013 0 O-C-N 123.349 0.406 . . . . 0.0 113.524 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -148.09 80.81 8.5 Favored Pre-proline 0 CA--C 1.547 0.852 0 CA-C-N 116.653 0.226 . . . . 0.0 111.352 179.744 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.611 ' O ' HG22 ' A' ' 12' ' ' VAL . 58.3 Cg_endo -87.25 -27.73 5.04 Favored 'Cis proline' 0 C--N 1.37 1.684 0 C-N-CA 124.516 -1.035 . . . . 0.0 113.353 -0.246 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -88.73 147.98 24.21 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.675 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.418 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -150.2 -174.27 21.24 Favored Glycine 0 C--N 1.335 0.526 0 CA-C-N 115.624 -0.716 . . . . 0.0 112.674 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.504 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.3 OUTLIER -127.22 143.38 51.26 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.321 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.438 ' HA ' ' O ' ' A' ' 24' ' ' THR . 55.6 m -87.58 114.17 23.94 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-O 121.095 0.474 . . . . 0.0 111.962 -179.433 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' TYR . . . . . 0.467 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 43.8 m-85 -126.7 160.22 31.43 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 114.988 -1.006 . . . . 0.0 110.429 179.274 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.576 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.5 t80 -94.07 134.33 36.61 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.979 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.112 -0.947 . . . . 0.0 110.833 179.779 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.412 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.1 p . . . . . 0 C--O 1.235 0.315 0 CA-C-O 120.513 0.196 . . . . 0.0 110.928 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.8 151.94 19.73 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.664 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 17.1 p90 -99.05 173.12 6.98 Favored 'General case' 0 CA--C 1.537 0.468 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.839 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.58 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 14.0 tt0 -60.87 130.91 48.83 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.308 0.643 . . . . 0.0 112.284 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 107.62 -25.33 21.54 Favored Glycine 0 C--N 1.337 0.618 0 CA-C-N 115.657 -0.702 . . . . 0.0 114.217 178.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -103.72 178.75 4.47 Favored 'General case' 0 CA--C 1.541 0.608 0 CA-C-N 117.251 0.525 . . . . 0.0 111.833 -179.145 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 51.3 m -93.34 151.1 19.99 Favored 'General case' 0 C--N 1.344 0.362 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.163 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.1 p -139.77 132.2 28.54 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.843 -179.52 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -99.78 118.42 36.23 Favored 'General case' 0 C--O 1.236 0.387 0 O-C-N 123.635 0.584 . . . . 0.0 110.657 179.366 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 30' ' ' PRO . 30.6 m -71.05 10.45 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -178.849 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.505 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.1 OUTLIER -101.58 -34.86 9.34 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.204 -179.479 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.505 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.8 p90 -146.72 -27.35 0.4 Allowed 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -178.497 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.8 t80 -121.79 86.12 45.31 Favored Pre-proline 0 CA--C 1.545 0.77 0 N-CA-C 111.75 0.278 . . . . 0.0 111.75 -178.71 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.412 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.9 Cg_endo -78.0 176.53 9.87 Favored 'Trans proline' 0 C--N 1.369 1.607 0 C-N-CA 122.251 1.967 . . . . 0.0 112.671 179.356 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.711 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 4.6 t -86.45 162.14 18.27 Favored 'General case' 0 N--CA 1.468 0.452 0 O-C-N 123.203 0.314 . . . . 0.0 110.824 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.7 m -79.94 108.64 9.68 Favored Pre-proline 0 CA--C 1.545 0.756 0 N-CA-C 112.06 0.393 . . . . 0.0 112.06 -179.224 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.436 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 74.7 Cg_endo -83.02 177.67 6.52 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.467 2.111 . . . . 0.0 112.927 179.363 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.49 -41.17 2.24 Favored Glycine 0 C--N 1.339 0.731 0 C-N-CA 121.352 -0.451 . . . . 0.0 112.909 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.27 -39.02 13.78 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 122.464 0.306 . . . . 0.0 111.402 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.422 ' O ' ' HA ' ' A' ' 36' ' ' TYR . . . 124.02 55.05 0.19 Allowed Glycine 0 C--N 1.338 0.69 0 O-C-N 123.509 0.506 . . . . 0.0 112.535 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.476 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 25.4 mt -119.73 147.96 43.97 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-O 120.571 0.224 . . . . 0.0 110.897 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -140.1 155.36 47.04 Favored 'General case' 0 CA--C 1.536 0.434 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.358 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.711 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 91.0 m -98.3 117.42 32.66 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.512 179.446 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.8 mt -127.2 125.82 24.13 Favored Pre-proline 0 CA--C 1.544 0.743 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.348 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -69.18 -41.9 0.82 Allowed 'Cis proline' 0 C--N 1.376 1.985 0 C-N-CA 124.569 -1.013 . . . . 0.0 113.509 -0.038 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 84.42 38.2 10.1 Favored Glycine 0 C--N 1.344 0.991 0 O-C-N 123.376 0.422 . . . . 0.0 113.471 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -150.92 81.05 6.44 Favored Pre-proline 0 CA--C 1.547 0.859 0 C-N-CA 122.279 0.231 . . . . 0.0 111.232 179.54 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.595 ' O ' HG22 ' A' ' 12' ' ' VAL . 57.0 Cg_endo -87.25 -28.25 4.59 Favored 'Cis proline' 0 C--N 1.37 1.663 0 C-N-CA 124.584 -1.007 . . . . 0.0 113.35 -0.312 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -87.15 148.7 25.08 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.637 -179.608 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.91 158.58 28.93 Favored Glycine 0 C--N 1.335 0.513 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.13 179.35 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.416 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.2 OUTLIER -97.2 144.15 27.29 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 110.285 -0.265 . . . . 0.0 110.285 179.868 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 19.5 m -88.07 110.94 21.02 Favored 'General case' 0 C--O 1.239 0.528 0 O-C-N 123.428 0.455 . . . . 0.0 111.584 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' TYR . . . . . 0.476 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 45.7 m-85 -123.55 161.04 25.73 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.703 179.569 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.58 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.1 t80 -94.15 136.21 34.68 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.872 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.2 mt . . . . . 0 C--O 1.249 1.029 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.847 179.75 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.425 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.6 p . . . . . 0 C--O 1.236 0.344 0 CA-C-O 120.459 0.171 . . . . 0.0 110.923 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.8 152.11 20.28 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.811 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 18.7 p90 -98.0 174.03 6.76 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.705 179.083 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.58 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.1 tt0 -64.16 130.1 42.6 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 123.186 0.594 . . . . 0.0 112.326 -179.291 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 102.19 9.61 41.51 Favored Glycine 0 C--N 1.339 0.71 0 CA-C-N 115.68 -0.691 . . . . 0.0 114.702 178.659 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -135.16 177.53 7.74 Favored 'General case' 0 CA--C 1.541 0.596 0 CA-C-N 117.707 0.754 . . . . 0.0 111.545 179.729 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 15.9 t -90.71 141.75 28.47 Favored 'General case' 0 C--N 1.343 0.317 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.941 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.5 p -133.66 128.91 36.03 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.894 -179.727 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.16 119.92 39.08 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.912 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.603 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.8 m -72.68 11.85 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 N-CA-C 112.926 0.713 . . . . 0.0 112.926 -178.839 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 5.7 tp60 -105.41 -29.91 9.93 Favored 'General case' 0 CA--C 1.535 0.372 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.6 -179.369 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -148.99 -26.57 0.3 Allowed 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 112.789 0.663 . . . . 0.0 112.789 -178.827 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.2 t80 -125.65 87.62 55.54 Favored Pre-proline 0 CA--C 1.545 0.76 0 N-CA-C 111.67 0.248 . . . . 0.0 111.67 -178.754 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.425 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.5 Cg_endo -77.86 177.47 8.76 Favored 'Trans proline' 0 C--N 1.369 1.648 0 C-N-CA 122.267 1.978 . . . . 0.0 112.796 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.69 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.9 t -89.92 160.01 16.65 Favored 'General case' 0 N--CA 1.467 0.387 0 O-C-N 123.233 0.333 . . . . 0.0 110.837 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 74.8 m -79.94 108.55 9.47 Favored Pre-proline 0 CA--C 1.545 0.763 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.953 -179.342 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.2 Cg_endo -83.28 177.43 6.52 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.49 2.127 . . . . 0.0 112.911 179.342 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.33 -40.24 2.49 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 121.373 -0.441 . . . . 0.0 113.003 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.34 -38.64 14.0 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 122.439 0.296 . . . . 0.0 111.508 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.58 50.46 0.21 Allowed Glycine 0 C--N 1.339 0.728 0 O-C-N 123.491 0.494 . . . . 0.0 112.495 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.443 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.2 mt -113.24 150.12 32.83 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 122.294 0.238 . . . . 0.0 110.92 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -139.54 154.45 47.66 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.392 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.69 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 60.0 m -97.45 123.2 41.22 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.536 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.453 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.8 mt -126.58 123.45 23.97 Favored Pre-proline 0 CA--C 1.545 0.758 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.322 -179.792 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.422 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.85 -40.76 1.1 Allowed 'Cis proline' 0 C--N 1.375 1.965 0 C-N-CA 124.646 -0.981 . . . . 0.0 112.561 0.062 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.81 32.6 9.86 Favored Glycine 0 C--N 1.342 0.885 0 CA-C-N 116.017 -0.538 . . . . 0.0 112.887 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.422 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.11 78.7 13.58 Favored Pre-proline 0 CA--C 1.546 0.821 0 C-N-CA 122.156 0.182 . . . . 0.0 111.321 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.603 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.3 Cg_endo -90.18 -26.4 4.45 Favored 'Cis proline' 0 C--N 1.369 1.636 0 C-N-CA 124.686 -0.964 . . . . 0.0 113.676 -0.276 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.6 152.63 20.81 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 115.96 -0.564 . . . . 0.0 112.011 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -155.33 -171.72 22.22 Favored Glycine 0 C--N 1.337 0.619 0 CA-C-N 115.449 -0.796 . . . . 0.0 112.57 179.561 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.517 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -127.25 145.26 50.84 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.55 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 51.3 m -89.06 111.89 22.72 Favored 'General case' 0 C--O 1.24 0.554 0 CA-C-O 121.076 0.465 . . . . 0.0 111.675 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' TYR . . . . . 0.443 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.8 m-85 -125.94 159.86 31.5 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.527 179.43 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.58 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 14.5 t80 -93.32 136.06 33.94 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.988 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.4 mt . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.151 -0.928 . . . . 0.0 110.943 179.693 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.412 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 28.0 p . . . . . 0 C--O 1.236 0.369 0 CA-C-O 120.43 0.157 . . . . 0.0 111.01 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.72 151.14 20.78 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.752 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 17.0 p90 -98.96 171.95 7.72 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.842 179.351 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.586 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.2 tt0 -60.45 129.55 42.19 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 123.38 0.672 . . . . 0.0 112.395 -179.337 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.18 -19.93 31.47 Favored Glycine 0 C--N 1.338 0.687 0 CA-C-N 115.659 -0.701 . . . . 0.0 114.468 178.826 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -108.04 177.54 4.78 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 117.464 0.632 . . . . 0.0 111.817 -179.303 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 41.0 p -91.56 144.45 25.53 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.078 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.1 p -133.1 128.7 36.72 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.946 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -99.91 120.19 39.4 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.764 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.608 HG22 ' O ' ' A' ' 30' ' ' PRO . 29.5 m -72.25 10.45 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 N-CA-C 113.051 0.76 . . . . 0.0 113.051 -178.792 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.408 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 1.6 tp-100 -104.43 -29.51 10.67 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.693 -179.4 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.408 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.7 -26.55 0.27 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -178.793 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -125.12 87.51 55.4 Favored Pre-proline 0 CA--C 1.546 0.793 0 N-CA-C 111.694 0.257 . . . . 0.0 111.694 -178.666 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.407 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.9 Cg_endo -77.82 175.68 10.92 Favored 'Trans proline' 0 C--N 1.369 1.654 0 C-N-CA 122.28 1.987 . . . . 0.0 112.704 179.466 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.699 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.8 t -88.68 160.78 17.19 Favored 'General case' 0 N--CA 1.468 0.467 0 O-C-N 123.221 0.325 . . . . 0.0 110.793 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.9 m -79.99 108.44 9.25 Favored Pre-proline 0 CA--C 1.545 0.777 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.45 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.6 Cg_endo -83.54 177.59 6.23 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.453 2.102 . . . . 0.0 112.93 179.286 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.89 -40.44 2.44 Favored Glycine 0 C--N 1.34 0.767 0 C-N-CA 121.324 -0.465 . . . . 0.0 112.951 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.9 mt -88.57 -38.63 14.74 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 122.418 0.287 . . . . 0.0 111.551 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.75 51.76 0.2 Allowed Glycine 0 C--N 1.339 0.723 0 O-C-N 123.461 0.475 . . . . 0.0 112.565 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.473 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 22.7 mt -115.76 149.26 38.77 Favored 'General case' 0 C--O 1.235 0.3 0 O-C-N 123.607 0.239 . . . . 0.0 110.874 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t -139.1 154.4 48.14 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.246 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.699 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 66.4 m -97.22 123.26 40.95 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.645 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.441 ' H ' ' H ' ' A' ' 33' ' ' THR . 11.3 mt -127.16 122.94 23.24 Favored Pre-proline 0 CA--C 1.546 0.789 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.315 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.414 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.87 -41.01 1.03 Allowed 'Cis proline' 0 C--N 1.374 1.893 0 C-N-CA 124.696 -0.96 . . . . 0.0 112.64 0.112 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.18 32.8 9.32 Favored Glycine 0 C--N 1.343 0.931 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.93 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.414 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.49 79.08 12.81 Favored Pre-proline 0 CA--C 1.547 0.842 0 C-N-CA 122.215 0.206 . . . . 0.0 111.322 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.608 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.2 Cg_endo -89.88 -26.59 4.48 Favored 'Cis proline' 0 C--N 1.37 1.682 0 C-N-CA 124.667 -0.972 . . . . 0.0 113.68 -0.284 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.43 152.65 20.87 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.941 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.27 -173.95 23.82 Favored Glycine 0 C--N 1.337 0.632 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.649 179.577 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.475 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.6 OUTLIER -124.54 143.66 50.55 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.563 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.3 m -88.11 110.41 20.63 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-O 121.085 0.469 . . . . 0.0 111.607 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' TYR . . . . . 0.473 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 34.2 m-85 -124.57 158.95 31.77 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.681 179.549 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.586 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 11.9 t80 -93.33 135.93 34.08 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.964 -179.878 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.7 mt . . . . . 0 C--O 1.249 1.05 0 CA-C-O 118.115 -0.945 . . . . 0.0 110.901 179.765 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.422 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.4 p . . . . . 0 C--O 1.235 0.336 0 CA-C-O 120.474 0.178 . . . . 0.0 110.805 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.43 151.58 20.75 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.763 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 18.2 p90 -98.27 173.6 6.91 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.688 179.263 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.579 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.0 tt0 -63.23 129.93 42.41 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.185 0.594 . . . . 0.0 112.364 -179.299 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 102.37 5.37 49.15 Favored Glycine 0 C--N 1.339 0.717 0 CA-C-N 115.673 -0.694 . . . . 0.0 114.725 178.606 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -131.72 177.86 7.19 Favored 'General case' 0 CA--C 1.539 0.538 0 CA-C-N 117.678 0.739 . . . . 0.0 111.599 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.439 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 43.1 p -90.24 146.49 24.2 Favored 'General case' 0 C--N 1.344 0.331 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.301 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.4 p -137.42 128.08 26.95 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.835 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 10.6 m-80 -97.68 118.99 35.44 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.839 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.584 HG22 ' O ' ' A' ' 30' ' ' PRO . 22.6 m -71.25 9.61 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 N-CA-C 113.239 0.829 . . . . 0.0 113.239 -178.826 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.51 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.1 OUTLIER -101.28 -34.67 9.55 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.222 -179.548 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.51 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.9 p90 -147.33 -27.01 0.38 Allowed 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 -178.484 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 6.5 t80 -120.83 85.07 39.12 Favored Pre-proline 0 CA--C 1.544 0.732 0 N-CA-C 111.705 0.261 . . . . 0.0 111.705 -178.712 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.422 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.2 Cg_endo -77.95 177.96 8.17 Favored 'Trans proline' 0 C--N 1.369 1.619 0 C-N-CA 122.241 1.961 . . . . 0.0 112.704 179.461 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.7 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -89.17 160.47 16.97 Favored 'General case' 0 N--CA 1.468 0.437 0 O-C-N 123.157 0.285 . . . . 0.0 110.921 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 75.8 m -79.93 108.41 9.11 Favored Pre-proline 0 CA--C 1.545 0.772 0 N-CA-C 111.976 0.361 . . . . 0.0 111.976 -179.394 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.444 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 79.1 Cg_endo -83.07 177.47 6.63 Favored 'Trans proline' 0 C--N 1.371 1.732 0 C-N-CA 122.445 2.097 . . . . 0.0 113.002 179.411 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.01 -39.64 2.68 Favored Glycine 0 C--N 1.34 0.791 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.986 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.8 mt -89.14 -38.73 14.09 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 122.493 0.317 . . . . 0.0 111.503 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.15 50.07 0.22 Allowed Glycine 0 C--N 1.339 0.748 0 O-C-N 123.448 0.468 . . . . 0.0 112.474 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.449 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 20.6 mt -113.51 150.02 33.5 Favored 'General case' 0 C--O 1.235 0.315 0 O-C-N 123.628 0.252 . . . . 0.0 110.872 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -138.99 154.18 48.24 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.232 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.7 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 59.5 m -97.12 123.06 40.78 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.659 179.429 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.469 ' H ' ' H ' ' A' ' 33' ' ' THR . 11.3 mt -127.34 123.24 23.19 Favored Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.268 -179.814 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -75.64 -40.87 1.07 Allowed 'Cis proline' 0 C--N 1.375 1.947 0 C-N-CA 124.636 -0.985 . . . . 0.0 112.507 0.094 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.04 33.62 8.79 Favored Glycine 0 C--N 1.342 0.877 0 O-C-N 123.596 0.56 . . . . 0.0 113.227 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -146.36 80.28 10.13 Favored Pre-proline 0 CA--C 1.547 0.855 0 CA-C-N 116.727 0.263 . . . . 0.0 111.556 179.575 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.584 ' O ' HG22 ' A' ' 12' ' ' VAL . 58.7 Cg_endo -89.27 -26.9 4.59 Favored 'Cis proline' 0 C--N 1.37 1.675 0 C-N-CA 124.729 -0.946 . . . . 0.0 113.463 -0.345 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -86.94 149.92 24.44 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.578 -179.634 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.439 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -151.09 -178.82 26.28 Favored Glycine 0 C--N 1.335 0.509 0 CA-C-N 115.581 -0.736 . . . . 0.0 112.394 179.425 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.48 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -124.62 141.6 51.98 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 179.282 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 54.1 m -87.3 112.2 21.82 Favored 'General case' 0 C--O 1.24 0.575 0 O-C-N 123.48 0.488 . . . . 0.0 111.792 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' TYR . . . . . 0.449 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 35.0 m-85 -126.05 159.14 33.55 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.081 -0.963 . . . . 0.0 110.552 179.304 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.579 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.8 t80 -93.23 135.01 34.85 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.937 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.0 mt . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.11 -0.948 . . . . 0.0 110.898 179.776 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.429 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.2 p . . . . . 0 C--O 1.236 0.35 0 CA-C-O 120.404 0.145 . . . . 0.0 110.981 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.6 147.97 22.45 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 112.138 0.422 . . . . 0.0 112.138 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' PHE . . . . . 0.475 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.25 177.4 7.51 Favored 'General case' 0 CA--C 1.538 0.491 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.463 178.813 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.55 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.4 tt0 -74.46 136.14 42.29 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 122.844 0.458 . . . . 0.0 111.695 -179.743 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.87 9.49 58.44 Favored Glycine 0 C--N 1.338 0.671 0 CA-C-N 115.633 -0.712 . . . . 0.0 114.258 179.017 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.475 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.2 pt-20 -132.83 177.66 7.47 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 117.321 0.561 . . . . 0.0 111.376 179.8 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 42.8 p -88.16 147.28 24.97 Favored 'General case' 0 C--N 1.345 0.372 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.603 -179.409 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.5 p -138.7 128.02 24.35 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.684 -179.743 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.35 119.07 37.87 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.896 179.678 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.607 HG22 ' O ' ' A' ' 30' ' ' PRO . 27.7 m -72.11 9.39 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 -178.741 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.5 tp-100 -102.65 -29.91 11.25 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 116.625 -0.261 . . . . 0.0 111.685 -179.361 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -149.28 -26.82 0.28 Allowed 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 -178.715 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 12.4 t80 -125.32 87.84 55.03 Favored Pre-proline 0 CA--C 1.546 0.803 0 N-CA-C 111.596 0.221 . . . . 0.0 111.596 -178.649 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.429 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.2 Cg_endo -77.05 177.93 8.28 Favored 'Trans proline' 0 C--N 1.371 1.715 0 C-N-CA 122.29 1.993 . . . . 0.0 112.704 179.484 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.711 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.5 t -90.06 159.94 16.58 Favored 'General case' 0 N--CA 1.468 0.468 0 O-C-N 123.265 0.353 . . . . 0.0 110.923 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.418 ' O ' HD12 ' A' ' 23' ' ' LEU . 74.7 m -79.87 108.06 8.22 Favored Pre-proline 0 CA--C 1.546 0.799 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -179.473 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.47 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 80.2 Cg_endo -84.02 177.91 5.7 Favored 'Trans proline' 0 C--N 1.372 1.778 0 C-N-CA 122.493 2.128 . . . . 0.0 112.955 179.453 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.64 -39.56 2.72 Favored Glycine 0 C--N 1.34 0.752 0 C-N-CA 121.371 -0.442 . . . . 0.0 112.953 179.76 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.6 mp -89.79 -37.07 14.76 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 122.45 0.3 . . . . 0.0 111.464 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.43 52.04 0.22 Allowed Glycine 0 C--N 1.338 0.687 0 O-C-N 123.455 0.472 . . . . 0.0 112.357 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.424 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 19.0 mt -113.62 149.56 34.39 Favored 'General case' 0 C--O 1.234 0.265 0 O-C-N 123.624 0.25 . . . . 0.0 110.972 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.2 t -138.94 152.08 47.42 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.315 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.711 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 55.7 m -96.76 122.69 39.99 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.608 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.42 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.9 mt -127.13 122.88 23.25 Favored Pre-proline 0 CA--C 1.545 0.772 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.328 -179.753 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -75.69 -41.28 0.99 Allowed 'Cis proline' 0 C--N 1.375 1.933 0 C-N-CA 124.651 -0.979 . . . . 0.0 112.593 0.04 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.7 31.68 9.97 Favored Glycine 0 C--N 1.342 0.905 0 O-C-N 123.582 0.551 . . . . 0.0 113.044 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -145.12 80.8 10.92 Favored Pre-proline 0 CA--C 1.547 0.832 0 CA-C-N 116.569 0.184 . . . . 0.0 111.258 179.705 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.607 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.8 Cg_endo -89.31 -26.57 4.86 Favored 'Cis proline' 0 C--N 1.369 1.648 0 C-N-CA 124.654 -0.978 . . . . 0.0 113.609 -0.336 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -92.29 153.96 18.91 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.891 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -155.97 -172.87 23.91 Favored Glycine 0 C--N 1.337 0.625 0 CA-C-N 115.482 -0.781 . . . . 0.0 112.608 179.54 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.496 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -126.51 144.95 50.7 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.576 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 60.8 m -89.61 113.92 25.44 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-O 121.072 0.463 . . . . 0.0 111.765 -179.634 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' TYR . . . . . 0.424 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 35.3 m-85 -125.58 157.45 37.1 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.471 179.327 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.55 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 19.4 t80 -92.5 133.65 35.73 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.985 -179.835 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt . . . . . 0 C--O 1.252 1.192 0 CA-C-O 118.507 -0.758 . . . . 0.0 110.898 179.787 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.427 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.1 p . . . . . 0 C--O 1.235 0.311 0 CA-C-O 120.409 0.147 . . . . 0.0 110.971 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.54 147.84 22.57 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 116.235 -0.439 . . . . 0.0 112.184 -179.696 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' PHE . . . . . 0.479 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.15 177.62 7.47 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.478 178.779 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.543 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.1 tt0 -74.64 135.92 41.95 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 122.905 0.482 . . . . 0.0 111.712 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.71 10.17 58.04 Favored Glycine 0 C--N 1.339 0.716 0 CA-C-N 115.596 -0.729 . . . . 0.0 114.292 179.027 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.479 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.3 pt-20 -132.99 177.55 7.57 Favored 'General case' 0 CA--C 1.54 0.578 0 CA-C-N 117.342 0.571 . . . . 0.0 111.403 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.8 m -88.33 146.42 25.3 Favored 'General case' 0 C--N 1.344 0.346 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.567 -179.478 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.5 p -138.26 128.57 26.03 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.689 -179.759 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -100.76 119.27 38.38 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.87 179.749 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.605 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.0 m -72.12 9.39 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 N-CA-C 113.063 0.764 . . . . 0.0 113.063 -178.785 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.6 tp-100 -102.72 -30.04 11.14 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.583 -0.28 . . . . 0.0 111.661 -179.331 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -149.0 -26.83 0.29 Allowed 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 112.864 0.69 . . . . 0.0 112.864 -178.745 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 12.5 t80 -125.28 87.77 55.12 Favored Pre-proline 0 CA--C 1.546 0.818 0 N-CA-C 111.63 0.233 . . . . 0.0 111.63 -178.639 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.427 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.2 Cg_endo -77.11 177.67 8.58 Favored 'Trans proline' 0 C--N 1.37 1.671 0 C-N-CA 122.269 1.979 . . . . 0.0 112.682 179.527 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.71 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.3 t -89.85 160.05 16.67 Favored 'General case' 0 N--CA 1.467 0.397 0 O-C-N 123.234 0.334 . . . . 0.0 110.947 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.426 ' O ' HD12 ' A' ' 23' ' ' LEU . 74.2 m -79.85 108.08 8.26 Favored Pre-proline 0 CA--C 1.545 0.782 0 O-C-N 123.247 0.342 . . . . 0.0 111.916 -179.47 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.469 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 79.6 Cg_endo -83.91 177.92 5.76 Favored 'Trans proline' 0 C--N 1.371 1.728 0 C-N-CA 122.554 2.169 . . . . 0.0 112.972 179.42 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.54 -38.97 2.9 Favored Glycine 0 C--N 1.34 0.773 0 C-N-CA 121.374 -0.441 . . . . 0.0 113.007 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.1 mt -89.83 -36.97 14.79 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 122.461 0.304 . . . . 0.0 111.469 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.06 52.08 0.23 Allowed Glycine 0 C--N 1.339 0.713 0 O-C-N 123.514 0.509 . . . . 0.0 112.335 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.426 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 18.9 mt -114.22 149.21 36.14 Favored 'General case' 0 C--O 1.235 0.321 0 O-C-N 123.671 0.277 . . . . 0.0 110.965 -179.687 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.1 t -138.83 151.93 47.42 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.29 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.71 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 56.1 m -96.76 122.48 39.76 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.595 179.411 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.4 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.6 mt -127.21 123.09 23.25 Favored Pre-proline 0 CA--C 1.545 0.759 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.372 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.419 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -76.0 -41.0 1.03 Allowed 'Cis proline' 0 C--N 1.374 1.914 0 C-N-CA 124.625 -0.99 . . . . 0.0 112.612 0.055 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.77 32.78 9.69 Favored Glycine 0 C--N 1.343 0.929 0 O-C-N 123.548 0.53 . . . . 0.0 112.945 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.419 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.37 79.42 12.73 Favored Pre-proline 0 CA--C 1.546 0.823 0 C-N-CA 122.213 0.205 . . . . 0.0 111.343 179.762 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.605 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.2 Cg_endo -89.73 -26.53 4.63 Favored 'Cis proline' 0 C--N 1.37 1.66 0 C-N-CA 124.722 -0.949 . . . . 0.0 113.58 -0.213 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -91.18 153.79 19.77 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.892 -179.363 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.34 -172.54 23.83 Favored Glycine 0 C--N 1.337 0.622 0 CA-C-N 115.518 -0.765 . . . . 0.0 112.646 179.493 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.506 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -126.7 145.44 50.59 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.601 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 59.3 m -90.01 114.09 25.89 Favored 'General case' 0 C--O 1.239 0.545 0 O-C-N 123.42 0.45 . . . . 0.0 111.779 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' TYR . . . . . 0.426 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 35.9 m-85 -125.39 157.33 37.06 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.103 -0.953 . . . . 0.0 110.419 179.326 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.543 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 17.5 t80 -92.58 133.41 35.99 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.003 -179.808 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.251 1.169 0 CA-C-O 118.507 -0.758 . . . . 0.0 110.907 179.835 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.419 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.5 p . . . . . 0 C--O 1.235 0.314 0 CA-C-O 120.477 0.179 . . . . 0.0 111.063 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.72 152.28 19.06 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.693 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -99.1 172.16 7.56 Favored 'General case' 0 CA--C 1.537 0.45 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.865 179.351 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.579 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.9 tt0 -60.63 129.81 43.39 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 123.36 0.664 . . . . 0.0 112.396 -179.29 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.3 -21.93 27.88 Favored Glycine 0 C--N 1.338 0.687 0 CA-C-N 115.639 -0.709 . . . . 0.0 114.383 178.846 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -105.61 177.42 4.86 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-N 117.458 0.629 . . . . 0.0 111.821 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 15.7 t -92.55 142.63 27.19 Favored 'General case' 0 C--N 1.343 0.321 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.966 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.8 p -132.46 129.27 39.01 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.853 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -97.59 119.11 35.55 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.049 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.606 HG22 ' O ' ' A' ' 30' ' ' PRO . 27.2 m -71.71 9.12 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.856 -179.021 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.448 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 23.1 tt0 -100.14 -30.17 12.08 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.251 -179.387 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.448 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.9 p90 -153.4 -27.68 0.14 Allowed 'General case' 0 N--CA 1.476 0.826 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -178.544 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.5 t80 -119.63 85.25 32.35 Favored Pre-proline 0 CA--C 1.545 0.757 0 N-CA-C 111.503 0.186 . . . . 0.0 111.503 -178.819 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.419 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.3 Cg_endo -77.69 175.28 11.42 Favored 'Trans proline' 0 C--N 1.368 1.597 0 C-N-CA 122.212 1.941 . . . . 0.0 112.757 179.619 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.65 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.2 t -87.28 162.28 17.51 Favored 'General case' 0 N--CA 1.467 0.396 0 O-C-N 123.246 0.341 . . . . 0.0 110.944 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.9 m -79.92 108.58 9.52 Favored Pre-proline 0 CA--C 1.545 0.762 0 N-CA-C 111.907 0.336 . . . . 0.0 111.907 -179.328 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.44 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 74.7 Cg_endo -82.85 177.58 6.69 Favored 'Trans proline' 0 C--N 1.372 1.792 0 C-N-CA 122.453 2.102 . . . . 0.0 112.993 179.385 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.08 -40.04 2.55 Favored Glycine 0 C--N 1.339 0.735 0 C-N-CA 121.356 -0.449 . . . . 0.0 112.904 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -90.16 -39.49 12.81 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 122.446 0.298 . . . . 0.0 111.386 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.28 53.76 0.19 Allowed Glycine 0 C--N 1.339 0.75 0 O-C-N 123.516 0.51 . . . . 0.0 112.514 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.47 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 23.0 mt -117.3 149.24 40.79 Favored 'General case' 0 C--O 1.235 0.297 0 O-C-N 123.632 0.254 . . . . 0.0 110.962 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.401 ' O ' ' HA ' ' A' ' 34' ' ' CYS . 8.9 t -139.58 156.97 46.56 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.276 -179.816 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.65 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 98.9 m -99.25 119.54 38.08 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.699 179.619 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.8 mt -129.79 126.12 22.45 Favored Pre-proline 0 CA--C 1.545 0.783 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.348 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.551 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 43.1 Cg_endo -69.81 -42.58 0.73 Allowed 'Cis proline' 0 C--N 1.375 1.956 0 C-N-CA 124.578 -1.009 . . . . 0.0 113.449 -0.22 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 82.1 39.34 11.58 Favored Glycine 0 C--N 1.345 1.03 0 O-C-N 123.358 0.411 . . . . 0.0 113.275 179.785 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.551 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -147.81 78.52 9.77 Favored Pre-proline 0 CA--C 1.548 0.87 0 C-N-CA 122.3 0.24 . . . . 0.0 111.402 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.606 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.6 Cg_endo -87.83 -26.86 5.5 Favored 'Cis proline' 0 C--N 1.369 1.612 0 C-N-CA 124.571 -1.012 . . . . 0.0 113.355 -0.273 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -87.06 147.54 25.64 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.705 -179.591 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -149.54 -175.78 22.14 Favored Glycine 0 C--N 1.336 0.556 0 CA-C-N 115.612 -0.722 . . . . 0.0 112.712 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.507 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.8 OUTLIER -124.24 143.15 50.69 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.505 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.401 ' HA ' ' O ' ' A' ' 24' ' ' THR . 34.5 m -87.47 112.01 21.75 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-O 121.086 0.469 . . . . 0.0 111.778 -179.598 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' TYR . . . . . 0.47 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 40.5 m-85 -125.81 159.87 31.31 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.605 179.458 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.579 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.4 t80 -93.74 135.15 35.33 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.94 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.5 mt . . . . . 0 C--O 1.251 1.136 0 CA-C-O 118.472 -0.775 . . . . 0.0 110.875 179.759 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.425 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 28.2 p . . . . . 0 C--O 1.235 0.339 0 CA-C-O 120.449 0.166 . . . . 0.0 111.03 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.3 147.72 22.85 Favored 'General case' 0 C--O 1.237 0.417 0 N-CA-C 112.176 0.435 . . . . 0.0 112.176 -179.621 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' PHE . . . . . 0.473 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.08 177.5 7.54 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 115.098 -0.955 . . . . 0.0 110.426 178.847 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.543 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.4 tt0 -74.85 135.89 41.56 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 122.875 0.47 . . . . 0.0 111.693 -179.698 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.44 10.91 57.72 Favored Glycine 0 C--N 1.339 0.725 0 CA-C-N 115.587 -0.733 . . . . 0.0 114.34 178.95 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.473 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.4 pt-20 -133.32 177.47 7.66 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 117.271 0.536 . . . . 0.0 111.392 179.821 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 43.1 p -88.04 145.65 25.87 Favored 'General case' 0 C--N 1.344 0.364 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.601 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.2 p -137.65 128.03 26.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.639 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.58 119.52 38.66 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.903 179.684 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.612 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.6 m -72.03 8.9 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 N-CA-C 113.024 0.749 . . . . 0.0 113.024 -178.752 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.409 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 1.5 tp-100 -102.55 -29.86 11.31 Favored 'General case' 0 CA--C 1.535 0.388 0 N-CA-C 111.706 0.262 . . . . 0.0 111.706 -179.333 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.409 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.9 p90 -149.43 -26.74 0.28 Allowed 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -178.761 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.6 t80 -124.64 87.17 54.91 Favored Pre-proline 0 CA--C 1.547 0.829 0 N-CA-C 111.577 0.214 . . . . 0.0 111.577 -178.657 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.413 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.1 Cg_endo -77.18 175.86 10.83 Favored 'Trans proline' 0 C--N 1.369 1.624 0 C-N-CA 122.293 1.995 . . . . 0.0 112.69 179.495 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.715 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.3 t -89.31 160.35 16.92 Favored 'General case' 0 N--CA 1.468 0.444 0 O-C-N 123.257 0.348 . . . . 0.0 110.886 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.444 ' O ' HD12 ' A' ' 23' ' ' LEU . 73.9 m -79.84 107.68 7.3 Favored Pre-proline 0 CA--C 1.545 0.777 0 O-C-N 123.286 0.367 . . . . 0.0 111.985 -179.561 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.48 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 81.5 Cg_endo -84.39 177.99 5.41 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.529 2.153 . . . . 0.0 112.984 179.41 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.66 -39.36 2.77 Favored Glycine 0 C--N 1.34 0.777 0 C-N-CA 121.41 -0.424 . . . . 0.0 113.033 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.6 mp -89.71 -38.05 14.14 Favored 'General case' 0 N--CA 1.467 0.423 0 C-N-CA 122.435 0.294 . . . . 0.0 111.489 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.65 52.55 0.19 Allowed Glycine 0 C--N 1.339 0.7 0 O-C-N 123.452 0.47 . . . . 0.0 112.422 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.444 HD12 ' O ' ' A' ' 18' ' ' CYS . 19.6 mt -115.3 148.56 39.08 Favored 'General case' 0 C--O 1.235 0.323 0 O-C-N 123.668 0.276 . . . . 0.0 110.846 -179.7 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.2 t -138.53 151.69 47.57 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.374 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.715 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 54.3 m -97.03 121.98 39.52 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.597 179.412 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.5 mt -127.4 123.36 23.18 Favored Pre-proline 0 CA--C 1.545 0.786 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.364 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.409 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.95 -41.06 1.02 Allowed 'Cis proline' 0 C--N 1.375 1.923 0 C-N-CA 124.652 -0.978 . . . . 0.0 112.598 0.067 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.55 32.71 9.95 Favored Glycine 0 C--N 1.343 0.947 0 O-C-N 123.55 0.531 . . . . 0.0 112.95 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.409 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.09 79.33 13.15 Favored Pre-proline 0 CA--C 1.546 0.822 0 C-N-CA 122.178 0.191 . . . . 0.0 111.291 179.722 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.612 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.7 Cg_endo -89.86 -26.32 4.73 Favored 'Cis proline' 0 C--N 1.37 1.708 0 C-N-CA 124.671 -0.97 . . . . 0.0 113.685 -0.338 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -91.1 153.65 19.93 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.93 -179.406 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.17 -172.37 23.52 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-N 115.533 -0.758 . . . . 0.0 112.662 179.467 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.49 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.6 OUTLIER -126.99 145.78 50.58 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.567 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 61.3 m -89.98 113.47 25.14 Favored 'General case' 0 C--O 1.239 0.549 0 O-C-N 123.455 0.472 . . . . 0.0 111.739 -179.643 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' TYR . . . . . 0.433 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 34.7 m-85 -123.77 157.19 34.58 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.47 179.316 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.543 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.7 t80 -93.41 132.72 37.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.989 -179.765 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt . . . . . 0 C--O 1.251 1.181 0 CA-C-O 118.455 -0.783 . . . . 0.0 110.872 179.797 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.421 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 28.5 p . . . . . 0 C--O 1.236 0.353 0 CA-C-O 120.435 0.16 . . . . 0.0 111.043 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.84 147.22 23.14 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 116.259 -0.428 . . . . 0.0 112.093 -179.609 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' PHE . . . . . 0.467 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.61 177.19 7.45 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.412 178.756 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.556 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 23.7 tt0 -74.1 134.69 42.91 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 122.9 0.48 . . . . 0.0 111.677 -179.649 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.45 9.73 57.55 Favored Glycine 0 C--N 1.339 0.712 0 CA-C-N 115.597 -0.729 . . . . 0.0 114.319 179.019 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.467 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.0 pt-20 -132.72 177.84 7.32 Favored 'General case' 0 CA--C 1.54 0.595 0 CA-C-N 117.371 0.586 . . . . 0.0 111.373 179.849 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.42 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 52.8 m -88.58 149.03 23.79 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.645 -179.379 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.2 p -141.38 129.12 21.64 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.615 -179.745 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -101.29 120.94 41.01 Favored 'General case' 0 N--CA 1.466 0.328 0 O-C-N 123.447 0.467 . . . . 0.0 110.516 179.632 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.583 HG22 ' O ' ' A' ' 30' ' ' PRO . 27.6 m -70.86 6.66 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 N-CA-C 113.689 0.996 . . . . 0.0 113.689 -178.228 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 5.9 tp60 -101.41 -30.3 11.53 Favored 'General case' 0 CA--C 1.534 0.354 0 N-CA-C 111.736 0.273 . . . . 0.0 111.736 -179.473 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.8 p90 -148.24 -27.55 0.33 Allowed 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 112.882 0.697 . . . . 0.0 112.882 -178.803 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -121.8 85.88 45.12 Favored Pre-proline 0 CA--C 1.545 0.786 0 N-CA-C 111.584 0.216 . . . . 0.0 111.584 -178.719 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.412 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.1 Cg_endo -77.4 176.83 9.59 Favored 'Trans proline' 0 C--N 1.369 1.614 0 C-N-CA 122.265 1.976 . . . . 0.0 112.606 179.51 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.706 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.0 t -89.07 160.1 17.23 Favored 'General case' 0 N--CA 1.468 0.442 0 O-C-N 123.226 0.329 . . . . 0.0 110.944 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.4 ' O ' HD12 ' A' ' 23' ' ' LEU . 72.3 m -79.84 108.09 8.27 Favored Pre-proline 0 CA--C 1.546 0.805 0 N-CA-C 111.948 0.351 . . . . 0.0 111.948 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.469 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 76.4 Cg_endo -83.69 178.0 5.84 Favored 'Trans proline' 0 C--N 1.372 1.797 0 C-N-CA 122.534 2.156 . . . . 0.0 112.979 179.473 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.69 -39.35 2.77 Favored Glycine 0 C--N 1.34 0.789 0 C-N-CA 121.401 -0.428 . . . . 0.0 112.935 179.81 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.6 mt -89.9 -36.68 14.9 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 122.447 0.299 . . . . 0.0 111.442 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.35 52.92 0.23 Allowed Glycine 0 C--N 1.339 0.716 0 O-C-N 123.496 0.498 . . . . 0.0 112.376 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.459 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 18.8 mt -115.4 148.53 39.24 Favored 'General case' 0 C--O 1.235 0.334 0 O-C-N 123.67 0.277 . . . . 0.0 110.953 -179.683 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.425 ' O ' ' HA ' ' A' ' 34' ' ' CYS . 9.8 t -138.83 152.22 47.67 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.296 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.706 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 61.7 m -96.47 122.34 39.26 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.551 179.43 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.6 mt -127.41 122.73 22.93 Favored Pre-proline 0 CA--C 1.546 0.809 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.385 -179.787 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -75.66 -41.54 0.95 Allowed 'Cis proline' 0 C--N 1.374 1.909 0 C-N-CA 124.677 -0.968 . . . . 0.0 112.569 0.083 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 91.17 31.47 9.72 Favored Glycine 0 C--N 1.342 0.914 0 O-C-N 123.562 0.538 . . . . 0.0 113.128 179.777 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -143.95 82.79 10.79 Favored Pre-proline 0 CA--C 1.547 0.845 0 CA-C-N 116.707 0.253 . . . . 0.0 111.391 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.583 ' O ' HG22 ' A' ' 12' ' ' VAL . 75.7 Cg_endo -87.26 -27.01 5.67 Favored 'Cis proline' 0 C--N 1.37 1.707 0 C-N-CA 124.59 -1.004 . . . . 0.0 113.439 -0.43 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -94.12 156.65 16.46 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.67 -179.032 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.42 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.65 -173.6 25.35 Favored Glycine 0 C--N 1.336 0.56 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.452 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.477 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.5 OUTLIER -124.77 143.81 50.59 Favored 'General case' 0 C--O 1.234 0.271 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.607 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.425 ' HA ' ' O ' ' A' ' 24' ' ' THR . 56.7 m -89.08 114.37 25.6 Favored 'General case' 0 C--O 1.239 0.536 0 O-C-N 123.452 0.47 . . . . 0.0 111.818 -179.569 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' TYR . . . . . 0.459 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.0 m-85 -125.51 157.97 35.67 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.051 -0.977 . . . . 0.0 110.466 179.287 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.556 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 17.7 t80 -92.53 133.12 36.25 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.984 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.104 -0.951 . . . . 0.0 110.977 179.827 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.438 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.6 p . . . . . 0 N--CA 1.466 0.332 0 CA-C-O 120.42 0.152 . . . . 0.0 110.868 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.84 151.72 20.44 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.784 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' PHE . . . . . 0.428 ' O ' ' HG2' ' A' ' 8' ' ' GLU . 15.3 p90 -97.32 174.78 6.53 Favored 'General case' 0 CA--C 1.537 0.477 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.687 179.117 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.573 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.1 tt0 -64.97 130.47 43.51 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 123.164 0.586 . . . . 0.0 112.253 -179.269 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 100.04 12.13 40.72 Favored Glycine 0 C--N 1.339 0.723 0 CA-C-N 115.62 -0.718 . . . . 0.0 114.674 178.656 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.428 ' HG2' ' O ' ' A' ' 5' ' ' PHE . 7.0 pt-20 -136.67 176.85 8.33 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 117.601 0.701 . . . . 0.0 111.47 179.632 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.435 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 40.6 p -90.23 144.8 25.53 Favored 'General case' 0 C--N 1.343 0.319 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.126 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 p -135.85 130.49 33.99 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.906 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -99.76 119.02 37.48 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.854 179.523 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.616 HG22 ' O ' ' A' ' 30' ' ' PRO . 30.5 m -72.71 10.58 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 N-CA-C 112.897 0.702 . . . . 0.0 112.897 -179.034 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.409 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.5 tp60 -104.26 -29.74 10.6 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.577 -179.425 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.409 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.48 -26.79 0.27 Allowed 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 112.819 0.674 . . . . 0.0 112.819 -178.78 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 9.7 t80 -124.98 86.96 55.99 Favored Pre-proline 0 CA--C 1.546 0.798 0 N-CA-C 111.622 0.23 . . . . 0.0 111.622 -178.697 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.438 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.1 Cg_endo -77.75 179.08 6.85 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 122.235 1.957 . . . . 0.0 112.739 179.512 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.7 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -89.91 160.22 16.54 Favored 'General case' 0 N--CA 1.467 0.376 0 O-C-N 123.183 0.302 . . . . 0.0 110.809 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 78.2 m -79.99 108.29 8.88 Favored Pre-proline 0 CA--C 1.545 0.773 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.907 -179.401 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.452 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.9 Cg_endo -83.44 177.53 6.34 Favored 'Trans proline' 0 C--N 1.371 1.753 0 C-N-CA 122.449 2.099 . . . . 0.0 112.95 179.441 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.79 -39.86 2.61 Favored Glycine 0 C--N 1.34 0.751 0 C-N-CA 121.374 -0.441 . . . . 0.0 112.946 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.8 mt -89.05 -38.1 14.64 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 122.444 0.298 . . . . 0.0 111.501 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.97 50.12 0.23 Allowed Glycine 0 C--N 1.339 0.706 0 O-C-N 123.481 0.488 . . . . 0.0 112.497 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.447 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.1 mt -113.85 149.73 34.62 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 122.294 0.238 . . . . 0.0 110.846 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -139.44 154.16 47.71 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.321 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.7 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.0 m -97.13 123.09 40.8 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.575 179.4 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.446 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.6 mt -127.2 123.09 23.25 Favored Pre-proline 0 CA--C 1.544 0.746 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.327 -179.772 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -75.7 -40.92 1.06 Allowed 'Cis proline' 0 C--N 1.375 1.922 0 C-N-CA 124.698 -0.959 . . . . 0.0 112.527 0.077 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.64 32.97 8.78 Favored Glycine 0 C--N 1.342 0.884 0 O-C-N 123.62 0.575 . . . . 0.0 113.123 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -145.68 81.39 10.08 Favored Pre-proline 0 CA--C 1.547 0.844 0 CA-C-N 116.756 0.278 . . . . 0.0 111.458 179.611 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.616 ' O ' HG22 ' A' ' 12' ' ' VAL . 60.7 Cg_endo -88.77 -26.53 5.24 Favored 'Cis proline' 0 C--N 1.371 1.715 0 C-N-CA 124.651 -0.979 . . . . 0.0 113.508 -0.407 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -90.46 155.24 19.06 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.347 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.435 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.19 -174.93 26.58 Favored Glycine 0 C--N 1.334 0.465 0 CA-C-N 115.379 -0.828 . . . . 0.0 112.464 179.549 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.495 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.6 OUTLIER -125.72 143.24 51.13 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.493 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 52.8 m -88.69 112.74 23.49 Favored 'General case' 0 C--O 1.239 0.523 0 O-C-N 123.439 0.462 . . . . 0.0 111.75 -179.644 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' TYR . . . . . 0.447 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 37.1 m-85 -126.48 159.26 33.89 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.051 -0.977 . . . . 0.0 110.519 179.36 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.573 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.5 t80 -92.77 135.34 34.2 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.006 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.9 mt . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.115 -0.945 . . . . 0.0 110.87 179.819 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.424 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 29.0 p . . . . . 0 C--O 1.235 0.314 0 CA-C-O 120.407 0.146 . . . . 0.0 111.004 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.0 147.81 22.52 Favored 'General case' 0 C--O 1.237 0.406 0 CA-C-N 116.243 -0.435 . . . . 0.0 112.121 -179.705 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' PHE . . . . . 0.468 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.4 m-85 -86.53 176.98 7.54 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.432 178.879 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.574 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.2 tt0 -73.79 136.09 43.55 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 122.905 0.482 . . . . 0.0 111.693 -179.792 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.49 8.81 58.26 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 115.624 -0.716 . . . . 0.0 114.289 179.008 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.468 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.3 pt-20 -132.53 177.39 7.65 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 117.333 0.567 . . . . 0.0 111.41 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.0 m -88.36 146.4 25.29 Favored 'General case' 0 C--N 1.344 0.351 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.619 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.0 p -138.42 128.6 25.74 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.729 -179.775 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.4 119.57 38.65 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.918 179.678 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.612 HG22 ' O ' ' A' ' 30' ' ' PRO . 29.0 m -71.95 8.93 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 N-CA-C 113.035 0.754 . . . . 0.0 113.035 -178.757 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.407 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.4 tp60 -102.7 -30.1 11.11 Favored 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 111.687 0.254 . . . . 0.0 111.687 -179.34 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.407 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.9 p90 -149.02 -26.92 0.29 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.824 0.676 . . . . 0.0 112.824 -178.763 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -124.32 87.15 54.16 Favored Pre-proline 0 CA--C 1.546 0.804 0 N-CA-C 111.561 0.208 . . . . 0.0 111.561 -178.704 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.42 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.2 Cg_endo -76.97 177.09 9.31 Favored 'Trans proline' 0 C--N 1.37 1.659 0 C-N-CA 122.234 1.956 . . . . 0.0 112.771 179.604 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.7 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.3 t -89.69 159.86 16.89 Favored 'General case' 0 N--CA 1.468 0.442 0 O-C-N 123.272 0.358 . . . . 0.0 110.957 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.1 m -79.85 108.24 8.64 Favored Pre-proline 0 CA--C 1.545 0.779 0 N-CA-C 112.024 0.379 . . . . 0.0 112.024 -179.524 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 79.1 Cg_endo -83.6 177.88 5.99 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 122.512 2.142 . . . . 0.0 113.025 179.39 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.72 -39.76 2.65 Favored Glycine 0 C--N 1.34 0.759 0 O-C-N 123.395 0.434 . . . . 0.0 112.95 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.6 mp -89.8 -36.64 15.01 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 122.47 0.308 . . . . 0.0 111.444 -179.878 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.43 51.63 0.24 Allowed Glycine 0 C--N 1.338 0.691 0 O-C-N 123.525 0.515 . . . . 0.0 112.323 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.438 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 19.3 mt -113.2 149.46 33.68 Favored 'General case' 0 C--O 1.234 0.288 0 O-C-N 123.632 0.254 . . . . 0.0 110.969 -179.663 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.0 t -139.08 153.0 47.98 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.239 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.7 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.1 m -96.81 123.09 40.41 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.546 179.448 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.425 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.9 mt -126.8 122.79 23.54 Favored Pre-proline 0 CA--C 1.545 0.771 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.401 -179.737 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.413 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.93 -41.04 1.02 Allowed 'Cis proline' 0 C--N 1.375 1.925 0 C-N-CA 124.695 -0.961 . . . . 0.0 112.643 0.042 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.08 32.64 9.58 Favored Glycine 0 C--N 1.343 0.948 0 CA-C-N 116.024 -0.535 . . . . 0.0 112.914 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.413 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -144.32 79.47 12.75 Favored Pre-proline 0 CA--C 1.546 0.803 0 C-N-CA 122.194 0.198 . . . . 0.0 111.349 179.761 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.612 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.3 Cg_endo -89.69 -26.47 4.7 Favored 'Cis proline' 0 C--N 1.37 1.666 0 C-N-CA 124.695 -0.96 . . . . 0.0 113.593 -0.252 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -91.14 153.44 20.06 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.937 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -155.91 -172.57 23.54 Favored Glycine 0 C--N 1.338 0.658 0 CA-C-N 115.55 -0.75 . . . . 0.0 112.649 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.503 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.5 OUTLIER -126.55 144.86 50.74 Favored 'General case' 0 C--O 1.235 0.318 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.556 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 57.5 m -89.47 114.82 26.37 Favored 'General case' 0 C--O 1.239 0.538 0 O-C-N 123.429 0.456 . . . . 0.0 111.832 -179.572 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' TYR . . . . . 0.438 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 38.0 m-85 -128.14 157.87 39.6 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.512 179.291 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.574 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 20.4 t80 -91.75 134.86 34.36 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.995 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.3 mt . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.085 -0.96 . . . . 0.0 110.963 179.797 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.423 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.0 p . . . . . 0 C--O 1.236 0.368 0 CA-C-O 120.453 0.168 . . . . 0.0 110.942 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.07 147.18 23.14 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-N 116.226 -0.443 . . . . 0.0 112.158 -179.668 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' PHE . . . . . 0.476 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.28 177.2 7.56 Favored 'General case' 0 CA--C 1.538 0.505 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.442 178.764 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.55 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 23.8 tt0 -73.95 134.87 43.18 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 122.932 0.493 . . . . 0.0 111.711 -179.755 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.27 9.39 58.05 Favored Glycine 0 C--N 1.339 0.713 0 CA-C-N 115.659 -0.7 . . . . 0.0 114.33 178.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.476 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.0 pt-20 -132.39 177.85 7.27 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 117.345 0.573 . . . . 0.0 111.419 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.43 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 51.8 m -88.47 149.15 23.81 Favored 'General case' 0 C--N 1.345 0.375 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.722 -179.393 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.4 p -141.56 129.48 21.87 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.656 -179.776 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -101.36 120.9 40.97 Favored 'General case' 0 C--O 1.235 0.326 0 O-C-N 123.384 0.428 . . . . 0.0 110.523 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 30' ' ' PRO . 27.4 m -71.04 7.12 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 N-CA-C 113.626 0.972 . . . . 0.0 113.626 -178.178 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.7 tp-100 -101.77 -30.6 11.2 Favored 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 -179.429 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.8 p90 -147.95 -27.44 0.34 Allowed 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 112.896 0.702 . . . . 0.0 112.896 -178.82 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -122.24 86.1 47.37 Favored Pre-proline 0 CA--C 1.546 0.798 0 N-CA-C 111.62 0.229 . . . . 0.0 111.62 -178.716 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.423 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.3 Cg_endo -77.51 177.59 8.66 Favored 'Trans proline' 0 C--N 1.369 1.653 0 C-N-CA 122.22 1.947 . . . . 0.0 112.573 179.458 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.706 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.0 t -89.19 160.11 17.13 Favored 'General case' 0 N--CA 1.468 0.44 0 O-C-N 123.202 0.314 . . . . 0.0 110.939 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.42 ' O ' HD12 ' A' ' 23' ' ' LEU . 73.5 m -79.82 108.27 8.67 Favored Pre-proline 0 CA--C 1.544 0.744 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.913 -179.589 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.46 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 75.8 Cg_endo -83.45 177.92 6.05 Favored 'Trans proline' 0 C--N 1.372 1.815 0 C-N-CA 122.525 2.15 . . . . 0.0 113.011 179.479 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.27 -39.05 2.86 Favored Glycine 0 C--N 1.34 0.771 0 C-N-CA 121.389 -0.434 . . . . 0.0 112.924 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.2 mt -90.25 -36.81 14.51 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 122.481 0.312 . . . . 0.0 111.468 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.1 53.05 0.23 Allowed Glycine 0 C--N 1.339 0.719 0 O-C-N 123.54 0.525 . . . . 0.0 112.338 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.451 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 18.3 mt -114.75 148.98 37.61 Favored 'General case' 0 C--O 1.235 0.317 0 O-C-N 123.686 0.286 . . . . 0.0 110.945 -179.648 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.422 ' O ' ' HA ' ' A' ' 34' ' ' CYS . 10.0 t -138.79 151.99 47.52 Favored 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.312 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.706 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 59.6 m -96.94 121.64 39.04 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.52 179.486 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.7 mt -127.69 123.69 23.08 Favored Pre-proline 0 CA--C 1.546 0.799 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.332 -179.758 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.426 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -76.01 -41.42 0.96 Allowed 'Cis proline' 0 C--N 1.374 1.903 0 C-N-CA 124.691 -0.962 . . . . 0.0 112.602 0.037 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.53 32.02 9.81 Favored Glycine 0 C--N 1.342 0.886 0 O-C-N 123.545 0.528 . . . . 0.0 113.062 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.426 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -141.86 81.17 14.94 Favored Pre-proline 0 CA--C 1.547 0.854 0 CA-C-N 116.65 0.225 . . . . 0.0 111.489 179.713 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.577 ' O ' HG22 ' A' ' 12' ' ' VAL . 76.3 Cg_endo -88.09 -26.0 6.19 Favored 'Cis proline' 0 C--N 1.371 1.719 0 C-N-CA 124.617 -0.993 . . . . 0.0 113.486 -0.326 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -93.68 156.71 16.54 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.637 -179.061 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.43 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.91 -172.5 24.22 Favored Glycine 0 C--N 1.337 0.59 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.436 179.558 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.486 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.3 OUTLIER -125.59 144.81 50.41 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.612 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 34' ' ' CYS . . . . . 0.422 ' HA ' ' O ' ' A' ' 24' ' ' THR . 57.0 m -89.44 114.3 25.76 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-O 121.094 0.473 . . . . 0.0 111.836 -179.676 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' TYR . . . . . 0.451 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 37.8 m-85 -124.92 157.74 35.28 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.418 179.302 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.55 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 19.8 t80 -92.85 133.03 36.48 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.959 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.251 1.146 0 CA-C-O 118.463 -0.78 . . . . 0.0 110.873 179.844 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.43 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.7 p . . . . . 0 C--O 1.235 0.328 0 CA-C-O 120.494 0.187 . . . . 0.0 110.874 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.15 151.15 20.53 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.755 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' PHE . . . . . 0.417 ' O ' ' HG2' ' A' ' 8' ' ' GLU . 17.4 p90 -97.8 174.42 6.61 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.733 179.206 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.582 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 16.4 tt0 -63.06 130.52 45.05 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.253 0.621 . . . . 0.0 112.382 -179.308 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.1 9.09 46.08 Favored Glycine 0 C--N 1.339 0.696 0 CA-C-N 115.663 -0.699 . . . . 0.0 114.78 178.483 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLU . . . . . 0.417 ' HG2' ' O ' ' A' ' 5' ' ' PHE . 6.4 pt-20 -134.93 176.94 8.2 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 117.708 0.754 . . . . 0.0 111.565 179.703 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.445 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 40.0 p -90.79 143.69 26.47 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.199 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.5 p -134.55 131.37 37.85 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.957 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -100.61 118.88 37.67 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.842 179.576 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.603 HG22 ' O ' ' A' ' 30' ' ' PRO . 30.4 m -71.7 10.31 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -178.906 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.512 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.1 OUTLIER -100.99 -35.12 9.49 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.254 -179.428 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.512 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.9 p90 -146.84 -26.7 0.4 Allowed 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 -178.494 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.0 t80 -122.3 86.3 47.76 Favored Pre-proline 0 CA--C 1.545 0.767 0 N-CA-C 111.725 0.269 . . . . 0.0 111.725 -178.724 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.43 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.4 Cg_endo -77.98 179.08 6.84 Favored 'Trans proline' 0 C--N 1.369 1.633 0 C-N-CA 122.279 1.986 . . . . 0.0 112.729 179.435 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.71 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.8 t -89.21 160.09 17.13 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 123.157 0.285 . . . . 0.0 110.87 179.756 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 72.6 m -79.99 108.64 9.74 Favored Pre-proline 0 CA--C 1.544 0.74 0 N-CA-C 111.96 0.356 . . . . 0.0 111.96 -179.356 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.436 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.6 Cg_endo -83.03 177.2 6.87 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 122.485 2.123 . . . . 0.0 112.905 179.316 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.21 -39.83 2.62 Favored Glycine 0 C--N 1.34 0.762 0 C-N-CA 121.312 -0.47 . . . . 0.0 112.992 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.1 mt -89.58 -38.16 14.16 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 122.435 0.294 . . . . 0.0 111.477 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.28 51.6 0.23 Allowed Glycine 0 C--N 1.34 0.751 0 CA-C-N 116.17 -0.468 . . . . 0.0 112.461 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.462 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.3 mt -114.88 150.74 35.13 Favored 'General case' 0 C--O 1.235 0.309 0 O-C-N 123.611 0.242 . . . . 0.0 110.958 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 t -139.73 154.26 47.4 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.305 -179.752 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.71 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.0 m -97.61 122.41 40.65 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.492 179.409 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.427 ' H ' ' H ' ' A' ' 33' ' ' THR . 9.6 mt -127.35 123.78 23.4 Favored Pre-proline 0 CA--C 1.545 0.765 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.4 -179.786 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.439 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.3 Cg_exo -76.0 -40.56 1.14 Allowed 'Cis proline' 0 C--N 1.375 1.934 0 C-N-CA 124.636 -0.985 . . . . 0.0 112.552 0.026 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.72 34.27 8.55 Favored Glycine 0 C--N 1.342 0.895 0 CA-C-N 115.915 -0.584 . . . . 0.0 113.045 179.865 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.439 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -144.71 79.96 11.92 Favored Pre-proline 0 CA--C 1.547 0.86 0 CA-C-N 116.68 0.24 . . . . 0.0 111.508 179.705 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.603 ' O ' HG22 ' A' ' 12' ' ' VAL . 65.6 Cg_endo -89.15 -26.0 5.47 Favored 'Cis proline' 0 C--N 1.37 1.692 0 C-N-CA 124.714 -0.952 . . . . 0.0 113.457 -0.348 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -89.75 155.25 19.32 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.349 -179.474 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.445 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.31 -174.49 26.15 Favored Glycine 0 C--N 1.335 0.493 0 CA-C-N 115.371 -0.831 . . . . 0.0 112.396 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.489 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -126.15 143.41 51.14 Favored 'General case' 0 C--O 1.234 0.258 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.511 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 45.9 m -88.56 112.52 23.13 Favored 'General case' 0 C--O 1.24 0.582 0 O-C-N 123.409 0.443 . . . . 0.0 111.681 -179.697 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' TYR . . . . . 0.462 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.9 m-85 -125.56 159.85 31.04 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.592 179.416 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.582 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.3 t80 -93.49 134.96 35.2 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.964 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.2 mt . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.145 -0.931 . . . . 0.0 110.903 179.751 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.272 . . . . . . . 0 C--O 1.235 0.327 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -106.75 -53.69 0.7 Allowed Glycine 0 C--N 1.336 0.541 0 O-C-N 123.685 0.616 . . . . 0.0 112.56 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.413 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.0 p -99.18 155.32 17.54 Favored 'General case' 0 C--O 1.235 0.325 0 C-N-CA 122.306 0.242 . . . . 0.0 110.993 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.01 151.14 20.62 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.781 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.6 p90 -98.93 171.82 7.82 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.856 179.415 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.585 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.2 tt0 -59.94 129.04 39.87 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 123.362 0.665 . . . . 0.0 112.428 -179.267 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.29 -20.86 29.84 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 115.572 -0.74 . . . . 0.0 114.388 178.736 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -107.02 177.47 4.85 Favored 'General case' 0 CA--C 1.539 0.558 0 CA-C-N 117.42 0.61 . . . . 0.0 111.828 -179.332 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 40.8 p -91.5 146.95 23.38 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.09 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.6 p -134.84 128.26 32.37 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.975 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -98.01 119.66 37.03 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.702 179.419 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 30' ' ' PRO . 24.2 m -72.41 10.35 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -178.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.406 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.7 tp60 -104.76 -29.22 10.69 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.637 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.406 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.94 -26.61 0.26 Allowed 'General case' 0 N--CA 1.477 0.899 0 N-CA-C 112.907 0.706 . . . . 0.0 112.907 -178.759 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.2 t80 -125.22 87.22 55.87 Favored Pre-proline 0 CA--C 1.545 0.779 0 N-CA-C 111.687 0.254 . . . . 0.0 111.687 -178.579 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.413 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.3 Cg_endo -77.88 176.84 9.52 Favored 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.311 2.007 . . . . 0.0 112.734 179.427 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.701 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -88.54 160.88 17.25 Favored 'General case' 0 N--CA 1.468 0.441 0 O-C-N 123.201 0.313 . . . . 0.0 110.809 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.9 m -79.94 108.45 9.23 Favored Pre-proline 0 CA--C 1.544 0.728 0 N-CA-C 112.078 0.399 . . . . 0.0 112.078 -179.284 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.448 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.1 Cg_endo -83.51 177.66 6.2 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.469 2.113 . . . . 0.0 112.896 179.341 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.82 -40.22 2.5 Favored Glycine 0 C--N 1.339 0.741 0 C-N-CA 121.349 -0.453 . . . . 0.0 112.985 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.8 mt -88.76 -38.52 14.62 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 122.456 0.302 . . . . 0.0 111.458 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.55 51.65 0.2 Allowed Glycine 0 C--N 1.338 0.69 0 O-C-N 123.475 0.485 . . . . 0.0 112.53 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.473 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 22.0 mt -115.72 149.17 38.85 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-O 120.618 0.247 . . . . 0.0 110.858 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t -138.93 154.84 48.37 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.201 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.701 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 65.7 m -97.19 123.28 40.92 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.709 179.548 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.47 ' H ' ' H ' ' A' ' 33' ' ' THR . 12.2 mt -127.38 122.85 23.01 Favored Pre-proline 0 CA--C 1.545 0.775 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.231 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -75.42 -40.82 1.09 Allowed 'Cis proline' 0 C--N 1.375 1.922 0 C-N-CA 124.697 -0.96 . . . . 0.0 112.648 0.133 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.03 33.85 8.65 Favored Glycine 0 C--N 1.343 0.918 0 CA-C-N 115.993 -0.549 . . . . 0.0 113.085 179.788 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.403 ' HA ' ' HA ' ' A' ' 30' ' ' PRO . 2.0 p-10 -147.06 79.63 9.84 Favored Pre-proline 0 CA--C 1.546 0.824 0 CA-C-N 116.641 0.221 . . . . 0.0 111.427 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.595 ' O ' HG22 ' A' ' 12' ' ' VAL . 56.1 Cg_endo -89.8 -27.4 3.9 Favored 'Cis proline' 0 C--N 1.37 1.671 0 C-N-CA 124.723 -0.949 . . . . 0.0 113.477 -0.368 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -86.11 149.59 25.02 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.633 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -151.13 -179.15 26.61 Favored Glycine 0 C--N 1.335 0.521 0 CA-C-N 115.654 -0.703 . . . . 0.0 112.627 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.47 ' H ' ' H ' ' A' ' 26' ' ' ILE . 0.9 OUTLIER -123.33 140.9 52.54 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 179.349 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.9 m -86.46 110.6 19.86 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 121.015 0.436 . . . . 0.0 111.698 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' TYR . . . . . 0.473 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 32.8 m-85 -125.47 158.37 34.61 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.624 179.546 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.585 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.1 t80 -92.89 135.65 33.95 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.943 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.6 mt . . . . . 0 C--O 1.249 1.059 0 CA-C-O 118.095 -0.955 . . . . 0.0 110.871 179.806 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.27 . . . . . . . 0 C--O 1.235 0.334 0 N-CA-C 112.46 0.541 . . . . 0.0 112.46 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.62 -62.15 0.62 Allowed Glycine 0 C--N 1.34 0.767 0 O-C-N 123.433 0.458 . . . . 0.0 112.452 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.423 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.5 p -100.29 154.49 18.44 Favored 'General case' 0 C--O 1.235 0.305 0 O-C-N 123.613 0.243 . . . . 0.0 110.961 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.07 152.88 19.74 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.757 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 18.6 p90 -98.23 174.08 6.68 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.725 179.161 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.565 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.3 tt0 -63.89 131.3 47.31 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 123.227 0.611 . . . . 0.0 112.348 -179.282 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.72 3.97 52.29 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-N 115.564 -0.744 . . . . 0.0 114.759 178.657 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -130.55 177.91 7.02 Favored 'General case' 0 CA--C 1.54 0.558 0 CA-C-N 117.636 0.718 . . . . 0.0 111.605 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.423 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 42.5 p -90.4 146.11 24.41 Favored 'General case' 0 C--N 1.343 0.315 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.293 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.9 p -136.47 128.01 28.69 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.782 -179.613 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 8.4 m-80 -98.22 119.57 37.11 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.87 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 30' ' ' PRO . 23.1 m -72.38 10.02 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 N-CA-C 112.963 0.727 . . . . 0.0 112.963 -178.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.429 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 15.0 tt0 -99.81 -30.23 12.17 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.206 -179.572 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.429 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.1 p90 -154.01 -26.77 0.13 Allowed 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 112.729 0.64 . . . . 0.0 112.729 -178.55 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -120.43 85.23 37.01 Favored Pre-proline 0 CA--C 1.544 0.749 0 N-CA-C 111.613 0.227 . . . . 0.0 111.613 -178.678 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.423 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.8 Cg_endo -78.2 179.12 6.79 Favored 'Trans proline' 0 C--N 1.369 1.65 0 C-N-CA 122.306 2.004 . . . . 0.0 112.664 179.478 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.709 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -89.62 159.82 16.96 Favored 'General case' 0 N--CA 1.467 0.402 0 O-C-N 123.163 0.29 . . . . 0.0 110.917 179.788 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.2 m -79.97 108.56 9.51 Favored Pre-proline 0 CA--C 1.545 0.76 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.881 -179.374 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.445 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.2 Cg_endo -83.27 177.42 6.54 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 122.521 2.147 . . . . 0.0 112.959 179.376 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.27 -40.12 2.53 Favored Glycine 0 C--N 1.34 0.751 0 C-N-CA 121.336 -0.459 . . . . 0.0 113.015 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.4 -38.91 13.76 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 122.462 0.305 . . . . 0.0 111.494 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.06 50.51 0.21 Allowed Glycine 0 C--N 1.339 0.723 0 O-C-N 123.479 0.487 . . . . 0.0 112.485 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.461 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.7 mt -113.87 150.33 33.77 Favored 'General case' 0 C--O 1.235 0.324 0 O-C-N 123.661 0.271 . . . . 0.0 110.854 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 t -139.28 154.59 47.98 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.347 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.709 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 56.9 m -97.49 123.17 41.25 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.822 -0.627 . . . . 0.0 110.595 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.468 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.9 mt -127.53 123.35 23.07 Favored Pre-proline 0 CA--C 1.544 0.741 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.238 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -75.69 -40.85 1.08 Allowed 'Cis proline' 0 C--N 1.375 1.927 0 C-N-CA 124.69 -0.962 . . . . 0.0 112.527 0.085 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.19 33.49 8.77 Favored Glycine 0 C--N 1.342 0.915 0 CA-C-N 115.964 -0.562 . . . . 0.0 113.147 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -147.06 79.86 9.73 Favored Pre-proline 0 CA--C 1.546 0.821 0 CA-C-N 116.649 0.224 . . . . 0.0 111.509 179.64 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.595 ' O ' HG22 ' A' ' 12' ' ' VAL . 57.5 Cg_endo -89.62 -27.23 4.11 Favored 'Cis proline' 0 C--N 1.37 1.681 0 C-N-CA 124.666 -0.973 . . . . 0.0 113.496 -0.367 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -86.83 150.03 24.41 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.559 -179.49 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.423 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -151.6 -178.09 26.01 Favored Glycine 0 C--N 1.336 0.535 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.45 179.453 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.471 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -125.75 142.25 51.6 Favored 'General case' 0 C--O 1.234 0.278 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 179.328 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 54.3 m -87.64 112.23 22.1 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-O 121.093 0.473 . . . . 0.0 111.783 -179.601 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' TYR . . . . . 0.461 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 34.8 m-85 -125.89 159.43 32.56 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.538 179.361 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.565 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.6 t80 -93.38 135.21 34.84 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.951 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.129 -0.939 . . . . 0.0 110.857 179.738 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' PCA . . . . . 0.46 ' HB2' ' OH ' ' A' ' 15' ' ' TYR 0.273 . . . . . . . 0 C--O 1.234 0.287 0 N-CA-C 112.177 0.436 . . . . 0.0 112.177 . . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -106.99 -56.19 0.63 Allowed Glycine 0 C--N 1.336 0.566 0 CA-C-N 115.841 -0.618 . . . . 0.0 112.498 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.416 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.2 p -100.39 154.84 18.19 Favored 'General case' 0 C--O 1.235 0.329 0 O-C-N 123.617 0.245 . . . . 0.0 110.999 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.9 151.62 20.45 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.701 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.9 p90 -98.75 172.82 7.21 Favored 'General case' 0 CA--C 1.536 0.427 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.873 179.3 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.588 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 14.4 tt0 -61.04 130.31 45.74 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 123.326 0.651 . . . . 0.0 112.334 -179.386 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.08 -25.62 19.77 Favored Glycine 0 C--N 1.338 0.669 0 CA-C-N 115.656 -0.702 . . . . 0.0 114.179 178.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -103.06 178.67 4.49 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 117.273 0.536 . . . . 0.0 111.851 -179.159 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 43.8 p -92.8 151.56 19.94 Favored 'General case' 0 C--N 1.344 0.348 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.221 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 p -139.48 130.49 26.38 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.863 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -100.14 119.88 39.01 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.597 179.322 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 30' ' ' PRO . 25.5 m -71.32 9.43 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -178.825 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.501 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -100.44 -32.81 10.63 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.3 -179.496 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.501 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.1 p90 -149.93 -26.8 0.26 Allowed 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 112.897 0.703 . . . . 0.0 112.897 -178.486 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.46 ' OH ' ' HB2' ' A' ' 1' ' ' PCA . 6.8 t80 -121.09 85.53 41.26 Favored Pre-proline 0 CA--C 1.545 0.757 0 N-CA-C 111.747 0.277 . . . . 0.0 111.747 -178.663 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.416 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.1 Cg_endo -78.06 177.16 9.12 Favored 'Trans proline' 0 C--N 1.369 1.607 0 C-N-CA 122.202 1.935 . . . . 0.0 112.67 179.385 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.712 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 4.6 t -88.27 160.73 17.54 Favored 'General case' 0 N--CA 1.467 0.418 0 O-C-N 123.186 0.304 . . . . 0.0 110.796 179.759 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.0 m -79.97 108.67 9.77 Favored Pre-proline 0 CA--C 1.545 0.768 0 N-CA-C 111.99 0.367 . . . . 0.0 111.99 -179.18 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 76.0 Cg_endo -83.22 177.65 6.4 Favored 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.5 2.133 . . . . 0.0 112.918 179.286 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.94 -41.09 2.25 Favored Glycine 0 C--N 1.34 0.77 0 C-N-CA 121.384 -0.436 . . . . 0.0 112.928 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.1 -38.86 14.03 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 122.486 0.314 . . . . 0.0 111.431 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.442 ' O ' ' HA ' ' A' ' 36' ' ' TYR . . . 124.27 53.41 0.19 Allowed Glycine 0 C--N 1.339 0.715 0 O-C-N 123.521 0.513 . . . . 0.0 112.512 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.475 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 23.7 mt -117.64 147.48 42.84 Favored 'General case' 0 C--O 1.234 0.267 0 O-C-N 123.623 0.249 . . . . 0.0 110.785 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -139.3 154.51 47.94 Favored 'General case' 0 CA--C 1.535 0.404 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.391 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.712 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 89.7 m -97.35 118.3 33.5 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.52 179.496 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 11.6 mt -122.75 122.23 27.22 Favored Pre-proline 0 CA--C 1.545 0.756 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.235 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.424 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.42 -40.72 1.12 Allowed 'Cis proline' 0 C--N 1.373 1.843 0 C-N-CA 124.695 -0.961 . . . . 0.0 112.701 0.232 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.13 34.43 8.8 Favored Glycine 0 C--N 1.342 0.868 0 O-C-N 123.588 0.555 . . . . 0.0 112.928 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.424 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -145.74 79.58 11.11 Favored Pre-proline 0 CA--C 1.548 0.876 0 C-N-CA 122.204 0.202 . . . . 0.0 111.423 179.724 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.595 ' O ' HG22 ' A' ' 12' ' ' VAL . 56.8 Cg_endo -88.79 -27.76 4.18 Favored 'Cis proline' 0 C--N 1.37 1.666 0 C-N-CA 124.739 -0.942 . . . . 0.0 113.486 -0.254 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -86.9 149.34 24.87 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.66 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.81 160.29 30.22 Favored Glycine 0 C--N 1.335 0.52 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.137 179.335 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.426 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.5 OUTLIER -99.1 143.96 28.78 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.823 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 18.8 m -88.31 110.04 20.45 Favored 'General case' 0 C--O 1.238 0.476 0 O-C-N 123.464 0.477 . . . . 0.0 111.528 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' TYR . . . . . 0.475 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 38.1 m-85 -124.73 160.13 29.31 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.289 -0.868 . . . . 0.0 110.744 179.628 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.588 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 15.8 t80 -93.07 137.23 32.61 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.872 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 14.6 mt . . . . . 0 C--O 1.251 1.172 0 CA-C-O 118.531 -0.747 . . . . 0.0 110.876 179.742 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.273 . . . . . . . 0 C--O 1.234 0.285 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -154.78 54.35 0.43 Allowed Glycine 0 C--N 1.337 0.613 0 O-C-N 123.713 0.633 . . . . 0.0 112.507 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.417 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.4 p -104.1 154.91 19.16 Favored 'General case' 0 C--O 1.235 0.331 0 O-C-N 123.609 0.241 . . . . 0.0 110.989 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.406 ' HB1' ' HG3' ' A' ' 8' ' ' GLU . . . -92.52 150.19 20.91 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.654 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.5 p90 -98.65 171.91 7.82 Favored 'General case' 0 CA--C 1.537 0.458 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.848 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.58 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 14.8 tt0 -59.53 128.63 37.96 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 123.305 0.642 . . . . 0.0 112.389 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.3 -21.02 27.34 Favored Glycine 0 C--N 1.339 0.718 0 CA-C-N 115.66 -0.7 . . . . 0.0 114.421 178.855 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.406 ' HG3' ' HB1' ' A' ' 4' ' ' ALA . 6.8 pt-20 -107.48 177.39 4.85 Favored 'General case' 0 CA--C 1.541 0.604 0 CA-C-N 117.43 0.615 . . . . 0.0 111.835 -179.222 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 53.0 m -91.47 145.4 24.65 Favored 'General case' 0 C--N 1.343 0.312 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.079 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.7 p -134.0 129.09 35.65 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.93 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.27 119.93 39.15 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.818 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.603 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.5 m -72.4 10.48 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 112.994 0.738 . . . . 0.0 112.994 -178.797 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.401 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.6 tp60 -104.03 -29.31 10.98 Favored 'General case' 0 CA--C 1.535 0.377 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.615 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.401 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.84 -26.74 0.26 Allowed 'General case' 0 N--CA 1.476 0.874 0 N-CA-C 112.851 0.686 . . . . 0.0 112.851 -178.759 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.402 ' HE2' ' HB2' ' A' ' 4' ' ' ALA . 12.6 t80 -125.75 88.33 54.4 Favored Pre-proline 0 CA--C 1.545 0.775 0 N-CA-C 111.702 0.26 . . . . 0.0 111.702 -178.614 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.417 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.8 Cg_endo -77.74 176.17 10.34 Favored 'Trans proline' 0 C--N 1.37 1.686 0 C-N-CA 122.27 1.98 . . . . 0.0 112.708 179.333 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.683 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.1 t -88.26 161.36 17.23 Favored 'General case' 0 N--CA 1.467 0.399 0 O-C-N 123.208 0.318 . . . . 0.0 110.841 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.3 m -79.97 108.47 9.3 Favored Pre-proline 0 CA--C 1.544 0.745 0 N-CA-C 112.03 0.381 . . . . 0.0 112.03 -179.276 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.448 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.9 Cg_endo -83.51 177.53 6.29 Favored 'Trans proline' 0 C--N 1.371 1.756 0 C-N-CA 122.512 2.142 . . . . 0.0 112.906 179.369 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.0 -40.56 2.38 Favored Glycine 0 C--N 1.34 0.775 0 C-N-CA 121.313 -0.47 . . . . 0.0 113.003 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.08 -38.91 14.01 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 122.424 0.29 . . . . 0.0 111.453 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.92 51.96 0.2 Allowed Glycine 0 C--N 1.339 0.719 0 O-C-N 123.466 0.479 . . . . 0.0 112.568 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.459 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 22.0 mt -115.26 149.32 37.96 Favored 'General case' 0 C--O 1.234 0.286 0 O-C-N 123.654 0.267 . . . . 0.0 110.847 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -138.95 154.69 48.34 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.266 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.683 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 67.9 m -97.24 123.31 40.99 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.64 179.538 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.445 ' H ' ' H ' ' A' ' 33' ' ' THR . 12.0 mt -126.63 122.94 23.77 Favored Pre-proline 0 CA--C 1.545 0.775 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.279 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.422 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.85 -40.89 1.06 Allowed 'Cis proline' 0 C--N 1.375 1.929 0 C-N-CA 124.595 -1.002 . . . . 0.0 112.644 0.111 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.08 33.07 9.14 Favored Glycine 0 C--N 1.342 0.883 0 O-C-N 123.548 0.53 . . . . 0.0 112.848 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.422 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.8 79.08 12.4 Favored Pre-proline 0 CA--C 1.547 0.843 0 C-N-CA 122.193 0.197 . . . . 0.0 111.291 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.603 ' O ' HG22 ' A' ' 12' ' ' VAL . 58.6 Cg_endo -89.89 -26.71 4.36 Favored 'Cis proline' 0 C--N 1.37 1.682 0 C-N-CA 124.708 -0.955 . . . . 0.0 113.682 -0.35 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.06 152.56 21.1 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.933 -179.406 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.41 -174.2 24.2 Favored Glycine 0 C--N 1.337 0.637 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.659 179.591 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.499 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -124.21 143.85 50.28 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.589 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.6 m -88.11 110.24 20.5 Favored 'General case' 0 C--O 1.238 0.448 0 O-C-N 123.44 0.462 . . . . 0.0 111.571 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' TYR . . . . . 0.459 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 33.0 m-85 -124.76 159.1 31.71 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.657 179.603 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.58 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.3 t80 -93.18 136.11 33.75 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.96 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.7 mt . . . . . 0 C--O 1.251 1.146 0 CA-C-O 118.486 -0.769 . . . . 0.0 110.892 179.775 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.271 . . . . . . . 0 C--O 1.235 0.32 0 N-CA-C 112.144 0.424 . . . . 0.0 112.144 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 171.44 54.7 0.04 OUTLIER Glycine 0 C--N 1.336 0.582 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.55 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.424 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.7 p -100.54 154.63 18.4 Favored 'General case' 0 C--O 1.235 0.324 0 O-C-N 123.67 0.277 . . . . 0.0 110.924 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.76 152.03 20.35 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.827 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 19.1 p90 -98.42 173.92 6.72 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.626 179.165 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.581 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 17.5 tt0 -63.82 130.0 42.38 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 123.213 0.605 . . . . 0.0 112.359 -179.326 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 102.06 9.61 41.89 Favored Glycine 0 C--N 1.339 0.717 0 CA-C-N 115.662 -0.699 . . . . 0.0 114.764 178.627 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -135.23 177.39 7.85 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 117.676 0.738 . . . . 0.0 111.535 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 52.4 m -90.82 141.65 28.59 Favored 'General case' 0 C--N 1.343 0.314 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.137 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.5 p -133.17 128.8 36.8 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.844 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.33 119.88 39.09 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.868 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.604 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.3 m -72.78 12.2 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.031 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -178.823 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.7 tp-100 -105.51 -29.91 9.88 Favored 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 116.593 -0.276 . . . . 0.0 111.559 -179.391 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -148.78 -26.68 0.31 Allowed 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 8.8 t80 -126.21 88.19 54.77 Favored Pre-proline 0 CA--C 1.546 0.805 0 N-CA-C 111.696 0.258 . . . . 0.0 111.696 -178.755 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.424 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.4 Cg_endo -77.91 177.89 8.25 Favored 'Trans proline' 0 C--N 1.369 1.635 0 C-N-CA 122.31 2.007 . . . . 0.0 112.724 179.378 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.698 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.9 t -90.09 160.13 16.46 Favored 'General case' 0 N--CA 1.468 0.447 0 O-C-N 123.218 0.324 . . . . 0.0 110.799 179.802 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 76.3 m -80.06 108.45 9.34 Favored Pre-proline 0 CA--C 1.545 0.774 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.93 -179.322 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.45 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 80.5 Cg_endo -83.41 177.44 6.43 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.465 2.11 . . . . 0.0 112.961 179.296 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.04 -40.44 2.42 Favored Glycine 0 C--N 1.339 0.741 0 O-C-N 123.434 0.459 . . . . 0.0 113.016 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.07 -39.13 13.85 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 122.437 0.295 . . . . 0.0 111.52 -179.823 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.47 50.66 0.2 Allowed Glycine 0 C--N 1.339 0.736 0 O-C-N 123.505 0.503 . . . . 0.0 112.51 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.442 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.8 mt -113.86 150.21 33.94 Favored 'General case' 0 C--O 1.235 0.329 0 O-C-N 123.617 0.245 . . . . 0.0 110.846 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 t -139.58 154.27 47.58 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.326 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.698 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.9 m -97.33 123.3 41.1 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.582 179.366 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.453 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.8 mt -126.9 123.32 23.62 Favored Pre-proline 0 CA--C 1.545 0.772 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.333 -179.77 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.419 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.9 -40.84 1.07 Allowed 'Cis proline' 0 C--N 1.375 1.949 0 C-N-CA 124.66 -0.975 . . . . 0.0 112.554 0.055 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.98 32.45 9.88 Favored Glycine 0 C--N 1.341 0.859 0 O-C-N 123.621 0.576 . . . . 0.0 112.899 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.419 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -144.34 78.9 13.14 Favored Pre-proline 0 CA--C 1.546 0.817 0 C-N-CA 122.245 0.218 . . . . 0.0 111.313 179.776 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.604 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.2 Cg_endo -90.02 -26.5 4.46 Favored 'Cis proline' 0 C--N 1.369 1.634 0 C-N-CA 124.74 -0.942 . . . . 0.0 113.668 -0.306 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.85 152.78 20.62 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.972 -179.362 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.402 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -155.47 -171.84 22.44 Favored Glycine 0 C--N 1.338 0.647 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.589 179.502 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.515 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -127.22 145.33 50.81 Favored 'General case' 0 C--O 1.235 0.316 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 179.553 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 51.6 m -89.22 111.93 22.84 Favored 'General case' 0 C--O 1.24 0.565 0 O-C-N 123.481 0.488 . . . . 0.0 111.627 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' TYR . . . . . 0.442 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.5 m-85 -125.72 159.76 31.48 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.523 179.423 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.581 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.6 t80 -93.35 136.03 34.01 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.005 -179.83 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.0 mt . . . . . 0 C--O 1.251 1.148 0 CA-C-O 118.502 -0.761 . . . . 0.0 110.891 179.745 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.273 . . . . . . . 0 C--O 1.235 0.314 0 N-CA-C 112.149 0.425 . . . . 0.0 112.149 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -105.17 -54.74 0.74 Allowed Glycine 0 C--N 1.336 0.571 0 O-C-N 123.737 0.648 . . . . 0.0 112.53 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.415 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.1 p -99.25 155.06 17.69 Favored 'General case' 0 C--O 1.235 0.314 0 O-C-N 123.593 0.231 . . . . 0.0 111.003 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.83 150.48 21.05 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.676 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.9 p90 -98.7 171.88 7.83 Favored 'General case' 0 CA--C 1.536 0.44 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.93 179.355 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.587 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.0 tt0 -59.98 128.63 37.82 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.352 0.661 . . . . 0.0 112.381 -179.312 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.25 -20.89 27.62 Favored Glycine 0 C--N 1.338 0.68 0 CA-C-N 115.688 -0.687 . . . . 0.0 114.421 178.851 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -107.29 177.47 4.83 Favored 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 117.444 0.622 . . . . 0.0 111.813 -179.289 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.7 m -91.42 144.9 25.1 Favored 'General case' 0 C--N 1.344 0.337 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.063 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.9 p -133.61 128.45 35.17 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.974 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.07 120.08 39.3 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.754 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.608 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.0 m -72.28 10.38 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 113.023 0.749 . . . . 0.0 113.023 -178.776 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.407 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 1.6 tp-100 -104.12 -29.69 10.7 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.661 -179.358 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.407 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.48 -26.63 0.28 Allowed 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -178.791 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -125.32 87.79 55.1 Favored Pre-proline 0 CA--C 1.546 0.803 0 N-CA-C 111.652 0.242 . . . . 0.0 111.652 -178.651 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.415 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.7 Cg_endo -77.66 175.4 11.29 Favored 'Trans proline' 0 C--N 1.369 1.632 0 C-N-CA 122.304 2.003 . . . . 0.0 112.706 179.444 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.681 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -88.46 161.06 17.24 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.848 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 72.0 m -79.91 108.6 9.56 Favored Pre-proline 0 CA--C 1.544 0.738 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.206 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.5 Cg_endo -83.43 177.63 6.28 Favored 'Trans proline' 0 C--N 1.371 1.753 0 C-N-CA 122.491 2.128 . . . . 0.0 112.933 179.262 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.07 -40.01 2.57 Favored Glycine 0 C--N 1.339 0.727 0 C-N-CA 121.386 -0.435 . . . . 0.0 112.969 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.9 mt -88.83 -38.64 14.44 Favored 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 122.488 0.315 . . . . 0.0 111.466 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.19 51.26 0.21 Allowed Glycine 0 C--N 1.339 0.721 0 O-C-N 123.481 0.488 . . . . 0.0 112.539 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.468 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.6 mt -114.58 149.19 36.92 Favored 'General case' 0 C--O 1.235 0.308 0 O-C-N 123.65 0.265 . . . . 0.0 110.881 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t -138.85 154.34 48.41 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.201 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.681 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 68.3 m -97.0 123.23 40.66 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.659 179.514 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.449 ' H ' ' H ' ' A' ' 33' ' ' THR . 12.7 mt -125.92 122.63 24.46 Favored Pre-proline 0 CA--C 1.545 0.768 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.26 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -75.51 -41.08 1.03 Allowed 'Cis proline' 0 C--N 1.375 1.923 0 C-N-CA 124.664 -0.973 . . . . 0.0 112.641 0.072 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.78 31.84 9.73 Favored Glycine 0 C--N 1.341 0.847 0 O-C-N 123.548 0.53 . . . . 0.0 113.043 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -145.42 80.12 11.08 Favored Pre-proline 0 CA--C 1.547 0.841 0 C-N-CA 122.131 0.173 . . . . 0.0 111.229 179.694 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.608 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.1 Cg_endo -89.65 -26.92 4.33 Favored 'Cis proline' 0 C--N 1.369 1.636 0 C-N-CA 124.676 -0.968 . . . . 0.0 113.681 -0.321 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -90.97 152.45 20.69 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.912 -179.273 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.44 -174.48 24.54 Favored Glycine 0 C--N 1.338 0.652 0 CA-C-N 115.442 -0.799 . . . . 0.0 112.634 179.593 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.496 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -123.79 143.93 50.01 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.561 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.6 m -88.08 110.23 20.48 Favored 'General case' 0 C--O 1.238 0.468 0 O-C-N 123.477 0.485 . . . . 0.0 111.588 -179.768 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' TYR . . . . . 0.468 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 33.0 m-85 -125.2 158.78 33.15 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 115.178 -0.919 . . . . 0.0 110.65 179.586 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.587 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.8 t80 -93.02 136.47 33.25 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.912 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.2 mt . . . . . 0 C--O 1.251 1.181 0 CA-C-O 118.478 -0.772 . . . . 0.0 110.878 179.754 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.272 . . . . . . . 0 C--O 1.235 0.307 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 170.42 51.35 0.04 OUTLIER Glycine 0 C--N 1.337 0.592 0 CA-C-N 115.791 -0.641 . . . . 0.0 112.576 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.424 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.1 p -129.03 155.27 45.67 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 122.298 0.239 . . . . 0.0 110.864 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.28 152.8 18.95 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.828 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.458 ' O ' ' HG2' ' A' ' 8' ' ' GLU . 14.2 p90 -97.64 174.99 6.36 Favored 'General case' 0 CA--C 1.537 0.464 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.615 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.576 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.4 tt0 -65.23 130.99 45.35 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 123.095 0.558 . . . . 0.0 112.362 -179.287 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 100.08 12.85 38.34 Favored Glycine 0 C--N 1.339 0.723 0 CA-C-N 115.628 -0.714 . . . . 0.0 114.661 178.623 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.458 ' HG2' ' O ' ' A' ' 5' ' ' PHE . 8.8 pt-20 -136.87 175.96 9.14 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 117.592 0.696 . . . . 0.0 111.455 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.418 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 53.0 m -90.85 138.39 31.63 Favored 'General case' 0 C--N 1.343 0.299 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.132 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 p -131.52 128.18 38.78 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.837 -179.669 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -97.07 118.86 34.42 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.02 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.611 HG22 ' O ' ' A' ' 30' ' ' PRO . 26.8 m -72.45 12.74 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.86 -178.87 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 5.9 tp60 -106.46 -31.02 8.73 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.518 -179.4 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.7 p90 -146.87 -27.22 0.4 Allowed 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 112.81 0.67 . . . . 0.0 112.81 -178.818 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -126.45 88.37 54.48 Favored Pre-proline 0 CA--C 1.545 0.766 0 N-CA-C 111.607 0.225 . . . . 0.0 111.607 -178.791 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.424 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 62.3 Cg_endo -78.16 177.86 8.27 Favored 'Trans proline' 0 C--N 1.37 1.681 0 C-N-CA 122.348 2.032 . . . . 0.0 112.732 179.366 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.709 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.7 t -88.91 161.15 16.82 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.904 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 75.5 m -79.96 108.49 9.33 Favored Pre-proline 0 CA--C 1.545 0.758 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.87 -179.383 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.442 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 75.7 Cg_endo -83.07 177.52 6.6 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.485 2.123 . . . . 0.0 112.929 179.423 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.81 -40.11 2.53 Favored Glycine 0 C--N 1.34 0.759 0 C-N-CA 121.392 -0.432 . . . . 0.0 112.969 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.86 -39.18 13.22 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 122.408 0.283 . . . . 0.0 111.427 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.01 52.33 0.19 Allowed Glycine 0 C--N 1.339 0.709 0 O-C-N 123.467 0.479 . . . . 0.0 112.497 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.9 mt -115.74 149.79 37.9 Favored 'General case' 0 C--O 1.235 0.319 0 O-C-N 123.584 0.226 . . . . 0.0 110.86 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.438 ' O ' ' HA ' ' A' ' 34' ' ' CYS . 8.8 t -139.36 155.34 47.73 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.353 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.709 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 68.1 m -98.66 118.8 36.2 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.548 179.53 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.5 mt -129.1 126.55 23.13 Favored Pre-proline 0 CA--C 1.544 0.736 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.433 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -68.69 -42.5 0.7 Allowed 'Cis proline' 0 C--N 1.376 2.005 0 C-N-CA 124.597 -1.001 . . . . 0.0 113.453 -0.208 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 82.29 35.56 20.2 Favored Glycine 0 C--N 1.344 1.013 0 O-C-N 123.349 0.406 . . . . 0.0 113.524 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -148.09 80.81 8.5 Favored Pre-proline 0 CA--C 1.547 0.852 0 CA-C-N 116.653 0.226 . . . . 0.0 111.352 179.744 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.611 ' O ' HG22 ' A' ' 12' ' ' VAL . 58.3 Cg_endo -87.25 -27.73 5.04 Favored 'Cis proline' 0 C--N 1.37 1.684 0 C-N-CA 124.516 -1.035 . . . . 0.0 113.353 -0.246 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -88.73 147.98 24.21 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.675 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.418 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -150.2 -174.27 21.24 Favored Glycine 0 C--N 1.335 0.526 0 CA-C-N 115.624 -0.716 . . . . 0.0 112.674 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.504 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.3 OUTLIER -127.22 143.38 51.26 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.321 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.438 ' HA ' ' O ' ' A' ' 24' ' ' THR . 55.6 m -87.58 114.17 23.94 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-O 121.095 0.474 . . . . 0.0 111.962 -179.433 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' TYR . . . . . 0.467 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 43.8 m-85 -126.7 160.22 31.43 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 114.988 -1.006 . . . . 0.0 110.429 179.274 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.576 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.5 t80 -94.07 134.33 36.61 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.979 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.112 -0.947 . . . . 0.0 110.833 179.779 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.268 . . . . . . . 0 CA--C 1.534 0.332 0 N-CA-C 112.493 0.553 . . . . 0.0 112.493 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.15 53.4 1.09 Allowed Glycine 0 C--N 1.341 0.82 0 O-C-N 123.436 0.46 . . . . 0.0 112.541 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.412 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.1 p -128.94 155.09 45.87 Favored 'General case' 0 C--O 1.235 0.315 0 C-N-CA 122.296 0.238 . . . . 0.0 110.928 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.8 151.94 19.73 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.664 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 17.1 p90 -99.05 173.12 6.98 Favored 'General case' 0 CA--C 1.537 0.468 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.839 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.58 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 14.0 tt0 -60.87 130.91 48.83 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.308 0.643 . . . . 0.0 112.284 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 107.62 -25.33 21.54 Favored Glycine 0 C--N 1.337 0.618 0 CA-C-N 115.657 -0.702 . . . . 0.0 114.217 178.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -103.72 178.75 4.47 Favored 'General case' 0 CA--C 1.541 0.608 0 CA-C-N 117.251 0.525 . . . . 0.0 111.833 -179.145 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 51.3 m -93.34 151.1 19.99 Favored 'General case' 0 C--N 1.344 0.362 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.163 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.1 p -139.77 132.2 28.54 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.843 -179.52 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -99.78 118.42 36.23 Favored 'General case' 0 C--O 1.236 0.387 0 O-C-N 123.635 0.584 . . . . 0.0 110.657 179.366 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 30' ' ' PRO . 30.6 m -71.05 10.45 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -178.849 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.505 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.1 OUTLIER -101.58 -34.86 9.34 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.204 -179.479 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.505 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.8 p90 -146.72 -27.35 0.4 Allowed 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -178.497 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.8 t80 -121.79 86.12 45.31 Favored Pre-proline 0 CA--C 1.545 0.77 0 N-CA-C 111.75 0.278 . . . . 0.0 111.75 -178.71 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.412 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.9 Cg_endo -78.0 176.53 9.87 Favored 'Trans proline' 0 C--N 1.369 1.607 0 C-N-CA 122.251 1.967 . . . . 0.0 112.671 179.356 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.711 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 4.6 t -86.45 162.14 18.27 Favored 'General case' 0 N--CA 1.468 0.452 0 O-C-N 123.203 0.314 . . . . 0.0 110.824 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.7 m -79.94 108.64 9.68 Favored Pre-proline 0 CA--C 1.545 0.756 0 N-CA-C 112.06 0.393 . . . . 0.0 112.06 -179.224 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.436 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 74.7 Cg_endo -83.02 177.67 6.52 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.467 2.111 . . . . 0.0 112.927 179.363 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.49 -41.17 2.24 Favored Glycine 0 C--N 1.339 0.731 0 C-N-CA 121.352 -0.451 . . . . 0.0 112.909 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.27 -39.02 13.78 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 122.464 0.306 . . . . 0.0 111.402 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.422 ' O ' ' HA ' ' A' ' 36' ' ' TYR . . . 124.02 55.05 0.19 Allowed Glycine 0 C--N 1.338 0.69 0 O-C-N 123.509 0.506 . . . . 0.0 112.535 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.476 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 25.4 mt -119.73 147.96 43.97 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-O 120.571 0.224 . . . . 0.0 110.897 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -140.1 155.36 47.04 Favored 'General case' 0 CA--C 1.536 0.434 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.358 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.711 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 91.0 m -98.3 117.42 32.66 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.512 179.446 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.8 mt -127.2 125.82 24.13 Favored Pre-proline 0 CA--C 1.544 0.743 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.348 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -69.18 -41.9 0.82 Allowed 'Cis proline' 0 C--N 1.376 1.985 0 C-N-CA 124.569 -1.013 . . . . 0.0 113.509 -0.038 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 84.42 38.2 10.1 Favored Glycine 0 C--N 1.344 0.991 0 O-C-N 123.376 0.422 . . . . 0.0 113.471 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -150.92 81.05 6.44 Favored Pre-proline 0 CA--C 1.547 0.859 0 C-N-CA 122.279 0.231 . . . . 0.0 111.232 179.54 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.595 ' O ' HG22 ' A' ' 12' ' ' VAL . 57.0 Cg_endo -87.25 -28.25 4.59 Favored 'Cis proline' 0 C--N 1.37 1.663 0 C-N-CA 124.584 -1.007 . . . . 0.0 113.35 -0.312 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -87.15 148.7 25.08 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.637 -179.608 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.91 158.58 28.93 Favored Glycine 0 C--N 1.335 0.513 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.13 179.35 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.416 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.2 OUTLIER -97.2 144.15 27.29 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 110.285 -0.265 . . . . 0.0 110.285 179.868 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 19.5 m -88.07 110.94 21.02 Favored 'General case' 0 C--O 1.239 0.528 0 O-C-N 123.428 0.455 . . . . 0.0 111.584 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' TYR . . . . . 0.476 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 45.7 m-85 -123.55 161.04 25.73 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.703 179.569 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.58 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.1 t80 -94.15 136.21 34.68 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.872 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.2 mt . . . . . 0 C--O 1.249 1.029 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.847 179.75 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.273 . . . . . . . 0 C--O 1.235 0.337 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -112.31 65.93 0.25 Allowed Glycine 0 C--N 1.337 0.602 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.536 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.425 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.6 p -100.19 154.64 18.28 Favored 'General case' 0 C--O 1.236 0.344 0 O-C-N 123.593 0.231 . . . . 0.0 110.923 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.8 152.11 20.28 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.811 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 18.7 p90 -98.0 174.03 6.76 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.705 179.083 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.58 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.1 tt0 -64.16 130.1 42.6 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 123.186 0.594 . . . . 0.0 112.326 -179.291 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 102.19 9.61 41.51 Favored Glycine 0 C--N 1.339 0.71 0 CA-C-N 115.68 -0.691 . . . . 0.0 114.702 178.659 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -135.16 177.53 7.74 Favored 'General case' 0 CA--C 1.541 0.596 0 CA-C-N 117.707 0.754 . . . . 0.0 111.545 179.729 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 15.9 t -90.71 141.75 28.47 Favored 'General case' 0 C--N 1.343 0.317 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.941 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.5 p -133.66 128.91 36.03 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.894 -179.727 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.16 119.92 39.08 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.912 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.603 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.8 m -72.68 11.85 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 N-CA-C 112.926 0.713 . . . . 0.0 112.926 -178.839 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 5.7 tp60 -105.41 -29.91 9.93 Favored 'General case' 0 CA--C 1.535 0.372 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.6 -179.369 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -148.99 -26.57 0.3 Allowed 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 112.789 0.663 . . . . 0.0 112.789 -178.827 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.2 t80 -125.65 87.62 55.54 Favored Pre-proline 0 CA--C 1.545 0.76 0 N-CA-C 111.67 0.248 . . . . 0.0 111.67 -178.754 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.425 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.5 Cg_endo -77.86 177.47 8.76 Favored 'Trans proline' 0 C--N 1.369 1.648 0 C-N-CA 122.267 1.978 . . . . 0.0 112.796 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.69 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.9 t -89.92 160.01 16.65 Favored 'General case' 0 N--CA 1.467 0.387 0 O-C-N 123.233 0.333 . . . . 0.0 110.837 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 74.8 m -79.94 108.55 9.47 Favored Pre-proline 0 CA--C 1.545 0.763 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.953 -179.342 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.2 Cg_endo -83.28 177.43 6.52 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.49 2.127 . . . . 0.0 112.911 179.342 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.33 -40.24 2.49 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 121.373 -0.441 . . . . 0.0 113.003 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.34 -38.64 14.0 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 122.439 0.296 . . . . 0.0 111.508 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.58 50.46 0.21 Allowed Glycine 0 C--N 1.339 0.728 0 O-C-N 123.491 0.494 . . . . 0.0 112.495 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.443 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.2 mt -113.24 150.12 32.83 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 122.294 0.238 . . . . 0.0 110.92 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -139.54 154.45 47.66 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.392 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.69 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 60.0 m -97.45 123.2 41.22 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.536 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.453 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.8 mt -126.58 123.45 23.97 Favored Pre-proline 0 CA--C 1.545 0.758 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.322 -179.792 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.422 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.85 -40.76 1.1 Allowed 'Cis proline' 0 C--N 1.375 1.965 0 C-N-CA 124.646 -0.981 . . . . 0.0 112.561 0.062 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.81 32.6 9.86 Favored Glycine 0 C--N 1.342 0.885 0 CA-C-N 116.017 -0.538 . . . . 0.0 112.887 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.422 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.11 78.7 13.58 Favored Pre-proline 0 CA--C 1.546 0.821 0 C-N-CA 122.156 0.182 . . . . 0.0 111.321 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.603 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.3 Cg_endo -90.18 -26.4 4.45 Favored 'Cis proline' 0 C--N 1.369 1.636 0 C-N-CA 124.686 -0.964 . . . . 0.0 113.676 -0.276 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.6 152.63 20.81 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 115.96 -0.564 . . . . 0.0 112.011 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -155.33 -171.72 22.22 Favored Glycine 0 C--N 1.337 0.619 0 CA-C-N 115.449 -0.796 . . . . 0.0 112.57 179.561 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.517 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -127.25 145.26 50.84 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.55 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 51.3 m -89.06 111.89 22.72 Favored 'General case' 0 C--O 1.24 0.554 0 CA-C-O 121.076 0.465 . . . . 0.0 111.675 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' TYR . . . . . 0.443 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.8 m-85 -125.94 159.86 31.5 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.527 179.43 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.58 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 14.5 t80 -93.32 136.06 33.94 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.988 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.4 mt . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.151 -0.928 . . . . 0.0 110.943 179.693 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.272 . . . . . . . 0 C--O 1.235 0.317 0 N-CA-C 112.152 0.427 . . . . 0.0 112.152 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -100.2 -52.82 1.13 Allowed Glycine 0 C--N 1.337 0.612 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.61 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.412 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 28.0 p -98.57 155.29 17.36 Favored 'General case' 0 C--O 1.236 0.369 0 C-N-CA 122.316 0.247 . . . . 0.0 111.01 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.72 151.14 20.78 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.752 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 17.0 p90 -98.96 171.95 7.72 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.842 179.351 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.586 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.2 tt0 -60.45 129.55 42.19 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 123.38 0.672 . . . . 0.0 112.395 -179.337 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.18 -19.93 31.47 Favored Glycine 0 C--N 1.338 0.687 0 CA-C-N 115.659 -0.701 . . . . 0.0 114.468 178.826 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -108.04 177.54 4.78 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 117.464 0.632 . . . . 0.0 111.817 -179.303 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 41.0 p -91.56 144.45 25.53 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.078 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.1 p -133.1 128.7 36.72 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.946 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -99.91 120.19 39.4 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.764 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.608 HG22 ' O ' ' A' ' 30' ' ' PRO . 29.5 m -72.25 10.45 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 N-CA-C 113.051 0.76 . . . . 0.0 113.051 -178.792 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.408 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 1.6 tp-100 -104.43 -29.51 10.67 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.693 -179.4 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.408 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.7 -26.55 0.27 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -178.793 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -125.12 87.51 55.4 Favored Pre-proline 0 CA--C 1.546 0.793 0 N-CA-C 111.694 0.257 . . . . 0.0 111.694 -178.666 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.407 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.9 Cg_endo -77.82 175.68 10.92 Favored 'Trans proline' 0 C--N 1.369 1.654 0 C-N-CA 122.28 1.987 . . . . 0.0 112.704 179.466 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.699 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.8 t -88.68 160.78 17.19 Favored 'General case' 0 N--CA 1.468 0.467 0 O-C-N 123.221 0.325 . . . . 0.0 110.793 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.9 m -79.99 108.44 9.25 Favored Pre-proline 0 CA--C 1.545 0.777 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.45 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.6 Cg_endo -83.54 177.59 6.23 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.453 2.102 . . . . 0.0 112.93 179.286 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.89 -40.44 2.44 Favored Glycine 0 C--N 1.34 0.767 0 C-N-CA 121.324 -0.465 . . . . 0.0 112.951 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.9 mt -88.57 -38.63 14.74 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 122.418 0.287 . . . . 0.0 111.551 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.75 51.76 0.2 Allowed Glycine 0 C--N 1.339 0.723 0 O-C-N 123.461 0.475 . . . . 0.0 112.565 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.473 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 22.7 mt -115.76 149.26 38.77 Favored 'General case' 0 C--O 1.235 0.3 0 O-C-N 123.607 0.239 . . . . 0.0 110.874 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t -139.1 154.4 48.14 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.246 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.699 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 66.4 m -97.22 123.26 40.95 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.645 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.441 ' H ' ' H ' ' A' ' 33' ' ' THR . 11.3 mt -127.16 122.94 23.24 Favored Pre-proline 0 CA--C 1.546 0.789 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.315 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.414 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.87 -41.01 1.03 Allowed 'Cis proline' 0 C--N 1.374 1.893 0 C-N-CA 124.696 -0.96 . . . . 0.0 112.64 0.112 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.18 32.8 9.32 Favored Glycine 0 C--N 1.343 0.931 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.93 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.414 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.49 79.08 12.81 Favored Pre-proline 0 CA--C 1.547 0.842 0 C-N-CA 122.215 0.206 . . . . 0.0 111.322 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.608 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.2 Cg_endo -89.88 -26.59 4.48 Favored 'Cis proline' 0 C--N 1.37 1.682 0 C-N-CA 124.667 -0.972 . . . . 0.0 113.68 -0.284 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.43 152.65 20.87 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.941 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.27 -173.95 23.82 Favored Glycine 0 C--N 1.337 0.632 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.649 179.577 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.475 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.6 OUTLIER -124.54 143.66 50.55 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.563 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.3 m -88.11 110.41 20.63 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-O 121.085 0.469 . . . . 0.0 111.607 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' TYR . . . . . 0.473 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 34.2 m-85 -124.57 158.95 31.77 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.681 179.549 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.586 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 11.9 t80 -93.33 135.93 34.08 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.964 -179.878 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.7 mt . . . . . 0 C--O 1.249 1.05 0 CA-C-O 118.115 -0.945 . . . . 0.0 110.901 179.765 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.269 . . . . . . . 0 CA--C 1.534 0.338 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 137.65 38.94 0.13 Allowed Glycine 0 C--N 1.34 0.777 0 O-C-N 123.434 0.459 . . . . 0.0 112.886 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.422 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.4 p -134.96 154.36 51.74 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 122.481 0.312 . . . . 0.0 110.805 179.862 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.43 151.58 20.75 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.763 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 18.2 p90 -98.27 173.6 6.91 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.688 179.263 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.579 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.0 tt0 -63.23 129.93 42.41 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.185 0.594 . . . . 0.0 112.364 -179.299 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 102.37 5.37 49.15 Favored Glycine 0 C--N 1.339 0.717 0 CA-C-N 115.673 -0.694 . . . . 0.0 114.725 178.606 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -131.72 177.86 7.19 Favored 'General case' 0 CA--C 1.539 0.538 0 CA-C-N 117.678 0.739 . . . . 0.0 111.599 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.439 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 43.1 p -90.24 146.49 24.2 Favored 'General case' 0 C--N 1.344 0.331 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.301 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.4 p -137.42 128.08 26.95 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.835 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 10.6 m-80 -97.68 118.99 35.44 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.839 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.584 HG22 ' O ' ' A' ' 30' ' ' PRO . 22.6 m -71.25 9.61 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 N-CA-C 113.239 0.829 . . . . 0.0 113.239 -178.826 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.51 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.1 OUTLIER -101.28 -34.67 9.55 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.222 -179.548 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.51 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.9 p90 -147.33 -27.01 0.38 Allowed 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 -178.484 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 6.5 t80 -120.83 85.07 39.12 Favored Pre-proline 0 CA--C 1.544 0.732 0 N-CA-C 111.705 0.261 . . . . 0.0 111.705 -178.712 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.422 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.2 Cg_endo -77.95 177.96 8.17 Favored 'Trans proline' 0 C--N 1.369 1.619 0 C-N-CA 122.241 1.961 . . . . 0.0 112.704 179.461 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.7 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -89.17 160.47 16.97 Favored 'General case' 0 N--CA 1.468 0.437 0 O-C-N 123.157 0.285 . . . . 0.0 110.921 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 75.8 m -79.93 108.41 9.11 Favored Pre-proline 0 CA--C 1.545 0.772 0 N-CA-C 111.976 0.361 . . . . 0.0 111.976 -179.394 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.444 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 79.1 Cg_endo -83.07 177.47 6.63 Favored 'Trans proline' 0 C--N 1.371 1.732 0 C-N-CA 122.445 2.097 . . . . 0.0 113.002 179.411 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.01 -39.64 2.68 Favored Glycine 0 C--N 1.34 0.791 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.986 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.8 mt -89.14 -38.73 14.09 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 122.493 0.317 . . . . 0.0 111.503 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.15 50.07 0.22 Allowed Glycine 0 C--N 1.339 0.748 0 O-C-N 123.448 0.468 . . . . 0.0 112.474 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.449 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 20.6 mt -113.51 150.02 33.5 Favored 'General case' 0 C--O 1.235 0.315 0 O-C-N 123.628 0.252 . . . . 0.0 110.872 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -138.99 154.18 48.24 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.232 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.7 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 59.5 m -97.12 123.06 40.78 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.659 179.429 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.469 ' H ' ' H ' ' A' ' 33' ' ' THR . 11.3 mt -127.34 123.24 23.19 Favored Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.268 -179.814 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -75.64 -40.87 1.07 Allowed 'Cis proline' 0 C--N 1.375 1.947 0 C-N-CA 124.636 -0.985 . . . . 0.0 112.507 0.094 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.04 33.62 8.79 Favored Glycine 0 C--N 1.342 0.877 0 O-C-N 123.596 0.56 . . . . 0.0 113.227 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -146.36 80.28 10.13 Favored Pre-proline 0 CA--C 1.547 0.855 0 CA-C-N 116.727 0.263 . . . . 0.0 111.556 179.575 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.584 ' O ' HG22 ' A' ' 12' ' ' VAL . 58.7 Cg_endo -89.27 -26.9 4.59 Favored 'Cis proline' 0 C--N 1.37 1.675 0 C-N-CA 124.729 -0.946 . . . . 0.0 113.463 -0.345 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -86.94 149.92 24.44 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.578 -179.634 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.439 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -151.09 -178.82 26.28 Favored Glycine 0 C--N 1.335 0.509 0 CA-C-N 115.581 -0.736 . . . . 0.0 112.394 179.425 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.48 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -124.62 141.6 51.98 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 179.282 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 54.1 m -87.3 112.2 21.82 Favored 'General case' 0 C--O 1.24 0.575 0 O-C-N 123.48 0.488 . . . . 0.0 111.792 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' TYR . . . . . 0.449 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 35.0 m-85 -126.05 159.14 33.55 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.081 -0.963 . . . . 0.0 110.552 179.304 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.579 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.8 t80 -93.23 135.01 34.85 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.937 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.0 mt . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.11 -0.948 . . . . 0.0 110.898 179.776 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.272 . . . . . . . 0 C--O 1.235 0.34 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -125.05 57.46 0.68 Allowed Glycine 0 C--N 1.337 0.628 0 CA-C-N 115.897 -0.592 . . . . 0.0 112.489 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.429 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.2 p -99.93 156.69 17.01 Favored 'General case' 0 C--O 1.236 0.35 0 O-C-N 123.62 0.247 . . . . 0.0 110.981 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.6 147.97 22.45 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 112.138 0.422 . . . . 0.0 112.138 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.475 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.25 177.4 7.51 Favored 'General case' 0 CA--C 1.538 0.491 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.463 178.813 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.55 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.4 tt0 -74.46 136.14 42.29 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 122.844 0.458 . . . . 0.0 111.695 -179.743 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.87 9.49 58.44 Favored Glycine 0 C--N 1.338 0.671 0 CA-C-N 115.633 -0.712 . . . . 0.0 114.258 179.017 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.475 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.2 pt-20 -132.83 177.66 7.47 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 117.321 0.561 . . . . 0.0 111.376 179.8 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 42.8 p -88.16 147.28 24.97 Favored 'General case' 0 C--N 1.345 0.372 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.603 -179.409 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.5 p -138.7 128.02 24.35 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.684 -179.743 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.35 119.07 37.87 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.896 179.678 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.607 HG22 ' O ' ' A' ' 30' ' ' PRO . 27.7 m -72.11 9.39 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 -178.741 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.5 tp-100 -102.65 -29.91 11.25 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 116.625 -0.261 . . . . 0.0 111.685 -179.361 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -149.28 -26.82 0.28 Allowed 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 -178.715 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 12.4 t80 -125.32 87.84 55.03 Favored Pre-proline 0 CA--C 1.546 0.803 0 N-CA-C 111.596 0.221 . . . . 0.0 111.596 -178.649 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.429 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.2 Cg_endo -77.05 177.93 8.28 Favored 'Trans proline' 0 C--N 1.371 1.715 0 C-N-CA 122.29 1.993 . . . . 0.0 112.704 179.484 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.711 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.5 t -90.06 159.94 16.58 Favored 'General case' 0 N--CA 1.468 0.468 0 O-C-N 123.265 0.353 . . . . 0.0 110.923 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.418 ' O ' HD12 ' A' ' 23' ' ' LEU . 74.7 m -79.87 108.06 8.22 Favored Pre-proline 0 CA--C 1.546 0.799 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -179.473 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.47 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 80.2 Cg_endo -84.02 177.91 5.7 Favored 'Trans proline' 0 C--N 1.372 1.778 0 C-N-CA 122.493 2.128 . . . . 0.0 112.955 179.453 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.64 -39.56 2.72 Favored Glycine 0 C--N 1.34 0.752 0 C-N-CA 121.371 -0.442 . . . . 0.0 112.953 179.76 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.6 mp -89.79 -37.07 14.76 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 122.45 0.3 . . . . 0.0 111.464 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.43 52.04 0.22 Allowed Glycine 0 C--N 1.338 0.687 0 O-C-N 123.455 0.472 . . . . 0.0 112.357 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.424 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 19.0 mt -113.62 149.56 34.39 Favored 'General case' 0 C--O 1.234 0.265 0 O-C-N 123.624 0.25 . . . . 0.0 110.972 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.2 t -138.94 152.08 47.42 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.315 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.711 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 55.7 m -96.76 122.69 39.99 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.608 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.42 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.9 mt -127.13 122.88 23.25 Favored Pre-proline 0 CA--C 1.545 0.772 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.328 -179.753 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -75.69 -41.28 0.99 Allowed 'Cis proline' 0 C--N 1.375 1.933 0 C-N-CA 124.651 -0.979 . . . . 0.0 112.593 0.04 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.7 31.68 9.97 Favored Glycine 0 C--N 1.342 0.905 0 O-C-N 123.582 0.551 . . . . 0.0 113.044 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -145.12 80.8 10.92 Favored Pre-proline 0 CA--C 1.547 0.832 0 CA-C-N 116.569 0.184 . . . . 0.0 111.258 179.705 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.607 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.8 Cg_endo -89.31 -26.57 4.86 Favored 'Cis proline' 0 C--N 1.369 1.648 0 C-N-CA 124.654 -0.978 . . . . 0.0 113.609 -0.336 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -92.29 153.96 18.91 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.891 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -155.97 -172.87 23.91 Favored Glycine 0 C--N 1.337 0.625 0 CA-C-N 115.482 -0.781 . . . . 0.0 112.608 179.54 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.496 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -126.51 144.95 50.7 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.576 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 60.8 m -89.61 113.92 25.44 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-O 121.072 0.463 . . . . 0.0 111.765 -179.634 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' TYR . . . . . 0.424 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 35.3 m-85 -125.58 157.45 37.1 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.471 179.327 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.55 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 19.4 t80 -92.5 133.65 35.73 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.985 -179.835 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt . . . . . 0 C--O 1.252 1.192 0 CA-C-O 118.507 -0.758 . . . . 0.0 110.898 179.787 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.271 . . . . . . . 0 C--O 1.236 0.354 0 N-CA-C 112.202 0.445 . . . . 0.0 112.202 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -145.17 59.77 0.5 Allowed Glycine 0 C--N 1.336 0.568 0 CA-C-N 115.875 -0.602 . . . . 0.0 112.511 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.427 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.1 p -99.82 156.8 16.92 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 122.305 0.242 . . . . 0.0 110.971 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.54 147.84 22.57 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 116.235 -0.439 . . . . 0.0 112.184 -179.696 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.479 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.15 177.62 7.47 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.478 178.779 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.543 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.1 tt0 -74.64 135.92 41.95 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 122.905 0.482 . . . . 0.0 111.712 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.71 10.17 58.04 Favored Glycine 0 C--N 1.339 0.716 0 CA-C-N 115.596 -0.729 . . . . 0.0 114.292 179.027 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.479 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.3 pt-20 -132.99 177.55 7.57 Favored 'General case' 0 CA--C 1.54 0.578 0 CA-C-N 117.342 0.571 . . . . 0.0 111.403 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.8 m -88.33 146.42 25.3 Favored 'General case' 0 C--N 1.344 0.346 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.567 -179.478 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.5 p -138.26 128.57 26.03 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.689 -179.759 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -100.76 119.27 38.38 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.87 179.749 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.605 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.0 m -72.12 9.39 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 N-CA-C 113.063 0.764 . . . . 0.0 113.063 -178.785 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.6 tp-100 -102.72 -30.04 11.14 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.583 -0.28 . . . . 0.0 111.661 -179.331 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -149.0 -26.83 0.29 Allowed 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 112.864 0.69 . . . . 0.0 112.864 -178.745 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 12.5 t80 -125.28 87.77 55.12 Favored Pre-proline 0 CA--C 1.546 0.818 0 N-CA-C 111.63 0.233 . . . . 0.0 111.63 -178.639 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.427 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.2 Cg_endo -77.11 177.67 8.58 Favored 'Trans proline' 0 C--N 1.37 1.671 0 C-N-CA 122.269 1.979 . . . . 0.0 112.682 179.527 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.71 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.3 t -89.85 160.05 16.67 Favored 'General case' 0 N--CA 1.467 0.397 0 O-C-N 123.234 0.334 . . . . 0.0 110.947 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.426 ' O ' HD12 ' A' ' 23' ' ' LEU . 74.2 m -79.85 108.08 8.26 Favored Pre-proline 0 CA--C 1.545 0.782 0 O-C-N 123.247 0.342 . . . . 0.0 111.916 -179.47 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.469 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 79.6 Cg_endo -83.91 177.92 5.76 Favored 'Trans proline' 0 C--N 1.371 1.728 0 C-N-CA 122.554 2.169 . . . . 0.0 112.972 179.42 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.54 -38.97 2.9 Favored Glycine 0 C--N 1.34 0.773 0 C-N-CA 121.374 -0.441 . . . . 0.0 113.007 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.1 mt -89.83 -36.97 14.79 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 122.461 0.304 . . . . 0.0 111.469 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.06 52.08 0.23 Allowed Glycine 0 C--N 1.339 0.713 0 O-C-N 123.514 0.509 . . . . 0.0 112.335 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.426 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 18.9 mt -114.22 149.21 36.14 Favored 'General case' 0 C--O 1.235 0.321 0 O-C-N 123.671 0.277 . . . . 0.0 110.965 -179.687 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.1 t -138.83 151.93 47.42 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.29 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.71 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 56.1 m -96.76 122.48 39.76 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.595 179.411 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.4 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.6 mt -127.21 123.09 23.25 Favored Pre-proline 0 CA--C 1.545 0.759 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.372 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.419 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -76.0 -41.0 1.03 Allowed 'Cis proline' 0 C--N 1.374 1.914 0 C-N-CA 124.625 -0.99 . . . . 0.0 112.612 0.055 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.77 32.78 9.69 Favored Glycine 0 C--N 1.343 0.929 0 O-C-N 123.548 0.53 . . . . 0.0 112.945 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.419 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.37 79.42 12.73 Favored Pre-proline 0 CA--C 1.546 0.823 0 C-N-CA 122.213 0.205 . . . . 0.0 111.343 179.762 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.605 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.2 Cg_endo -89.73 -26.53 4.63 Favored 'Cis proline' 0 C--N 1.37 1.66 0 C-N-CA 124.722 -0.949 . . . . 0.0 113.58 -0.213 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -91.18 153.79 19.77 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.892 -179.363 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.34 -172.54 23.83 Favored Glycine 0 C--N 1.337 0.622 0 CA-C-N 115.518 -0.765 . . . . 0.0 112.646 179.493 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.506 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -126.7 145.44 50.59 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.601 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 59.3 m -90.01 114.09 25.89 Favored 'General case' 0 C--O 1.239 0.545 0 O-C-N 123.42 0.45 . . . . 0.0 111.779 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' TYR . . . . . 0.426 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 35.9 m-85 -125.39 157.33 37.06 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.103 -0.953 . . . . 0.0 110.419 179.326 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.543 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 17.5 t80 -92.58 133.41 35.99 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.003 -179.808 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.251 1.169 0 CA-C-O 118.507 -0.758 . . . . 0.0 110.907 179.835 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.272 . . . . . . . 0 C--O 1.235 0.32 0 N-CA-C 112.122 0.416 . . . . 0.0 112.122 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -140.77 81.62 0.25 Allowed Glycine 0 C--N 1.337 0.616 0 CA-C-N 115.868 -0.606 . . . . 0.0 112.48 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.419 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.5 p -99.56 155.57 17.51 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 122.259 0.224 . . . . 0.0 111.063 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.72 152.28 19.06 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.693 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -99.1 172.16 7.56 Favored 'General case' 0 CA--C 1.537 0.45 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.865 179.351 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.579 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.9 tt0 -60.63 129.81 43.39 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 123.36 0.664 . . . . 0.0 112.396 -179.29 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.3 -21.93 27.88 Favored Glycine 0 C--N 1.338 0.687 0 CA-C-N 115.639 -0.709 . . . . 0.0 114.383 178.846 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -105.61 177.42 4.86 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-N 117.458 0.629 . . . . 0.0 111.821 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 15.7 t -92.55 142.63 27.19 Favored 'General case' 0 C--N 1.343 0.321 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.966 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.8 p -132.46 129.27 39.01 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.853 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -97.59 119.11 35.55 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.049 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.606 HG22 ' O ' ' A' ' 30' ' ' PRO . 27.2 m -71.71 9.12 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.856 -179.021 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.448 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 23.1 tt0 -100.14 -30.17 12.08 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.251 -179.387 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.448 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.9 p90 -153.4 -27.68 0.14 Allowed 'General case' 0 N--CA 1.476 0.826 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -178.544 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.5 t80 -119.63 85.25 32.35 Favored Pre-proline 0 CA--C 1.545 0.757 0 N-CA-C 111.503 0.186 . . . . 0.0 111.503 -178.819 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.419 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.3 Cg_endo -77.69 175.28 11.42 Favored 'Trans proline' 0 C--N 1.368 1.597 0 C-N-CA 122.212 1.941 . . . . 0.0 112.757 179.619 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.65 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.2 t -87.28 162.28 17.51 Favored 'General case' 0 N--CA 1.467 0.396 0 O-C-N 123.246 0.341 . . . . 0.0 110.944 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.9 m -79.92 108.58 9.52 Favored Pre-proline 0 CA--C 1.545 0.762 0 N-CA-C 111.907 0.336 . . . . 0.0 111.907 -179.328 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.44 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 74.7 Cg_endo -82.85 177.58 6.69 Favored 'Trans proline' 0 C--N 1.372 1.792 0 C-N-CA 122.453 2.102 . . . . 0.0 112.993 179.385 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.08 -40.04 2.55 Favored Glycine 0 C--N 1.339 0.735 0 C-N-CA 121.356 -0.449 . . . . 0.0 112.904 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -90.16 -39.49 12.81 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 122.446 0.298 . . . . 0.0 111.386 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.28 53.76 0.19 Allowed Glycine 0 C--N 1.339 0.75 0 O-C-N 123.516 0.51 . . . . 0.0 112.514 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.47 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 23.0 mt -117.3 149.24 40.79 Favored 'General case' 0 C--O 1.235 0.297 0 O-C-N 123.632 0.254 . . . . 0.0 110.962 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.401 ' O ' ' HA ' ' A' ' 34' ' ' CYS . 8.9 t -139.58 156.97 46.56 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.276 -179.816 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.65 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 98.9 m -99.25 119.54 38.08 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.699 179.619 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.8 mt -129.79 126.12 22.45 Favored Pre-proline 0 CA--C 1.545 0.783 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.348 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.551 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 43.1 Cg_endo -69.81 -42.58 0.73 Allowed 'Cis proline' 0 C--N 1.375 1.956 0 C-N-CA 124.578 -1.009 . . . . 0.0 113.449 -0.22 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 82.1 39.34 11.58 Favored Glycine 0 C--N 1.345 1.03 0 O-C-N 123.358 0.411 . . . . 0.0 113.275 179.785 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.551 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -147.81 78.52 9.77 Favored Pre-proline 0 CA--C 1.548 0.87 0 C-N-CA 122.3 0.24 . . . . 0.0 111.402 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.606 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.6 Cg_endo -87.83 -26.86 5.5 Favored 'Cis proline' 0 C--N 1.369 1.612 0 C-N-CA 124.571 -1.012 . . . . 0.0 113.355 -0.273 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -87.06 147.54 25.64 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.705 -179.591 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -149.54 -175.78 22.14 Favored Glycine 0 C--N 1.336 0.556 0 CA-C-N 115.612 -0.722 . . . . 0.0 112.712 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.507 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.8 OUTLIER -124.24 143.15 50.69 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.505 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.401 ' HA ' ' O ' ' A' ' 24' ' ' THR . 34.5 m -87.47 112.01 21.75 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-O 121.086 0.469 . . . . 0.0 111.778 -179.598 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' TYR . . . . . 0.47 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 40.5 m-85 -125.81 159.87 31.31 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.605 179.458 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.579 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.4 t80 -93.74 135.15 35.33 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.94 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.5 mt . . . . . 0 C--O 1.251 1.136 0 CA-C-O 118.472 -0.775 . . . . 0.0 110.875 179.759 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.271 . . . . . . . 0 C--O 1.235 0.315 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -119.98 -50.19 0.29 Allowed Glycine 0 C--N 1.336 0.56 0 CA-C-N 115.872 -0.604 . . . . 0.0 112.633 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.425 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 28.2 p -97.65 157.22 16.16 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 122.357 0.263 . . . . 0.0 111.03 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.3 147.72 22.85 Favored 'General case' 0 C--O 1.237 0.417 0 N-CA-C 112.176 0.435 . . . . 0.0 112.176 -179.621 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.473 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.08 177.5 7.54 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 115.098 -0.955 . . . . 0.0 110.426 178.847 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.543 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.4 tt0 -74.85 135.89 41.56 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 122.875 0.47 . . . . 0.0 111.693 -179.698 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.44 10.91 57.72 Favored Glycine 0 C--N 1.339 0.725 0 CA-C-N 115.587 -0.733 . . . . 0.0 114.34 178.95 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.473 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.4 pt-20 -133.32 177.47 7.66 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 117.271 0.536 . . . . 0.0 111.392 179.821 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 43.1 p -88.04 145.65 25.87 Favored 'General case' 0 C--N 1.344 0.364 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.601 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.2 p -137.65 128.03 26.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.639 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.58 119.52 38.66 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.903 179.684 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.612 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.6 m -72.03 8.9 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 N-CA-C 113.024 0.749 . . . . 0.0 113.024 -178.752 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.409 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 1.5 tp-100 -102.55 -29.86 11.31 Favored 'General case' 0 CA--C 1.535 0.388 0 N-CA-C 111.706 0.262 . . . . 0.0 111.706 -179.333 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.409 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.9 p90 -149.43 -26.74 0.28 Allowed 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -178.761 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.6 t80 -124.64 87.17 54.91 Favored Pre-proline 0 CA--C 1.547 0.829 0 N-CA-C 111.577 0.214 . . . . 0.0 111.577 -178.657 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.413 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.1 Cg_endo -77.18 175.86 10.83 Favored 'Trans proline' 0 C--N 1.369 1.624 0 C-N-CA 122.293 1.995 . . . . 0.0 112.69 179.495 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.715 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.3 t -89.31 160.35 16.92 Favored 'General case' 0 N--CA 1.468 0.444 0 O-C-N 123.257 0.348 . . . . 0.0 110.886 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.444 ' O ' HD12 ' A' ' 23' ' ' LEU . 73.9 m -79.84 107.68 7.3 Favored Pre-proline 0 CA--C 1.545 0.777 0 O-C-N 123.286 0.367 . . . . 0.0 111.985 -179.561 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.48 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 81.5 Cg_endo -84.39 177.99 5.41 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.529 2.153 . . . . 0.0 112.984 179.41 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.66 -39.36 2.77 Favored Glycine 0 C--N 1.34 0.777 0 C-N-CA 121.41 -0.424 . . . . 0.0 113.033 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.6 mp -89.71 -38.05 14.14 Favored 'General case' 0 N--CA 1.467 0.423 0 C-N-CA 122.435 0.294 . . . . 0.0 111.489 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.65 52.55 0.19 Allowed Glycine 0 C--N 1.339 0.7 0 O-C-N 123.452 0.47 . . . . 0.0 112.422 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.444 HD12 ' O ' ' A' ' 18' ' ' CYS . 19.6 mt -115.3 148.56 39.08 Favored 'General case' 0 C--O 1.235 0.323 0 O-C-N 123.668 0.276 . . . . 0.0 110.846 -179.7 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.2 t -138.53 151.69 47.57 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.374 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.715 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 54.3 m -97.03 121.98 39.52 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.597 179.412 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.5 mt -127.4 123.36 23.18 Favored Pre-proline 0 CA--C 1.545 0.786 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.364 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.409 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.95 -41.06 1.02 Allowed 'Cis proline' 0 C--N 1.375 1.923 0 C-N-CA 124.652 -0.978 . . . . 0.0 112.598 0.067 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.55 32.71 9.95 Favored Glycine 0 C--N 1.343 0.947 0 O-C-N 123.55 0.531 . . . . 0.0 112.95 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.409 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.09 79.33 13.15 Favored Pre-proline 0 CA--C 1.546 0.822 0 C-N-CA 122.178 0.191 . . . . 0.0 111.291 179.722 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.612 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.7 Cg_endo -89.86 -26.32 4.73 Favored 'Cis proline' 0 C--N 1.37 1.708 0 C-N-CA 124.671 -0.97 . . . . 0.0 113.685 -0.338 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -91.1 153.65 19.93 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.93 -179.406 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.17 -172.37 23.52 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-N 115.533 -0.758 . . . . 0.0 112.662 179.467 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.49 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.6 OUTLIER -126.99 145.78 50.58 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.567 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 61.3 m -89.98 113.47 25.14 Favored 'General case' 0 C--O 1.239 0.549 0 O-C-N 123.455 0.472 . . . . 0.0 111.739 -179.643 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' TYR . . . . . 0.433 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 34.7 m-85 -123.77 157.19 34.58 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.47 179.316 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.543 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.7 t80 -93.41 132.72 37.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.989 -179.765 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt . . . . . 0 C--O 1.251 1.181 0 CA-C-O 118.455 -0.783 . . . . 0.0 110.872 179.797 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.273 . . . . . . . 0 C--O 1.235 0.292 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -122.02 -50.73 0.24 Allowed Glycine 0 C--N 1.337 0.589 0 CA-C-N 115.773 -0.649 . . . . 0.0 112.579 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.421 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 28.5 p -98.65 157.47 16.24 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 122.324 0.25 . . . . 0.0 111.043 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.84 147.22 23.14 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 116.259 -0.428 . . . . 0.0 112.093 -179.609 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.467 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.61 177.19 7.45 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.412 178.756 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.556 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 23.7 tt0 -74.1 134.69 42.91 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 122.9 0.48 . . . . 0.0 111.677 -179.649 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.45 9.73 57.55 Favored Glycine 0 C--N 1.339 0.712 0 CA-C-N 115.597 -0.729 . . . . 0.0 114.319 179.019 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.467 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.0 pt-20 -132.72 177.84 7.32 Favored 'General case' 0 CA--C 1.54 0.595 0 CA-C-N 117.371 0.586 . . . . 0.0 111.373 179.849 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.42 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 52.8 m -88.58 149.03 23.79 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.645 -179.379 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.2 p -141.38 129.12 21.64 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.615 -179.745 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -101.29 120.94 41.01 Favored 'General case' 0 N--CA 1.466 0.328 0 O-C-N 123.447 0.467 . . . . 0.0 110.516 179.632 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.583 HG22 ' O ' ' A' ' 30' ' ' PRO . 27.6 m -70.86 6.66 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 N-CA-C 113.689 0.996 . . . . 0.0 113.689 -178.228 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 5.9 tp60 -101.41 -30.3 11.53 Favored 'General case' 0 CA--C 1.534 0.354 0 N-CA-C 111.736 0.273 . . . . 0.0 111.736 -179.473 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.8 p90 -148.24 -27.55 0.33 Allowed 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 112.882 0.697 . . . . 0.0 112.882 -178.803 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -121.8 85.88 45.12 Favored Pre-proline 0 CA--C 1.545 0.786 0 N-CA-C 111.584 0.216 . . . . 0.0 111.584 -178.719 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.412 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.1 Cg_endo -77.4 176.83 9.59 Favored 'Trans proline' 0 C--N 1.369 1.614 0 C-N-CA 122.265 1.976 . . . . 0.0 112.606 179.51 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.706 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.0 t -89.07 160.1 17.23 Favored 'General case' 0 N--CA 1.468 0.442 0 O-C-N 123.226 0.329 . . . . 0.0 110.944 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.4 ' O ' HD12 ' A' ' 23' ' ' LEU . 72.3 m -79.84 108.09 8.27 Favored Pre-proline 0 CA--C 1.546 0.805 0 N-CA-C 111.948 0.351 . . . . 0.0 111.948 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.469 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 76.4 Cg_endo -83.69 178.0 5.84 Favored 'Trans proline' 0 C--N 1.372 1.797 0 C-N-CA 122.534 2.156 . . . . 0.0 112.979 179.473 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.69 -39.35 2.77 Favored Glycine 0 C--N 1.34 0.789 0 C-N-CA 121.401 -0.428 . . . . 0.0 112.935 179.81 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.6 mt -89.9 -36.68 14.9 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 122.447 0.299 . . . . 0.0 111.442 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.35 52.92 0.23 Allowed Glycine 0 C--N 1.339 0.716 0 O-C-N 123.496 0.498 . . . . 0.0 112.376 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.459 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 18.8 mt -115.4 148.53 39.24 Favored 'General case' 0 C--O 1.235 0.334 0 O-C-N 123.67 0.277 . . . . 0.0 110.953 -179.683 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.425 ' O ' ' HA ' ' A' ' 34' ' ' CYS . 9.8 t -138.83 152.22 47.67 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.296 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.706 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 61.7 m -96.47 122.34 39.26 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.551 179.43 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.6 mt -127.41 122.73 22.93 Favored Pre-proline 0 CA--C 1.546 0.809 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.385 -179.787 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -75.66 -41.54 0.95 Allowed 'Cis proline' 0 C--N 1.374 1.909 0 C-N-CA 124.677 -0.968 . . . . 0.0 112.569 0.083 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 91.17 31.47 9.72 Favored Glycine 0 C--N 1.342 0.914 0 O-C-N 123.562 0.538 . . . . 0.0 113.128 179.777 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -143.95 82.79 10.79 Favored Pre-proline 0 CA--C 1.547 0.845 0 CA-C-N 116.707 0.253 . . . . 0.0 111.391 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.583 ' O ' HG22 ' A' ' 12' ' ' VAL . 75.7 Cg_endo -87.26 -27.01 5.67 Favored 'Cis proline' 0 C--N 1.37 1.707 0 C-N-CA 124.59 -1.004 . . . . 0.0 113.439 -0.43 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -94.12 156.65 16.46 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.67 -179.032 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.42 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.65 -173.6 25.35 Favored Glycine 0 C--N 1.336 0.56 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.452 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.477 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.5 OUTLIER -124.77 143.81 50.59 Favored 'General case' 0 C--O 1.234 0.271 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.607 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.425 ' HA ' ' O ' ' A' ' 24' ' ' THR . 56.7 m -89.08 114.37 25.6 Favored 'General case' 0 C--O 1.239 0.536 0 O-C-N 123.452 0.47 . . . . 0.0 111.818 -179.569 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' TYR . . . . . 0.459 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.0 m-85 -125.51 157.97 35.67 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.051 -0.977 . . . . 0.0 110.466 179.287 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.556 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 17.7 t80 -92.53 133.12 36.25 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.984 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.104 -0.951 . . . . 0.0 110.977 179.827 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.273 . . . . . . . 0 C--O 1.236 0.353 0 N-CA-C 112.19 0.441 . . . . 0.0 112.19 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -145.73 24.75 1.8 Allowed Glycine 0 C--N 1.337 0.598 0 CA-C-N 115.95 -0.568 . . . . 0.0 113.195 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.438 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.6 p -134.51 153.89 51.71 Favored 'General case' 0 N--CA 1.466 0.332 0 C-N-CA 122.301 0.24 . . . . 0.0 110.868 179.827 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.84 151.72 20.44 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.784 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.428 ' O ' ' HG2' ' A' ' 8' ' ' GLU . 15.3 p90 -97.32 174.78 6.53 Favored 'General case' 0 CA--C 1.537 0.477 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.687 179.117 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.573 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.1 tt0 -64.97 130.47 43.51 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 123.164 0.586 . . . . 0.0 112.253 -179.269 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 100.04 12.13 40.72 Favored Glycine 0 C--N 1.339 0.723 0 CA-C-N 115.62 -0.718 . . . . 0.0 114.674 178.656 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.428 ' HG2' ' O ' ' A' ' 5' ' ' PHE . 7.0 pt-20 -136.67 176.85 8.33 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 117.601 0.701 . . . . 0.0 111.47 179.632 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.435 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 40.6 p -90.23 144.8 25.53 Favored 'General case' 0 C--N 1.343 0.319 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.126 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 p -135.85 130.49 33.99 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.906 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -99.76 119.02 37.48 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.854 179.523 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.616 HG22 ' O ' ' A' ' 30' ' ' PRO . 30.5 m -72.71 10.58 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 N-CA-C 112.897 0.702 . . . . 0.0 112.897 -179.034 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.409 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.5 tp60 -104.26 -29.74 10.6 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.577 -179.425 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.409 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.48 -26.79 0.27 Allowed 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 112.819 0.674 . . . . 0.0 112.819 -178.78 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 9.7 t80 -124.98 86.96 55.99 Favored Pre-proline 0 CA--C 1.546 0.798 0 N-CA-C 111.622 0.23 . . . . 0.0 111.622 -178.697 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.438 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.1 Cg_endo -77.75 179.08 6.85 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 122.235 1.957 . . . . 0.0 112.739 179.512 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.7 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -89.91 160.22 16.54 Favored 'General case' 0 N--CA 1.467 0.376 0 O-C-N 123.183 0.302 . . . . 0.0 110.809 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 78.2 m -79.99 108.29 8.88 Favored Pre-proline 0 CA--C 1.545 0.773 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.907 -179.401 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.452 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.9 Cg_endo -83.44 177.53 6.34 Favored 'Trans proline' 0 C--N 1.371 1.753 0 C-N-CA 122.449 2.099 . . . . 0.0 112.95 179.441 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.79 -39.86 2.61 Favored Glycine 0 C--N 1.34 0.751 0 C-N-CA 121.374 -0.441 . . . . 0.0 112.946 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.8 mt -89.05 -38.1 14.64 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 122.444 0.298 . . . . 0.0 111.501 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.97 50.12 0.23 Allowed Glycine 0 C--N 1.339 0.706 0 O-C-N 123.481 0.488 . . . . 0.0 112.497 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.447 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.1 mt -113.85 149.73 34.62 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 122.294 0.238 . . . . 0.0 110.846 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -139.44 154.16 47.71 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.321 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.7 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.0 m -97.13 123.09 40.8 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.575 179.4 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.446 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.6 mt -127.2 123.09 23.25 Favored Pre-proline 0 CA--C 1.544 0.746 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.327 -179.772 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -75.7 -40.92 1.06 Allowed 'Cis proline' 0 C--N 1.375 1.922 0 C-N-CA 124.698 -0.959 . . . . 0.0 112.527 0.077 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.64 32.97 8.78 Favored Glycine 0 C--N 1.342 0.884 0 O-C-N 123.62 0.575 . . . . 0.0 113.123 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -145.68 81.39 10.08 Favored Pre-proline 0 CA--C 1.547 0.844 0 CA-C-N 116.756 0.278 . . . . 0.0 111.458 179.611 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.616 ' O ' HG22 ' A' ' 12' ' ' VAL . 60.7 Cg_endo -88.77 -26.53 5.24 Favored 'Cis proline' 0 C--N 1.371 1.715 0 C-N-CA 124.651 -0.979 . . . . 0.0 113.508 -0.407 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -90.46 155.24 19.06 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.347 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.435 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.19 -174.93 26.58 Favored Glycine 0 C--N 1.334 0.465 0 CA-C-N 115.379 -0.828 . . . . 0.0 112.464 179.549 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.495 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.6 OUTLIER -125.72 143.24 51.13 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.493 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 52.8 m -88.69 112.74 23.49 Favored 'General case' 0 C--O 1.239 0.523 0 O-C-N 123.439 0.462 . . . . 0.0 111.75 -179.644 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' TYR . . . . . 0.447 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 37.1 m-85 -126.48 159.26 33.89 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.051 -0.977 . . . . 0.0 110.519 179.36 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.573 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.5 t80 -92.77 135.34 34.2 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.006 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.9 mt . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.115 -0.945 . . . . 0.0 110.87 179.819 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.269 . . . . . . . 0 CA--C 1.534 0.347 0 N-CA-C 112.465 0.543 . . . . 0.0 112.465 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 118.32 -74.04 0.29 Allowed Glycine 0 C--N 1.341 0.821 0 O-C-N 123.427 0.454 . . . . 0.0 112.541 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.424 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 29.0 p -100.22 156.9 16.96 Favored 'General case' 0 C--O 1.235 0.314 0 O-C-N 123.625 0.25 . . . . 0.0 111.004 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.0 147.81 22.52 Favored 'General case' 0 C--O 1.237 0.406 0 CA-C-N 116.243 -0.435 . . . . 0.0 112.121 -179.705 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.468 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.4 m-85 -86.53 176.98 7.54 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.432 178.879 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.574 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.2 tt0 -73.79 136.09 43.55 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 122.905 0.482 . . . . 0.0 111.693 -179.792 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.49 8.81 58.26 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 115.624 -0.716 . . . . 0.0 114.289 179.008 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.468 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.3 pt-20 -132.53 177.39 7.65 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 117.333 0.567 . . . . 0.0 111.41 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.0 m -88.36 146.4 25.29 Favored 'General case' 0 C--N 1.344 0.351 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.619 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.0 p -138.42 128.6 25.74 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.729 -179.775 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.4 119.57 38.65 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.918 179.678 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.612 HG22 ' O ' ' A' ' 30' ' ' PRO . 29.0 m -71.95 8.93 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 N-CA-C 113.035 0.754 . . . . 0.0 113.035 -178.757 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.407 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.4 tp60 -102.7 -30.1 11.11 Favored 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 111.687 0.254 . . . . 0.0 111.687 -179.34 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.407 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.9 p90 -149.02 -26.92 0.29 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.824 0.676 . . . . 0.0 112.824 -178.763 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -124.32 87.15 54.16 Favored Pre-proline 0 CA--C 1.546 0.804 0 N-CA-C 111.561 0.208 . . . . 0.0 111.561 -178.704 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.42 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.2 Cg_endo -76.97 177.09 9.31 Favored 'Trans proline' 0 C--N 1.37 1.659 0 C-N-CA 122.234 1.956 . . . . 0.0 112.771 179.604 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.7 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.3 t -89.69 159.86 16.89 Favored 'General case' 0 N--CA 1.468 0.442 0 O-C-N 123.272 0.358 . . . . 0.0 110.957 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.1 m -79.85 108.24 8.64 Favored Pre-proline 0 CA--C 1.545 0.779 0 N-CA-C 112.024 0.379 . . . . 0.0 112.024 -179.524 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 79.1 Cg_endo -83.6 177.88 5.99 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 122.512 2.142 . . . . 0.0 113.025 179.39 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.72 -39.76 2.65 Favored Glycine 0 C--N 1.34 0.759 0 O-C-N 123.395 0.434 . . . . 0.0 112.95 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.6 mp -89.8 -36.64 15.01 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 122.47 0.308 . . . . 0.0 111.444 -179.878 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.43 51.63 0.24 Allowed Glycine 0 C--N 1.338 0.691 0 O-C-N 123.525 0.515 . . . . 0.0 112.323 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.438 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 19.3 mt -113.2 149.46 33.68 Favored 'General case' 0 C--O 1.234 0.288 0 O-C-N 123.632 0.254 . . . . 0.0 110.969 -179.663 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.0 t -139.08 153.0 47.98 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.239 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.7 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.1 m -96.81 123.09 40.41 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.546 179.448 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.425 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.9 mt -126.8 122.79 23.54 Favored Pre-proline 0 CA--C 1.545 0.771 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.401 -179.737 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.413 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.93 -41.04 1.02 Allowed 'Cis proline' 0 C--N 1.375 1.925 0 C-N-CA 124.695 -0.961 . . . . 0.0 112.643 0.042 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.08 32.64 9.58 Favored Glycine 0 C--N 1.343 0.948 0 CA-C-N 116.024 -0.535 . . . . 0.0 112.914 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.413 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -144.32 79.47 12.75 Favored Pre-proline 0 CA--C 1.546 0.803 0 C-N-CA 122.194 0.198 . . . . 0.0 111.349 179.761 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.612 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.3 Cg_endo -89.69 -26.47 4.7 Favored 'Cis proline' 0 C--N 1.37 1.666 0 C-N-CA 124.695 -0.96 . . . . 0.0 113.593 -0.252 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -91.14 153.44 20.06 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.937 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -155.91 -172.57 23.54 Favored Glycine 0 C--N 1.338 0.658 0 CA-C-N 115.55 -0.75 . . . . 0.0 112.649 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.503 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.5 OUTLIER -126.55 144.86 50.74 Favored 'General case' 0 C--O 1.235 0.318 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.556 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 57.5 m -89.47 114.82 26.37 Favored 'General case' 0 C--O 1.239 0.538 0 O-C-N 123.429 0.456 . . . . 0.0 111.832 -179.572 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' TYR . . . . . 0.438 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 38.0 m-85 -128.14 157.87 39.6 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.512 179.291 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.574 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 20.4 t80 -91.75 134.86 34.36 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.995 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.3 mt . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.085 -0.96 . . . . 0.0 110.963 179.797 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.273 . . . . . . . 0 C--O 1.235 0.323 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -117.19 68.59 0.3 Allowed Glycine 0 C--N 1.337 0.614 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.54 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.423 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.0 p -98.69 156.69 16.7 Favored 'General case' 0 C--O 1.236 0.368 0 O-C-N 123.656 0.268 . . . . 0.0 110.942 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.07 147.18 23.14 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-N 116.226 -0.443 . . . . 0.0 112.158 -179.668 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.476 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.28 177.2 7.56 Favored 'General case' 0 CA--C 1.538 0.505 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.442 178.764 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.55 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 23.8 tt0 -73.95 134.87 43.18 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 122.932 0.493 . . . . 0.0 111.711 -179.755 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.27 9.39 58.05 Favored Glycine 0 C--N 1.339 0.713 0 CA-C-N 115.659 -0.7 . . . . 0.0 114.33 178.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.476 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.0 pt-20 -132.39 177.85 7.27 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 117.345 0.573 . . . . 0.0 111.419 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.43 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 51.8 m -88.47 149.15 23.81 Favored 'General case' 0 C--N 1.345 0.375 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.722 -179.393 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.4 p -141.56 129.48 21.87 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.656 -179.776 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -101.36 120.9 40.97 Favored 'General case' 0 C--O 1.235 0.326 0 O-C-N 123.384 0.428 . . . . 0.0 110.523 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 30' ' ' PRO . 27.4 m -71.04 7.12 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 N-CA-C 113.626 0.972 . . . . 0.0 113.626 -178.178 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.7 tp-100 -101.77 -30.6 11.2 Favored 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 -179.429 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.8 p90 -147.95 -27.44 0.34 Allowed 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 112.896 0.702 . . . . 0.0 112.896 -178.82 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -122.24 86.1 47.37 Favored Pre-proline 0 CA--C 1.546 0.798 0 N-CA-C 111.62 0.229 . . . . 0.0 111.62 -178.716 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.423 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.3 Cg_endo -77.51 177.59 8.66 Favored 'Trans proline' 0 C--N 1.369 1.653 0 C-N-CA 122.22 1.947 . . . . 0.0 112.573 179.458 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.706 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.0 t -89.19 160.11 17.13 Favored 'General case' 0 N--CA 1.468 0.44 0 O-C-N 123.202 0.314 . . . . 0.0 110.939 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.42 ' O ' HD12 ' A' ' 23' ' ' LEU . 73.5 m -79.82 108.27 8.67 Favored Pre-proline 0 CA--C 1.544 0.744 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.913 -179.589 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.46 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 75.8 Cg_endo -83.45 177.92 6.05 Favored 'Trans proline' 0 C--N 1.372 1.815 0 C-N-CA 122.525 2.15 . . . . 0.0 113.011 179.479 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.27 -39.05 2.86 Favored Glycine 0 C--N 1.34 0.771 0 C-N-CA 121.389 -0.434 . . . . 0.0 112.924 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.2 mt -90.25 -36.81 14.51 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 122.481 0.312 . . . . 0.0 111.468 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.1 53.05 0.23 Allowed Glycine 0 C--N 1.339 0.719 0 O-C-N 123.54 0.525 . . . . 0.0 112.338 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.451 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 18.3 mt -114.75 148.98 37.61 Favored 'General case' 0 C--O 1.235 0.317 0 O-C-N 123.686 0.286 . . . . 0.0 110.945 -179.648 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.422 ' O ' ' HA ' ' A' ' 34' ' ' CYS . 10.0 t -138.79 151.99 47.52 Favored 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.312 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.706 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 59.6 m -96.94 121.64 39.04 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.52 179.486 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.7 mt -127.69 123.69 23.08 Favored Pre-proline 0 CA--C 1.546 0.799 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.332 -179.758 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.426 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -76.01 -41.42 0.96 Allowed 'Cis proline' 0 C--N 1.374 1.903 0 C-N-CA 124.691 -0.962 . . . . 0.0 112.602 0.037 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.53 32.02 9.81 Favored Glycine 0 C--N 1.342 0.886 0 O-C-N 123.545 0.528 . . . . 0.0 113.062 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.426 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -141.86 81.17 14.94 Favored Pre-proline 0 CA--C 1.547 0.854 0 CA-C-N 116.65 0.225 . . . . 0.0 111.489 179.713 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.577 ' O ' HG22 ' A' ' 12' ' ' VAL . 76.3 Cg_endo -88.09 -26.0 6.19 Favored 'Cis proline' 0 C--N 1.371 1.719 0 C-N-CA 124.617 -0.993 . . . . 0.0 113.486 -0.326 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -93.68 156.71 16.54 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.637 -179.061 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.43 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.91 -172.5 24.22 Favored Glycine 0 C--N 1.337 0.59 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.436 179.558 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.486 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.3 OUTLIER -125.59 144.81 50.41 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.612 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 34' ' ' CYS . . . . . 0.422 ' HA ' ' O ' ' A' ' 24' ' ' THR . 57.0 m -89.44 114.3 25.76 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-O 121.094 0.473 . . . . 0.0 111.836 -179.676 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' TYR . . . . . 0.451 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 37.8 m-85 -124.92 157.74 35.28 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.418 179.302 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.55 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 19.8 t80 -92.85 133.03 36.48 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.959 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.251 1.146 0 CA-C-O 118.463 -0.78 . . . . 0.0 110.873 179.844 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.273 . . . . . . . 0 C--O 1.235 0.337 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -134.76 54.41 0.76 Allowed Glycine 0 C--N 1.336 0.572 0 O-C-N 123.695 0.622 . . . . 0.0 112.515 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.43 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.7 p -99.26 153.88 18.6 Favored 'General case' 0 C--O 1.235 0.328 0 O-C-N 123.608 0.24 . . . . 0.0 110.874 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.15 151.15 20.53 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.755 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.417 ' O ' ' HG2' ' A' ' 8' ' ' GLU . 17.4 p90 -97.8 174.42 6.61 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.733 179.206 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.582 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 16.4 tt0 -63.06 130.52 45.05 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.253 0.621 . . . . 0.0 112.382 -179.308 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.1 9.09 46.08 Favored Glycine 0 C--N 1.339 0.696 0 CA-C-N 115.663 -0.699 . . . . 0.0 114.78 178.483 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.417 ' HG2' ' O ' ' A' ' 5' ' ' PHE . 6.4 pt-20 -134.93 176.94 8.2 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 117.708 0.754 . . . . 0.0 111.565 179.703 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.445 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 40.0 p -90.79 143.69 26.47 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.199 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.5 p -134.55 131.37 37.85 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.957 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -100.61 118.88 37.67 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.842 179.576 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.603 HG22 ' O ' ' A' ' 30' ' ' PRO . 30.4 m -71.7 10.31 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -178.906 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.512 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.1 OUTLIER -100.99 -35.12 9.49 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.254 -179.428 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.512 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.9 p90 -146.84 -26.7 0.4 Allowed 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 -178.494 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.0 t80 -122.3 86.3 47.76 Favored Pre-proline 0 CA--C 1.545 0.767 0 N-CA-C 111.725 0.269 . . . . 0.0 111.725 -178.724 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.43 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.4 Cg_endo -77.98 179.08 6.84 Favored 'Trans proline' 0 C--N 1.369 1.633 0 C-N-CA 122.279 1.986 . . . . 0.0 112.729 179.435 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.71 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.8 t -89.21 160.09 17.13 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 123.157 0.285 . . . . 0.0 110.87 179.756 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 72.6 m -79.99 108.64 9.74 Favored Pre-proline 0 CA--C 1.544 0.74 0 N-CA-C 111.96 0.356 . . . . 0.0 111.96 -179.356 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.436 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.6 Cg_endo -83.03 177.2 6.87 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 122.485 2.123 . . . . 0.0 112.905 179.316 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.21 -39.83 2.62 Favored Glycine 0 C--N 1.34 0.762 0 C-N-CA 121.312 -0.47 . . . . 0.0 112.992 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.1 mt -89.58 -38.16 14.16 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 122.435 0.294 . . . . 0.0 111.477 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.28 51.6 0.23 Allowed Glycine 0 C--N 1.34 0.751 0 CA-C-N 116.17 -0.468 . . . . 0.0 112.461 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.462 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.3 mt -114.88 150.74 35.13 Favored 'General case' 0 C--O 1.235 0.309 0 O-C-N 123.611 0.242 . . . . 0.0 110.958 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 t -139.73 154.26 47.4 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.305 -179.752 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.71 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.0 m -97.61 122.41 40.65 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.492 179.409 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.427 ' H ' ' H ' ' A' ' 33' ' ' THR . 9.6 mt -127.35 123.78 23.4 Favored Pre-proline 0 CA--C 1.545 0.765 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.4 -179.786 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.439 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.3 Cg_exo -76.0 -40.56 1.14 Allowed 'Cis proline' 0 C--N 1.375 1.934 0 C-N-CA 124.636 -0.985 . . . . 0.0 112.552 0.026 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.72 34.27 8.55 Favored Glycine 0 C--N 1.342 0.895 0 CA-C-N 115.915 -0.584 . . . . 0.0 113.045 179.865 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.439 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -144.71 79.96 11.92 Favored Pre-proline 0 CA--C 1.547 0.86 0 CA-C-N 116.68 0.24 . . . . 0.0 111.508 179.705 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.603 ' O ' HG22 ' A' ' 12' ' ' VAL . 65.6 Cg_endo -89.15 -26.0 5.47 Favored 'Cis proline' 0 C--N 1.37 1.692 0 C-N-CA 124.714 -0.952 . . . . 0.0 113.457 -0.348 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -89.75 155.25 19.32 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.349 -179.474 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.445 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.31 -174.49 26.15 Favored Glycine 0 C--N 1.335 0.493 0 CA-C-N 115.371 -0.831 . . . . 0.0 112.396 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.489 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -126.15 143.41 51.14 Favored 'General case' 0 C--O 1.234 0.258 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.511 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 45.9 m -88.56 112.52 23.13 Favored 'General case' 0 C--O 1.24 0.582 0 O-C-N 123.409 0.443 . . . . 0.0 111.681 -179.697 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' TYR . . . . . 0.462 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.9 m-85 -125.56 159.85 31.04 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.592 179.416 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.582 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.3 t80 -93.49 134.96 35.2 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.964 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.2 mt . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.145 -0.931 . . . . 0.0 110.903 179.751 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.413 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.0 p . . . . . 0 C--O 1.235 0.325 0 CA-C-O 120.458 0.17 . . . . 0.0 110.993 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.01 151.14 20.62 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.781 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.6 p90 -98.93 171.82 7.82 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.856 179.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.585 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.2 tt0 -59.94 129.04 39.87 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 123.362 0.665 . . . . 0.0 112.428 -179.267 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.29 -20.86 29.84 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 115.572 -0.74 . . . . 0.0 114.388 178.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -107.02 177.47 4.85 Favored 'General case' 0 CA--C 1.539 0.558 0 CA-C-N 117.42 0.61 . . . . 0.0 111.828 -179.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 40.8 p -91.5 146.95 23.38 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.09 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.6 p -134.84 128.26 32.37 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.975 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -98.01 119.66 37.03 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.702 179.419 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 30' ' ' PRO . 24.2 m -72.41 10.35 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -178.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.406 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.7 tp60 -104.76 -29.22 10.69 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.637 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.406 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.94 -26.61 0.26 Allowed 'General case' 0 N--CA 1.477 0.899 0 N-CA-C 112.907 0.706 . . . . 0.0 112.907 -178.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.2 t80 -125.22 87.22 55.87 Favored Pre-proline 0 CA--C 1.545 0.779 0 N-CA-C 111.687 0.254 . . . . 0.0 111.687 -178.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.413 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.3 Cg_endo -77.88 176.84 9.52 Favored 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.311 2.007 . . . . 0.0 112.734 179.427 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.701 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -88.54 160.88 17.25 Favored 'General case' 0 N--CA 1.468 0.441 0 O-C-N 123.201 0.313 . . . . 0.0 110.809 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.9 m -79.94 108.45 9.23 Favored Pre-proline 0 CA--C 1.544 0.728 0 N-CA-C 112.078 0.399 . . . . 0.0 112.078 -179.284 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.448 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.1 Cg_endo -83.51 177.66 6.2 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.469 2.113 . . . . 0.0 112.896 179.341 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.82 -40.22 2.5 Favored Glycine 0 C--N 1.339 0.741 0 C-N-CA 121.349 -0.453 . . . . 0.0 112.985 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.8 mt -88.76 -38.52 14.62 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 122.456 0.302 . . . . 0.0 111.458 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.55 51.65 0.2 Allowed Glycine 0 C--N 1.338 0.69 0 O-C-N 123.475 0.485 . . . . 0.0 112.53 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.473 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 22.0 mt -115.72 149.17 38.85 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-O 120.618 0.247 . . . . 0.0 110.858 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t -138.93 154.84 48.37 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.201 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.701 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 65.7 m -97.19 123.28 40.92 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.709 179.548 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.47 ' H ' ' H ' ' A' ' 33' ' ' THR . 12.2 mt -127.38 122.85 23.01 Favored Pre-proline 0 CA--C 1.545 0.775 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.231 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.435 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.3 Cg_exo -75.42 -40.82 1.09 Allowed 'Cis proline' 0 C--N 1.375 1.922 0 C-N-CA 124.697 -0.96 . . . . 0.0 112.648 0.133 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.03 33.85 8.65 Favored Glycine 0 C--N 1.343 0.918 0 CA-C-N 115.993 -0.549 . . . . 0.0 113.085 179.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.435 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.8 p30 -147.06 79.63 9.84 Favored Pre-proline 0 CA--C 1.546 0.824 0 CA-C-N 116.641 0.221 . . . . 0.0 111.427 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.595 ' O ' HG22 ' A' ' 12' ' ' VAL . 56.1 Cg_endo -89.8 -27.4 3.9 Favored 'Cis proline' 0 C--N 1.37 1.671 0 C-N-CA 124.723 -0.949 . . . . 0.0 113.477 -0.368 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -86.11 149.59 25.02 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.633 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -151.13 -179.15 26.61 Favored Glycine 0 C--N 1.335 0.521 0 CA-C-N 115.654 -0.703 . . . . 0.0 112.627 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.47 ' H ' ' H ' ' A' ' 26' ' ' ILE . 0.9 OUTLIER -123.33 140.9 52.54 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 179.349 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.9 m -86.46 110.6 19.86 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 121.015 0.436 . . . . 0.0 111.698 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' TYR . . . . . 0.473 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 32.8 m-85 -125.47 158.37 34.61 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.624 179.546 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.585 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.1 t80 -92.89 135.65 33.95 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.943 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.6 mt . . . . . 0 C--O 1.249 1.059 0 CA-C-O 118.095 -0.955 . . . . 0.0 110.871 179.806 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.423 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.5 p . . . . . 0 C--O 1.235 0.305 0 CA-C-O 120.479 0.181 . . . . 0.0 110.961 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.07 152.88 19.74 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.757 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 18.6 p90 -98.23 174.08 6.68 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.725 179.161 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.565 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.3 tt0 -63.89 131.3 47.31 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 123.227 0.611 . . . . 0.0 112.348 -179.282 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.72 3.97 52.29 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-N 115.564 -0.744 . . . . 0.0 114.759 178.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -130.55 177.91 7.02 Favored 'General case' 0 CA--C 1.54 0.558 0 CA-C-N 117.636 0.718 . . . . 0.0 111.605 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.423 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 42.5 p -90.4 146.11 24.41 Favored 'General case' 0 C--N 1.343 0.315 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.293 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.9 p -136.47 128.01 28.69 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.782 -179.613 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -98.22 119.57 37.11 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.87 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 30' ' ' PRO . 23.1 m -72.38 10.02 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 N-CA-C 112.963 0.727 . . . . 0.0 112.963 -178.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.429 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 15.0 tt0 -99.81 -30.23 12.17 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.206 -179.572 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.429 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.1 p90 -154.01 -26.77 0.13 Allowed 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 112.729 0.64 . . . . 0.0 112.729 -178.55 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -120.43 85.23 37.01 Favored Pre-proline 0 CA--C 1.544 0.749 0 N-CA-C 111.613 0.227 . . . . 0.0 111.613 -178.678 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.423 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.8 Cg_endo -78.2 179.12 6.79 Favored 'Trans proline' 0 C--N 1.369 1.65 0 C-N-CA 122.306 2.004 . . . . 0.0 112.664 179.478 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.709 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -89.62 159.82 16.96 Favored 'General case' 0 N--CA 1.467 0.402 0 O-C-N 123.163 0.29 . . . . 0.0 110.917 179.788 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.2 m -79.97 108.56 9.51 Favored Pre-proline 0 CA--C 1.545 0.76 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.881 -179.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.445 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.2 Cg_endo -83.27 177.42 6.54 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 122.521 2.147 . . . . 0.0 112.959 179.376 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.27 -40.12 2.53 Favored Glycine 0 C--N 1.34 0.751 0 C-N-CA 121.336 -0.459 . . . . 0.0 113.015 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.4 -38.91 13.76 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 122.462 0.305 . . . . 0.0 111.494 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.06 50.51 0.21 Allowed Glycine 0 C--N 1.339 0.723 0 O-C-N 123.479 0.487 . . . . 0.0 112.485 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.461 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.7 mt -113.87 150.33 33.77 Favored 'General case' 0 C--O 1.235 0.324 0 O-C-N 123.661 0.271 . . . . 0.0 110.854 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 t -139.28 154.59 47.98 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.347 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.709 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 56.9 m -97.49 123.17 41.25 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.822 -0.627 . . . . 0.0 110.595 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.468 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.9 mt -127.53 123.35 23.07 Favored Pre-proline 0 CA--C 1.544 0.741 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.238 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.429 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.2 Cg_exo -75.69 -40.85 1.08 Allowed 'Cis proline' 0 C--N 1.375 1.927 0 C-N-CA 124.69 -0.962 . . . . 0.0 112.527 0.085 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.19 33.49 8.77 Favored Glycine 0 C--N 1.342 0.915 0 CA-C-N 115.964 -0.562 . . . . 0.0 113.147 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.429 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.8 p30 -147.06 79.86 9.73 Favored Pre-proline 0 CA--C 1.546 0.821 0 CA-C-N 116.649 0.224 . . . . 0.0 111.509 179.64 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.595 ' O ' HG22 ' A' ' 12' ' ' VAL . 57.5 Cg_endo -89.62 -27.23 4.11 Favored 'Cis proline' 0 C--N 1.37 1.681 0 C-N-CA 124.666 -0.973 . . . . 0.0 113.496 -0.367 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -86.83 150.03 24.41 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.559 -179.49 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.423 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -151.6 -178.09 26.01 Favored Glycine 0 C--N 1.336 0.535 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.45 179.453 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.471 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -125.75 142.25 51.6 Favored 'General case' 0 C--O 1.234 0.278 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 179.328 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 54.3 m -87.64 112.23 22.1 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-O 121.093 0.473 . . . . 0.0 111.783 -179.601 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' TYR . . . . . 0.461 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 34.8 m-85 -125.89 159.43 32.56 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.538 179.361 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.565 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.6 t80 -93.38 135.21 34.84 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.951 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.129 -0.939 . . . . 0.0 110.857 179.738 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.416 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.2 p . . . . . 0 C--O 1.235 0.329 0 CA-C-O 120.453 0.168 . . . . 0.0 110.999 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.9 151.62 20.45 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.701 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.9 p90 -98.75 172.82 7.21 Favored 'General case' 0 CA--C 1.536 0.427 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.873 179.3 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.588 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 14.4 tt0 -61.04 130.31 45.74 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 123.326 0.651 . . . . 0.0 112.334 -179.386 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.08 -25.62 19.77 Favored Glycine 0 C--N 1.338 0.669 0 CA-C-N 115.656 -0.702 . . . . 0.0 114.179 178.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -103.06 178.67 4.49 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 117.273 0.536 . . . . 0.0 111.851 -179.159 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 43.8 p -92.8 151.56 19.94 Favored 'General case' 0 C--N 1.344 0.348 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.221 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 p -139.48 130.49 26.38 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.863 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -100.14 119.88 39.01 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.597 179.322 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 30' ' ' PRO . 25.5 m -71.32 9.43 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -178.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.501 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -100.44 -32.81 10.63 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.3 -179.496 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.501 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.1 p90 -149.93 -26.8 0.26 Allowed 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 112.897 0.703 . . . . 0.0 112.897 -178.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 6.8 t80 -121.09 85.53 41.26 Favored Pre-proline 0 CA--C 1.545 0.757 0 N-CA-C 111.747 0.277 . . . . 0.0 111.747 -178.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.416 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.1 Cg_endo -78.06 177.16 9.12 Favored 'Trans proline' 0 C--N 1.369 1.607 0 C-N-CA 122.202 1.935 . . . . 0.0 112.67 179.385 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.712 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 4.6 t -88.27 160.73 17.54 Favored 'General case' 0 N--CA 1.467 0.418 0 O-C-N 123.186 0.304 . . . . 0.0 110.796 179.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.0 m -79.97 108.67 9.77 Favored Pre-proline 0 CA--C 1.545 0.768 0 N-CA-C 111.99 0.367 . . . . 0.0 111.99 -179.18 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 76.0 Cg_endo -83.22 177.65 6.4 Favored 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.5 2.133 . . . . 0.0 112.918 179.286 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.94 -41.09 2.25 Favored Glycine 0 C--N 1.34 0.77 0 C-N-CA 121.384 -0.436 . . . . 0.0 112.928 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.1 -38.86 14.03 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 122.486 0.314 . . . . 0.0 111.431 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.442 ' O ' ' HA ' ' A' ' 36' ' ' TYR . . . 124.27 53.41 0.19 Allowed Glycine 0 C--N 1.339 0.715 0 O-C-N 123.521 0.513 . . . . 0.0 112.512 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.475 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 23.7 mt -117.64 147.48 42.84 Favored 'General case' 0 C--O 1.234 0.267 0 O-C-N 123.623 0.249 . . . . 0.0 110.785 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -139.3 154.51 47.94 Favored 'General case' 0 CA--C 1.535 0.404 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.391 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.712 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 89.7 m -97.35 118.3 33.5 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.52 179.496 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 11.6 mt -122.75 122.23 27.22 Favored Pre-proline 0 CA--C 1.545 0.756 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.235 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.424 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.42 -40.72 1.12 Allowed 'Cis proline' 0 C--N 1.373 1.843 0 C-N-CA 124.695 -0.961 . . . . 0.0 112.701 0.232 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.13 34.43 8.8 Favored Glycine 0 C--N 1.342 0.868 0 O-C-N 123.588 0.555 . . . . 0.0 112.928 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.424 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -145.74 79.58 11.11 Favored Pre-proline 0 CA--C 1.548 0.876 0 C-N-CA 122.204 0.202 . . . . 0.0 111.423 179.724 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.595 ' O ' HG22 ' A' ' 12' ' ' VAL . 56.8 Cg_endo -88.79 -27.76 4.18 Favored 'Cis proline' 0 C--N 1.37 1.666 0 C-N-CA 124.739 -0.942 . . . . 0.0 113.486 -0.254 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -86.9 149.34 24.87 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.66 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.81 160.29 30.22 Favored Glycine 0 C--N 1.335 0.52 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.137 179.335 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.426 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.5 OUTLIER -99.1 143.96 28.78 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.823 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 18.8 m -88.31 110.04 20.45 Favored 'General case' 0 C--O 1.238 0.476 0 O-C-N 123.464 0.477 . . . . 0.0 111.528 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' TYR . . . . . 0.475 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 38.1 m-85 -124.73 160.13 29.31 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.289 -0.868 . . . . 0.0 110.744 179.628 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.588 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 15.8 t80 -93.07 137.23 32.61 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.872 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 14.6 mt . . . . . 0 C--O 1.251 1.172 0 CA-C-O 118.531 -0.747 . . . . 0.0 110.876 179.742 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.417 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.4 p . . . . . 0 C--O 1.235 0.331 0 CA-C-O 120.438 0.161 . . . . 0.0 110.989 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.406 ' HB1' ' HG3' ' A' ' 8' ' ' GLU . . . -92.52 150.19 20.91 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.654 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.5 p90 -98.65 171.91 7.82 Favored 'General case' 0 CA--C 1.537 0.458 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.848 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.58 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 14.8 tt0 -59.53 128.63 37.96 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 123.305 0.642 . . . . 0.0 112.389 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.3 -21.02 27.34 Favored Glycine 0 C--N 1.339 0.718 0 CA-C-N 115.66 -0.7 . . . . 0.0 114.421 178.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.406 ' HG3' ' HB1' ' A' ' 4' ' ' ALA . 6.8 pt-20 -107.48 177.39 4.85 Favored 'General case' 0 CA--C 1.541 0.604 0 CA-C-N 117.43 0.615 . . . . 0.0 111.835 -179.222 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 53.0 m -91.47 145.4 24.65 Favored 'General case' 0 C--N 1.343 0.312 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.079 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.7 p -134.0 129.09 35.65 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.93 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.27 119.93 39.15 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.818 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.603 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.5 m -72.4 10.48 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 112.994 0.738 . . . . 0.0 112.994 -178.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.401 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.6 tp60 -104.03 -29.31 10.98 Favored 'General case' 0 CA--C 1.535 0.377 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.615 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.401 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.84 -26.74 0.26 Allowed 'General case' 0 N--CA 1.476 0.874 0 N-CA-C 112.851 0.686 . . . . 0.0 112.851 -178.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.402 ' HE2' ' HB2' ' A' ' 4' ' ' ALA . 12.6 t80 -125.75 88.33 54.4 Favored Pre-proline 0 CA--C 1.545 0.775 0 N-CA-C 111.702 0.26 . . . . 0.0 111.702 -178.614 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.417 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.8 Cg_endo -77.74 176.17 10.34 Favored 'Trans proline' 0 C--N 1.37 1.686 0 C-N-CA 122.27 1.98 . . . . 0.0 112.708 179.333 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.683 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.1 t -88.26 161.36 17.23 Favored 'General case' 0 N--CA 1.467 0.399 0 O-C-N 123.208 0.318 . . . . 0.0 110.841 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.3 m -79.97 108.47 9.3 Favored Pre-proline 0 CA--C 1.544 0.745 0 N-CA-C 112.03 0.381 . . . . 0.0 112.03 -179.276 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.448 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.9 Cg_endo -83.51 177.53 6.29 Favored 'Trans proline' 0 C--N 1.371 1.756 0 C-N-CA 122.512 2.142 . . . . 0.0 112.906 179.369 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.0 -40.56 2.38 Favored Glycine 0 C--N 1.34 0.775 0 C-N-CA 121.313 -0.47 . . . . 0.0 113.003 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.08 -38.91 14.01 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 122.424 0.29 . . . . 0.0 111.453 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.92 51.96 0.2 Allowed Glycine 0 C--N 1.339 0.719 0 O-C-N 123.466 0.479 . . . . 0.0 112.568 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.459 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 22.0 mt -115.26 149.32 37.96 Favored 'General case' 0 C--O 1.234 0.286 0 O-C-N 123.654 0.267 . . . . 0.0 110.847 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -138.95 154.69 48.34 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.266 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.683 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 67.9 m -97.24 123.31 40.99 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.64 179.538 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.445 ' H ' ' H ' ' A' ' 33' ' ' THR . 12.0 mt -126.63 122.94 23.77 Favored Pre-proline 0 CA--C 1.545 0.775 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.279 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.422 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.85 -40.89 1.06 Allowed 'Cis proline' 0 C--N 1.375 1.929 0 C-N-CA 124.595 -1.002 . . . . 0.0 112.644 0.111 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.08 33.07 9.14 Favored Glycine 0 C--N 1.342 0.883 0 O-C-N 123.548 0.53 . . . . 0.0 112.848 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.422 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.8 79.08 12.4 Favored Pre-proline 0 CA--C 1.547 0.843 0 C-N-CA 122.193 0.197 . . . . 0.0 111.291 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.603 ' O ' HG22 ' A' ' 12' ' ' VAL . 58.6 Cg_endo -89.89 -26.71 4.36 Favored 'Cis proline' 0 C--N 1.37 1.682 0 C-N-CA 124.708 -0.955 . . . . 0.0 113.682 -0.35 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.06 152.56 21.1 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.933 -179.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.41 -174.2 24.2 Favored Glycine 0 C--N 1.337 0.637 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.659 179.591 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.499 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -124.21 143.85 50.28 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.589 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.6 m -88.11 110.24 20.5 Favored 'General case' 0 C--O 1.238 0.448 0 O-C-N 123.44 0.462 . . . . 0.0 111.571 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' TYR . . . . . 0.459 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 33.0 m-85 -124.76 159.1 31.71 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.657 179.603 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.58 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.3 t80 -93.18 136.11 33.75 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.96 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.7 mt . . . . . 0 C--O 1.251 1.146 0 CA-C-O 118.486 -0.769 . . . . 0.0 110.892 179.775 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.424 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.7 p . . . . . 0 C--O 1.235 0.324 0 CA-C-O 120.467 0.175 . . . . 0.0 110.924 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.76 152.03 20.35 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.827 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 19.1 p90 -98.42 173.92 6.72 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.626 179.165 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.581 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 17.5 tt0 -63.82 130.0 42.38 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 123.213 0.605 . . . . 0.0 112.359 -179.326 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 102.06 9.61 41.89 Favored Glycine 0 C--N 1.339 0.717 0 CA-C-N 115.662 -0.699 . . . . 0.0 114.764 178.627 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -135.23 177.39 7.85 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 117.676 0.738 . . . . 0.0 111.535 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 52.4 m -90.82 141.65 28.59 Favored 'General case' 0 C--N 1.343 0.314 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.137 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.5 p -133.17 128.8 36.8 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.844 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.33 119.88 39.09 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.868 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.604 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.3 m -72.78 12.2 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.031 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -178.823 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.7 tp-100 -105.51 -29.91 9.88 Favored 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 116.593 -0.276 . . . . 0.0 111.559 -179.391 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -148.78 -26.68 0.31 Allowed 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 8.8 t80 -126.21 88.19 54.77 Favored Pre-proline 0 CA--C 1.546 0.805 0 N-CA-C 111.696 0.258 . . . . 0.0 111.696 -178.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.424 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.4 Cg_endo -77.91 177.89 8.25 Favored 'Trans proline' 0 C--N 1.369 1.635 0 C-N-CA 122.31 2.007 . . . . 0.0 112.724 179.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.698 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.9 t -90.09 160.13 16.46 Favored 'General case' 0 N--CA 1.468 0.447 0 O-C-N 123.218 0.324 . . . . 0.0 110.799 179.802 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 76.3 m -80.06 108.45 9.34 Favored Pre-proline 0 CA--C 1.545 0.774 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.93 -179.322 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.45 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 80.5 Cg_endo -83.41 177.44 6.43 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.465 2.11 . . . . 0.0 112.961 179.296 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.04 -40.44 2.42 Favored Glycine 0 C--N 1.339 0.741 0 O-C-N 123.434 0.459 . . . . 0.0 113.016 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.07 -39.13 13.85 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 122.437 0.295 . . . . 0.0 111.52 -179.823 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.47 50.66 0.2 Allowed Glycine 0 C--N 1.339 0.736 0 O-C-N 123.505 0.503 . . . . 0.0 112.51 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.442 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.8 mt -113.86 150.21 33.94 Favored 'General case' 0 C--O 1.235 0.329 0 O-C-N 123.617 0.245 . . . . 0.0 110.846 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 t -139.58 154.27 47.58 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.326 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.698 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.9 m -97.33 123.3 41.1 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.582 179.366 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.453 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.8 mt -126.9 123.32 23.62 Favored Pre-proline 0 CA--C 1.545 0.772 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.333 -179.77 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.419 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.9 -40.84 1.07 Allowed 'Cis proline' 0 C--N 1.375 1.949 0 C-N-CA 124.66 -0.975 . . . . 0.0 112.554 0.055 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.98 32.45 9.88 Favored Glycine 0 C--N 1.341 0.859 0 O-C-N 123.621 0.576 . . . . 0.0 112.899 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.419 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -144.34 78.9 13.14 Favored Pre-proline 0 CA--C 1.546 0.817 0 C-N-CA 122.245 0.218 . . . . 0.0 111.313 179.776 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.604 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.2 Cg_endo -90.02 -26.5 4.46 Favored 'Cis proline' 0 C--N 1.369 1.634 0 C-N-CA 124.74 -0.942 . . . . 0.0 113.668 -0.306 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.85 152.78 20.62 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.972 -179.362 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.402 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -155.47 -171.84 22.44 Favored Glycine 0 C--N 1.338 0.647 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.589 179.502 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.515 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -127.22 145.33 50.81 Favored 'General case' 0 C--O 1.235 0.316 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 179.553 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 51.6 m -89.22 111.93 22.84 Favored 'General case' 0 C--O 1.24 0.565 0 O-C-N 123.481 0.488 . . . . 0.0 111.627 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' TYR . . . . . 0.442 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.5 m-85 -125.72 159.76 31.48 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.523 179.423 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.581 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.6 t80 -93.35 136.03 34.01 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.005 -179.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.0 mt . . . . . 0 C--O 1.251 1.148 0 CA-C-O 118.502 -0.761 . . . . 0.0 110.891 179.745 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.415 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.1 p . . . . . 0 C--O 1.235 0.314 0 CA-C-O 120.497 0.189 . . . . 0.0 111.003 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.83 150.48 21.05 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.676 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.9 p90 -98.7 171.88 7.83 Favored 'General case' 0 CA--C 1.536 0.44 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.93 179.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.587 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.0 tt0 -59.98 128.63 37.82 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.352 0.661 . . . . 0.0 112.381 -179.312 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.25 -20.89 27.62 Favored Glycine 0 C--N 1.338 0.68 0 CA-C-N 115.688 -0.687 . . . . 0.0 114.421 178.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -107.29 177.47 4.83 Favored 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 117.444 0.622 . . . . 0.0 111.813 -179.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.7 m -91.42 144.9 25.1 Favored 'General case' 0 C--N 1.344 0.337 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.063 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.9 p -133.61 128.45 35.17 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.974 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.07 120.08 39.3 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.754 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.608 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.0 m -72.28 10.38 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 113.023 0.749 . . . . 0.0 113.023 -178.776 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.407 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 1.6 tp-100 -104.12 -29.69 10.7 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.661 -179.358 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.407 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.48 -26.63 0.28 Allowed 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -178.791 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -125.32 87.79 55.1 Favored Pre-proline 0 CA--C 1.546 0.803 0 N-CA-C 111.652 0.242 . . . . 0.0 111.652 -178.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.415 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.7 Cg_endo -77.66 175.4 11.29 Favored 'Trans proline' 0 C--N 1.369 1.632 0 C-N-CA 122.304 2.003 . . . . 0.0 112.706 179.444 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.681 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -88.46 161.06 17.24 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.848 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 72.0 m -79.91 108.6 9.56 Favored Pre-proline 0 CA--C 1.544 0.738 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.206 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.5 Cg_endo -83.43 177.63 6.28 Favored 'Trans proline' 0 C--N 1.371 1.753 0 C-N-CA 122.491 2.128 . . . . 0.0 112.933 179.262 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.07 -40.01 2.57 Favored Glycine 0 C--N 1.339 0.727 0 C-N-CA 121.386 -0.435 . . . . 0.0 112.969 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.9 mt -88.83 -38.64 14.44 Favored 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 122.488 0.315 . . . . 0.0 111.466 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.19 51.26 0.21 Allowed Glycine 0 C--N 1.339 0.721 0 O-C-N 123.481 0.488 . . . . 0.0 112.539 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.468 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.6 mt -114.58 149.19 36.92 Favored 'General case' 0 C--O 1.235 0.308 0 O-C-N 123.65 0.265 . . . . 0.0 110.881 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t -138.85 154.34 48.41 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.201 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.681 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 68.3 m -97.0 123.23 40.66 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.659 179.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.449 ' H ' ' H ' ' A' ' 33' ' ' THR . 12.7 mt -125.92 122.63 24.46 Favored Pre-proline 0 CA--C 1.545 0.768 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.26 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.43 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.51 -41.08 1.03 Allowed 'Cis proline' 0 C--N 1.375 1.923 0 C-N-CA 124.664 -0.973 . . . . 0.0 112.641 0.072 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.78 31.84 9.73 Favored Glycine 0 C--N 1.341 0.847 0 O-C-N 123.548 0.53 . . . . 0.0 113.043 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.43 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.8 p30 -145.42 80.12 11.08 Favored Pre-proline 0 CA--C 1.547 0.841 0 C-N-CA 122.131 0.173 . . . . 0.0 111.229 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.608 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.1 Cg_endo -89.65 -26.92 4.33 Favored 'Cis proline' 0 C--N 1.369 1.636 0 C-N-CA 124.676 -0.968 . . . . 0.0 113.681 -0.321 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -90.97 152.45 20.69 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.912 -179.273 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.44 -174.48 24.54 Favored Glycine 0 C--N 1.338 0.652 0 CA-C-N 115.442 -0.799 . . . . 0.0 112.634 179.593 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.496 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -123.79 143.93 50.01 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.561 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.6 m -88.08 110.23 20.48 Favored 'General case' 0 C--O 1.238 0.468 0 O-C-N 123.477 0.485 . . . . 0.0 111.588 -179.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' TYR . . . . . 0.468 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 33.0 m-85 -125.2 158.78 33.15 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 115.178 -0.919 . . . . 0.0 110.65 179.586 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.587 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.8 t80 -93.02 136.47 33.25 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.912 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.2 mt . . . . . 0 C--O 1.251 1.181 0 CA-C-O 118.478 -0.772 . . . . 0.0 110.878 179.754 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.424 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.1 p . . . . . 0 C--O 1.234 0.289 0 CA-C-O 120.468 0.175 . . . . 0.0 110.864 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.28 152.8 18.95 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.828 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . 0.458 ' O ' ' HG2' ' A' ' 8' ' ' GLU . 14.2 p90 -97.64 174.99 6.36 Favored 'General case' 0 CA--C 1.537 0.464 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.615 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.576 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.4 tt0 -65.23 130.99 45.35 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 123.095 0.558 . . . . 0.0 112.362 -179.287 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 100.08 12.85 38.34 Favored Glycine 0 C--N 1.339 0.723 0 CA-C-N 115.628 -0.714 . . . . 0.0 114.661 178.623 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.458 ' HG2' ' O ' ' A' ' 5' ' ' PHE . 8.8 pt-20 -136.87 175.96 9.14 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 117.592 0.696 . . . . 0.0 111.455 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.418 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 53.0 m -90.85 138.39 31.63 Favored 'General case' 0 C--N 1.343 0.299 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.132 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 p -131.52 128.18 38.78 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.837 -179.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -97.07 118.86 34.42 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.02 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.611 HG22 ' O ' ' A' ' 30' ' ' PRO . 26.8 m -72.45 12.74 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.86 -178.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 5.9 tp60 -106.46 -31.02 8.73 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.518 -179.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.7 p90 -146.87 -27.22 0.4 Allowed 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 112.81 0.67 . . . . 0.0 112.81 -178.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -126.45 88.37 54.48 Favored Pre-proline 0 CA--C 1.545 0.766 0 N-CA-C 111.607 0.225 . . . . 0.0 111.607 -178.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.424 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 62.3 Cg_endo -78.16 177.86 8.27 Favored 'Trans proline' 0 C--N 1.37 1.681 0 C-N-CA 122.348 2.032 . . . . 0.0 112.732 179.366 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.709 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.7 t -88.91 161.15 16.82 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.904 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 75.5 m -79.96 108.49 9.33 Favored Pre-proline 0 CA--C 1.545 0.758 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.87 -179.383 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.442 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 75.7 Cg_endo -83.07 177.52 6.6 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.485 2.123 . . . . 0.0 112.929 179.423 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.81 -40.11 2.53 Favored Glycine 0 C--N 1.34 0.759 0 C-N-CA 121.392 -0.432 . . . . 0.0 112.969 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.86 -39.18 13.22 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 122.408 0.283 . . . . 0.0 111.427 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.01 52.33 0.19 Allowed Glycine 0 C--N 1.339 0.709 0 O-C-N 123.467 0.479 . . . . 0.0 112.497 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.9 mt -115.74 149.79 37.9 Favored 'General case' 0 C--O 1.235 0.319 0 O-C-N 123.584 0.226 . . . . 0.0 110.86 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.438 ' O ' ' HA ' ' A' ' 34' ' ' CYS . 8.8 t -139.36 155.34 47.73 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.353 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.709 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 68.1 m -98.66 118.8 36.2 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.548 179.53 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.5 mt -129.1 126.55 23.13 Favored Pre-proline 0 CA--C 1.544 0.736 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.433 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.478 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 38.3 Cg_endo -68.69 -42.5 0.7 Allowed 'Cis proline' 0 C--N 1.376 2.005 0 C-N-CA 124.597 -1.001 . . . . 0.0 113.453 -0.208 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 82.29 35.56 20.2 Favored Glycine 0 C--N 1.344 1.013 0 O-C-N 123.349 0.406 . . . . 0.0 113.524 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.478 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.8 p30 -148.09 80.81 8.5 Favored Pre-proline 0 CA--C 1.547 0.852 0 CA-C-N 116.653 0.226 . . . . 0.0 111.352 179.744 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.611 ' O ' HG22 ' A' ' 12' ' ' VAL . 58.3 Cg_endo -87.25 -27.73 5.04 Favored 'Cis proline' 0 C--N 1.37 1.684 0 C-N-CA 124.516 -1.035 . . . . 0.0 113.353 -0.246 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -88.73 147.98 24.21 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.675 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.418 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -150.2 -174.27 21.24 Favored Glycine 0 C--N 1.335 0.526 0 CA-C-N 115.624 -0.716 . . . . 0.0 112.674 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.504 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.3 OUTLIER -127.22 143.38 51.26 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.321 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.438 ' HA ' ' O ' ' A' ' 24' ' ' THR . 55.6 m -87.58 114.17 23.94 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-O 121.095 0.474 . . . . 0.0 111.962 -179.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' TYR . . . . . 0.467 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 43.8 m-85 -126.7 160.22 31.43 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 114.988 -1.006 . . . . 0.0 110.429 179.274 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.576 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.5 t80 -94.07 134.33 36.61 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.979 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.112 -0.947 . . . . 0.0 110.833 179.779 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.412 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.1 p . . . . . 0 C--O 1.235 0.315 0 CA-C-O 120.513 0.196 . . . . 0.0 110.928 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.8 151.94 19.73 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.664 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 17.1 p90 -99.05 173.12 6.98 Favored 'General case' 0 CA--C 1.537 0.468 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.839 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.58 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 14.0 tt0 -60.87 130.91 48.83 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.308 0.643 . . . . 0.0 112.284 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 107.62 -25.33 21.54 Favored Glycine 0 C--N 1.337 0.618 0 CA-C-N 115.657 -0.702 . . . . 0.0 114.217 178.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -103.72 178.75 4.47 Favored 'General case' 0 CA--C 1.541 0.608 0 CA-C-N 117.251 0.525 . . . . 0.0 111.833 -179.145 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 51.3 m -93.34 151.1 19.99 Favored 'General case' 0 C--N 1.344 0.362 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.163 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.1 p -139.77 132.2 28.54 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.843 -179.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -99.78 118.42 36.23 Favored 'General case' 0 C--O 1.236 0.387 0 O-C-N 123.635 0.584 . . . . 0.0 110.657 179.366 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 30' ' ' PRO . 30.6 m -71.05 10.45 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -178.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.505 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.1 OUTLIER -101.58 -34.86 9.34 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.204 -179.479 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.505 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.8 p90 -146.72 -27.35 0.4 Allowed 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -178.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.8 t80 -121.79 86.12 45.31 Favored Pre-proline 0 CA--C 1.545 0.77 0 N-CA-C 111.75 0.278 . . . . 0.0 111.75 -178.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.412 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.9 Cg_endo -78.0 176.53 9.87 Favored 'Trans proline' 0 C--N 1.369 1.607 0 C-N-CA 122.251 1.967 . . . . 0.0 112.671 179.356 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.711 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 4.6 t -86.45 162.14 18.27 Favored 'General case' 0 N--CA 1.468 0.452 0 O-C-N 123.203 0.314 . . . . 0.0 110.824 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.7 m -79.94 108.64 9.68 Favored Pre-proline 0 CA--C 1.545 0.756 0 N-CA-C 112.06 0.393 . . . . 0.0 112.06 -179.224 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.436 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 74.7 Cg_endo -83.02 177.67 6.52 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.467 2.111 . . . . 0.0 112.927 179.363 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.49 -41.17 2.24 Favored Glycine 0 C--N 1.339 0.731 0 C-N-CA 121.352 -0.451 . . . . 0.0 112.909 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.27 -39.02 13.78 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 122.464 0.306 . . . . 0.0 111.402 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.422 ' O ' ' HA ' ' A' ' 36' ' ' TYR . . . 124.02 55.05 0.19 Allowed Glycine 0 C--N 1.338 0.69 0 O-C-N 123.509 0.506 . . . . 0.0 112.535 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.476 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 25.4 mt -119.73 147.96 43.97 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-O 120.571 0.224 . . . . 0.0 110.897 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -140.1 155.36 47.04 Favored 'General case' 0 CA--C 1.536 0.434 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.358 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.711 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 91.0 m -98.3 117.42 32.66 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.512 179.446 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.8 mt -127.2 125.82 24.13 Favored Pre-proline 0 CA--C 1.544 0.743 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.348 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.466 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 41.8 Cg_endo -69.18 -41.9 0.82 Allowed 'Cis proline' 0 C--N 1.376 1.985 0 C-N-CA 124.569 -1.013 . . . . 0.0 113.509 -0.038 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 84.42 38.2 10.1 Favored Glycine 0 C--N 1.344 0.991 0 O-C-N 123.376 0.422 . . . . 0.0 113.471 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.466 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.9 p30 -150.92 81.05 6.44 Favored Pre-proline 0 CA--C 1.547 0.859 0 C-N-CA 122.279 0.231 . . . . 0.0 111.232 179.54 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.595 ' O ' HG22 ' A' ' 12' ' ' VAL . 57.0 Cg_endo -87.25 -28.25 4.59 Favored 'Cis proline' 0 C--N 1.37 1.663 0 C-N-CA 124.584 -1.007 . . . . 0.0 113.35 -0.312 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -87.15 148.7 25.08 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.637 -179.608 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.91 158.58 28.93 Favored Glycine 0 C--N 1.335 0.513 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.13 179.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.416 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.2 OUTLIER -97.2 144.15 27.29 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 110.285 -0.265 . . . . 0.0 110.285 179.868 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 19.5 m -88.07 110.94 21.02 Favored 'General case' 0 C--O 1.239 0.528 0 O-C-N 123.428 0.455 . . . . 0.0 111.584 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' TYR . . . . . 0.476 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 45.7 m-85 -123.55 161.04 25.73 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.703 179.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.58 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.1 t80 -94.15 136.21 34.68 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.872 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.2 mt . . . . . 0 C--O 1.249 1.029 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.847 179.75 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.425 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.6 p . . . . . 0 C--O 1.236 0.344 0 CA-C-O 120.459 0.171 . . . . 0.0 110.923 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.8 152.11 20.28 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.811 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 18.7 p90 -98.0 174.03 6.76 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.705 179.083 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.58 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.1 tt0 -64.16 130.1 42.6 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 123.186 0.594 . . . . 0.0 112.326 -179.291 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 102.19 9.61 41.51 Favored Glycine 0 C--N 1.339 0.71 0 CA-C-N 115.68 -0.691 . . . . 0.0 114.702 178.659 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -135.16 177.53 7.74 Favored 'General case' 0 CA--C 1.541 0.596 0 CA-C-N 117.707 0.754 . . . . 0.0 111.545 179.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 15.9 t -90.71 141.75 28.47 Favored 'General case' 0 C--N 1.343 0.317 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.941 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.5 p -133.66 128.91 36.03 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.894 -179.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.16 119.92 39.08 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.912 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.603 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.8 m -72.68 11.85 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 N-CA-C 112.926 0.713 . . . . 0.0 112.926 -178.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 5.7 tp60 -105.41 -29.91 9.93 Favored 'General case' 0 CA--C 1.535 0.372 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.6 -179.369 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -148.99 -26.57 0.3 Allowed 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 112.789 0.663 . . . . 0.0 112.789 -178.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.2 t80 -125.65 87.62 55.54 Favored Pre-proline 0 CA--C 1.545 0.76 0 N-CA-C 111.67 0.248 . . . . 0.0 111.67 -178.754 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.425 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.5 Cg_endo -77.86 177.47 8.76 Favored 'Trans proline' 0 C--N 1.369 1.648 0 C-N-CA 122.267 1.978 . . . . 0.0 112.796 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.69 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.9 t -89.92 160.01 16.65 Favored 'General case' 0 N--CA 1.467 0.387 0 O-C-N 123.233 0.333 . . . . 0.0 110.837 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 74.8 m -79.94 108.55 9.47 Favored Pre-proline 0 CA--C 1.545 0.763 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.953 -179.342 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.2 Cg_endo -83.28 177.43 6.52 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.49 2.127 . . . . 0.0 112.911 179.342 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.33 -40.24 2.49 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 121.373 -0.441 . . . . 0.0 113.003 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.34 -38.64 14.0 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 122.439 0.296 . . . . 0.0 111.508 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.58 50.46 0.21 Allowed Glycine 0 C--N 1.339 0.728 0 O-C-N 123.491 0.494 . . . . 0.0 112.495 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.443 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.2 mt -113.24 150.12 32.83 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 122.294 0.238 . . . . 0.0 110.92 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -139.54 154.45 47.66 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.392 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.69 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 60.0 m -97.45 123.2 41.22 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.536 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.453 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.8 mt -126.58 123.45 23.97 Favored Pre-proline 0 CA--C 1.545 0.758 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.322 -179.792 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.422 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.85 -40.76 1.1 Allowed 'Cis proline' 0 C--N 1.375 1.965 0 C-N-CA 124.646 -0.981 . . . . 0.0 112.561 0.062 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.81 32.6 9.86 Favored Glycine 0 C--N 1.342 0.885 0 CA-C-N 116.017 -0.538 . . . . 0.0 112.887 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.422 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.11 78.7 13.58 Favored Pre-proline 0 CA--C 1.546 0.821 0 C-N-CA 122.156 0.182 . . . . 0.0 111.321 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.603 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.3 Cg_endo -90.18 -26.4 4.45 Favored 'Cis proline' 0 C--N 1.369 1.636 0 C-N-CA 124.686 -0.964 . . . . 0.0 113.676 -0.276 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.6 152.63 20.81 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 115.96 -0.564 . . . . 0.0 112.011 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -155.33 -171.72 22.22 Favored Glycine 0 C--N 1.337 0.619 0 CA-C-N 115.449 -0.796 . . . . 0.0 112.57 179.561 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.517 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -127.25 145.26 50.84 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.55 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 51.3 m -89.06 111.89 22.72 Favored 'General case' 0 C--O 1.24 0.554 0 CA-C-O 121.076 0.465 . . . . 0.0 111.675 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' TYR . . . . . 0.443 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.8 m-85 -125.94 159.86 31.5 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.527 179.43 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.58 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 14.5 t80 -93.32 136.06 33.94 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.988 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.4 mt . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.151 -0.928 . . . . 0.0 110.943 179.693 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.412 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 28.0 p . . . . . 0 C--O 1.236 0.369 0 CA-C-O 120.43 0.157 . . . . 0.0 111.01 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.72 151.14 20.78 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.752 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 17.0 p90 -98.96 171.95 7.72 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.842 179.351 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.586 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.2 tt0 -60.45 129.55 42.19 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 123.38 0.672 . . . . 0.0 112.395 -179.337 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.18 -19.93 31.47 Favored Glycine 0 C--N 1.338 0.687 0 CA-C-N 115.659 -0.701 . . . . 0.0 114.468 178.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -108.04 177.54 4.78 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 117.464 0.632 . . . . 0.0 111.817 -179.303 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 41.0 p -91.56 144.45 25.53 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.078 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.1 p -133.1 128.7 36.72 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.946 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -99.91 120.19 39.4 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.764 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.608 HG22 ' O ' ' A' ' 30' ' ' PRO . 29.5 m -72.25 10.45 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 N-CA-C 113.051 0.76 . . . . 0.0 113.051 -178.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.408 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 1.6 tp-100 -104.43 -29.51 10.67 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.693 -179.4 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.408 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.7 -26.55 0.27 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -178.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -125.12 87.51 55.4 Favored Pre-proline 0 CA--C 1.546 0.793 0 N-CA-C 111.694 0.257 . . . . 0.0 111.694 -178.666 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.407 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.9 Cg_endo -77.82 175.68 10.92 Favored 'Trans proline' 0 C--N 1.369 1.654 0 C-N-CA 122.28 1.987 . . . . 0.0 112.704 179.466 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.699 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.8 t -88.68 160.78 17.19 Favored 'General case' 0 N--CA 1.468 0.467 0 O-C-N 123.221 0.325 . . . . 0.0 110.793 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.9 m -79.99 108.44 9.25 Favored Pre-proline 0 CA--C 1.545 0.777 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.45 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.6 Cg_endo -83.54 177.59 6.23 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.453 2.102 . . . . 0.0 112.93 179.286 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.89 -40.44 2.44 Favored Glycine 0 C--N 1.34 0.767 0 C-N-CA 121.324 -0.465 . . . . 0.0 112.951 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.9 mt -88.57 -38.63 14.74 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 122.418 0.287 . . . . 0.0 111.551 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.75 51.76 0.2 Allowed Glycine 0 C--N 1.339 0.723 0 O-C-N 123.461 0.475 . . . . 0.0 112.565 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.473 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 22.7 mt -115.76 149.26 38.77 Favored 'General case' 0 C--O 1.235 0.3 0 O-C-N 123.607 0.239 . . . . 0.0 110.874 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t -139.1 154.4 48.14 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.246 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.699 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 66.4 m -97.22 123.26 40.95 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.645 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.441 ' H ' ' H ' ' A' ' 33' ' ' THR . 11.3 mt -127.16 122.94 23.24 Favored Pre-proline 0 CA--C 1.546 0.789 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.315 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.414 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.87 -41.01 1.03 Allowed 'Cis proline' 0 C--N 1.374 1.893 0 C-N-CA 124.696 -0.96 . . . . 0.0 112.64 0.112 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.18 32.8 9.32 Favored Glycine 0 C--N 1.343 0.931 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.93 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.414 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.49 79.08 12.81 Favored Pre-proline 0 CA--C 1.547 0.842 0 C-N-CA 122.215 0.206 . . . . 0.0 111.322 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.608 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.2 Cg_endo -89.88 -26.59 4.48 Favored 'Cis proline' 0 C--N 1.37 1.682 0 C-N-CA 124.667 -0.972 . . . . 0.0 113.68 -0.284 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.43 152.65 20.87 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.941 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.27 -173.95 23.82 Favored Glycine 0 C--N 1.337 0.632 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.649 179.577 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.475 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.6 OUTLIER -124.54 143.66 50.55 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.563 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.3 m -88.11 110.41 20.63 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-O 121.085 0.469 . . . . 0.0 111.607 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' TYR . . . . . 0.473 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 34.2 m-85 -124.57 158.95 31.77 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.681 179.549 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.586 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 11.9 t80 -93.33 135.93 34.08 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.964 -179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.7 mt . . . . . 0 C--O 1.249 1.05 0 CA-C-O 118.115 -0.945 . . . . 0.0 110.901 179.765 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.422 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.4 p . . . . . 0 C--O 1.235 0.336 0 CA-C-O 120.474 0.178 . . . . 0.0 110.805 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.43 151.58 20.75 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.763 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 18.2 p90 -98.27 173.6 6.91 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.688 179.263 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.579 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.0 tt0 -63.23 129.93 42.41 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.185 0.594 . . . . 0.0 112.364 -179.299 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 102.37 5.37 49.15 Favored Glycine 0 C--N 1.339 0.717 0 CA-C-N 115.673 -0.694 . . . . 0.0 114.725 178.606 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -131.72 177.86 7.19 Favored 'General case' 0 CA--C 1.539 0.538 0 CA-C-N 117.678 0.739 . . . . 0.0 111.599 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.439 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 43.1 p -90.24 146.49 24.2 Favored 'General case' 0 C--N 1.344 0.331 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.301 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.4 p -137.42 128.08 26.95 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.835 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -97.68 118.99 35.44 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.839 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.584 HG22 ' O ' ' A' ' 30' ' ' PRO . 22.6 m -71.25 9.61 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 N-CA-C 113.239 0.829 . . . . 0.0 113.239 -178.826 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.51 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.1 OUTLIER -101.28 -34.67 9.55 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.222 -179.548 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.51 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.9 p90 -147.33 -27.01 0.38 Allowed 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 -178.484 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 6.5 t80 -120.83 85.07 39.12 Favored Pre-proline 0 CA--C 1.544 0.732 0 N-CA-C 111.705 0.261 . . . . 0.0 111.705 -178.712 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.422 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.2 Cg_endo -77.95 177.96 8.17 Favored 'Trans proline' 0 C--N 1.369 1.619 0 C-N-CA 122.241 1.961 . . . . 0.0 112.704 179.461 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.7 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -89.17 160.47 16.97 Favored 'General case' 0 N--CA 1.468 0.437 0 O-C-N 123.157 0.285 . . . . 0.0 110.921 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 75.8 m -79.93 108.41 9.11 Favored Pre-proline 0 CA--C 1.545 0.772 0 N-CA-C 111.976 0.361 . . . . 0.0 111.976 -179.394 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.444 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 79.1 Cg_endo -83.07 177.47 6.63 Favored 'Trans proline' 0 C--N 1.371 1.732 0 C-N-CA 122.445 2.097 . . . . 0.0 113.002 179.411 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.01 -39.64 2.68 Favored Glycine 0 C--N 1.34 0.791 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.986 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.8 mt -89.14 -38.73 14.09 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 122.493 0.317 . . . . 0.0 111.503 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.15 50.07 0.22 Allowed Glycine 0 C--N 1.339 0.748 0 O-C-N 123.448 0.468 . . . . 0.0 112.474 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.449 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 20.6 mt -113.51 150.02 33.5 Favored 'General case' 0 C--O 1.235 0.315 0 O-C-N 123.628 0.252 . . . . 0.0 110.872 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -138.99 154.18 48.24 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.232 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.7 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 59.5 m -97.12 123.06 40.78 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.659 179.429 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.469 ' H ' ' H ' ' A' ' 33' ' ' THR . 11.3 mt -127.34 123.24 23.19 Favored Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.268 -179.814 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.437 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.3 Cg_exo -75.64 -40.87 1.07 Allowed 'Cis proline' 0 C--N 1.375 1.947 0 C-N-CA 124.636 -0.985 . . . . 0.0 112.507 0.094 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.04 33.62 8.79 Favored Glycine 0 C--N 1.342 0.877 0 O-C-N 123.596 0.56 . . . . 0.0 113.227 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.437 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.9 p30 -146.36 80.28 10.13 Favored Pre-proline 0 CA--C 1.547 0.855 0 CA-C-N 116.727 0.263 . . . . 0.0 111.556 179.575 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.584 ' O ' HG22 ' A' ' 12' ' ' VAL . 58.7 Cg_endo -89.27 -26.9 4.59 Favored 'Cis proline' 0 C--N 1.37 1.675 0 C-N-CA 124.729 -0.946 . . . . 0.0 113.463 -0.345 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -86.94 149.92 24.44 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.578 -179.634 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.439 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -151.09 -178.82 26.28 Favored Glycine 0 C--N 1.335 0.509 0 CA-C-N 115.581 -0.736 . . . . 0.0 112.394 179.425 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.48 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -124.62 141.6 51.98 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 179.282 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 54.1 m -87.3 112.2 21.82 Favored 'General case' 0 C--O 1.24 0.575 0 O-C-N 123.48 0.488 . . . . 0.0 111.792 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' TYR . . . . . 0.449 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 35.0 m-85 -126.05 159.14 33.55 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.081 -0.963 . . . . 0.0 110.552 179.304 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.579 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.8 t80 -93.23 135.01 34.85 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.937 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.0 mt . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.11 -0.948 . . . . 0.0 110.898 179.776 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.429 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.2 p . . . . . 0 C--O 1.236 0.35 0 CA-C-O 120.404 0.145 . . . . 0.0 110.981 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.6 147.97 22.45 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 112.138 0.422 . . . . 0.0 112.138 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . 0.475 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.25 177.4 7.51 Favored 'General case' 0 CA--C 1.538 0.491 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.463 178.813 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.55 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.4 tt0 -74.46 136.14 42.29 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 122.844 0.458 . . . . 0.0 111.695 -179.743 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.87 9.49 58.44 Favored Glycine 0 C--N 1.338 0.671 0 CA-C-N 115.633 -0.712 . . . . 0.0 114.258 179.017 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.475 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.2 pt-20 -132.83 177.66 7.47 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 117.321 0.561 . . . . 0.0 111.376 179.8 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 42.8 p -88.16 147.28 24.97 Favored 'General case' 0 C--N 1.345 0.372 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.603 -179.409 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.5 p -138.7 128.02 24.35 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.684 -179.743 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.35 119.07 37.87 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.896 179.678 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.607 HG22 ' O ' ' A' ' 30' ' ' PRO . 27.7 m -72.11 9.39 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 -178.741 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.5 tp-100 -102.65 -29.91 11.25 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 116.625 -0.261 . . . . 0.0 111.685 -179.361 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -149.28 -26.82 0.28 Allowed 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 -178.715 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 12.4 t80 -125.32 87.84 55.03 Favored Pre-proline 0 CA--C 1.546 0.803 0 N-CA-C 111.596 0.221 . . . . 0.0 111.596 -178.649 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.429 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.2 Cg_endo -77.05 177.93 8.28 Favored 'Trans proline' 0 C--N 1.371 1.715 0 C-N-CA 122.29 1.993 . . . . 0.0 112.704 179.484 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.711 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.5 t -90.06 159.94 16.58 Favored 'General case' 0 N--CA 1.468 0.468 0 O-C-N 123.265 0.353 . . . . 0.0 110.923 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.418 ' O ' HD12 ' A' ' 23' ' ' LEU . 74.7 m -79.87 108.06 8.22 Favored Pre-proline 0 CA--C 1.546 0.799 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -179.473 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.47 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 80.2 Cg_endo -84.02 177.91 5.7 Favored 'Trans proline' 0 C--N 1.372 1.778 0 C-N-CA 122.493 2.128 . . . . 0.0 112.955 179.453 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.64 -39.56 2.72 Favored Glycine 0 C--N 1.34 0.752 0 C-N-CA 121.371 -0.442 . . . . 0.0 112.953 179.76 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.6 mp -89.79 -37.07 14.76 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 122.45 0.3 . . . . 0.0 111.464 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.43 52.04 0.22 Allowed Glycine 0 C--N 1.338 0.687 0 O-C-N 123.455 0.472 . . . . 0.0 112.357 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.424 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 19.0 mt -113.62 149.56 34.39 Favored 'General case' 0 C--O 1.234 0.265 0 O-C-N 123.624 0.25 . . . . 0.0 110.972 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.2 t -138.94 152.08 47.42 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.315 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.711 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 55.7 m -96.76 122.69 39.99 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.608 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.42 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.9 mt -127.13 122.88 23.25 Favored Pre-proline 0 CA--C 1.545 0.772 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.328 -179.753 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.417 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.69 -41.28 0.99 Allowed 'Cis proline' 0 C--N 1.375 1.933 0 C-N-CA 124.651 -0.979 . . . . 0.0 112.593 0.04 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.7 31.68 9.97 Favored Glycine 0 C--N 1.342 0.905 0 O-C-N 123.582 0.551 . . . . 0.0 113.044 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.417 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.8 p30 -145.12 80.8 10.92 Favored Pre-proline 0 CA--C 1.547 0.832 0 CA-C-N 116.569 0.184 . . . . 0.0 111.258 179.705 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.607 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.8 Cg_endo -89.31 -26.57 4.86 Favored 'Cis proline' 0 C--N 1.369 1.648 0 C-N-CA 124.654 -0.978 . . . . 0.0 113.609 -0.336 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -92.29 153.96 18.91 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.891 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -155.97 -172.87 23.91 Favored Glycine 0 C--N 1.337 0.625 0 CA-C-N 115.482 -0.781 . . . . 0.0 112.608 179.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.496 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -126.51 144.95 50.7 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.576 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 60.8 m -89.61 113.92 25.44 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-O 121.072 0.463 . . . . 0.0 111.765 -179.634 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' TYR . . . . . 0.424 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 35.3 m-85 -125.58 157.45 37.1 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.471 179.327 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.55 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 19.4 t80 -92.5 133.65 35.73 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.985 -179.835 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt . . . . . 0 C--O 1.252 1.192 0 CA-C-O 118.507 -0.758 . . . . 0.0 110.898 179.787 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.427 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.1 p . . . . . 0 C--O 1.235 0.311 0 CA-C-O 120.409 0.147 . . . . 0.0 110.971 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.54 147.84 22.57 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 116.235 -0.439 . . . . 0.0 112.184 -179.696 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . 0.479 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.15 177.62 7.47 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.478 178.779 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.543 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.1 tt0 -74.64 135.92 41.95 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 122.905 0.482 . . . . 0.0 111.712 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.71 10.17 58.04 Favored Glycine 0 C--N 1.339 0.716 0 CA-C-N 115.596 -0.729 . . . . 0.0 114.292 179.027 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.479 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.3 pt-20 -132.99 177.55 7.57 Favored 'General case' 0 CA--C 1.54 0.578 0 CA-C-N 117.342 0.571 . . . . 0.0 111.403 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.8 m -88.33 146.42 25.3 Favored 'General case' 0 C--N 1.344 0.346 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.567 -179.478 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.5 p -138.26 128.57 26.03 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.689 -179.759 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -100.76 119.27 38.38 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.87 179.749 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.605 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.0 m -72.12 9.39 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 N-CA-C 113.063 0.764 . . . . 0.0 113.063 -178.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.6 tp-100 -102.72 -30.04 11.14 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.583 -0.28 . . . . 0.0 111.661 -179.331 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -149.0 -26.83 0.29 Allowed 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 112.864 0.69 . . . . 0.0 112.864 -178.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 12.5 t80 -125.28 87.77 55.12 Favored Pre-proline 0 CA--C 1.546 0.818 0 N-CA-C 111.63 0.233 . . . . 0.0 111.63 -178.639 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.427 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.2 Cg_endo -77.11 177.67 8.58 Favored 'Trans proline' 0 C--N 1.37 1.671 0 C-N-CA 122.269 1.979 . . . . 0.0 112.682 179.527 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.71 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.3 t -89.85 160.05 16.67 Favored 'General case' 0 N--CA 1.467 0.397 0 O-C-N 123.234 0.334 . . . . 0.0 110.947 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.426 ' O ' HD12 ' A' ' 23' ' ' LEU . 74.2 m -79.85 108.08 8.26 Favored Pre-proline 0 CA--C 1.545 0.782 0 O-C-N 123.247 0.342 . . . . 0.0 111.916 -179.47 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.469 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 79.6 Cg_endo -83.91 177.92 5.76 Favored 'Trans proline' 0 C--N 1.371 1.728 0 C-N-CA 122.554 2.169 . . . . 0.0 112.972 179.42 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.54 -38.97 2.9 Favored Glycine 0 C--N 1.34 0.773 0 C-N-CA 121.374 -0.441 . . . . 0.0 113.007 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.1 mt -89.83 -36.97 14.79 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 122.461 0.304 . . . . 0.0 111.469 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.06 52.08 0.23 Allowed Glycine 0 C--N 1.339 0.713 0 O-C-N 123.514 0.509 . . . . 0.0 112.335 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.426 HD12 ' O ' ' A' ' 18' ' ' CYS . 18.9 mt -114.22 149.21 36.14 Favored 'General case' 0 C--O 1.235 0.321 0 O-C-N 123.671 0.277 . . . . 0.0 110.965 -179.687 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.1 t -138.83 151.93 47.42 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.29 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.71 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 56.1 m -96.76 122.48 39.76 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.595 179.411 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.4 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.6 mt -127.21 123.09 23.25 Favored Pre-proline 0 CA--C 1.545 0.759 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.372 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.419 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -76.0 -41.0 1.03 Allowed 'Cis proline' 0 C--N 1.374 1.914 0 C-N-CA 124.625 -0.99 . . . . 0.0 112.612 0.055 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.77 32.78 9.69 Favored Glycine 0 C--N 1.343 0.929 0 O-C-N 123.548 0.53 . . . . 0.0 112.945 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.419 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.37 79.42 12.73 Favored Pre-proline 0 CA--C 1.546 0.823 0 C-N-CA 122.213 0.205 . . . . 0.0 111.343 179.762 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.605 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.2 Cg_endo -89.73 -26.53 4.63 Favored 'Cis proline' 0 C--N 1.37 1.66 0 C-N-CA 124.722 -0.949 . . . . 0.0 113.58 -0.213 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -91.18 153.79 19.77 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.892 -179.363 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.34 -172.54 23.83 Favored Glycine 0 C--N 1.337 0.622 0 CA-C-N 115.518 -0.765 . . . . 0.0 112.646 179.493 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.506 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -126.7 145.44 50.59 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.601 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 59.3 m -90.01 114.09 25.89 Favored 'General case' 0 C--O 1.239 0.545 0 O-C-N 123.42 0.45 . . . . 0.0 111.779 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' TYR . . . . . 0.426 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 35.9 m-85 -125.39 157.33 37.06 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.103 -0.953 . . . . 0.0 110.419 179.326 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.543 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 17.5 t80 -92.58 133.41 35.99 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.003 -179.808 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.251 1.169 0 CA-C-O 118.507 -0.758 . . . . 0.0 110.907 179.835 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.419 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.5 p . . . . . 0 C--O 1.235 0.314 0 CA-C-O 120.477 0.179 . . . . 0.0 111.063 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.72 152.28 19.06 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.693 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -99.1 172.16 7.56 Favored 'General case' 0 CA--C 1.537 0.45 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.865 179.351 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.579 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.9 tt0 -60.63 129.81 43.39 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 123.36 0.664 . . . . 0.0 112.396 -179.29 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.3 -21.93 27.88 Favored Glycine 0 C--N 1.338 0.687 0 CA-C-N 115.639 -0.709 . . . . 0.0 114.383 178.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -105.61 177.42 4.86 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-N 117.458 0.629 . . . . 0.0 111.821 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 15.7 t -92.55 142.63 27.19 Favored 'General case' 0 C--N 1.343 0.321 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.966 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.8 p -132.46 129.27 39.01 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.853 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -97.59 119.11 35.55 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.049 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.606 HG22 ' O ' ' A' ' 30' ' ' PRO . 27.2 m -71.71 9.12 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.856 -179.021 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.448 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 23.1 tt0 -100.14 -30.17 12.08 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.251 -179.387 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.448 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.9 p90 -153.4 -27.68 0.14 Allowed 'General case' 0 N--CA 1.476 0.826 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -178.544 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.5 t80 -119.63 85.25 32.35 Favored Pre-proline 0 CA--C 1.545 0.757 0 N-CA-C 111.503 0.186 . . . . 0.0 111.503 -178.819 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.419 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.3 Cg_endo -77.69 175.28 11.42 Favored 'Trans proline' 0 C--N 1.368 1.597 0 C-N-CA 122.212 1.941 . . . . 0.0 112.757 179.619 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.65 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.2 t -87.28 162.28 17.51 Favored 'General case' 0 N--CA 1.467 0.396 0 O-C-N 123.246 0.341 . . . . 0.0 110.944 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.9 m -79.92 108.58 9.52 Favored Pre-proline 0 CA--C 1.545 0.762 0 N-CA-C 111.907 0.336 . . . . 0.0 111.907 -179.328 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.44 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 74.7 Cg_endo -82.85 177.58 6.69 Favored 'Trans proline' 0 C--N 1.372 1.792 0 C-N-CA 122.453 2.102 . . . . 0.0 112.993 179.385 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.08 -40.04 2.55 Favored Glycine 0 C--N 1.339 0.735 0 C-N-CA 121.356 -0.449 . . . . 0.0 112.904 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -90.16 -39.49 12.81 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 122.446 0.298 . . . . 0.0 111.386 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.28 53.76 0.19 Allowed Glycine 0 C--N 1.339 0.75 0 O-C-N 123.516 0.51 . . . . 0.0 112.514 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.47 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 23.0 mt -117.3 149.24 40.79 Favored 'General case' 0 C--O 1.235 0.297 0 O-C-N 123.632 0.254 . . . . 0.0 110.962 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.401 ' O ' ' HA ' ' A' ' 34' ' ' CYS . 8.9 t -139.58 156.97 46.56 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.276 -179.816 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.65 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 98.9 m -99.25 119.54 38.08 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.699 179.619 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.8 mt -129.79 126.12 22.45 Favored Pre-proline 0 CA--C 1.545 0.783 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.348 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.551 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 43.1 Cg_endo -69.81 -42.58 0.73 Allowed 'Cis proline' 0 C--N 1.375 1.956 0 C-N-CA 124.578 -1.009 . . . . 0.0 113.449 -0.22 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 82.1 39.34 11.58 Favored Glycine 0 C--N 1.345 1.03 0 O-C-N 123.358 0.411 . . . . 0.0 113.275 179.785 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.551 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -147.81 78.52 9.77 Favored Pre-proline 0 CA--C 1.548 0.87 0 C-N-CA 122.3 0.24 . . . . 0.0 111.402 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.606 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.6 Cg_endo -87.83 -26.86 5.5 Favored 'Cis proline' 0 C--N 1.369 1.612 0 C-N-CA 124.571 -1.012 . . . . 0.0 113.355 -0.273 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -87.06 147.54 25.64 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.705 -179.591 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -149.54 -175.78 22.14 Favored Glycine 0 C--N 1.336 0.556 0 CA-C-N 115.612 -0.722 . . . . 0.0 112.712 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.507 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.8 OUTLIER -124.24 143.15 50.69 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.505 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.401 ' HA ' ' O ' ' A' ' 24' ' ' THR . 34.5 m -87.47 112.01 21.75 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-O 121.086 0.469 . . . . 0.0 111.778 -179.598 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' TYR . . . . . 0.47 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 40.5 m-85 -125.81 159.87 31.31 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.605 179.458 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.579 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.4 t80 -93.74 135.15 35.33 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.94 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.5 mt . . . . . 0 C--O 1.251 1.136 0 CA-C-O 118.472 -0.775 . . . . 0.0 110.875 179.759 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.425 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 28.2 p . . . . . 0 C--O 1.235 0.339 0 CA-C-O 120.449 0.166 . . . . 0.0 111.03 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.3 147.72 22.85 Favored 'General case' 0 C--O 1.237 0.417 0 N-CA-C 112.176 0.435 . . . . 0.0 112.176 -179.621 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . 0.473 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.08 177.5 7.54 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 115.098 -0.955 . . . . 0.0 110.426 178.847 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.543 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.4 tt0 -74.85 135.89 41.56 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 122.875 0.47 . . . . 0.0 111.693 -179.698 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.44 10.91 57.72 Favored Glycine 0 C--N 1.339 0.725 0 CA-C-N 115.587 -0.733 . . . . 0.0 114.34 178.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.473 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.4 pt-20 -133.32 177.47 7.66 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 117.271 0.536 . . . . 0.0 111.392 179.821 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 43.1 p -88.04 145.65 25.87 Favored 'General case' 0 C--N 1.344 0.364 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.601 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.2 p -137.65 128.03 26.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.639 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.58 119.52 38.66 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.903 179.684 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.612 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.6 m -72.03 8.9 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 N-CA-C 113.024 0.749 . . . . 0.0 113.024 -178.752 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.409 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 1.5 tp-100 -102.55 -29.86 11.31 Favored 'General case' 0 CA--C 1.535 0.388 0 N-CA-C 111.706 0.262 . . . . 0.0 111.706 -179.333 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.409 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.9 p90 -149.43 -26.74 0.28 Allowed 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -178.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.6 t80 -124.64 87.17 54.91 Favored Pre-proline 0 CA--C 1.547 0.829 0 N-CA-C 111.577 0.214 . . . . 0.0 111.577 -178.657 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.413 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.1 Cg_endo -77.18 175.86 10.83 Favored 'Trans proline' 0 C--N 1.369 1.624 0 C-N-CA 122.293 1.995 . . . . 0.0 112.69 179.495 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.715 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.3 t -89.31 160.35 16.92 Favored 'General case' 0 N--CA 1.468 0.444 0 O-C-N 123.257 0.348 . . . . 0.0 110.886 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.444 ' O ' HD12 ' A' ' 23' ' ' LEU . 73.9 m -79.84 107.68 7.3 Favored Pre-proline 0 CA--C 1.545 0.777 0 O-C-N 123.286 0.367 . . . . 0.0 111.985 -179.561 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.48 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 81.5 Cg_endo -84.39 177.99 5.41 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.529 2.153 . . . . 0.0 112.984 179.41 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.66 -39.36 2.77 Favored Glycine 0 C--N 1.34 0.777 0 C-N-CA 121.41 -0.424 . . . . 0.0 113.033 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.6 mp -89.71 -38.05 14.14 Favored 'General case' 0 N--CA 1.467 0.423 0 C-N-CA 122.435 0.294 . . . . 0.0 111.489 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.65 52.55 0.19 Allowed Glycine 0 C--N 1.339 0.7 0 O-C-N 123.452 0.47 . . . . 0.0 112.422 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.444 HD12 ' O ' ' A' ' 18' ' ' CYS . 19.6 mt -115.3 148.56 39.08 Favored 'General case' 0 C--O 1.235 0.323 0 O-C-N 123.668 0.276 . . . . 0.0 110.846 -179.7 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.2 t -138.53 151.69 47.57 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.374 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.715 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 54.3 m -97.03 121.98 39.52 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.597 179.412 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.5 mt -127.4 123.36 23.18 Favored Pre-proline 0 CA--C 1.545 0.786 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.364 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.409 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.95 -41.06 1.02 Allowed 'Cis proline' 0 C--N 1.375 1.923 0 C-N-CA 124.652 -0.978 . . . . 0.0 112.598 0.067 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.55 32.71 9.95 Favored Glycine 0 C--N 1.343 0.947 0 O-C-N 123.55 0.531 . . . . 0.0 112.95 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.409 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.09 79.33 13.15 Favored Pre-proline 0 CA--C 1.546 0.822 0 C-N-CA 122.178 0.191 . . . . 0.0 111.291 179.722 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.612 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.7 Cg_endo -89.86 -26.32 4.73 Favored 'Cis proline' 0 C--N 1.37 1.708 0 C-N-CA 124.671 -0.97 . . . . 0.0 113.685 -0.338 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -91.1 153.65 19.93 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.93 -179.406 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.17 -172.37 23.52 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-N 115.533 -0.758 . . . . 0.0 112.662 179.467 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.49 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.6 OUTLIER -126.99 145.78 50.58 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.567 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 61.3 m -89.98 113.47 25.14 Favored 'General case' 0 C--O 1.239 0.549 0 O-C-N 123.455 0.472 . . . . 0.0 111.739 -179.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' TYR . . . . . 0.433 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 34.7 m-85 -123.77 157.19 34.58 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.47 179.316 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.543 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.7 t80 -93.41 132.72 37.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.989 -179.765 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt . . . . . 0 C--O 1.251 1.181 0 CA-C-O 118.455 -0.783 . . . . 0.0 110.872 179.797 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.421 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 28.5 p . . . . . 0 C--O 1.236 0.353 0 CA-C-O 120.435 0.16 . . . . 0.0 111.043 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.84 147.22 23.14 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 116.259 -0.428 . . . . 0.0 112.093 -179.609 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . 0.467 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.61 177.19 7.45 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.412 178.756 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.556 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 23.7 tt0 -74.1 134.69 42.91 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 122.9 0.48 . . . . 0.0 111.677 -179.649 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.45 9.73 57.55 Favored Glycine 0 C--N 1.339 0.712 0 CA-C-N 115.597 -0.729 . . . . 0.0 114.319 179.019 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.467 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.0 pt-20 -132.72 177.84 7.32 Favored 'General case' 0 CA--C 1.54 0.595 0 CA-C-N 117.371 0.586 . . . . 0.0 111.373 179.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.42 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 52.8 m -88.58 149.03 23.79 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.645 -179.379 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.2 p -141.38 129.12 21.64 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.615 -179.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -101.29 120.94 41.01 Favored 'General case' 0 N--CA 1.466 0.328 0 O-C-N 123.447 0.467 . . . . 0.0 110.516 179.632 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.583 HG22 ' O ' ' A' ' 30' ' ' PRO . 27.6 m -70.86 6.66 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 N-CA-C 113.689 0.996 . . . . 0.0 113.689 -178.228 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 5.9 tp60 -101.41 -30.3 11.53 Favored 'General case' 0 CA--C 1.534 0.354 0 N-CA-C 111.736 0.273 . . . . 0.0 111.736 -179.473 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.8 p90 -148.24 -27.55 0.33 Allowed 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 112.882 0.697 . . . . 0.0 112.882 -178.803 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -121.8 85.88 45.12 Favored Pre-proline 0 CA--C 1.545 0.786 0 N-CA-C 111.584 0.216 . . . . 0.0 111.584 -178.719 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.412 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.1 Cg_endo -77.4 176.83 9.59 Favored 'Trans proline' 0 C--N 1.369 1.614 0 C-N-CA 122.265 1.976 . . . . 0.0 112.606 179.51 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.706 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.0 t -89.07 160.1 17.23 Favored 'General case' 0 N--CA 1.468 0.442 0 O-C-N 123.226 0.329 . . . . 0.0 110.944 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.4 ' O ' HD12 ' A' ' 23' ' ' LEU . 72.3 m -79.84 108.09 8.27 Favored Pre-proline 0 CA--C 1.546 0.805 0 N-CA-C 111.948 0.351 . . . . 0.0 111.948 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.469 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 76.4 Cg_endo -83.69 178.0 5.84 Favored 'Trans proline' 0 C--N 1.372 1.797 0 C-N-CA 122.534 2.156 . . . . 0.0 112.979 179.473 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.69 -39.35 2.77 Favored Glycine 0 C--N 1.34 0.789 0 C-N-CA 121.401 -0.428 . . . . 0.0 112.935 179.81 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.6 mt -89.9 -36.68 14.9 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 122.447 0.299 . . . . 0.0 111.442 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.35 52.92 0.23 Allowed Glycine 0 C--N 1.339 0.716 0 O-C-N 123.496 0.498 . . . . 0.0 112.376 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.459 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 18.8 mt -115.4 148.53 39.24 Favored 'General case' 0 C--O 1.235 0.334 0 O-C-N 123.67 0.277 . . . . 0.0 110.953 -179.683 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.425 ' O ' ' HA ' ' A' ' 34' ' ' CYS . 9.8 t -138.83 152.22 47.67 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.296 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.706 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 61.7 m -96.47 122.34 39.26 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.551 179.43 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.6 mt -127.41 122.73 22.93 Favored Pre-proline 0 CA--C 1.546 0.809 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.385 -179.787 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.431 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.66 -41.54 0.95 Allowed 'Cis proline' 0 C--N 1.374 1.909 0 C-N-CA 124.677 -0.968 . . . . 0.0 112.569 0.083 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 91.17 31.47 9.72 Favored Glycine 0 C--N 1.342 0.914 0 O-C-N 123.562 0.538 . . . . 0.0 113.128 179.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.431 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.9 p30 -143.95 82.79 10.79 Favored Pre-proline 0 CA--C 1.547 0.845 0 CA-C-N 116.707 0.253 . . . . 0.0 111.391 179.633 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.583 ' O ' HG22 ' A' ' 12' ' ' VAL . 75.7 Cg_endo -87.26 -27.01 5.67 Favored 'Cis proline' 0 C--N 1.37 1.707 0 C-N-CA 124.59 -1.004 . . . . 0.0 113.439 -0.43 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -94.12 156.65 16.46 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.67 -179.032 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.42 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.65 -173.6 25.35 Favored Glycine 0 C--N 1.336 0.56 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.452 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.477 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.5 OUTLIER -124.77 143.81 50.59 Favored 'General case' 0 C--O 1.234 0.271 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.607 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.425 ' HA ' ' O ' ' A' ' 24' ' ' THR . 56.7 m -89.08 114.37 25.6 Favored 'General case' 0 C--O 1.239 0.536 0 O-C-N 123.452 0.47 . . . . 0.0 111.818 -179.569 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' TYR . . . . . 0.459 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.0 m-85 -125.51 157.97 35.67 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.051 -0.977 . . . . 0.0 110.466 179.287 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.556 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 17.7 t80 -92.53 133.12 36.25 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.984 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.104 -0.951 . . . . 0.0 110.977 179.827 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.438 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.6 p . . . . . 0 N--CA 1.466 0.332 0 CA-C-O 120.42 0.152 . . . . 0.0 110.868 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.84 151.72 20.44 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.784 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . 0.428 ' O ' ' HG2' ' A' ' 8' ' ' GLU . 15.3 p90 -97.32 174.78 6.53 Favored 'General case' 0 CA--C 1.537 0.477 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.687 179.117 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.573 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.1 tt0 -64.97 130.47 43.51 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 123.164 0.586 . . . . 0.0 112.253 -179.269 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 100.04 12.13 40.72 Favored Glycine 0 C--N 1.339 0.723 0 CA-C-N 115.62 -0.718 . . . . 0.0 114.674 178.656 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.428 ' HG2' ' O ' ' A' ' 5' ' ' PHE . 7.0 pt-20 -136.67 176.85 8.33 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 117.601 0.701 . . . . 0.0 111.47 179.632 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.435 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 40.6 p -90.23 144.8 25.53 Favored 'General case' 0 C--N 1.343 0.319 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.126 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 p -135.85 130.49 33.99 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.906 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -99.76 119.02 37.48 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.854 179.523 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.616 HG22 ' O ' ' A' ' 30' ' ' PRO . 30.5 m -72.71 10.58 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 N-CA-C 112.897 0.702 . . . . 0.0 112.897 -179.034 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.409 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.5 tp60 -104.26 -29.74 10.6 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.577 -179.425 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.409 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.48 -26.79 0.27 Allowed 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 112.819 0.674 . . . . 0.0 112.819 -178.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 9.7 t80 -124.98 86.96 55.99 Favored Pre-proline 0 CA--C 1.546 0.798 0 N-CA-C 111.622 0.23 . . . . 0.0 111.622 -178.697 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.438 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.1 Cg_endo -77.75 179.08 6.85 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 122.235 1.957 . . . . 0.0 112.739 179.512 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.7 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -89.91 160.22 16.54 Favored 'General case' 0 N--CA 1.467 0.376 0 O-C-N 123.183 0.302 . . . . 0.0 110.809 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 78.2 m -79.99 108.29 8.88 Favored Pre-proline 0 CA--C 1.545 0.773 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.907 -179.401 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.452 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.9 Cg_endo -83.44 177.53 6.34 Favored 'Trans proline' 0 C--N 1.371 1.753 0 C-N-CA 122.449 2.099 . . . . 0.0 112.95 179.441 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.79 -39.86 2.61 Favored Glycine 0 C--N 1.34 0.751 0 C-N-CA 121.374 -0.441 . . . . 0.0 112.946 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.8 mt -89.05 -38.1 14.64 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 122.444 0.298 . . . . 0.0 111.501 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.97 50.12 0.23 Allowed Glycine 0 C--N 1.339 0.706 0 O-C-N 123.481 0.488 . . . . 0.0 112.497 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.447 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.1 mt -113.85 149.73 34.62 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 122.294 0.238 . . . . 0.0 110.846 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -139.44 154.16 47.71 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.321 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.7 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.0 m -97.13 123.09 40.8 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.575 179.4 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.446 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.6 mt -127.2 123.09 23.25 Favored Pre-proline 0 CA--C 1.544 0.746 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.327 -179.772 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.44 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.2 Cg_exo -75.7 -40.92 1.06 Allowed 'Cis proline' 0 C--N 1.375 1.922 0 C-N-CA 124.698 -0.959 . . . . 0.0 112.527 0.077 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.64 32.97 8.78 Favored Glycine 0 C--N 1.342 0.884 0 O-C-N 123.62 0.575 . . . . 0.0 113.123 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.44 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.7 p30 -145.68 81.39 10.08 Favored Pre-proline 0 CA--C 1.547 0.844 0 CA-C-N 116.756 0.278 . . . . 0.0 111.458 179.611 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.616 ' O ' HG22 ' A' ' 12' ' ' VAL . 60.7 Cg_endo -88.77 -26.53 5.24 Favored 'Cis proline' 0 C--N 1.371 1.715 0 C-N-CA 124.651 -0.979 . . . . 0.0 113.508 -0.407 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -90.46 155.24 19.06 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.347 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.435 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.19 -174.93 26.58 Favored Glycine 0 C--N 1.334 0.465 0 CA-C-N 115.379 -0.828 . . . . 0.0 112.464 179.549 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.495 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.6 OUTLIER -125.72 143.24 51.13 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.493 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 52.8 m -88.69 112.74 23.49 Favored 'General case' 0 C--O 1.239 0.523 0 O-C-N 123.439 0.462 . . . . 0.0 111.75 -179.644 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' TYR . . . . . 0.447 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 37.1 m-85 -126.48 159.26 33.89 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.051 -0.977 . . . . 0.0 110.519 179.36 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.573 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.5 t80 -92.77 135.34 34.2 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.006 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.9 mt . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.115 -0.945 . . . . 0.0 110.87 179.819 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.424 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 29.0 p . . . . . 0 C--O 1.235 0.314 0 CA-C-O 120.407 0.146 . . . . 0.0 111.004 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.0 147.81 22.52 Favored 'General case' 0 C--O 1.237 0.406 0 CA-C-N 116.243 -0.435 . . . . 0.0 112.121 -179.705 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . 0.468 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.4 m-85 -86.53 176.98 7.54 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.432 178.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.574 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.2 tt0 -73.79 136.09 43.55 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 122.905 0.482 . . . . 0.0 111.693 -179.792 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.49 8.81 58.26 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 115.624 -0.716 . . . . 0.0 114.289 179.008 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.468 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.3 pt-20 -132.53 177.39 7.65 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 117.333 0.567 . . . . 0.0 111.41 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.0 m -88.36 146.4 25.29 Favored 'General case' 0 C--N 1.344 0.351 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.619 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.0 p -138.42 128.6 25.74 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.729 -179.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.4 119.57 38.65 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.918 179.678 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.612 HG22 ' O ' ' A' ' 30' ' ' PRO . 29.0 m -71.95 8.93 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 N-CA-C 113.035 0.754 . . . . 0.0 113.035 -178.757 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.407 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.4 tp60 -102.7 -30.1 11.11 Favored 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 111.687 0.254 . . . . 0.0 111.687 -179.34 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.407 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.9 p90 -149.02 -26.92 0.29 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.824 0.676 . . . . 0.0 112.824 -178.763 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -124.32 87.15 54.16 Favored Pre-proline 0 CA--C 1.546 0.804 0 N-CA-C 111.561 0.208 . . . . 0.0 111.561 -178.704 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.42 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.2 Cg_endo -76.97 177.09 9.31 Favored 'Trans proline' 0 C--N 1.37 1.659 0 C-N-CA 122.234 1.956 . . . . 0.0 112.771 179.604 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.7 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.3 t -89.69 159.86 16.89 Favored 'General case' 0 N--CA 1.468 0.442 0 O-C-N 123.272 0.358 . . . . 0.0 110.957 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.1 m -79.85 108.24 8.64 Favored Pre-proline 0 CA--C 1.545 0.779 0 N-CA-C 112.024 0.379 . . . . 0.0 112.024 -179.524 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 79.1 Cg_endo -83.6 177.88 5.99 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 122.512 2.142 . . . . 0.0 113.025 179.39 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.72 -39.76 2.65 Favored Glycine 0 C--N 1.34 0.759 0 O-C-N 123.395 0.434 . . . . 0.0 112.95 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.6 mp -89.8 -36.64 15.01 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 122.47 0.308 . . . . 0.0 111.444 -179.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.43 51.63 0.24 Allowed Glycine 0 C--N 1.338 0.691 0 O-C-N 123.525 0.515 . . . . 0.0 112.323 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.438 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 19.3 mt -113.2 149.46 33.68 Favored 'General case' 0 C--O 1.234 0.288 0 O-C-N 123.632 0.254 . . . . 0.0 110.969 -179.663 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.0 t -139.08 153.0 47.98 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.239 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.7 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.1 m -96.81 123.09 40.41 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.546 179.448 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.425 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.9 mt -126.8 122.79 23.54 Favored Pre-proline 0 CA--C 1.545 0.771 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.401 -179.737 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.413 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.93 -41.04 1.02 Allowed 'Cis proline' 0 C--N 1.375 1.925 0 C-N-CA 124.695 -0.961 . . . . 0.0 112.643 0.042 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.08 32.64 9.58 Favored Glycine 0 C--N 1.343 0.948 0 CA-C-N 116.024 -0.535 . . . . 0.0 112.914 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.413 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -144.32 79.47 12.75 Favored Pre-proline 0 CA--C 1.546 0.803 0 C-N-CA 122.194 0.198 . . . . 0.0 111.349 179.761 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.612 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.3 Cg_endo -89.69 -26.47 4.7 Favored 'Cis proline' 0 C--N 1.37 1.666 0 C-N-CA 124.695 -0.96 . . . . 0.0 113.593 -0.252 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -91.14 153.44 20.06 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.937 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -155.91 -172.57 23.54 Favored Glycine 0 C--N 1.338 0.658 0 CA-C-N 115.55 -0.75 . . . . 0.0 112.649 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.503 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.5 OUTLIER -126.55 144.86 50.74 Favored 'General case' 0 C--O 1.235 0.318 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.556 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 57.5 m -89.47 114.82 26.37 Favored 'General case' 0 C--O 1.239 0.538 0 O-C-N 123.429 0.456 . . . . 0.0 111.832 -179.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' TYR . . . . . 0.438 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 38.0 m-85 -128.14 157.87 39.6 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.512 179.291 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.574 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 20.4 t80 -91.75 134.86 34.36 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.995 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.3 mt . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.085 -0.96 . . . . 0.0 110.963 179.797 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.423 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.0 p . . . . . 0 C--O 1.236 0.368 0 CA-C-O 120.453 0.168 . . . . 0.0 110.942 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.07 147.18 23.14 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-N 116.226 -0.443 . . . . 0.0 112.158 -179.668 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . 0.476 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.28 177.2 7.56 Favored 'General case' 0 CA--C 1.538 0.505 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.442 178.764 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.55 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 23.8 tt0 -73.95 134.87 43.18 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 122.932 0.493 . . . . 0.0 111.711 -179.755 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.27 9.39 58.05 Favored Glycine 0 C--N 1.339 0.713 0 CA-C-N 115.659 -0.7 . . . . 0.0 114.33 178.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.476 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.0 pt-20 -132.39 177.85 7.27 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 117.345 0.573 . . . . 0.0 111.419 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.43 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 51.8 m -88.47 149.15 23.81 Favored 'General case' 0 C--N 1.345 0.375 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.722 -179.393 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.4 p -141.56 129.48 21.87 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.656 -179.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -101.36 120.9 40.97 Favored 'General case' 0 C--O 1.235 0.326 0 O-C-N 123.384 0.428 . . . . 0.0 110.523 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 30' ' ' PRO . 27.4 m -71.04 7.12 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 N-CA-C 113.626 0.972 . . . . 0.0 113.626 -178.178 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.7 tp-100 -101.77 -30.6 11.2 Favored 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 -179.429 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.8 p90 -147.95 -27.44 0.34 Allowed 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 112.896 0.702 . . . . 0.0 112.896 -178.82 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -122.24 86.1 47.37 Favored Pre-proline 0 CA--C 1.546 0.798 0 N-CA-C 111.62 0.229 . . . . 0.0 111.62 -178.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.423 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.3 Cg_endo -77.51 177.59 8.66 Favored 'Trans proline' 0 C--N 1.369 1.653 0 C-N-CA 122.22 1.947 . . . . 0.0 112.573 179.458 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.706 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.0 t -89.19 160.11 17.13 Favored 'General case' 0 N--CA 1.468 0.44 0 O-C-N 123.202 0.314 . . . . 0.0 110.939 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.42 ' O ' HD12 ' A' ' 23' ' ' LEU . 73.5 m -79.82 108.27 8.67 Favored Pre-proline 0 CA--C 1.544 0.744 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.913 -179.589 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.46 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 75.8 Cg_endo -83.45 177.92 6.05 Favored 'Trans proline' 0 C--N 1.372 1.815 0 C-N-CA 122.525 2.15 . . . . 0.0 113.011 179.479 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.27 -39.05 2.86 Favored Glycine 0 C--N 1.34 0.771 0 C-N-CA 121.389 -0.434 . . . . 0.0 112.924 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.2 mt -90.25 -36.81 14.51 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 122.481 0.312 . . . . 0.0 111.468 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.1 53.05 0.23 Allowed Glycine 0 C--N 1.339 0.719 0 O-C-N 123.54 0.525 . . . . 0.0 112.338 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.451 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 18.3 mt -114.75 148.98 37.61 Favored 'General case' 0 C--O 1.235 0.317 0 O-C-N 123.686 0.286 . . . . 0.0 110.945 -179.648 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.422 ' O ' ' HA ' ' A' ' 34' ' ' CYS . 10.0 t -138.79 151.99 47.52 Favored 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.312 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.706 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 59.6 m -96.94 121.64 39.04 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.52 179.486 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.7 mt -127.69 123.69 23.08 Favored Pre-proline 0 CA--C 1.546 0.799 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.332 -179.758 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.426 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -76.01 -41.42 0.96 Allowed 'Cis proline' 0 C--N 1.374 1.903 0 C-N-CA 124.691 -0.962 . . . . 0.0 112.602 0.037 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.53 32.02 9.81 Favored Glycine 0 C--N 1.342 0.886 0 O-C-N 123.545 0.528 . . . . 0.0 113.062 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.426 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -141.86 81.17 14.94 Favored Pre-proline 0 CA--C 1.547 0.854 0 CA-C-N 116.65 0.225 . . . . 0.0 111.489 179.713 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.577 ' O ' HG22 ' A' ' 12' ' ' VAL . 76.3 Cg_endo -88.09 -26.0 6.19 Favored 'Cis proline' 0 C--N 1.371 1.719 0 C-N-CA 124.617 -0.993 . . . . 0.0 113.486 -0.326 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -93.68 156.71 16.54 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.637 -179.061 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.43 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.91 -172.5 24.22 Favored Glycine 0 C--N 1.337 0.59 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.436 179.558 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.486 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.3 OUTLIER -125.59 144.81 50.41 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.612 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . 0.422 ' HA ' ' O ' ' A' ' 24' ' ' THR . 57.0 m -89.44 114.3 25.76 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-O 121.094 0.473 . . . . 0.0 111.836 -179.676 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' TYR . . . . . 0.451 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 37.8 m-85 -124.92 157.74 35.28 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.418 179.302 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.55 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 19.8 t80 -92.85 133.03 36.48 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.959 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.251 1.146 0 CA-C-O 118.463 -0.78 . . . . 0.0 110.873 179.844 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.43 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.7 p . . . . . 0 C--O 1.235 0.328 0 CA-C-O 120.494 0.187 . . . . 0.0 110.874 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.15 151.15 20.53 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.755 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . 0.417 ' O ' ' HG2' ' A' ' 8' ' ' GLU . 17.4 p90 -97.8 174.42 6.61 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.733 179.206 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.582 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 16.4 tt0 -63.06 130.52 45.05 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.253 0.621 . . . . 0.0 112.382 -179.308 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.1 9.09 46.08 Favored Glycine 0 C--N 1.339 0.696 0 CA-C-N 115.663 -0.699 . . . . 0.0 114.78 178.483 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . 0.417 ' HG2' ' O ' ' A' ' 5' ' ' PHE . 6.4 pt-20 -134.93 176.94 8.2 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 117.708 0.754 . . . . 0.0 111.565 179.703 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.445 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 40.0 p -90.79 143.69 26.47 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.199 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.5 p -134.55 131.37 37.85 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.957 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -100.61 118.88 37.67 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.842 179.576 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.603 HG22 ' O ' ' A' ' 30' ' ' PRO . 30.4 m -71.7 10.31 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -178.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.512 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.1 OUTLIER -100.99 -35.12 9.49 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.254 -179.428 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.512 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.9 p90 -146.84 -26.7 0.4 Allowed 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 -178.494 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.0 t80 -122.3 86.3 47.76 Favored Pre-proline 0 CA--C 1.545 0.767 0 N-CA-C 111.725 0.269 . . . . 0.0 111.725 -178.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.43 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.4 Cg_endo -77.98 179.08 6.84 Favored 'Trans proline' 0 C--N 1.369 1.633 0 C-N-CA 122.279 1.986 . . . . 0.0 112.729 179.435 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.71 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.8 t -89.21 160.09 17.13 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 123.157 0.285 . . . . 0.0 110.87 179.756 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 72.6 m -79.99 108.64 9.74 Favored Pre-proline 0 CA--C 1.544 0.74 0 N-CA-C 111.96 0.356 . . . . 0.0 111.96 -179.356 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.436 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.6 Cg_endo -83.03 177.2 6.87 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 122.485 2.123 . . . . 0.0 112.905 179.316 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.21 -39.83 2.62 Favored Glycine 0 C--N 1.34 0.762 0 C-N-CA 121.312 -0.47 . . . . 0.0 112.992 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.1 mt -89.58 -38.16 14.16 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 122.435 0.294 . . . . 0.0 111.477 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.28 51.6 0.23 Allowed Glycine 0 C--N 1.34 0.751 0 CA-C-N 116.17 -0.468 . . . . 0.0 112.461 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.462 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.3 mt -114.88 150.74 35.13 Favored 'General case' 0 C--O 1.235 0.309 0 O-C-N 123.611 0.242 . . . . 0.0 110.958 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 t -139.73 154.26 47.4 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.305 -179.752 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.71 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.0 m -97.61 122.41 40.65 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.492 179.409 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.427 ' H ' ' H ' ' A' ' 33' ' ' THR . 9.6 mt -127.35 123.78 23.4 Favored Pre-proline 0 CA--C 1.545 0.765 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.4 -179.786 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.439 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.3 Cg_exo -76.0 -40.56 1.14 Allowed 'Cis proline' 0 C--N 1.375 1.934 0 C-N-CA 124.636 -0.985 . . . . 0.0 112.552 0.026 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.72 34.27 8.55 Favored Glycine 0 C--N 1.342 0.895 0 CA-C-N 115.915 -0.584 . . . . 0.0 113.045 179.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.439 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -144.71 79.96 11.92 Favored Pre-proline 0 CA--C 1.547 0.86 0 CA-C-N 116.68 0.24 . . . . 0.0 111.508 179.705 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.603 ' O ' HG22 ' A' ' 12' ' ' VAL . 65.6 Cg_endo -89.15 -26.0 5.47 Favored 'Cis proline' 0 C--N 1.37 1.692 0 C-N-CA 124.714 -0.952 . . . . 0.0 113.457 -0.348 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -89.75 155.25 19.32 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.349 -179.474 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.445 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.31 -174.49 26.15 Favored Glycine 0 C--N 1.335 0.493 0 CA-C-N 115.371 -0.831 . . . . 0.0 112.396 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.489 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -126.15 143.41 51.14 Favored 'General case' 0 C--O 1.234 0.258 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.511 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 45.9 m -88.56 112.52 23.13 Favored 'General case' 0 C--O 1.24 0.582 0 O-C-N 123.409 0.443 . . . . 0.0 111.681 -179.697 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' TYR . . . . . 0.462 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.9 m-85 -125.56 159.85 31.04 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.592 179.416 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.582 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.3 t80 -93.49 134.96 35.2 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.964 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.2 mt . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.145 -0.931 . . . . 0.0 110.903 179.751 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.272 . . . . . . . 0 C--O 1.235 0.327 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -106.75 -53.69 0.7 Allowed Glycine 0 C--N 1.336 0.541 0 O-C-N 123.685 0.616 . . . . 0.0 112.56 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.413 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.0 p -99.18 155.32 17.54 Favored 'General case' 0 C--O 1.235 0.325 0 C-N-CA 122.306 0.242 . . . . 0.0 110.993 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.01 151.14 20.62 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.781 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.6 p90 -98.93 171.82 7.82 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.856 179.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.585 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.2 tt0 -59.94 129.04 39.87 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 123.362 0.665 . . . . 0.0 112.428 -179.267 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.29 -20.86 29.84 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 115.572 -0.74 . . . . 0.0 114.388 178.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -107.02 177.47 4.85 Favored 'General case' 0 CA--C 1.539 0.558 0 CA-C-N 117.42 0.61 . . . . 0.0 111.828 -179.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 40.8 p -91.5 146.95 23.38 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.09 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.6 p -134.84 128.26 32.37 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.975 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -98.01 119.66 37.03 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.702 179.419 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 30' ' ' PRO . 24.2 m -72.41 10.35 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -178.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.406 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.7 tp60 -104.76 -29.22 10.69 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.637 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.406 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.94 -26.61 0.26 Allowed 'General case' 0 N--CA 1.477 0.899 0 N-CA-C 112.907 0.706 . . . . 0.0 112.907 -178.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.2 t80 -125.22 87.22 55.87 Favored Pre-proline 0 CA--C 1.545 0.779 0 N-CA-C 111.687 0.254 . . . . 0.0 111.687 -178.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.413 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.3 Cg_endo -77.88 176.84 9.52 Favored 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.311 2.007 . . . . 0.0 112.734 179.427 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.701 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -88.54 160.88 17.25 Favored 'General case' 0 N--CA 1.468 0.441 0 O-C-N 123.201 0.313 . . . . 0.0 110.809 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.9 m -79.94 108.45 9.23 Favored Pre-proline 0 CA--C 1.544 0.728 0 N-CA-C 112.078 0.399 . . . . 0.0 112.078 -179.284 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.448 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.1 Cg_endo -83.51 177.66 6.2 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.469 2.113 . . . . 0.0 112.896 179.341 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.82 -40.22 2.5 Favored Glycine 0 C--N 1.339 0.741 0 C-N-CA 121.349 -0.453 . . . . 0.0 112.985 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.8 mt -88.76 -38.52 14.62 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 122.456 0.302 . . . . 0.0 111.458 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.55 51.65 0.2 Allowed Glycine 0 C--N 1.338 0.69 0 O-C-N 123.475 0.485 . . . . 0.0 112.53 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.473 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 22.0 mt -115.72 149.17 38.85 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-O 120.618 0.247 . . . . 0.0 110.858 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t -138.93 154.84 48.37 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.201 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.701 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 65.7 m -97.19 123.28 40.92 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.709 179.548 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.47 ' H ' ' H ' ' A' ' 33' ' ' THR . 12.2 mt -127.38 122.85 23.01 Favored Pre-proline 0 CA--C 1.545 0.775 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.231 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.435 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.3 Cg_exo -75.42 -40.82 1.09 Allowed 'Cis proline' 0 C--N 1.375 1.922 0 C-N-CA 124.697 -0.96 . . . . 0.0 112.648 0.133 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.03 33.85 8.65 Favored Glycine 0 C--N 1.343 0.918 0 CA-C-N 115.993 -0.549 . . . . 0.0 113.085 179.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.435 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.8 p30 -147.06 79.63 9.84 Favored Pre-proline 0 CA--C 1.546 0.824 0 CA-C-N 116.641 0.221 . . . . 0.0 111.427 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.595 ' O ' HG22 ' A' ' 12' ' ' VAL . 56.1 Cg_endo -89.8 -27.4 3.9 Favored 'Cis proline' 0 C--N 1.37 1.671 0 C-N-CA 124.723 -0.949 . . . . 0.0 113.477 -0.368 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -86.11 149.59 25.02 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.633 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -151.13 -179.15 26.61 Favored Glycine 0 C--N 1.335 0.521 0 CA-C-N 115.654 -0.703 . . . . 0.0 112.627 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.47 ' H ' ' H ' ' A' ' 26' ' ' ILE . 0.9 OUTLIER -123.33 140.9 52.54 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 179.349 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.9 m -86.46 110.6 19.86 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 121.015 0.436 . . . . 0.0 111.698 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . 0.473 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 32.8 m-85 -125.47 158.37 34.61 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.624 179.546 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.585 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.1 t80 -92.89 135.65 33.95 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.943 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.6 mt . . . . . 0 C--O 1.249 1.059 0 CA-C-O 118.095 -0.955 . . . . 0.0 110.871 179.806 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.27 . . . . . . . 0 C--O 1.235 0.334 0 N-CA-C 112.46 0.541 . . . . 0.0 112.46 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.62 -62.15 0.62 Allowed Glycine 0 C--N 1.34 0.767 0 O-C-N 123.433 0.458 . . . . 0.0 112.452 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.423 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.5 p -100.29 154.49 18.44 Favored 'General case' 0 C--O 1.235 0.305 0 O-C-N 123.613 0.243 . . . . 0.0 110.961 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.07 152.88 19.74 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.757 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 18.6 p90 -98.23 174.08 6.68 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.725 179.161 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.565 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.3 tt0 -63.89 131.3 47.31 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 123.227 0.611 . . . . 0.0 112.348 -179.282 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.72 3.97 52.29 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-N 115.564 -0.744 . . . . 0.0 114.759 178.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -130.55 177.91 7.02 Favored 'General case' 0 CA--C 1.54 0.558 0 CA-C-N 117.636 0.718 . . . . 0.0 111.605 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.423 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 42.5 p -90.4 146.11 24.41 Favored 'General case' 0 C--N 1.343 0.315 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.293 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.9 p -136.47 128.01 28.69 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.782 -179.613 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -98.22 119.57 37.11 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.87 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 30' ' ' PRO . 23.1 m -72.38 10.02 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 N-CA-C 112.963 0.727 . . . . 0.0 112.963 -178.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.429 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 15.0 tt0 -99.81 -30.23 12.17 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.206 -179.572 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.429 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.1 p90 -154.01 -26.77 0.13 Allowed 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 112.729 0.64 . . . . 0.0 112.729 -178.55 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -120.43 85.23 37.01 Favored Pre-proline 0 CA--C 1.544 0.749 0 N-CA-C 111.613 0.227 . . . . 0.0 111.613 -178.678 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.423 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.8 Cg_endo -78.2 179.12 6.79 Favored 'Trans proline' 0 C--N 1.369 1.65 0 C-N-CA 122.306 2.004 . . . . 0.0 112.664 179.478 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.709 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -89.62 159.82 16.96 Favored 'General case' 0 N--CA 1.467 0.402 0 O-C-N 123.163 0.29 . . . . 0.0 110.917 179.788 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.2 m -79.97 108.56 9.51 Favored Pre-proline 0 CA--C 1.545 0.76 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.881 -179.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.445 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.2 Cg_endo -83.27 177.42 6.54 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 122.521 2.147 . . . . 0.0 112.959 179.376 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.27 -40.12 2.53 Favored Glycine 0 C--N 1.34 0.751 0 C-N-CA 121.336 -0.459 . . . . 0.0 113.015 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.4 -38.91 13.76 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 122.462 0.305 . . . . 0.0 111.494 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.06 50.51 0.21 Allowed Glycine 0 C--N 1.339 0.723 0 O-C-N 123.479 0.487 . . . . 0.0 112.485 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.461 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.7 mt -113.87 150.33 33.77 Favored 'General case' 0 C--O 1.235 0.324 0 O-C-N 123.661 0.271 . . . . 0.0 110.854 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 t -139.28 154.59 47.98 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.347 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.709 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 56.9 m -97.49 123.17 41.25 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.822 -0.627 . . . . 0.0 110.595 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.468 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.9 mt -127.53 123.35 23.07 Favored Pre-proline 0 CA--C 1.544 0.741 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.238 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.429 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.2 Cg_exo -75.69 -40.85 1.08 Allowed 'Cis proline' 0 C--N 1.375 1.927 0 C-N-CA 124.69 -0.962 . . . . 0.0 112.527 0.085 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.19 33.49 8.77 Favored Glycine 0 C--N 1.342 0.915 0 CA-C-N 115.964 -0.562 . . . . 0.0 113.147 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.429 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.8 p30 -147.06 79.86 9.73 Favored Pre-proline 0 CA--C 1.546 0.821 0 CA-C-N 116.649 0.224 . . . . 0.0 111.509 179.64 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.595 ' O ' HG22 ' A' ' 12' ' ' VAL . 57.5 Cg_endo -89.62 -27.23 4.11 Favored 'Cis proline' 0 C--N 1.37 1.681 0 C-N-CA 124.666 -0.973 . . . . 0.0 113.496 -0.367 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -86.83 150.03 24.41 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.559 -179.49 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.423 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -151.6 -178.09 26.01 Favored Glycine 0 C--N 1.336 0.535 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.45 179.453 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.471 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -125.75 142.25 51.6 Favored 'General case' 0 C--O 1.234 0.278 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 179.328 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 54.3 m -87.64 112.23 22.1 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-O 121.093 0.473 . . . . 0.0 111.783 -179.601 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . 0.461 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 34.8 m-85 -125.89 159.43 32.56 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.538 179.361 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.565 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.6 t80 -93.38 135.21 34.84 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.951 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.129 -0.939 . . . . 0.0 110.857 179.738 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . 0.46 ' HB2' ' OH ' ' A' ' 15' ' ' TYR 0.273 . . . . . . . 0 C--O 1.234 0.287 0 N-CA-C 112.177 0.436 . . . . 0.0 112.177 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -106.99 -56.19 0.63 Allowed Glycine 0 C--N 1.336 0.566 0 CA-C-N 115.841 -0.618 . . . . 0.0 112.498 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.416 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.2 p -100.39 154.84 18.19 Favored 'General case' 0 C--O 1.235 0.329 0 O-C-N 123.617 0.245 . . . . 0.0 110.999 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.9 151.62 20.45 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.701 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.9 p90 -98.75 172.82 7.21 Favored 'General case' 0 CA--C 1.536 0.427 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.873 179.3 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.588 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 14.4 tt0 -61.04 130.31 45.74 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 123.326 0.651 . . . . 0.0 112.334 -179.386 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.08 -25.62 19.77 Favored Glycine 0 C--N 1.338 0.669 0 CA-C-N 115.656 -0.702 . . . . 0.0 114.179 178.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -103.06 178.67 4.49 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 117.273 0.536 . . . . 0.0 111.851 -179.159 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 43.8 p -92.8 151.56 19.94 Favored 'General case' 0 C--N 1.344 0.348 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.221 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 p -139.48 130.49 26.38 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.863 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -100.14 119.88 39.01 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.597 179.322 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 30' ' ' PRO . 25.5 m -71.32 9.43 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 -178.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.501 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -100.44 -32.81 10.63 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.3 -179.496 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.501 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.1 p90 -149.93 -26.8 0.26 Allowed 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 112.897 0.703 . . . . 0.0 112.897 -178.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.46 ' OH ' ' HB2' ' A' ' 1' ' ' PCA . 6.8 t80 -121.09 85.53 41.26 Favored Pre-proline 0 CA--C 1.545 0.757 0 N-CA-C 111.747 0.277 . . . . 0.0 111.747 -178.663 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.416 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.1 Cg_endo -78.06 177.16 9.12 Favored 'Trans proline' 0 C--N 1.369 1.607 0 C-N-CA 122.202 1.935 . . . . 0.0 112.67 179.385 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.712 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 4.6 t -88.27 160.73 17.54 Favored 'General case' 0 N--CA 1.467 0.418 0 O-C-N 123.186 0.304 . . . . 0.0 110.796 179.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.0 m -79.97 108.67 9.77 Favored Pre-proline 0 CA--C 1.545 0.768 0 N-CA-C 111.99 0.367 . . . . 0.0 111.99 -179.18 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 76.0 Cg_endo -83.22 177.65 6.4 Favored 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.5 2.133 . . . . 0.0 112.918 179.286 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.94 -41.09 2.25 Favored Glycine 0 C--N 1.34 0.77 0 C-N-CA 121.384 -0.436 . . . . 0.0 112.928 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.1 -38.86 14.03 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 122.486 0.314 . . . . 0.0 111.431 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.442 ' O ' ' HA ' ' A' ' 36' ' ' TYR . . . 124.27 53.41 0.19 Allowed Glycine 0 C--N 1.339 0.715 0 O-C-N 123.521 0.513 . . . . 0.0 112.512 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.475 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 23.7 mt -117.64 147.48 42.84 Favored 'General case' 0 C--O 1.234 0.267 0 O-C-N 123.623 0.249 . . . . 0.0 110.785 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -139.3 154.51 47.94 Favored 'General case' 0 CA--C 1.535 0.404 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.391 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.712 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 89.7 m -97.35 118.3 33.5 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.52 179.496 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 11.6 mt -122.75 122.23 27.22 Favored Pre-proline 0 CA--C 1.545 0.756 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.235 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.424 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.42 -40.72 1.12 Allowed 'Cis proline' 0 C--N 1.373 1.843 0 C-N-CA 124.695 -0.961 . . . . 0.0 112.701 0.232 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.13 34.43 8.8 Favored Glycine 0 C--N 1.342 0.868 0 O-C-N 123.588 0.555 . . . . 0.0 112.928 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.424 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -145.74 79.58 11.11 Favored Pre-proline 0 CA--C 1.548 0.876 0 C-N-CA 122.204 0.202 . . . . 0.0 111.423 179.724 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.595 ' O ' HG22 ' A' ' 12' ' ' VAL . 56.8 Cg_endo -88.79 -27.76 4.18 Favored 'Cis proline' 0 C--N 1.37 1.666 0 C-N-CA 124.739 -0.942 . . . . 0.0 113.486 -0.254 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -86.9 149.34 24.87 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.66 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.81 160.29 30.22 Favored Glycine 0 C--N 1.335 0.52 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.137 179.335 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.426 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.5 OUTLIER -99.1 143.96 28.78 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.823 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 18.8 m -88.31 110.04 20.45 Favored 'General case' 0 C--O 1.238 0.476 0 O-C-N 123.464 0.477 . . . . 0.0 111.528 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . 0.475 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 38.1 m-85 -124.73 160.13 29.31 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.289 -0.868 . . . . 0.0 110.744 179.628 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.588 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 15.8 t80 -93.07 137.23 32.61 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.872 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 14.6 mt . . . . . 0 C--O 1.251 1.172 0 CA-C-O 118.531 -0.747 . . . . 0.0 110.876 179.742 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.273 . . . . . . . 0 C--O 1.234 0.285 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -154.78 54.35 0.43 Allowed Glycine 0 C--N 1.337 0.613 0 O-C-N 123.713 0.633 . . . . 0.0 112.507 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.417 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.4 p -104.1 154.91 19.16 Favored 'General case' 0 C--O 1.235 0.331 0 O-C-N 123.609 0.241 . . . . 0.0 110.989 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.406 ' HB1' ' HG3' ' A' ' 8' ' ' GLU . . . -92.52 150.19 20.91 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.654 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.5 p90 -98.65 171.91 7.82 Favored 'General case' 0 CA--C 1.537 0.458 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.848 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.58 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 14.8 tt0 -59.53 128.63 37.96 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 123.305 0.642 . . . . 0.0 112.389 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.3 -21.02 27.34 Favored Glycine 0 C--N 1.339 0.718 0 CA-C-N 115.66 -0.7 . . . . 0.0 114.421 178.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.406 ' HG3' ' HB1' ' A' ' 4' ' ' ALA . 6.8 pt-20 -107.48 177.39 4.85 Favored 'General case' 0 CA--C 1.541 0.604 0 CA-C-N 117.43 0.615 . . . . 0.0 111.835 -179.222 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 53.0 m -91.47 145.4 24.65 Favored 'General case' 0 C--N 1.343 0.312 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.079 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.7 p -134.0 129.09 35.65 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.93 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.27 119.93 39.15 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.818 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.603 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.5 m -72.4 10.48 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 112.994 0.738 . . . . 0.0 112.994 -178.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.401 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.6 tp60 -104.03 -29.31 10.98 Favored 'General case' 0 CA--C 1.535 0.377 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.615 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.401 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.84 -26.74 0.26 Allowed 'General case' 0 N--CA 1.476 0.874 0 N-CA-C 112.851 0.686 . . . . 0.0 112.851 -178.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.402 ' HE2' ' HB2' ' A' ' 4' ' ' ALA . 12.6 t80 -125.75 88.33 54.4 Favored Pre-proline 0 CA--C 1.545 0.775 0 N-CA-C 111.702 0.26 . . . . 0.0 111.702 -178.614 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.417 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.8 Cg_endo -77.74 176.17 10.34 Favored 'Trans proline' 0 C--N 1.37 1.686 0 C-N-CA 122.27 1.98 . . . . 0.0 112.708 179.333 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.683 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.1 t -88.26 161.36 17.23 Favored 'General case' 0 N--CA 1.467 0.399 0 O-C-N 123.208 0.318 . . . . 0.0 110.841 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.3 m -79.97 108.47 9.3 Favored Pre-proline 0 CA--C 1.544 0.745 0 N-CA-C 112.03 0.381 . . . . 0.0 112.03 -179.276 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.448 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.9 Cg_endo -83.51 177.53 6.29 Favored 'Trans proline' 0 C--N 1.371 1.756 0 C-N-CA 122.512 2.142 . . . . 0.0 112.906 179.369 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.0 -40.56 2.38 Favored Glycine 0 C--N 1.34 0.775 0 C-N-CA 121.313 -0.47 . . . . 0.0 113.003 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.08 -38.91 14.01 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 122.424 0.29 . . . . 0.0 111.453 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.92 51.96 0.2 Allowed Glycine 0 C--N 1.339 0.719 0 O-C-N 123.466 0.479 . . . . 0.0 112.568 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.459 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 22.0 mt -115.26 149.32 37.96 Favored 'General case' 0 C--O 1.234 0.286 0 O-C-N 123.654 0.267 . . . . 0.0 110.847 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -138.95 154.69 48.34 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.266 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.683 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 67.9 m -97.24 123.31 40.99 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.64 179.538 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.445 ' H ' ' H ' ' A' ' 33' ' ' THR . 12.0 mt -126.63 122.94 23.77 Favored Pre-proline 0 CA--C 1.545 0.775 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.279 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.422 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.85 -40.89 1.06 Allowed 'Cis proline' 0 C--N 1.375 1.929 0 C-N-CA 124.595 -1.002 . . . . 0.0 112.644 0.111 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.08 33.07 9.14 Favored Glycine 0 C--N 1.342 0.883 0 O-C-N 123.548 0.53 . . . . 0.0 112.848 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.422 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.8 79.08 12.4 Favored Pre-proline 0 CA--C 1.547 0.843 0 C-N-CA 122.193 0.197 . . . . 0.0 111.291 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.603 ' O ' HG22 ' A' ' 12' ' ' VAL . 58.6 Cg_endo -89.89 -26.71 4.36 Favored 'Cis proline' 0 C--N 1.37 1.682 0 C-N-CA 124.708 -0.955 . . . . 0.0 113.682 -0.35 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.06 152.56 21.1 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.933 -179.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.41 -174.2 24.2 Favored Glycine 0 C--N 1.337 0.637 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.659 179.591 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.499 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -124.21 143.85 50.28 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.589 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.6 m -88.11 110.24 20.5 Favored 'General case' 0 C--O 1.238 0.448 0 O-C-N 123.44 0.462 . . . . 0.0 111.571 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . 0.459 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 33.0 m-85 -124.76 159.1 31.71 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.657 179.603 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.58 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.3 t80 -93.18 136.11 33.75 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.96 -179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.7 mt . . . . . 0 C--O 1.251 1.146 0 CA-C-O 118.486 -0.769 . . . . 0.0 110.892 179.775 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.271 . . . . . . . 0 C--O 1.235 0.32 0 N-CA-C 112.144 0.424 . . . . 0.0 112.144 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 171.44 54.7 0.04 OUTLIER Glycine 0 C--N 1.336 0.582 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.55 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.424 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.7 p -100.54 154.63 18.4 Favored 'General case' 0 C--O 1.235 0.324 0 O-C-N 123.67 0.277 . . . . 0.0 110.924 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.76 152.03 20.35 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.827 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 19.1 p90 -98.42 173.92 6.72 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.626 179.165 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.581 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 17.5 tt0 -63.82 130.0 42.38 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 123.213 0.605 . . . . 0.0 112.359 -179.326 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 102.06 9.61 41.89 Favored Glycine 0 C--N 1.339 0.717 0 CA-C-N 115.662 -0.699 . . . . 0.0 114.764 178.627 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -135.23 177.39 7.85 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 117.676 0.738 . . . . 0.0 111.535 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 52.4 m -90.82 141.65 28.59 Favored 'General case' 0 C--N 1.343 0.314 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.137 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.5 p -133.17 128.8 36.8 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.844 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.33 119.88 39.09 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.868 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.604 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.3 m -72.78 12.2 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.031 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -178.823 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.7 tp-100 -105.51 -29.91 9.88 Favored 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 116.593 -0.276 . . . . 0.0 111.559 -179.391 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -148.78 -26.68 0.31 Allowed 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -178.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 8.8 t80 -126.21 88.19 54.77 Favored Pre-proline 0 CA--C 1.546 0.805 0 N-CA-C 111.696 0.258 . . . . 0.0 111.696 -178.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.424 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.4 Cg_endo -77.91 177.89 8.25 Favored 'Trans proline' 0 C--N 1.369 1.635 0 C-N-CA 122.31 2.007 . . . . 0.0 112.724 179.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.698 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.9 t -90.09 160.13 16.46 Favored 'General case' 0 N--CA 1.468 0.447 0 O-C-N 123.218 0.324 . . . . 0.0 110.799 179.802 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 76.3 m -80.06 108.45 9.34 Favored Pre-proline 0 CA--C 1.545 0.774 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.93 -179.322 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.45 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 80.5 Cg_endo -83.41 177.44 6.43 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.465 2.11 . . . . 0.0 112.961 179.296 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.04 -40.44 2.42 Favored Glycine 0 C--N 1.339 0.741 0 O-C-N 123.434 0.459 . . . . 0.0 113.016 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.07 -39.13 13.85 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 122.437 0.295 . . . . 0.0 111.52 -179.823 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.47 50.66 0.2 Allowed Glycine 0 C--N 1.339 0.736 0 O-C-N 123.505 0.503 . . . . 0.0 112.51 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.442 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.8 mt -113.86 150.21 33.94 Favored 'General case' 0 C--O 1.235 0.329 0 O-C-N 123.617 0.245 . . . . 0.0 110.846 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 t -139.58 154.27 47.58 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.326 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.698 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.9 m -97.33 123.3 41.1 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.582 179.366 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.453 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.8 mt -126.9 123.32 23.62 Favored Pre-proline 0 CA--C 1.545 0.772 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.333 -179.77 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.419 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.9 -40.84 1.07 Allowed 'Cis proline' 0 C--N 1.375 1.949 0 C-N-CA 124.66 -0.975 . . . . 0.0 112.554 0.055 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.98 32.45 9.88 Favored Glycine 0 C--N 1.341 0.859 0 O-C-N 123.621 0.576 . . . . 0.0 112.899 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.419 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -144.34 78.9 13.14 Favored Pre-proline 0 CA--C 1.546 0.817 0 C-N-CA 122.245 0.218 . . . . 0.0 111.313 179.776 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.604 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.2 Cg_endo -90.02 -26.5 4.46 Favored 'Cis proline' 0 C--N 1.369 1.634 0 C-N-CA 124.74 -0.942 . . . . 0.0 113.668 -0.306 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.85 152.78 20.62 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.972 -179.362 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.402 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -155.47 -171.84 22.44 Favored Glycine 0 C--N 1.338 0.647 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.589 179.502 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.515 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -127.22 145.33 50.81 Favored 'General case' 0 C--O 1.235 0.316 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 179.553 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 51.6 m -89.22 111.93 22.84 Favored 'General case' 0 C--O 1.24 0.565 0 O-C-N 123.481 0.488 . . . . 0.0 111.627 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . 0.442 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.5 m-85 -125.72 159.76 31.48 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.523 179.423 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.581 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.6 t80 -93.35 136.03 34.01 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.005 -179.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.0 mt . . . . . 0 C--O 1.251 1.148 0 CA-C-O 118.502 -0.761 . . . . 0.0 110.891 179.745 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.273 . . . . . . . 0 C--O 1.235 0.314 0 N-CA-C 112.149 0.425 . . . . 0.0 112.149 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -105.17 -54.74 0.74 Allowed Glycine 0 C--N 1.336 0.571 0 O-C-N 123.737 0.648 . . . . 0.0 112.53 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.415 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.1 p -99.25 155.06 17.69 Favored 'General case' 0 C--O 1.235 0.314 0 O-C-N 123.593 0.231 . . . . 0.0 111.003 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.83 150.48 21.05 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.676 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.9 p90 -98.7 171.88 7.83 Favored 'General case' 0 CA--C 1.536 0.44 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.93 179.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.587 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.0 tt0 -59.98 128.63 37.82 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.352 0.661 . . . . 0.0 112.381 -179.312 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.25 -20.89 27.62 Favored Glycine 0 C--N 1.338 0.68 0 CA-C-N 115.688 -0.687 . . . . 0.0 114.421 178.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -107.29 177.47 4.83 Favored 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 117.444 0.622 . . . . 0.0 111.813 -179.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.7 m -91.42 144.9 25.1 Favored 'General case' 0 C--N 1.344 0.337 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.063 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.9 p -133.61 128.45 35.17 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.974 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.07 120.08 39.3 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.754 179.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.608 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.0 m -72.28 10.38 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 113.023 0.749 . . . . 0.0 113.023 -178.776 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.407 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 1.6 tp-100 -104.12 -29.69 10.7 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.661 -179.358 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.407 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.48 -26.63 0.28 Allowed 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -178.791 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.0 t80 -125.32 87.79 55.1 Favored Pre-proline 0 CA--C 1.546 0.803 0 N-CA-C 111.652 0.242 . . . . 0.0 111.652 -178.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.415 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.7 Cg_endo -77.66 175.4 11.29 Favored 'Trans proline' 0 C--N 1.369 1.632 0 C-N-CA 122.304 2.003 . . . . 0.0 112.706 179.444 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.681 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -88.46 161.06 17.24 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.848 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 72.0 m -79.91 108.6 9.56 Favored Pre-proline 0 CA--C 1.544 0.738 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.206 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.5 Cg_endo -83.43 177.63 6.28 Favored 'Trans proline' 0 C--N 1.371 1.753 0 C-N-CA 122.491 2.128 . . . . 0.0 112.933 179.262 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.07 -40.01 2.57 Favored Glycine 0 C--N 1.339 0.727 0 C-N-CA 121.386 -0.435 . . . . 0.0 112.969 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.9 mt -88.83 -38.64 14.44 Favored 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 122.488 0.315 . . . . 0.0 111.466 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.19 51.26 0.21 Allowed Glycine 0 C--N 1.339 0.721 0 O-C-N 123.481 0.488 . . . . 0.0 112.539 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.468 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.6 mt -114.58 149.19 36.92 Favored 'General case' 0 C--O 1.235 0.308 0 O-C-N 123.65 0.265 . . . . 0.0 110.881 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t -138.85 154.34 48.41 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.201 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.681 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 68.3 m -97.0 123.23 40.66 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.659 179.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.449 ' H ' ' H ' ' A' ' 33' ' ' THR . 12.7 mt -125.92 122.63 24.46 Favored Pre-proline 0 CA--C 1.545 0.768 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.26 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.43 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.51 -41.08 1.03 Allowed 'Cis proline' 0 C--N 1.375 1.923 0 C-N-CA 124.664 -0.973 . . . . 0.0 112.641 0.072 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.78 31.84 9.73 Favored Glycine 0 C--N 1.341 0.847 0 O-C-N 123.548 0.53 . . . . 0.0 113.043 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.43 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.8 p30 -145.42 80.12 11.08 Favored Pre-proline 0 CA--C 1.547 0.841 0 C-N-CA 122.131 0.173 . . . . 0.0 111.229 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.608 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.1 Cg_endo -89.65 -26.92 4.33 Favored 'Cis proline' 0 C--N 1.369 1.636 0 C-N-CA 124.676 -0.968 . . . . 0.0 113.681 -0.321 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -90.97 152.45 20.69 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.912 -179.273 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.44 -174.48 24.54 Favored Glycine 0 C--N 1.338 0.652 0 CA-C-N 115.442 -0.799 . . . . 0.0 112.634 179.593 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.496 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -123.79 143.93 50.01 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.561 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.6 m -88.08 110.23 20.48 Favored 'General case' 0 C--O 1.238 0.468 0 O-C-N 123.477 0.485 . . . . 0.0 111.588 -179.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . 0.468 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 33.0 m-85 -125.2 158.78 33.15 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 115.178 -0.919 . . . . 0.0 110.65 179.586 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.587 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.8 t80 -93.02 136.47 33.25 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.912 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.2 mt . . . . . 0 C--O 1.251 1.181 0 CA-C-O 118.478 -0.772 . . . . 0.0 110.878 179.754 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.272 . . . . . . . 0 C--O 1.235 0.307 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 170.42 51.35 0.04 OUTLIER Glycine 0 C--N 1.337 0.592 0 CA-C-N 115.791 -0.641 . . . . 0.0 112.576 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.424 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.1 p -129.03 155.27 45.67 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 122.298 0.239 . . . . 0.0 110.864 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.28 152.8 18.95 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.828 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.458 ' O ' ' HG2' ' A' ' 8' ' ' GLU . 14.2 p90 -97.64 174.99 6.36 Favored 'General case' 0 CA--C 1.537 0.464 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.615 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.576 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.4 tt0 -65.23 130.99 45.35 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 123.095 0.558 . . . . 0.0 112.362 -179.287 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 100.08 12.85 38.34 Favored Glycine 0 C--N 1.339 0.723 0 CA-C-N 115.628 -0.714 . . . . 0.0 114.661 178.623 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.458 ' HG2' ' O ' ' A' ' 5' ' ' PHE . 8.8 pt-20 -136.87 175.96 9.14 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 117.592 0.696 . . . . 0.0 111.455 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.418 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 53.0 m -90.85 138.39 31.63 Favored 'General case' 0 C--N 1.343 0.299 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.132 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.9 p -131.52 128.18 38.78 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.837 -179.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -97.07 118.86 34.42 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.02 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.611 HG22 ' O ' ' A' ' 30' ' ' PRO . 26.8 m -72.45 12.74 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.86 -178.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 5.9 tp60 -106.46 -31.02 8.73 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.518 -179.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.7 p90 -146.87 -27.22 0.4 Allowed 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 112.81 0.67 . . . . 0.0 112.81 -178.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -126.45 88.37 54.48 Favored Pre-proline 0 CA--C 1.545 0.766 0 N-CA-C 111.607 0.225 . . . . 0.0 111.607 -178.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.424 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 62.3 Cg_endo -78.16 177.86 8.27 Favored 'Trans proline' 0 C--N 1.37 1.681 0 C-N-CA 122.348 2.032 . . . . 0.0 112.732 179.366 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.709 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.7 t -88.91 161.15 16.82 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.904 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 75.5 m -79.96 108.49 9.33 Favored Pre-proline 0 CA--C 1.545 0.758 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.87 -179.383 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.442 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 75.7 Cg_endo -83.07 177.52 6.6 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.485 2.123 . . . . 0.0 112.929 179.423 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.81 -40.11 2.53 Favored Glycine 0 C--N 1.34 0.759 0 C-N-CA 121.392 -0.432 . . . . 0.0 112.969 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.86 -39.18 13.22 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 122.408 0.283 . . . . 0.0 111.427 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.01 52.33 0.19 Allowed Glycine 0 C--N 1.339 0.709 0 O-C-N 123.467 0.479 . . . . 0.0 112.497 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.9 mt -115.74 149.79 37.9 Favored 'General case' 0 C--O 1.235 0.319 0 O-C-N 123.584 0.226 . . . . 0.0 110.86 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.438 ' O ' ' HA ' ' A' ' 34' ' ' CYS . 8.8 t -139.36 155.34 47.73 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.353 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.709 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 68.1 m -98.66 118.8 36.2 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.548 179.53 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.5 mt -129.1 126.55 23.13 Favored Pre-proline 0 CA--C 1.544 0.736 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.433 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.478 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 38.3 Cg_endo -68.69 -42.5 0.7 Allowed 'Cis proline' 0 C--N 1.376 2.005 0 C-N-CA 124.597 -1.001 . . . . 0.0 113.453 -0.208 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 82.29 35.56 20.2 Favored Glycine 0 C--N 1.344 1.013 0 O-C-N 123.349 0.406 . . . . 0.0 113.524 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.478 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.8 p30 -148.09 80.81 8.5 Favored Pre-proline 0 CA--C 1.547 0.852 0 CA-C-N 116.653 0.226 . . . . 0.0 111.352 179.744 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.611 ' O ' HG22 ' A' ' 12' ' ' VAL . 58.3 Cg_endo -87.25 -27.73 5.04 Favored 'Cis proline' 0 C--N 1.37 1.684 0 C-N-CA 124.516 -1.035 . . . . 0.0 113.353 -0.246 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -88.73 147.98 24.21 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.675 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.418 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -150.2 -174.27 21.24 Favored Glycine 0 C--N 1.335 0.526 0 CA-C-N 115.624 -0.716 . . . . 0.0 112.674 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.504 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.3 OUTLIER -127.22 143.38 51.26 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.321 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.438 ' HA ' ' O ' ' A' ' 24' ' ' THR . 55.6 m -87.58 114.17 23.94 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-O 121.095 0.474 . . . . 0.0 111.962 -179.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . 0.467 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 43.8 m-85 -126.7 160.22 31.43 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 114.988 -1.006 . . . . 0.0 110.429 179.274 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.576 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.5 t80 -94.07 134.33 36.61 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.979 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.112 -0.947 . . . . 0.0 110.833 179.779 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.268 . . . . . . . 0 CA--C 1.534 0.332 0 N-CA-C 112.493 0.553 . . . . 0.0 112.493 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.15 53.4 1.09 Allowed Glycine 0 C--N 1.341 0.82 0 O-C-N 123.436 0.46 . . . . 0.0 112.541 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.412 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.1 p -128.94 155.09 45.87 Favored 'General case' 0 C--O 1.235 0.315 0 C-N-CA 122.296 0.238 . . . . 0.0 110.928 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.8 151.94 19.73 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.664 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 17.1 p90 -99.05 173.12 6.98 Favored 'General case' 0 CA--C 1.537 0.468 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.839 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.58 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 14.0 tt0 -60.87 130.91 48.83 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.308 0.643 . . . . 0.0 112.284 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 107.62 -25.33 21.54 Favored Glycine 0 C--N 1.337 0.618 0 CA-C-N 115.657 -0.702 . . . . 0.0 114.217 178.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -103.72 178.75 4.47 Favored 'General case' 0 CA--C 1.541 0.608 0 CA-C-N 117.251 0.525 . . . . 0.0 111.833 -179.145 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 51.3 m -93.34 151.1 19.99 Favored 'General case' 0 C--N 1.344 0.362 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.163 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.1 p -139.77 132.2 28.54 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.843 -179.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -99.78 118.42 36.23 Favored 'General case' 0 C--O 1.236 0.387 0 O-C-N 123.635 0.584 . . . . 0.0 110.657 179.366 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 30' ' ' PRO . 30.6 m -71.05 10.45 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -178.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.505 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.1 OUTLIER -101.58 -34.86 9.34 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.204 -179.479 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.505 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.8 p90 -146.72 -27.35 0.4 Allowed 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -178.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.8 t80 -121.79 86.12 45.31 Favored Pre-proline 0 CA--C 1.545 0.77 0 N-CA-C 111.75 0.278 . . . . 0.0 111.75 -178.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.412 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.9 Cg_endo -78.0 176.53 9.87 Favored 'Trans proline' 0 C--N 1.369 1.607 0 C-N-CA 122.251 1.967 . . . . 0.0 112.671 179.356 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.711 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 4.6 t -86.45 162.14 18.27 Favored 'General case' 0 N--CA 1.468 0.452 0 O-C-N 123.203 0.314 . . . . 0.0 110.824 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.7 m -79.94 108.64 9.68 Favored Pre-proline 0 CA--C 1.545 0.756 0 N-CA-C 112.06 0.393 . . . . 0.0 112.06 -179.224 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.436 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 74.7 Cg_endo -83.02 177.67 6.52 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.467 2.111 . . . . 0.0 112.927 179.363 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.49 -41.17 2.24 Favored Glycine 0 C--N 1.339 0.731 0 C-N-CA 121.352 -0.451 . . . . 0.0 112.909 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.27 -39.02 13.78 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 122.464 0.306 . . . . 0.0 111.402 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.422 ' O ' ' HA ' ' A' ' 36' ' ' TYR . . . 124.02 55.05 0.19 Allowed Glycine 0 C--N 1.338 0.69 0 O-C-N 123.509 0.506 . . . . 0.0 112.535 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.476 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 25.4 mt -119.73 147.96 43.97 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-O 120.571 0.224 . . . . 0.0 110.897 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -140.1 155.36 47.04 Favored 'General case' 0 CA--C 1.536 0.434 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.358 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.711 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 91.0 m -98.3 117.42 32.66 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.512 179.446 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.8 mt -127.2 125.82 24.13 Favored Pre-proline 0 CA--C 1.544 0.743 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.348 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.466 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 41.8 Cg_endo -69.18 -41.9 0.82 Allowed 'Cis proline' 0 C--N 1.376 1.985 0 C-N-CA 124.569 -1.013 . . . . 0.0 113.509 -0.038 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 84.42 38.2 10.1 Favored Glycine 0 C--N 1.344 0.991 0 O-C-N 123.376 0.422 . . . . 0.0 113.471 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.466 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.9 p30 -150.92 81.05 6.44 Favored Pre-proline 0 CA--C 1.547 0.859 0 C-N-CA 122.279 0.231 . . . . 0.0 111.232 179.54 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.595 ' O ' HG22 ' A' ' 12' ' ' VAL . 57.0 Cg_endo -87.25 -28.25 4.59 Favored 'Cis proline' 0 C--N 1.37 1.663 0 C-N-CA 124.584 -1.007 . . . . 0.0 113.35 -0.312 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -87.15 148.7 25.08 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.637 -179.608 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.91 158.58 28.93 Favored Glycine 0 C--N 1.335 0.513 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.13 179.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.416 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.2 OUTLIER -97.2 144.15 27.29 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 110.285 -0.265 . . . . 0.0 110.285 179.868 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 19.5 m -88.07 110.94 21.02 Favored 'General case' 0 C--O 1.239 0.528 0 O-C-N 123.428 0.455 . . . . 0.0 111.584 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . 0.476 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 45.7 m-85 -123.55 161.04 25.73 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.703 179.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.58 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.1 t80 -94.15 136.21 34.68 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.872 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.2 mt . . . . . 0 C--O 1.249 1.029 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.847 179.75 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.273 . . . . . . . 0 C--O 1.235 0.337 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -112.31 65.93 0.25 Allowed Glycine 0 C--N 1.337 0.602 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.536 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.425 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.6 p -100.19 154.64 18.28 Favored 'General case' 0 C--O 1.236 0.344 0 O-C-N 123.593 0.231 . . . . 0.0 110.923 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.8 152.11 20.28 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.811 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 18.7 p90 -98.0 174.03 6.76 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.705 179.083 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.58 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.1 tt0 -64.16 130.1 42.6 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 123.186 0.594 . . . . 0.0 112.326 -179.291 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 102.19 9.61 41.51 Favored Glycine 0 C--N 1.339 0.71 0 CA-C-N 115.68 -0.691 . . . . 0.0 114.702 178.659 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -135.16 177.53 7.74 Favored 'General case' 0 CA--C 1.541 0.596 0 CA-C-N 117.707 0.754 . . . . 0.0 111.545 179.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 15.9 t -90.71 141.75 28.47 Favored 'General case' 0 C--N 1.343 0.317 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.941 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.5 p -133.66 128.91 36.03 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.894 -179.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.16 119.92 39.08 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.912 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.603 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.8 m -72.68 11.85 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 N-CA-C 112.926 0.713 . . . . 0.0 112.926 -178.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 5.7 tp60 -105.41 -29.91 9.93 Favored 'General case' 0 CA--C 1.535 0.372 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.6 -179.369 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -148.99 -26.57 0.3 Allowed 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 112.789 0.663 . . . . 0.0 112.789 -178.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.2 t80 -125.65 87.62 55.54 Favored Pre-proline 0 CA--C 1.545 0.76 0 N-CA-C 111.67 0.248 . . . . 0.0 111.67 -178.754 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.425 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.5 Cg_endo -77.86 177.47 8.76 Favored 'Trans proline' 0 C--N 1.369 1.648 0 C-N-CA 122.267 1.978 . . . . 0.0 112.796 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.69 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.9 t -89.92 160.01 16.65 Favored 'General case' 0 N--CA 1.467 0.387 0 O-C-N 123.233 0.333 . . . . 0.0 110.837 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 74.8 m -79.94 108.55 9.47 Favored Pre-proline 0 CA--C 1.545 0.763 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.953 -179.342 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.2 Cg_endo -83.28 177.43 6.52 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.49 2.127 . . . . 0.0 112.911 179.342 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.33 -40.24 2.49 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 121.373 -0.441 . . . . 0.0 113.003 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -89.34 -38.64 14.0 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 122.439 0.296 . . . . 0.0 111.508 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.58 50.46 0.21 Allowed Glycine 0 C--N 1.339 0.728 0 O-C-N 123.491 0.494 . . . . 0.0 112.495 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.443 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.2 mt -113.24 150.12 32.83 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 122.294 0.238 . . . . 0.0 110.92 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -139.54 154.45 47.66 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.392 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.69 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 60.0 m -97.45 123.2 41.22 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.536 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.453 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.8 mt -126.58 123.45 23.97 Favored Pre-proline 0 CA--C 1.545 0.758 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.322 -179.792 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.422 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.85 -40.76 1.1 Allowed 'Cis proline' 0 C--N 1.375 1.965 0 C-N-CA 124.646 -0.981 . . . . 0.0 112.561 0.062 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.81 32.6 9.86 Favored Glycine 0 C--N 1.342 0.885 0 CA-C-N 116.017 -0.538 . . . . 0.0 112.887 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.422 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.11 78.7 13.58 Favored Pre-proline 0 CA--C 1.546 0.821 0 C-N-CA 122.156 0.182 . . . . 0.0 111.321 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.603 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.3 Cg_endo -90.18 -26.4 4.45 Favored 'Cis proline' 0 C--N 1.369 1.636 0 C-N-CA 124.686 -0.964 . . . . 0.0 113.676 -0.276 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.6 152.63 20.81 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 115.96 -0.564 . . . . 0.0 112.011 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -155.33 -171.72 22.22 Favored Glycine 0 C--N 1.337 0.619 0 CA-C-N 115.449 -0.796 . . . . 0.0 112.57 179.561 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.517 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -127.25 145.26 50.84 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.55 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 51.3 m -89.06 111.89 22.72 Favored 'General case' 0 C--O 1.24 0.554 0 CA-C-O 121.076 0.465 . . . . 0.0 111.675 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . 0.443 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.8 m-85 -125.94 159.86 31.5 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.527 179.43 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.58 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 14.5 t80 -93.32 136.06 33.94 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.988 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.4 mt . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.151 -0.928 . . . . 0.0 110.943 179.693 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.272 . . . . . . . 0 C--O 1.235 0.317 0 N-CA-C 112.152 0.427 . . . . 0.0 112.152 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -100.2 -52.82 1.13 Allowed Glycine 0 C--N 1.337 0.612 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.61 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.412 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 28.0 p -98.57 155.29 17.36 Favored 'General case' 0 C--O 1.236 0.369 0 C-N-CA 122.316 0.247 . . . . 0.0 111.01 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.72 151.14 20.78 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.752 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 17.0 p90 -98.96 171.95 7.72 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.842 179.351 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.586 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.2 tt0 -60.45 129.55 42.19 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 123.38 0.672 . . . . 0.0 112.395 -179.337 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.18 -19.93 31.47 Favored Glycine 0 C--N 1.338 0.687 0 CA-C-N 115.659 -0.701 . . . . 0.0 114.468 178.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -108.04 177.54 4.78 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 117.464 0.632 . . . . 0.0 111.817 -179.303 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 41.0 p -91.56 144.45 25.53 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.078 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.1 p -133.1 128.7 36.72 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.946 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -99.91 120.19 39.4 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.764 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.608 HG22 ' O ' ' A' ' 30' ' ' PRO . 29.5 m -72.25 10.45 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 N-CA-C 113.051 0.76 . . . . 0.0 113.051 -178.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.408 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 1.6 tp-100 -104.43 -29.51 10.67 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.693 -179.4 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.408 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.7 -26.55 0.27 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -178.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -125.12 87.51 55.4 Favored Pre-proline 0 CA--C 1.546 0.793 0 N-CA-C 111.694 0.257 . . . . 0.0 111.694 -178.666 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.407 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.9 Cg_endo -77.82 175.68 10.92 Favored 'Trans proline' 0 C--N 1.369 1.654 0 C-N-CA 122.28 1.987 . . . . 0.0 112.704 179.466 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.699 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.8 t -88.68 160.78 17.19 Favored 'General case' 0 N--CA 1.468 0.467 0 O-C-N 123.221 0.325 . . . . 0.0 110.793 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 71.9 m -79.99 108.44 9.25 Favored Pre-proline 0 CA--C 1.545 0.777 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.45 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 77.6 Cg_endo -83.54 177.59 6.23 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.453 2.102 . . . . 0.0 112.93 179.286 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.89 -40.44 2.44 Favored Glycine 0 C--N 1.34 0.767 0 C-N-CA 121.324 -0.465 . . . . 0.0 112.951 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.9 mt -88.57 -38.63 14.74 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 122.418 0.287 . . . . 0.0 111.551 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.75 51.76 0.2 Allowed Glycine 0 C--N 1.339 0.723 0 O-C-N 123.461 0.475 . . . . 0.0 112.565 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.473 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 22.7 mt -115.76 149.26 38.77 Favored 'General case' 0 C--O 1.235 0.3 0 O-C-N 123.607 0.239 . . . . 0.0 110.874 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t -139.1 154.4 48.14 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.246 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.699 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 66.4 m -97.22 123.26 40.95 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.645 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.441 ' H ' ' H ' ' A' ' 33' ' ' THR . 11.3 mt -127.16 122.94 23.24 Favored Pre-proline 0 CA--C 1.546 0.789 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.315 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.414 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.87 -41.01 1.03 Allowed 'Cis proline' 0 C--N 1.374 1.893 0 C-N-CA 124.696 -0.96 . . . . 0.0 112.64 0.112 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.18 32.8 9.32 Favored Glycine 0 C--N 1.343 0.931 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.93 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.414 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.49 79.08 12.81 Favored Pre-proline 0 CA--C 1.547 0.842 0 C-N-CA 122.215 0.206 . . . . 0.0 111.322 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.608 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.2 Cg_endo -89.88 -26.59 4.48 Favored 'Cis proline' 0 C--N 1.37 1.682 0 C-N-CA 124.667 -0.972 . . . . 0.0 113.68 -0.284 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -90.43 152.65 20.87 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.941 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.27 -173.95 23.82 Favored Glycine 0 C--N 1.337 0.632 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.649 179.577 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.475 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.6 OUTLIER -124.54 143.66 50.55 Favored 'General case' 0 C--O 1.235 0.304 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.563 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 34.3 m -88.11 110.41 20.63 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-O 121.085 0.469 . . . . 0.0 111.607 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . 0.473 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 34.2 m-85 -124.57 158.95 31.77 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.681 179.549 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.586 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 11.9 t80 -93.33 135.93 34.08 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.964 -179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.7 mt . . . . . 0 C--O 1.249 1.05 0 CA-C-O 118.115 -0.945 . . . . 0.0 110.901 179.765 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.269 . . . . . . . 0 CA--C 1.534 0.338 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 137.65 38.94 0.13 Allowed Glycine 0 C--N 1.34 0.777 0 O-C-N 123.434 0.459 . . . . 0.0 112.886 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.422 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.4 p -134.96 154.36 51.74 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 122.481 0.312 . . . . 0.0 110.805 179.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.43 151.58 20.75 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.763 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 18.2 p90 -98.27 173.6 6.91 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.688 179.263 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.579 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.0 tt0 -63.23 129.93 42.41 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.185 0.594 . . . . 0.0 112.364 -179.299 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 102.37 5.37 49.15 Favored Glycine 0 C--N 1.339 0.717 0 CA-C-N 115.673 -0.694 . . . . 0.0 114.725 178.606 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -131.72 177.86 7.19 Favored 'General case' 0 CA--C 1.539 0.538 0 CA-C-N 117.678 0.739 . . . . 0.0 111.599 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.439 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 43.1 p -90.24 146.49 24.2 Favored 'General case' 0 C--N 1.344 0.331 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.301 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.4 p -137.42 128.08 26.95 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.835 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -97.68 118.99 35.44 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.839 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.584 HG22 ' O ' ' A' ' 30' ' ' PRO . 22.6 m -71.25 9.61 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 N-CA-C 113.239 0.829 . . . . 0.0 113.239 -178.826 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.51 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.1 OUTLIER -101.28 -34.67 9.55 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.222 -179.548 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.51 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.9 p90 -147.33 -27.01 0.38 Allowed 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 -178.484 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 6.5 t80 -120.83 85.07 39.12 Favored Pre-proline 0 CA--C 1.544 0.732 0 N-CA-C 111.705 0.261 . . . . 0.0 111.705 -178.712 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.422 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.2 Cg_endo -77.95 177.96 8.17 Favored 'Trans proline' 0 C--N 1.369 1.619 0 C-N-CA 122.241 1.961 . . . . 0.0 112.704 179.461 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.7 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -89.17 160.47 16.97 Favored 'General case' 0 N--CA 1.468 0.437 0 O-C-N 123.157 0.285 . . . . 0.0 110.921 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 75.8 m -79.93 108.41 9.11 Favored Pre-proline 0 CA--C 1.545 0.772 0 N-CA-C 111.976 0.361 . . . . 0.0 111.976 -179.394 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.444 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 79.1 Cg_endo -83.07 177.47 6.63 Favored 'Trans proline' 0 C--N 1.371 1.732 0 C-N-CA 122.445 2.097 . . . . 0.0 113.002 179.411 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.01 -39.64 2.68 Favored Glycine 0 C--N 1.34 0.791 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.986 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.8 mt -89.14 -38.73 14.09 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 122.493 0.317 . . . . 0.0 111.503 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.15 50.07 0.22 Allowed Glycine 0 C--N 1.339 0.748 0 O-C-N 123.448 0.468 . . . . 0.0 112.474 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.449 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 20.6 mt -113.51 150.02 33.5 Favored 'General case' 0 C--O 1.235 0.315 0 O-C-N 123.628 0.252 . . . . 0.0 110.872 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -138.99 154.18 48.24 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.232 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.7 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 59.5 m -97.12 123.06 40.78 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.659 179.429 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.469 ' H ' ' H ' ' A' ' 33' ' ' THR . 11.3 mt -127.34 123.24 23.19 Favored Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.268 -179.814 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.437 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.3 Cg_exo -75.64 -40.87 1.07 Allowed 'Cis proline' 0 C--N 1.375 1.947 0 C-N-CA 124.636 -0.985 . . . . 0.0 112.507 0.094 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.04 33.62 8.79 Favored Glycine 0 C--N 1.342 0.877 0 O-C-N 123.596 0.56 . . . . 0.0 113.227 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.437 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.9 p30 -146.36 80.28 10.13 Favored Pre-proline 0 CA--C 1.547 0.855 0 CA-C-N 116.727 0.263 . . . . 0.0 111.556 179.575 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.584 ' O ' HG22 ' A' ' 12' ' ' VAL . 58.7 Cg_endo -89.27 -26.9 4.59 Favored 'Cis proline' 0 C--N 1.37 1.675 0 C-N-CA 124.729 -0.946 . . . . 0.0 113.463 -0.345 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -86.94 149.92 24.44 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 115.74 -0.664 . . . . 0.0 111.578 -179.634 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.439 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -151.09 -178.82 26.28 Favored Glycine 0 C--N 1.335 0.509 0 CA-C-N 115.581 -0.736 . . . . 0.0 112.394 179.425 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.48 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.7 OUTLIER -124.62 141.6 51.98 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 179.282 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 54.1 m -87.3 112.2 21.82 Favored 'General case' 0 C--O 1.24 0.575 0 O-C-N 123.48 0.488 . . . . 0.0 111.792 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . 0.449 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 35.0 m-85 -126.05 159.14 33.55 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.081 -0.963 . . . . 0.0 110.552 179.304 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.579 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.8 t80 -93.23 135.01 34.85 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.937 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.0 mt . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.11 -0.948 . . . . 0.0 110.898 179.776 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.272 . . . . . . . 0 C--O 1.235 0.34 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -125.05 57.46 0.68 Allowed Glycine 0 C--N 1.337 0.628 0 CA-C-N 115.897 -0.592 . . . . 0.0 112.489 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.429 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.2 p -99.93 156.69 17.01 Favored 'General case' 0 C--O 1.236 0.35 0 O-C-N 123.62 0.247 . . . . 0.0 110.981 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.6 147.97 22.45 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 112.138 0.422 . . . . 0.0 112.138 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.475 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.25 177.4 7.51 Favored 'General case' 0 CA--C 1.538 0.491 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.463 178.813 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.55 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.4 tt0 -74.46 136.14 42.29 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 122.844 0.458 . . . . 0.0 111.695 -179.743 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.87 9.49 58.44 Favored Glycine 0 C--N 1.338 0.671 0 CA-C-N 115.633 -0.712 . . . . 0.0 114.258 179.017 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.475 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.2 pt-20 -132.83 177.66 7.47 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 117.321 0.561 . . . . 0.0 111.376 179.8 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 42.8 p -88.16 147.28 24.97 Favored 'General case' 0 C--N 1.345 0.372 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.603 -179.409 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.5 p -138.7 128.02 24.35 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.684 -179.743 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.35 119.07 37.87 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.896 179.678 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.607 HG22 ' O ' ' A' ' 30' ' ' PRO . 27.7 m -72.11 9.39 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 -178.741 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.5 tp-100 -102.65 -29.91 11.25 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 116.625 -0.261 . . . . 0.0 111.685 -179.361 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -149.28 -26.82 0.28 Allowed 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 -178.715 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 12.4 t80 -125.32 87.84 55.03 Favored Pre-proline 0 CA--C 1.546 0.803 0 N-CA-C 111.596 0.221 . . . . 0.0 111.596 -178.649 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.429 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.2 Cg_endo -77.05 177.93 8.28 Favored 'Trans proline' 0 C--N 1.371 1.715 0 C-N-CA 122.29 1.993 . . . . 0.0 112.704 179.484 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.711 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.5 t -90.06 159.94 16.58 Favored 'General case' 0 N--CA 1.468 0.468 0 O-C-N 123.265 0.353 . . . . 0.0 110.923 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.418 ' O ' HD12 ' A' ' 23' ' ' LEU . 74.7 m -79.87 108.06 8.22 Favored Pre-proline 0 CA--C 1.546 0.799 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -179.473 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.47 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 80.2 Cg_endo -84.02 177.91 5.7 Favored 'Trans proline' 0 C--N 1.372 1.778 0 C-N-CA 122.493 2.128 . . . . 0.0 112.955 179.453 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.64 -39.56 2.72 Favored Glycine 0 C--N 1.34 0.752 0 C-N-CA 121.371 -0.442 . . . . 0.0 112.953 179.76 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.6 mp -89.79 -37.07 14.76 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 122.45 0.3 . . . . 0.0 111.464 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.43 52.04 0.22 Allowed Glycine 0 C--N 1.338 0.687 0 O-C-N 123.455 0.472 . . . . 0.0 112.357 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.424 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 19.0 mt -113.62 149.56 34.39 Favored 'General case' 0 C--O 1.234 0.265 0 O-C-N 123.624 0.25 . . . . 0.0 110.972 -179.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.2 t -138.94 152.08 47.42 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.315 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.711 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 55.7 m -96.76 122.69 39.99 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.608 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.42 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.9 mt -127.13 122.88 23.25 Favored Pre-proline 0 CA--C 1.545 0.772 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.328 -179.753 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.417 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.69 -41.28 0.99 Allowed 'Cis proline' 0 C--N 1.375 1.933 0 C-N-CA 124.651 -0.979 . . . . 0.0 112.593 0.04 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.7 31.68 9.97 Favored Glycine 0 C--N 1.342 0.905 0 O-C-N 123.582 0.551 . . . . 0.0 113.044 179.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.417 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.8 p30 -145.12 80.8 10.92 Favored Pre-proline 0 CA--C 1.547 0.832 0 CA-C-N 116.569 0.184 . . . . 0.0 111.258 179.705 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.607 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.8 Cg_endo -89.31 -26.57 4.86 Favored 'Cis proline' 0 C--N 1.369 1.648 0 C-N-CA 124.654 -0.978 . . . . 0.0 113.609 -0.336 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -92.29 153.96 18.91 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.891 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -155.97 -172.87 23.91 Favored Glycine 0 C--N 1.337 0.625 0 CA-C-N 115.482 -0.781 . . . . 0.0 112.608 179.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.496 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -126.51 144.95 50.7 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.576 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 60.8 m -89.61 113.92 25.44 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-O 121.072 0.463 . . . . 0.0 111.765 -179.634 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . 0.424 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 35.3 m-85 -125.58 157.45 37.1 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.471 179.327 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.55 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 19.4 t80 -92.5 133.65 35.73 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.985 -179.835 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt . . . . . 0 C--O 1.252 1.192 0 CA-C-O 118.507 -0.758 . . . . 0.0 110.898 179.787 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.271 . . . . . . . 0 C--O 1.236 0.354 0 N-CA-C 112.202 0.445 . . . . 0.0 112.202 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -145.17 59.77 0.5 Allowed Glycine 0 C--N 1.336 0.568 0 CA-C-N 115.875 -0.602 . . . . 0.0 112.511 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.427 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.1 p -99.82 156.8 16.92 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 122.305 0.242 . . . . 0.0 110.971 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.54 147.84 22.57 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 116.235 -0.439 . . . . 0.0 112.184 -179.696 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.479 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.15 177.62 7.47 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.478 178.779 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.543 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.1 tt0 -74.64 135.92 41.95 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 122.905 0.482 . . . . 0.0 111.712 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.71 10.17 58.04 Favored Glycine 0 C--N 1.339 0.716 0 CA-C-N 115.596 -0.729 . . . . 0.0 114.292 179.027 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.479 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.3 pt-20 -132.99 177.55 7.57 Favored 'General case' 0 CA--C 1.54 0.578 0 CA-C-N 117.342 0.571 . . . . 0.0 111.403 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.8 m -88.33 146.42 25.3 Favored 'General case' 0 C--N 1.344 0.346 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.567 -179.478 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.5 p -138.26 128.57 26.03 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.689 -179.759 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -100.76 119.27 38.38 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.87 179.749 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.605 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.0 m -72.12 9.39 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 N-CA-C 113.063 0.764 . . . . 0.0 113.063 -178.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.6 tp-100 -102.72 -30.04 11.14 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.583 -0.28 . . . . 0.0 111.661 -179.331 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -149.0 -26.83 0.29 Allowed 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 112.864 0.69 . . . . 0.0 112.864 -178.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 12.5 t80 -125.28 87.77 55.12 Favored Pre-proline 0 CA--C 1.546 0.818 0 N-CA-C 111.63 0.233 . . . . 0.0 111.63 -178.639 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.427 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.2 Cg_endo -77.11 177.67 8.58 Favored 'Trans proline' 0 C--N 1.37 1.671 0 C-N-CA 122.269 1.979 . . . . 0.0 112.682 179.527 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.71 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.3 t -89.85 160.05 16.67 Favored 'General case' 0 N--CA 1.467 0.397 0 O-C-N 123.234 0.334 . . . . 0.0 110.947 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.426 ' O ' HD12 ' A' ' 23' ' ' LEU . 74.2 m -79.85 108.08 8.26 Favored Pre-proline 0 CA--C 1.545 0.782 0 O-C-N 123.247 0.342 . . . . 0.0 111.916 -179.47 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.469 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 79.6 Cg_endo -83.91 177.92 5.76 Favored 'Trans proline' 0 C--N 1.371 1.728 0 C-N-CA 122.554 2.169 . . . . 0.0 112.972 179.42 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.54 -38.97 2.9 Favored Glycine 0 C--N 1.34 0.773 0 C-N-CA 121.374 -0.441 . . . . 0.0 113.007 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.1 mt -89.83 -36.97 14.79 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 122.461 0.304 . . . . 0.0 111.469 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.06 52.08 0.23 Allowed Glycine 0 C--N 1.339 0.713 0 O-C-N 123.514 0.509 . . . . 0.0 112.335 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.426 HD12 ' O ' ' A' ' 18' ' ' CYS . 18.9 mt -114.22 149.21 36.14 Favored 'General case' 0 C--O 1.235 0.321 0 O-C-N 123.671 0.277 . . . . 0.0 110.965 -179.687 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.1 t -138.83 151.93 47.42 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.29 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.71 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 56.1 m -96.76 122.48 39.76 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.595 179.411 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.4 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.6 mt -127.21 123.09 23.25 Favored Pre-proline 0 CA--C 1.545 0.759 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.372 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.419 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -76.0 -41.0 1.03 Allowed 'Cis proline' 0 C--N 1.374 1.914 0 C-N-CA 124.625 -0.99 . . . . 0.0 112.612 0.055 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.77 32.78 9.69 Favored Glycine 0 C--N 1.343 0.929 0 O-C-N 123.548 0.53 . . . . 0.0 112.945 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.419 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.37 79.42 12.73 Favored Pre-proline 0 CA--C 1.546 0.823 0 C-N-CA 122.213 0.205 . . . . 0.0 111.343 179.762 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.605 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.2 Cg_endo -89.73 -26.53 4.63 Favored 'Cis proline' 0 C--N 1.37 1.66 0 C-N-CA 124.722 -0.949 . . . . 0.0 113.58 -0.213 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -91.18 153.79 19.77 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.892 -179.363 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.34 -172.54 23.83 Favored Glycine 0 C--N 1.337 0.622 0 CA-C-N 115.518 -0.765 . . . . 0.0 112.646 179.493 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.506 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -126.7 145.44 50.59 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.601 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 59.3 m -90.01 114.09 25.89 Favored 'General case' 0 C--O 1.239 0.545 0 O-C-N 123.42 0.45 . . . . 0.0 111.779 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . 0.426 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 35.9 m-85 -125.39 157.33 37.06 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.103 -0.953 . . . . 0.0 110.419 179.326 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.543 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 17.5 t80 -92.58 133.41 35.99 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.003 -179.808 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.251 1.169 0 CA-C-O 118.507 -0.758 . . . . 0.0 110.907 179.835 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.272 . . . . . . . 0 C--O 1.235 0.32 0 N-CA-C 112.122 0.416 . . . . 0.0 112.122 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -140.77 81.62 0.25 Allowed Glycine 0 C--N 1.337 0.616 0 CA-C-N 115.868 -0.606 . . . . 0.0 112.48 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.419 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.5 p -99.56 155.57 17.51 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 122.259 0.224 . . . . 0.0 111.063 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.72 152.28 19.06 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.693 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -99.1 172.16 7.56 Favored 'General case' 0 CA--C 1.537 0.45 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.865 179.351 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.579 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 15.9 tt0 -60.63 129.81 43.39 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 123.36 0.664 . . . . 0.0 112.396 -179.29 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 108.3 -21.93 27.88 Favored Glycine 0 C--N 1.338 0.687 0 CA-C-N 115.639 -0.709 . . . . 0.0 114.383 178.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -105.61 177.42 4.86 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-N 117.458 0.629 . . . . 0.0 111.821 -179.303 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 15.7 t -92.55 142.63 27.19 Favored 'General case' 0 C--N 1.343 0.321 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.966 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 2.8 p -132.46 129.27 39.01 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.853 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -97.59 119.11 35.55 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.049 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.606 HG22 ' O ' ' A' ' 30' ' ' PRO . 27.2 m -71.71 9.12 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.856 -179.021 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.448 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 23.1 tt0 -100.14 -30.17 12.08 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.251 -179.387 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.448 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.9 p90 -153.4 -27.68 0.14 Allowed 'General case' 0 N--CA 1.476 0.826 0 N-CA-C 112.773 0.657 . . . . 0.0 112.773 -178.544 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.5 t80 -119.63 85.25 32.35 Favored Pre-proline 0 CA--C 1.545 0.757 0 N-CA-C 111.503 0.186 . . . . 0.0 111.503 -178.819 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.419 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.3 Cg_endo -77.69 175.28 11.42 Favored 'Trans proline' 0 C--N 1.368 1.597 0 C-N-CA 122.212 1.941 . . . . 0.0 112.757 179.619 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.65 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.2 t -87.28 162.28 17.51 Favored 'General case' 0 N--CA 1.467 0.396 0 O-C-N 123.246 0.341 . . . . 0.0 110.944 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.9 m -79.92 108.58 9.52 Favored Pre-proline 0 CA--C 1.545 0.762 0 N-CA-C 111.907 0.336 . . . . 0.0 111.907 -179.328 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.44 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 74.7 Cg_endo -82.85 177.58 6.69 Favored 'Trans proline' 0 C--N 1.372 1.792 0 C-N-CA 122.453 2.102 . . . . 0.0 112.993 179.385 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.08 -40.04 2.55 Favored Glycine 0 C--N 1.339 0.735 0 C-N-CA 121.356 -0.449 . . . . 0.0 112.904 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.7 mp -90.16 -39.49 12.81 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 122.446 0.298 . . . . 0.0 111.386 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.28 53.76 0.19 Allowed Glycine 0 C--N 1.339 0.75 0 O-C-N 123.516 0.51 . . . . 0.0 112.514 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.47 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 23.0 mt -117.3 149.24 40.79 Favored 'General case' 0 C--O 1.235 0.297 0 O-C-N 123.632 0.254 . . . . 0.0 110.962 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.401 ' O ' ' HA ' ' A' ' 34' ' ' CYS . 8.9 t -139.58 156.97 46.56 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.276 -179.816 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.65 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 98.9 m -99.25 119.54 38.08 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.699 179.619 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.8 mt -129.79 126.12 22.45 Favored Pre-proline 0 CA--C 1.545 0.783 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.348 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.551 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 43.1 Cg_endo -69.81 -42.58 0.73 Allowed 'Cis proline' 0 C--N 1.375 1.956 0 C-N-CA 124.578 -1.009 . . . . 0.0 113.449 -0.22 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 82.1 39.34 11.58 Favored Glycine 0 C--N 1.345 1.03 0 O-C-N 123.358 0.411 . . . . 0.0 113.275 179.785 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.551 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -147.81 78.52 9.77 Favored Pre-proline 0 CA--C 1.548 0.87 0 C-N-CA 122.3 0.24 . . . . 0.0 111.402 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.606 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.6 Cg_endo -87.83 -26.86 5.5 Favored 'Cis proline' 0 C--N 1.369 1.612 0 C-N-CA 124.571 -1.012 . . . . 0.0 113.355 -0.273 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -87.06 147.54 25.64 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.705 -179.591 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -149.54 -175.78 22.14 Favored Glycine 0 C--N 1.336 0.556 0 CA-C-N 115.612 -0.722 . . . . 0.0 112.712 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.507 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.8 OUTLIER -124.24 143.15 50.69 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.505 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.401 ' HA ' ' O ' ' A' ' 24' ' ' THR . 34.5 m -87.47 112.01 21.75 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-O 121.086 0.469 . . . . 0.0 111.778 -179.598 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . 0.47 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 40.5 m-85 -125.81 159.87 31.31 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.605 179.458 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.579 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.4 t80 -93.74 135.15 35.33 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.94 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.5 mt . . . . . 0 C--O 1.251 1.136 0 CA-C-O 118.472 -0.775 . . . . 0.0 110.875 179.759 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.271 . . . . . . . 0 C--O 1.235 0.315 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -119.98 -50.19 0.29 Allowed Glycine 0 C--N 1.336 0.56 0 CA-C-N 115.872 -0.604 . . . . 0.0 112.633 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.425 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 28.2 p -97.65 157.22 16.16 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 122.357 0.263 . . . . 0.0 111.03 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.3 147.72 22.85 Favored 'General case' 0 C--O 1.237 0.417 0 N-CA-C 112.176 0.435 . . . . 0.0 112.176 -179.621 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.473 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.08 177.5 7.54 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 115.098 -0.955 . . . . 0.0 110.426 178.847 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.543 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.4 tt0 -74.85 135.89 41.56 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 122.875 0.47 . . . . 0.0 111.693 -179.698 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 94.44 10.91 57.72 Favored Glycine 0 C--N 1.339 0.725 0 CA-C-N 115.587 -0.733 . . . . 0.0 114.34 178.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.473 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.4 pt-20 -133.32 177.47 7.66 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 117.271 0.536 . . . . 0.0 111.392 179.821 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 43.1 p -88.04 145.65 25.87 Favored 'General case' 0 C--N 1.344 0.364 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.601 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.2 p -137.65 128.03 26.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.639 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.58 119.52 38.66 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.903 179.684 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.612 HG22 ' O ' ' A' ' 30' ' ' PRO . 28.6 m -72.03 8.9 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 N-CA-C 113.024 0.749 . . . . 0.0 113.024 -178.752 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.409 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 1.5 tp-100 -102.55 -29.86 11.31 Favored 'General case' 0 CA--C 1.535 0.388 0 N-CA-C 111.706 0.262 . . . . 0.0 111.706 -179.333 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.409 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.9 p90 -149.43 -26.74 0.28 Allowed 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -178.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.6 t80 -124.64 87.17 54.91 Favored Pre-proline 0 CA--C 1.547 0.829 0 N-CA-C 111.577 0.214 . . . . 0.0 111.577 -178.657 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.413 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.1 Cg_endo -77.18 175.86 10.83 Favored 'Trans proline' 0 C--N 1.369 1.624 0 C-N-CA 122.293 1.995 . . . . 0.0 112.69 179.495 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.715 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.3 t -89.31 160.35 16.92 Favored 'General case' 0 N--CA 1.468 0.444 0 O-C-N 123.257 0.348 . . . . 0.0 110.886 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.444 ' O ' HD12 ' A' ' 23' ' ' LEU . 73.9 m -79.84 107.68 7.3 Favored Pre-proline 0 CA--C 1.545 0.777 0 O-C-N 123.286 0.367 . . . . 0.0 111.985 -179.561 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.48 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 81.5 Cg_endo -84.39 177.99 5.41 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.529 2.153 . . . . 0.0 112.984 179.41 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.66 -39.36 2.77 Favored Glycine 0 C--N 1.34 0.777 0 C-N-CA 121.41 -0.424 . . . . 0.0 113.033 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.6 mp -89.71 -38.05 14.14 Favored 'General case' 0 N--CA 1.467 0.423 0 C-N-CA 122.435 0.294 . . . . 0.0 111.489 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.65 52.55 0.19 Allowed Glycine 0 C--N 1.339 0.7 0 O-C-N 123.452 0.47 . . . . 0.0 112.422 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.444 HD12 ' O ' ' A' ' 18' ' ' CYS . 19.6 mt -115.3 148.56 39.08 Favored 'General case' 0 C--O 1.235 0.323 0 O-C-N 123.668 0.276 . . . . 0.0 110.846 -179.7 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.2 t -138.53 151.69 47.57 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.374 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.715 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 54.3 m -97.03 121.98 39.52 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.597 179.412 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.5 mt -127.4 123.36 23.18 Favored Pre-proline 0 CA--C 1.545 0.786 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.364 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.409 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.95 -41.06 1.02 Allowed 'Cis proline' 0 C--N 1.375 1.923 0 C-N-CA 124.652 -0.978 . . . . 0.0 112.598 0.067 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.55 32.71 9.95 Favored Glycine 0 C--N 1.343 0.947 0 O-C-N 123.55 0.531 . . . . 0.0 112.95 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.409 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -144.09 79.33 13.15 Favored Pre-proline 0 CA--C 1.546 0.822 0 C-N-CA 122.178 0.191 . . . . 0.0 111.291 179.722 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.612 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.7 Cg_endo -89.86 -26.32 4.73 Favored 'Cis proline' 0 C--N 1.37 1.708 0 C-N-CA 124.671 -0.97 . . . . 0.0 113.685 -0.338 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -91.1 153.65 19.93 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.93 -179.406 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -156.17 -172.37 23.52 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-N 115.533 -0.758 . . . . 0.0 112.662 179.467 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.49 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.6 OUTLIER -126.99 145.78 50.58 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.567 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 61.3 m -89.98 113.47 25.14 Favored 'General case' 0 C--O 1.239 0.549 0 O-C-N 123.455 0.472 . . . . 0.0 111.739 -179.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . 0.433 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 34.7 m-85 -123.77 157.19 34.58 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.47 179.316 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.543 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 13.7 t80 -93.41 132.72 37.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.989 -179.765 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt . . . . . 0 C--O 1.251 1.181 0 CA-C-O 118.455 -0.783 . . . . 0.0 110.872 179.797 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.273 . . . . . . . 0 C--O 1.235 0.292 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -122.02 -50.73 0.24 Allowed Glycine 0 C--N 1.337 0.589 0 CA-C-N 115.773 -0.649 . . . . 0.0 112.579 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.421 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 28.5 p -98.65 157.47 16.24 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 122.324 0.25 . . . . 0.0 111.043 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.84 147.22 23.14 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 116.259 -0.428 . . . . 0.0 112.093 -179.609 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.467 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.61 177.19 7.45 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.412 178.756 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.556 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 23.7 tt0 -74.1 134.69 42.91 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 122.9 0.48 . . . . 0.0 111.677 -179.649 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.45 9.73 57.55 Favored Glycine 0 C--N 1.339 0.712 0 CA-C-N 115.597 -0.729 . . . . 0.0 114.319 179.019 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.467 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.0 pt-20 -132.72 177.84 7.32 Favored 'General case' 0 CA--C 1.54 0.595 0 CA-C-N 117.371 0.586 . . . . 0.0 111.373 179.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.42 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 52.8 m -88.58 149.03 23.79 Favored 'General case' 0 C--N 1.344 0.363 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.645 -179.379 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.2 p -141.38 129.12 21.64 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.615 -179.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -101.29 120.94 41.01 Favored 'General case' 0 N--CA 1.466 0.328 0 O-C-N 123.447 0.467 . . . . 0.0 110.516 179.632 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.583 HG22 ' O ' ' A' ' 30' ' ' PRO . 27.6 m -70.86 6.66 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 N-CA-C 113.689 0.996 . . . . 0.0 113.689 -178.228 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 5.9 tp60 -101.41 -30.3 11.53 Favored 'General case' 0 CA--C 1.534 0.354 0 N-CA-C 111.736 0.273 . . . . 0.0 111.736 -179.473 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.8 p90 -148.24 -27.55 0.33 Allowed 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 112.882 0.697 . . . . 0.0 112.882 -178.803 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -121.8 85.88 45.12 Favored Pre-proline 0 CA--C 1.545 0.786 0 N-CA-C 111.584 0.216 . . . . 0.0 111.584 -178.719 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.412 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.1 Cg_endo -77.4 176.83 9.59 Favored 'Trans proline' 0 C--N 1.369 1.614 0 C-N-CA 122.265 1.976 . . . . 0.0 112.606 179.51 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.706 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.0 t -89.07 160.1 17.23 Favored 'General case' 0 N--CA 1.468 0.442 0 O-C-N 123.226 0.329 . . . . 0.0 110.944 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.4 ' O ' HD12 ' A' ' 23' ' ' LEU . 72.3 m -79.84 108.09 8.27 Favored Pre-proline 0 CA--C 1.546 0.805 0 N-CA-C 111.948 0.351 . . . . 0.0 111.948 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.469 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 76.4 Cg_endo -83.69 178.0 5.84 Favored 'Trans proline' 0 C--N 1.372 1.797 0 C-N-CA 122.534 2.156 . . . . 0.0 112.979 179.473 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 99.69 -39.35 2.77 Favored Glycine 0 C--N 1.34 0.789 0 C-N-CA 121.401 -0.428 . . . . 0.0 112.935 179.81 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.6 mt -89.9 -36.68 14.9 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 122.447 0.299 . . . . 0.0 111.442 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.35 52.92 0.23 Allowed Glycine 0 C--N 1.339 0.716 0 O-C-N 123.496 0.498 . . . . 0.0 112.376 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.459 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 18.8 mt -115.4 148.53 39.24 Favored 'General case' 0 C--O 1.235 0.334 0 O-C-N 123.67 0.277 . . . . 0.0 110.953 -179.683 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.425 ' O ' ' HA ' ' A' ' 34' ' ' CYS . 9.8 t -138.83 152.22 47.67 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.296 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.706 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 61.7 m -96.47 122.34 39.26 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.551 179.43 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.6 mt -127.41 122.73 22.93 Favored Pre-proline 0 CA--C 1.546 0.809 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.385 -179.787 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.431 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.0 Cg_exo -75.66 -41.54 0.95 Allowed 'Cis proline' 0 C--N 1.374 1.909 0 C-N-CA 124.677 -0.968 . . . . 0.0 112.569 0.083 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 91.17 31.47 9.72 Favored Glycine 0 C--N 1.342 0.914 0 O-C-N 123.562 0.538 . . . . 0.0 113.128 179.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.431 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.9 p30 -143.95 82.79 10.79 Favored Pre-proline 0 CA--C 1.547 0.845 0 CA-C-N 116.707 0.253 . . . . 0.0 111.391 179.633 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.583 ' O ' HG22 ' A' ' 12' ' ' VAL . 75.7 Cg_endo -87.26 -27.01 5.67 Favored 'Cis proline' 0 C--N 1.37 1.707 0 C-N-CA 124.59 -1.004 . . . . 0.0 113.439 -0.43 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -94.12 156.65 16.46 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.67 -179.032 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.42 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.65 -173.6 25.35 Favored Glycine 0 C--N 1.336 0.56 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.452 179.55 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.477 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.5 OUTLIER -124.77 143.81 50.59 Favored 'General case' 0 C--O 1.234 0.271 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 179.607 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.425 ' HA ' ' O ' ' A' ' 24' ' ' THR . 56.7 m -89.08 114.37 25.6 Favored 'General case' 0 C--O 1.239 0.536 0 O-C-N 123.452 0.47 . . . . 0.0 111.818 -179.569 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . 0.459 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.0 m-85 -125.51 157.97 35.67 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.051 -0.977 . . . . 0.0 110.466 179.287 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.556 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 17.7 t80 -92.53 133.12 36.25 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.984 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.104 -0.951 . . . . 0.0 110.977 179.827 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.273 . . . . . . . 0 C--O 1.236 0.353 0 N-CA-C 112.19 0.441 . . . . 0.0 112.19 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -145.73 24.75 1.8 Allowed Glycine 0 C--N 1.337 0.598 0 CA-C-N 115.95 -0.568 . . . . 0.0 113.195 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.438 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.6 p -134.51 153.89 51.71 Favored 'General case' 0 N--CA 1.466 0.332 0 C-N-CA 122.301 0.24 . . . . 0.0 110.868 179.827 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.84 151.72 20.44 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.784 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.428 ' O ' ' HG2' ' A' ' 8' ' ' GLU . 15.3 p90 -97.32 174.78 6.53 Favored 'General case' 0 CA--C 1.537 0.477 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.687 179.117 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.573 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 18.1 tt0 -64.97 130.47 43.51 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 123.164 0.586 . . . . 0.0 112.253 -179.269 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 100.04 12.13 40.72 Favored Glycine 0 C--N 1.339 0.723 0 CA-C-N 115.62 -0.718 . . . . 0.0 114.674 178.656 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.428 ' HG2' ' O ' ' A' ' 5' ' ' PHE . 7.0 pt-20 -136.67 176.85 8.33 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 117.601 0.701 . . . . 0.0 111.47 179.632 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.435 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 40.6 p -90.23 144.8 25.53 Favored 'General case' 0 C--N 1.343 0.319 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.126 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.8 p -135.85 130.49 33.99 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.906 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -99.76 119.02 37.48 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.854 179.523 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.616 HG22 ' O ' ' A' ' 30' ' ' PRO . 30.5 m -72.71 10.58 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 N-CA-C 112.897 0.702 . . . . 0.0 112.897 -179.034 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.409 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.5 tp60 -104.26 -29.74 10.6 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.577 -179.425 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.409 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 3.0 p90 -149.48 -26.79 0.27 Allowed 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 112.819 0.674 . . . . 0.0 112.819 -178.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 9.7 t80 -124.98 86.96 55.99 Favored Pre-proline 0 CA--C 1.546 0.798 0 N-CA-C 111.622 0.23 . . . . 0.0 111.622 -178.697 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.438 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.1 Cg_endo -77.75 179.08 6.85 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 122.235 1.957 . . . . 0.0 112.739 179.512 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.7 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 6.0 t -89.91 160.22 16.54 Favored 'General case' 0 N--CA 1.467 0.376 0 O-C-N 123.183 0.302 . . . . 0.0 110.809 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 78.2 m -79.99 108.29 8.88 Favored Pre-proline 0 CA--C 1.545 0.773 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.907 -179.401 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.452 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.9 Cg_endo -83.44 177.53 6.34 Favored 'Trans proline' 0 C--N 1.371 1.753 0 C-N-CA 122.449 2.099 . . . . 0.0 112.95 179.441 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.79 -39.86 2.61 Favored Glycine 0 C--N 1.34 0.751 0 C-N-CA 121.374 -0.441 . . . . 0.0 112.946 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.8 mt -89.05 -38.1 14.64 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 122.444 0.298 . . . . 0.0 111.501 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.97 50.12 0.23 Allowed Glycine 0 C--N 1.339 0.706 0 O-C-N 123.481 0.488 . . . . 0.0 112.497 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.447 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.1 mt -113.85 149.73 34.62 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 122.294 0.238 . . . . 0.0 110.846 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.8 t -139.44 154.16 47.71 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.321 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.7 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.0 m -97.13 123.09 40.8 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.575 179.4 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.446 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.6 mt -127.2 123.09 23.25 Favored Pre-proline 0 CA--C 1.544 0.746 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.327 -179.772 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.44 ' HB2' ' ND2' ' A' ' 29' ' ' ASN . 6.2 Cg_exo -75.7 -40.92 1.06 Allowed 'Cis proline' 0 C--N 1.375 1.922 0 C-N-CA 124.698 -0.959 . . . . 0.0 112.527 0.077 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.64 32.97 8.78 Favored Glycine 0 C--N 1.342 0.884 0 O-C-N 123.62 0.575 . . . . 0.0 113.123 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.44 ' ND2' ' HB2' ' A' ' 27' ' ' PRO . 3.7 p30 -145.68 81.39 10.08 Favored Pre-proline 0 CA--C 1.547 0.844 0 CA-C-N 116.756 0.278 . . . . 0.0 111.458 179.611 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.616 ' O ' HG22 ' A' ' 12' ' ' VAL . 60.7 Cg_endo -88.77 -26.53 5.24 Favored 'Cis proline' 0 C--N 1.371 1.715 0 C-N-CA 124.651 -0.979 . . . . 0.0 113.508 -0.407 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -90.46 155.24 19.06 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.347 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.435 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.19 -174.93 26.58 Favored Glycine 0 C--N 1.334 0.465 0 CA-C-N 115.379 -0.828 . . . . 0.0 112.464 179.549 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.495 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.6 OUTLIER -125.72 143.24 51.13 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.493 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 52.8 m -88.69 112.74 23.49 Favored 'General case' 0 C--O 1.239 0.523 0 O-C-N 123.439 0.462 . . . . 0.0 111.75 -179.644 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . 0.447 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 37.1 m-85 -126.48 159.26 33.89 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.051 -0.977 . . . . 0.0 110.519 179.36 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.573 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.5 t80 -92.77 135.34 34.2 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.006 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.9 mt . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.115 -0.945 . . . . 0.0 110.87 179.819 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.269 . . . . . . . 0 CA--C 1.534 0.347 0 N-CA-C 112.465 0.543 . . . . 0.0 112.465 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 118.32 -74.04 0.29 Allowed Glycine 0 C--N 1.341 0.821 0 O-C-N 123.427 0.454 . . . . 0.0 112.541 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.424 ' HB2' ' C ' ' A' ' 17' ' ' CYS . 29.0 p -100.22 156.9 16.96 Favored 'General case' 0 C--O 1.235 0.314 0 O-C-N 123.625 0.25 . . . . 0.0 111.004 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -93.0 147.81 22.52 Favored 'General case' 0 C--O 1.237 0.406 0 CA-C-N 116.243 -0.435 . . . . 0.0 112.121 -179.705 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.468 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.4 m-85 -86.53 176.98 7.54 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.432 178.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.574 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 24.2 tt0 -73.79 136.09 43.55 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 122.905 0.482 . . . . 0.0 111.693 -179.792 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.49 8.81 58.26 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 115.624 -0.716 . . . . 0.0 114.289 179.008 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.468 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.3 pt-20 -132.53 177.39 7.65 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 117.333 0.567 . . . . 0.0 111.41 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 52.0 m -88.36 146.4 25.29 Favored 'General case' 0 C--N 1.344 0.351 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.619 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.0 p -138.42 128.6 25.74 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.729 -179.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -100.4 119.57 38.65 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.918 179.678 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.612 HG22 ' O ' ' A' ' 30' ' ' PRO . 29.0 m -71.95 8.93 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 N-CA-C 113.035 0.754 . . . . 0.0 113.035 -178.757 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.407 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 5.4 tp60 -102.7 -30.1 11.11 Favored 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 111.687 0.254 . . . . 0.0 111.687 -179.34 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.407 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 2.9 p90 -149.02 -26.92 0.29 Allowed 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.824 0.676 . . . . 0.0 112.824 -178.763 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -124.32 87.15 54.16 Favored Pre-proline 0 CA--C 1.546 0.804 0 N-CA-C 111.561 0.208 . . . . 0.0 111.561 -178.704 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.42 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.2 Cg_endo -76.97 177.09 9.31 Favored 'Trans proline' 0 C--N 1.37 1.659 0 C-N-CA 122.234 1.956 . . . . 0.0 112.771 179.604 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.7 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.3 t -89.69 159.86 16.89 Favored 'General case' 0 N--CA 1.468 0.442 0 O-C-N 123.272 0.358 . . . . 0.0 110.957 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.1 m -79.85 108.24 8.64 Favored Pre-proline 0 CA--C 1.545 0.779 0 N-CA-C 112.024 0.379 . . . . 0.0 112.024 -179.524 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 79.1 Cg_endo -83.6 177.88 5.99 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 122.512 2.142 . . . . 0.0 113.025 179.39 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.72 -39.76 2.65 Favored Glycine 0 C--N 1.34 0.759 0 O-C-N 123.395 0.434 . . . . 0.0 112.95 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 5.6 mp -89.8 -36.64 15.01 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 122.47 0.308 . . . . 0.0 111.444 -179.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.43 51.63 0.24 Allowed Glycine 0 C--N 1.338 0.691 0 O-C-N 123.525 0.515 . . . . 0.0 112.323 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.438 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 19.3 mt -113.2 149.46 33.68 Favored 'General case' 0 C--O 1.234 0.288 0 O-C-N 123.632 0.254 . . . . 0.0 110.969 -179.663 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.0 t -139.08 153.0 47.98 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.239 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.7 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.1 m -96.81 123.09 40.41 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.546 179.448 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.425 ' H ' ' H ' ' A' ' 33' ' ' THR . 10.9 mt -126.8 122.79 23.54 Favored Pre-proline 0 CA--C 1.545 0.771 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.401 -179.737 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.413 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -75.93 -41.04 1.02 Allowed 'Cis proline' 0 C--N 1.375 1.925 0 C-N-CA 124.695 -0.961 . . . . 0.0 112.643 0.042 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.08 32.64 9.58 Favored Glycine 0 C--N 1.343 0.948 0 CA-C-N 116.024 -0.535 . . . . 0.0 112.914 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.413 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -144.32 79.47 12.75 Favored Pre-proline 0 CA--C 1.546 0.803 0 C-N-CA 122.194 0.198 . . . . 0.0 111.349 179.761 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.612 ' O ' HG22 ' A' ' 12' ' ' VAL . 59.3 Cg_endo -89.69 -26.47 4.7 Favored 'Cis proline' 0 C--N 1.37 1.666 0 C-N-CA 124.695 -0.96 . . . . 0.0 113.593 -0.252 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -91.14 153.44 20.06 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.937 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -155.91 -172.57 23.54 Favored Glycine 0 C--N 1.338 0.658 0 CA-C-N 115.55 -0.75 . . . . 0.0 112.649 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.503 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.5 OUTLIER -126.55 144.86 50.74 Favored 'General case' 0 C--O 1.235 0.318 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 179.556 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 57.5 m -89.47 114.82 26.37 Favored 'General case' 0 C--O 1.239 0.538 0 O-C-N 123.429 0.456 . . . . 0.0 111.832 -179.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . 0.438 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 38.0 m-85 -128.14 157.87 39.6 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.512 179.291 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.574 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 20.4 t80 -91.75 134.86 34.36 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.995 -179.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 15.3 mt . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.085 -0.96 . . . . 0.0 110.963 179.797 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.273 . . . . . . . 0 C--O 1.235 0.323 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -117.19 68.59 0.3 Allowed Glycine 0 C--N 1.337 0.614 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.54 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.423 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 29.0 p -98.69 156.69 16.7 Favored 'General case' 0 C--O 1.236 0.368 0 O-C-N 123.656 0.268 . . . . 0.0 110.942 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.07 147.18 23.14 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-N 116.226 -0.443 . . . . 0.0 112.158 -179.668 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.476 ' HD2' ' OE1' ' A' ' 8' ' ' GLU . 2.5 m-85 -86.28 177.2 7.56 Favored 'General case' 0 CA--C 1.538 0.505 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.442 178.764 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.55 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 23.8 tt0 -73.95 134.87 43.18 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 122.932 0.493 . . . . 0.0 111.711 -179.755 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.27 9.39 58.05 Favored Glycine 0 C--N 1.339 0.713 0 CA-C-N 115.659 -0.7 . . . . 0.0 114.33 178.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.476 ' OE1' ' HD2' ' A' ' 5' ' ' PHE . 12.0 pt-20 -132.39 177.85 7.27 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 117.345 0.573 . . . . 0.0 111.419 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.43 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 51.8 m -88.47 149.15 23.81 Favored 'General case' 0 C--N 1.345 0.375 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.722 -179.393 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.4 p -141.56 129.48 21.87 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.656 -179.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -101.36 120.9 40.97 Favored 'General case' 0 C--O 1.235 0.326 0 O-C-N 123.384 0.428 . . . . 0.0 110.523 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 30' ' ' PRO . 27.4 m -71.04 7.12 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 N-CA-C 113.626 0.972 . . . . 0.0 113.626 -178.178 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.7 tp-100 -101.77 -30.6 11.2 Favored 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 -179.429 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.8 p90 -147.95 -27.44 0.34 Allowed 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 112.896 0.702 . . . . 0.0 112.896 -178.82 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -122.24 86.1 47.37 Favored Pre-proline 0 CA--C 1.546 0.798 0 N-CA-C 111.62 0.229 . . . . 0.0 111.62 -178.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.423 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 60.3 Cg_endo -77.51 177.59 8.66 Favored 'Trans proline' 0 C--N 1.369 1.653 0 C-N-CA 122.22 1.947 . . . . 0.0 112.573 179.458 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.706 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 7.0 t -89.19 160.11 17.13 Favored 'General case' 0 N--CA 1.468 0.44 0 O-C-N 123.202 0.314 . . . . 0.0 110.939 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.42 ' O ' HD12 ' A' ' 23' ' ' LEU . 73.5 m -79.82 108.27 8.67 Favored Pre-proline 0 CA--C 1.544 0.744 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.913 -179.589 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.46 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 75.8 Cg_endo -83.45 177.92 6.05 Favored 'Trans proline' 0 C--N 1.372 1.815 0 C-N-CA 122.525 2.15 . . . . 0.0 113.011 179.479 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 100.27 -39.05 2.86 Favored Glycine 0 C--N 1.34 0.771 0 C-N-CA 121.389 -0.434 . . . . 0.0 112.924 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.2 mt -90.25 -36.81 14.51 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 122.481 0.312 . . . . 0.0 111.468 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.1 53.05 0.23 Allowed Glycine 0 C--N 1.339 0.719 0 O-C-N 123.54 0.525 . . . . 0.0 112.338 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.451 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 18.3 mt -114.75 148.98 37.61 Favored 'General case' 0 C--O 1.235 0.317 0 O-C-N 123.686 0.286 . . . . 0.0 110.945 -179.648 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.422 ' O ' ' HA ' ' A' ' 34' ' ' CYS . 10.0 t -138.79 151.99 47.52 Favored 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.312 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.706 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 59.6 m -96.94 121.64 39.04 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.52 179.486 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.7 mt -127.69 123.69 23.08 Favored Pre-proline 0 CA--C 1.546 0.799 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.332 -179.758 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.426 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.1 Cg_exo -76.01 -41.42 0.96 Allowed 'Cis proline' 0 C--N 1.374 1.903 0 C-N-CA 124.691 -0.962 . . . . 0.0 112.602 0.037 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 90.53 32.02 9.81 Favored Glycine 0 C--N 1.342 0.886 0 O-C-N 123.545 0.528 . . . . 0.0 113.062 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.426 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.2 p-10 -141.86 81.17 14.94 Favored Pre-proline 0 CA--C 1.547 0.854 0 CA-C-N 116.65 0.225 . . . . 0.0 111.489 179.713 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.577 ' O ' HG22 ' A' ' 12' ' ' VAL . 76.3 Cg_endo -88.09 -26.0 6.19 Favored 'Cis proline' 0 C--N 1.371 1.719 0 C-N-CA 124.617 -0.993 . . . . 0.0 113.486 -0.326 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -93.68 156.71 16.54 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.637 -179.061 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.43 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.91 -172.5 24.22 Favored Glycine 0 C--N 1.337 0.59 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.436 179.558 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.486 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.3 OUTLIER -125.59 144.81 50.41 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 179.612 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . 0.422 ' HA ' ' O ' ' A' ' 24' ' ' THR . 57.0 m -89.44 114.3 25.76 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-O 121.094 0.473 . . . . 0.0 111.836 -179.676 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . 0.451 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 37.8 m-85 -124.92 157.74 35.28 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.418 179.302 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.55 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 19.8 t80 -92.85 133.03 36.48 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.959 -179.82 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.1 mt . . . . . 0 C--O 1.251 1.146 0 CA-C-O 118.463 -0.78 . . . . 0.0 110.873 179.844 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . 0.273 . . . . . . . 0 C--O 1.235 0.337 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -134.76 54.41 0.76 Allowed Glycine 0 C--N 1.336 0.572 0 O-C-N 123.695 0.622 . . . . 0.0 112.515 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.43 ' HA ' ' O ' ' A' ' 16' ' ' PRO . 28.7 p -99.26 153.88 18.6 Favored 'General case' 0 C--O 1.235 0.328 0 O-C-N 123.608 0.24 . . . . 0.0 110.874 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -92.15 151.15 20.53 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.755 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.417 ' O ' ' HG2' ' A' ' 8' ' ' GLU . 17.4 p90 -97.8 174.42 6.61 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.733 179.206 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.582 ' OE1' ' HB2' ' A' ' 36' ' ' TYR . 16.4 tt0 -63.06 130.52 45.05 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.253 0.621 . . . . 0.0 112.382 -179.308 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.1 9.09 46.08 Favored Glycine 0 C--N 1.339 0.696 0 CA-C-N 115.663 -0.699 . . . . 0.0 114.78 178.483 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.417 ' HG2' ' O ' ' A' ' 5' ' ' PHE . 6.4 pt-20 -134.93 176.94 8.2 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 117.708 0.754 . . . . 0.0 111.565 179.703 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.445 ' HA ' ' O ' ' A' ' 32' ' ' GLY . 40.0 p -90.79 143.69 26.47 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.199 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.5 p -134.55 131.37 37.85 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.957 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -100.61 118.88 37.67 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.842 179.576 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.603 HG22 ' O ' ' A' ' 30' ' ' PRO . 30.4 m -71.7 10.31 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -178.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.512 ' HB3' ' CD2' ' A' ' 14' ' ' PHE . 0.1 OUTLIER -100.99 -35.12 9.49 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.254 -179.428 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.512 ' CD2' ' HB3' ' A' ' 13' ' ' GLN . 1.9 p90 -146.84 -26.7 0.4 Allowed 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 -178.494 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.0 t80 -122.3 86.3 47.76 Favored Pre-proline 0 CA--C 1.545 0.767 0 N-CA-C 111.725 0.269 . . . . 0.0 111.725 -178.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.43 ' O ' ' HA ' ' A' ' 3' ' ' CYS . 61.4 Cg_endo -77.98 179.08 6.84 Favored 'Trans proline' 0 C--N 1.369 1.633 0 C-N-CA 122.279 1.986 . . . . 0.0 112.729 179.435 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.71 ' HB2' ' SG ' ' A' ' 25' ' ' CYS . 5.8 t -89.21 160.09 17.13 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 123.157 0.285 . . . . 0.0 110.87 179.756 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 72.6 m -79.99 108.64 9.74 Favored Pre-proline 0 CA--C 1.544 0.74 0 N-CA-C 111.96 0.356 . . . . 0.0 111.96 -179.356 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.436 ' HD3' ' O ' ' A' ' 17' ' ' CYS . 78.6 Cg_endo -83.03 177.2 6.87 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 122.485 2.123 . . . . 0.0 112.905 179.316 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.21 -39.83 2.62 Favored Glycine 0 C--N 1.34 0.762 0 C-N-CA 121.312 -0.47 . . . . 0.0 112.992 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 10.1 mt -89.58 -38.16 14.16 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 122.435 0.294 . . . . 0.0 111.477 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.28 51.6 0.23 Allowed Glycine 0 C--N 1.34 0.751 0 CA-C-N 116.17 -0.468 . . . . 0.0 112.461 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.462 ' HA ' ' O ' ' A' ' 35' ' ' TYR . 21.3 mt -114.88 150.74 35.13 Favored 'General case' 0 C--O 1.235 0.309 0 O-C-N 123.611 0.242 . . . . 0.0 110.958 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 t -139.73 154.26 47.4 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.305 -179.752 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.71 ' SG ' ' HB2' ' A' ' 17' ' ' CYS . 58.0 m -97.61 122.41 40.65 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.492 179.409 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.427 ' H ' ' H ' ' A' ' 33' ' ' THR . 9.6 mt -127.35 123.78 23.4 Favored Pre-proline 0 CA--C 1.545 0.765 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.4 -179.786 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.439 ' HB2' ' OD1' ' A' ' 29' ' ' ASN . 6.3 Cg_exo -76.0 -40.56 1.14 Allowed 'Cis proline' 0 C--N 1.375 1.934 0 C-N-CA 124.636 -0.985 . . . . 0.0 112.552 0.026 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.72 34.27 8.55 Favored Glycine 0 C--N 1.342 0.895 0 CA-C-N 115.915 -0.584 . . . . 0.0 113.045 179.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.439 ' OD1' ' HB2' ' A' ' 27' ' ' PRO . 2.3 p-10 -144.71 79.96 11.92 Favored Pre-proline 0 CA--C 1.547 0.86 0 CA-C-N 116.68 0.24 . . . . 0.0 111.508 179.705 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.603 ' O ' HG22 ' A' ' 12' ' ' VAL . 65.6 Cg_endo -89.15 -26.0 5.47 Favored 'Cis proline' 0 C--N 1.37 1.692 0 C-N-CA 124.714 -0.952 . . . . 0.0 113.457 -0.348 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -89.75 155.25 19.32 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.349 -179.474 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.445 ' O ' ' HA ' ' A' ' 9' ' ' SER . . . -156.31 -174.49 26.15 Favored Glycine 0 C--N 1.335 0.493 0 CA-C-N 115.371 -0.831 . . . . 0.0 112.396 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.489 ' O ' ' HA ' ' A' ' 25' ' ' CYS . 0.4 OUTLIER -126.15 143.41 51.14 Favored 'General case' 0 C--O 1.234 0.258 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.511 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' CYS . . . . . . . . . . . . . 45.9 m -88.56 112.52 23.13 Favored 'General case' 0 C--O 1.24 0.582 0 O-C-N 123.409 0.443 . . . . 0.0 111.681 -179.697 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' TYR . . . . . 0.462 ' O ' ' HA ' ' A' ' 23' ' ' LEU . 36.9 m-85 -125.56 159.85 31.04 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.112 -0.949 . . . . 0.0 110.592 179.416 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.582 ' HB2' ' OE1' ' A' ' 6' ' ' GLU . 12.3 t80 -93.49 134.96 35.2 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.964 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.2 mt . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.145 -0.931 . . . . 0.0 110.903 179.751 . . . . . . . . 0 0 . 1 stop_ save_